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Abstract
Eukaryotic elongation factor 1A (eEFlA) is a central component of the translational
machinery where it performs the GTP dependent transfer of aminoacyl tRNA to the
a-site of the ribosome. There are two variants of eEFlA called eEFl A1 and eEFlA2
that are 92% identical at the amino acid level and encoded at two different loci, 6ql4
and 20ql3 respectively. eEFl A1 is almost ubiquitously expressed except in skeletal
muscle, heart and neurons where it is replaced by eEFl A2 during development.
As well as its role in translation eEFlAl is thought to perform many additional non-
canonical functions. These include cytoskeletal remodelling, apoptosis,
susceptibility to transformation and senescence. There is some evidence that
eEFlA2 has different properties from eEFlAl. Importantly eEFlA2 has been
identified as a putative oncogene and has been shown to be overexpressed at the
RNA level in ovarian cancers. Additionally, EEF1A2 maps to 20ql3 and
amplifications in this region are common in breast and ovarian cancer. It is not
known whether it is the potential non-canonical function(s) of eEFl A2 that mediate
its role in oncogenesis or its function in translation and if these differ from eEFlAl.
The aim ofmy PhD was to investigate the expression of eEFlA2 in ovarian and
breast cancers and to try to determine the role that eEFl A2 may be performing in
cancer.
I investigated the expression of eEFl A2 in breast and ovarian cancers at both the
RNA and protein levels. I identified eEFlA2 overexpression in up to two-thirds of
breast cancers and moderate to high levels of eEFlA2 expression were associated
with oestrogen receptor positive cancers (p=0.016). In ovarian cancers eEFlA2 was
found to be expressed in up to one-third of cancers and was highly expressed in clear
cell carcinomas. The majority of ovarian cancers analysed showed amplification of
the EEF1A2 locus regardless ofwhether they expressed eEFlA2, suggesting this is
not the only mechanism mediating the overexpression of the elongation factor.
Mutation analysis of the exonic sequence ofEEF1A2 in low copy number ovarian
cancers lead to the identification of only one sequence variant that would not be
xvi
predicted to alter the sequence of the protein but may have an effect on post
transcriptional regulation of gene expression. Methylation analysis of the 5' CpG
island in EEF1A2 using bisulphite sequencing of DNA from ovarian cancers
overexpressing eEFlA2, not expressing eEFlA2 or DNA from normal whole ovary
showed no methylation ofEEFlA2 from any of the tissues suggesting methylation is
not controlling eEFlA2 expression in ovarian cancer.
Immunofluorescence analysis of the sub cellular localisation eEFl A1 and eEFlA2 in
breast (MCF-7) and ovarian (PEOl) cancer cell lines suggests that the two isoforms
show a similar diffuse cytoplasmic localisation with some concentration in the
perinuclear region of the cell. eEFl A1 and eEFl A2 partially co-localise with tubulin
in the perinuclear region and with F-actin in cellular protrusions. Finally analysis of
eEFl A2 function in the breast cancer cell line MCF-7 using RNA interference of
eEFl A2 showed that partial ablation of eEFlA2 does not alter the rate of
proliferation, cell cycle distribution or the percentage of cells in apoptosis. Therefore
eEFl A2 is frequently overexpressed in breast and ovarian cancers and this
overexpression does not appear to be consistently mediated by gene amplification,
mutation or methylation. Although the potential role that eEFl A2 is playing in
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Chapter 1 Introduction
1.1 General overview
Eukaryotic elongation factor 1A (eEFIA) is involved in the elongation step of
protein synthesis where it performs the GTP-dependent transfer of aminoacyl-tRNA
to the A-site of the ribosome. In mammals there are two EEFIA genes called
EEF1A1 and EEF1A2. The proteins encoded by these genes are 92% identical and
98% similar at the amino acid level (Knudsen et ah, 1993). Elowever, the two
proteins show different expression patterns: eEFlAl is almost ubiquitously
expressed whereas eEFlA2 expression is restricted to the brain, skeletal muscle and
heart (Lee et ah, 1992). As well as its role in elongation, eEFl A1 is also thought to
perform many other non-canonical functions. For instance eEFIA has been shown to
bind actin and tubulin and to perform cytoskeletal remodelling (Owen et ah, 1992;
Shiina et ah, 1994). It is unclear whether eEFlAl and eEFlA2 perform the same
non-canonical functions. Interestingly EEF1A2, and not EEFlAl, has been
identified as a potential oncogene in ovarian cancer (Anand et ah, 2002). The
existence of two eEFIA variants, eEFlAl and eEFlA2, is often overlooked in the
literature and in lower organisms such as Saccharomyces cerevisiae there is no
eEFlA2 homologue; therefore when the term eEFIA is used, this refers to the yeast
eEFIA protein or when a distinction between eEFlAl and eEFlA2 has not been
made in a published article and cannot be deduced from the experimental technique.
1.2 Protein synthesis
Protein synthesis can be divided into three main stages: initiation, elongation and
termination. Each stage is controlled by multi-subunit enzyme complexes; initiation
being controlled by eukaryotic initiation factors (elF), elongation being controlled by
eukaryotic elongation factors (eEF) and termination involving eukaryotic release
factors (eRF).
Initiation
Initiation involves the assembly of the 60S and 40S ribosomal subunits and
methionine charged tRNA at the AUG codon of the mRNA. It begins by the binding
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of eIF4F to the mRNA. The initiation factor eIF4F is a multimer of eIF4E, eIF4G,
eIF4A and eIF4B. eIF4E binds to the 5' methyl-cap upstream of the AUG codon.
Secondary structure in the 5'UTR of a mRNA molecule, due to a high GC content,
can hinder eIF4E binding. eIF4A is a helicase, eIF4B also binds the mRNA and
eIF4G acts as a scaffolding protein that links eIF4A, B and E together. It is thought
that binding of eIF4E is the rate limiting step of translation due to the effects of
5'UTR secondary structure. Binding of eIF4E to the 5' methyl-cap ofmRNA is
negatively regulated by 4EBP1, 2 and 3. The 40S subunit of the ribosome, bound by
eIF3, elFl, elFIA, eIF2 and tRNAmet forming the 43S preintiation complex is
brought to the mRNA by the eIF4F multimer. The ribosome is then thought to scan
along the mRNA until the start (AUG) codon is located. This occurs by the
recognition of the AUG by the initiator methionyl-tRNA, which is located onto the
ribosome P-site by eIF2. It is thought that the scanning ribosome is slowed at the
sequence surrounding the AUG site due to increased secondary structure in the
coding region compared to the 5' UTR. When bound by GTP eIF2 is active and this
GTP is hydrolysed to GDP when the initiation is completed. eIF2B is responsible for
GTP exchange on eIF2. The initiation factors then dissociate from the 40S ribosome
allowing the binding of the 60S ribosomal subunit.
Elongation
Eukaryotic elongation factors 1A1 (eEFlAl) and 1A2 (eEFl A2), as the names
suggest, are involved in the elongation stage of protein translation. eEFl A associates
with GTP and in this form it binds amino acylated tRNA and targets it to the A-site
of the ribosome. Following ribosome binding, but before codon/anticodon
recognition occurs, the bound GTP is hydrolysed to GDP and the resultant eEFlA-
GDP molecule dissociates from the ribosome. The free eEFlA-GDP then associates
with the eEFIB complex (consisting of three subunits a, P and y), that has GTP
exchange activity and acts to exchange GDP bound on eEFlA for GTP. This then
allows eEFlA to begin the cycle again by recruiting a new amino acylated tRNA
molecule. Finally, the elongation factor eEF2 is required for the translocation of the
peptidyl-tRNA from the A-site to the P-site of the ribosome in a GTP dependent
manner. A schematic depicting this process can be seen in figure 1.1.
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Figure 1.1 Translation elongation, taken from (Abbott and Proud, 2004).
Termination
When a termination codon is present in the A-site of the ribosome the eukaryotic
release factor eRFl recognises this and, in a GTP-dependent manner, the eRF
complex promotes the cleavage of the peptidyl-tRNA and release of the ribosome.
Mammalian translation is extensively reviewed in (Hershey, 1991) and (Merrick,
1992).
eEF1A1 and eEF1A2 in translation
As the sequence similarity would suggest, the enzymatic activities of eEFlAl and
eEFlA2 in an in vitro translation system were found to be similar (Kristensen et al.,
1998). However, eEFlA2 displays a higher affinity for GDP than GTP and the
opposite is true for eEFlAl in which the GDP dissociation rate constant is 7 times
higher than that of eEFlA2 (Kahns et al., 1998). Kahns et al. suggest that this
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difference in GDP affinity in eEFl A2 may play a role in one of the non-canonical
functions of eEFl A2. For instance, it may reflect the need for eEFlA2 to influence
actin binding, as GTP inhibits binding of eEFlA to G-actin (Dharmawardhane et al.,
1991). Kahns et al. also suggested that the slower rate of GDP dissociation in
eEF 1A2 could result in an increase in translational fidelity. Mutation of the GTP-
binding motifs in S. cerevisiae eEFl A, results in an increase in the Km of eEFl A for
GTP and a dramatic reduction in translational fidelity (Carr-Schmid et ah, 1999).
Therefore the slower rate of GDP dissociation on eEFlA2 could perhaps explain
why the expression of eEFlA2 is switched on only in terminally differentiated cell
types where translational accuracy would be important for cell viability over a long
time period.
Another difference between the two isoforms in protein elongation is that eEFlA2
only interacts weakly with the eEF IB complex in yeast-two hybrid analysis,
suggesting this complex is more unstable than the eEFl Al :eEFlB complex and
might not function in vivo (Mansilla et ah, 2002). This suggests that a different
factor is involved in nucleotide exchange on eEFlA2. EFip5a encodes a human
tissue-specific isoform of eEFlBa expressed in brain and skeletal muscle (Pizzuti et
ah, 1993) but this isoform does not exist in any other species and is unlikely to be a
functional guanine nucleotide exchange factor (GEF) (Chambers et ah, 2001). The
muscarinic acetylcholine receptor (mAChR) has been demonstrated to accelerate
nucleotide exchange on eEFl A2 suggesting this could be the factor responsible for
nucleotide exchange on eEFl A2 in the brain (McClatchy et ah, 2002). The
difference in nucleotide exchange factor for eEFlA2 could be due to the need for
specific regulation of translation in the terminally differentiated cell types in which
eEFlA2 is expressed.
1.3 The EEF1A genes and proteins
Mammalian EEF1A1 and EEF1A2
There are several EEFlA-genes in the mammalian genome but only EEF1A1 and
EEF1A2 are actively transcribed; the other EEFlA-like genes are thought to be retro-
pseudogenes originating from EEF1A1 (Lee et ah, 1993b; Lund et ah, 1996; Madsen
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et al., 1990). EEF1A1 has been mapped to chromosome 6ql4 and EEF1A2 has been
mapped to chromosome 20q 13.3 (Lund et al., 1996). EEF1A2 is 12kb in size,
including a 2kb upstream promoter region and is composed of 8 exons and 7 introns.
EEF1A1 is approximately 3.5kb in size and is also composed of 8 exons and 7
introns (Bischoff et al., 2000). The EEF1A2 promoter contains several potential cis
regulatory elements including E-boxes, binding sites for the EGR family of proteins
and a MEF2 binding site. There is also an Inr element that is thought to mediate
transcription initiation (Bischoff et al., 2000). A TATA box has been identified in
the promoter region ofEEF1A1 as well as Spl and Ap-1 binding sites. The promoter
of EEF1A1 can direct in vitro transcription 2-fold more effectively than the
adenovirus major late promoter indicating the gene has a very strong promoter
(Uetsuki et al., 1989).
The coding regions ofEEF1A1 and EEF1A2 are very similar (75% identical at the
nucleotide level (Knudsen et al., 1993) and the gene structure of the two EEF1A
genes is conserved however the 5' and 3'UTRs, introns and upstream promoter
regions are very different (Bischoff et al., 2000). The introns ofEEF1A2 are
considerably larger than those ofEEF1A1. The 5' flanking region ofEEF1A2 does
not contain a TATA box, which is present in EEFJA1, suggesting the regulation of
expression is different in these two genes. EEF1A1 and EEF1A2 both contain a
putative CpG island in the 5' flanking region of the genes that could be involved in
the regulation of expression (Ann et al., 1991). The difference in the 5' and 3' UTRs
of the eEFlA variants suggests that they may contain different sequence elements
involved in RNA processing and stability. Interestingly, EEFlA1 is a member of the
5' terminal oligopyrimidine tract (5'TOP) gene family. Exon 1 ofEEFlAl starts
with a cytosine nucleotide that is then followed by a stretch of 5 thymidines (Ts)
(Uetsuki et al., 1989). Three Ts are necessary in this 5'TOP sequence for high
transcriptional activity from the EEF1A1 promoter and eEFlAl mRNA has been
shown to contain a variable number of Ts (Shibui-Nihei et al., 2003). There is
evidence that the 5'TOP sequence is a cell growth dependent cA-regulatory element
in mammalian mRNA (Kaspar et al., 1992). Many housekeeping genes belong to the
5'TOP gene family including ribosomal protein genes and laminin binding protein
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(Kato et al., 1994; Yoshihama et al., 2002). There is no evidence that EEF1A2
contains a 5' TOP sequence.
The eEF1A1 and eEF1A2 proteins
In a variety of organisms eEFIA belongs to a multigene family and the members of
the family are often expressed in a developmental or tissue specific manner. There
are three EEFIA genes expressed at different developmental stages in Xenopus laevis
and recent evidence suggests that Xenopus laevis also express eEFlA2 (Newbery et
al., in preparation). In Drosophila melanogaster there are two EEFIA genes
expressed stage-specifically (Dje et al., 1990; Hovemann et al., 1988). In chicken
there was reported to be only one EEFIA gene (Wang et al., 1994), however it
appears that eEFlA2 is also expressed (Newbery et al., in preparation). In
Saccharomyces cerevisiae there are two genes TEF1 and TEF2 (Schirmaier and
Philippsen, 1984) and in S. pombe there are three genes (Mita et al., 1997). These
genes again show differential regulation. In Escherichia coli there are two EF-Tu
genes that show sequence identity.
eEFlA2 was first isolated from rat due to its antigenic similarity to statin, leading to
the provisional naming of the protein as SI (Ann et al., 1991). In humans eEFlAl
and eEFlA2 are 96% similar and 92% identical at the amino acid level, see figure
1.2 (Knudsen et al., 1993). eEFlAl and eEFlA2 are composed of 462 and 463
amino acids respectively, of which 34 amino acids are different between the two
proteins. This degree of similarity in amino acid sequence is perhaps surprising
considering there is only a 75% identity in nucleotide sequence between the human
EEFlAl and EEF1A2 sequence. This is due to redundancy in the amino acid code.
The lack of conservation at the nucleotide level may ensure that recombination
between the two genes does not occur.
eEFlA2 peptide sequences from different mammalian species also show a high
degree of similarity. The amino acid sequence of rabbit eEFlA2 is identical to
human eEF 1A2 and has a difference of only one amino acid with mouse and rat
eEFlA2 (Lee et al., 1994). The amino acids in rat eEFlA2 that differ from eEFlAl
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are totally conserved in mouse and human eEFlA2. This suggests that these amino
acid differences confer distinct roles to eEFlA2 and that these functions have been
subjected to evolutionary selection (Lee et ah, 1994). The differences between the
same variants of eEFlA in different species are less than the differences observed
between the two variants within the same species.
The functional domains of eEFlA in yeast have been mapped. These include three
consensus GTP binding domains (all three of which co-operate to bind GTP) that are
highly conserved between eEFlAl and eEFlA2. This makes the observation by
Khans et al. of a difference in nucleotide affinity between eEFl A1 and eEFlA2
somewhat surprising. This difference could be due to the amino acid difference at
nucleotide 197, which is an asparagine in eEFl Al and a histidine in eEFlA2 (Kahns
et ah, 1998). The crystal structure ofEF1A GDPNP from Thermus aquaticus (Song
et ah, 1999) suggests that the asparagine/histidine residue is close to the guanine
nucleotide binding domain. The serine at position 194 forms a hydrogen bond with
the guanine ring of the amino acid at position 196 a tryptophan, and stacks onto the
guanine base by hydrophobic interaction (Kahns et ah, 1998). Therefore a difference
at amino acid 197 could also affect nucleotide affinity.
Additionally, regions of eEFl A responsible for actin binding, as well as microtubule
interaction domains have been identified in eEFlA from S. cerevisiae. It had
previously been demonstrated that overexpression of eEFlA in S. cerevisiae lead to
slow growth, disorganisation of the actin cytoskeleton and accumulation of the cells
in G1 (Munshi et ah, 2001). Lui et al. identified the C-terminal 54 residues as
important for eEFl A binding to actin (Liu et ah, 2002). Gross and Kinzy used a
genetic screen to identify eEFlA mutants with reduced actin bundling activity called
N305S and N329S (the regions important for actin bundling are indicated on the
protein line up figure 1.2). Expression of these mutants in yeast resulted in an altered
actin cytoskeleton but no alteration in translation, thereby separating these two
functions of eEFlA (Gross and Kinzy, 2005). The expression of GFP fused,
truncated forms of eEFlA from carrot cells in leaf epidermal cells lead to the
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Figure 1.2 Protein line up showing homology between human eEFlA2 (Top line)
and eEFlAl (bottom line). Amino acid identity is indicated by a vertical line, one
dot denotes a conservative amino acid difference and two dots denote a semi-
conservative amino acid difference. Boxes are shown around the GTP-binding
domains showing sequence identity in these regions between eEFl A1 and eEFlA2
(Dever et ah, 1987). Mutations in S. cerevisiae eEFlA resulting in a loss of actin
bundling N305S and N329S (Gross and Kinzy, 2005). Underlined is the actin-
binding domain determined by Liu et al. (Liu et ah, 2002). There is less sequence
conservation in the actin binding regions of eEFlAl and eEFlA2 compared to the
regions responsible for GTP-binding.
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identification of the third domain of eEFIA (amino acids 318-447) as responsible for
interaction with microtubules (Moore and Cyr, 2000).
Post-translational modifications of eEFIA
Seven post-translationally modified residues have been identified on rabbit eEFlAl
using chemical protein sequencing. These modifications were dimethylation of
lysine residues 55 and 165, trimethyllysine at residues 36,79 and 318 and the
remaining two constituted the addition of ethanolamine to glutamic acid residues 301
and 379 (Dever et al., 1989). Phosphorylation of eEFIA was shown by Davydova et
al. when mono and polyribosomal fractions of rabbit reticulocytes were incubated
with [y-32P]ATP (Davydova et al., 1984). As well as this, eEFlAl isolated from
rabbit reticulocytes stimulated by phorbol 12-myristate 13-acetate (PMA) has been
shown to be phosphorylated by protein kinase C and this phosphorylation increases
the activity of eEFIA as measured by poly(U)-directed polyphenylalanine synthesis
(Venema et al., 1991a; Venema et al., 1991b).
When the post-translational modifications of rabbit eEFlA2 were compared to those
previously reported on eEFl Al the glycerylphosphorylethanolamine modifications
were found to be at the same position as on eEFl Al. Methylation is also found at
Lys 55 and Lys 165 but in eEFlAl these sites are dimethylated whereas in eEFlA2
they are trimethylated (Kahns et al., 1998). It is also possible that the
phosphorylation of the two eEFIA variants differs. For example, there are several
highly conserved predicted phosphorylation sites in eEFlA2 that are not present in
eEFl Al (Newbery et al., in preparation). Subtle differences in the protein sequences
of eEFlAl and eEFl A2 could result in these differences in post-translational
modifications and in turn could contribute to any differences in function, localisation
or activity of the variants.
Differential expression of eEF1A1 and eEF1A2
Mammalian elongation factors 1 Al and 1A2 exhibit very different expression
patterns. eEFlAl is near-ubiquitously expressed whereas eEFlA2 expression is
restricted to brain, heart and skeletal muscle in rats, mice and humans (Knudsen et
al.. 1993; Lee et al., 1992; Lee et al., 1995; Lee et al., 1993b). Analysis of
Chapter 1 Introduction 9
expression of eEFlA2 in the rat brain using in situ hybridisation showed it is
expressed in the post-mitotic neurons of the cerebral cortex, the motor neurons of the
brain stem and the Purkinje neurons in the cerebellum (Lee et al., 1995; Lee et al.,
1993a). The expression of the eEFIA variants also appears to be developmentally
regulated with eEFlA2 replacing eEFlAl as the dominant form during late
development of the brain, heart and muscle (Lee et al., 1993b). eEFlA2 is the only
eEFIA protein expressed in adult mouse muscle and therefore eEFlAl expression is
completely shut off in this tissue (Chambers et al., 1998; Khalyfa et al., 2001). It has
been suggested that the rise in eEFlA2 expression and concomitant decrease in
eEFlAl during postnatal development in mice and rat neurons, cardiomyocytes and
myocytes is coincidental with the terminal differentiation process (Lee et al., 1995).
No mechanism to explain this switching between eEFl Al and eEFlA2 expression
has been identified and it still remains unclear why eEFlA2 is expressed only in
long-lasting terminally differentiated cells such as cardiomyocytes, neurons and
myofibres. The translational function of the two variants of eEFIA is comparable,
and therefore it is reasonable to assume that this switch may occur in order to allow
specific cell types to utilize a non-canonical function unique to eEFl A2 or to abolish
a non-canonical function specific to eEFlAl. It is also important to note that the
above investigations into the expression of the eEFIA variants were carried out at the
RNA level using Northern blots and in situ hybridisation in rodent and human tissue
and therefore the protein level of the variants was not investigated.
1.4 The wasted mouse
One clue to the potentially unique role of eEFlA2 comes from the wasted (wst)
mouse. This mouse arose spontaneously in the inbred mouse colony HRS/J at the
Jackson Laboratories in 1972. These mice are bred as heterozygotes, as these mice
are phenotypically normal. The homozygous wst/wst mouse shows neurological
defects, muscle wasting and immune system abnormalities including a defective
response to DNA damage in lymphoid cells. Interestingly, wasted mice are normal
until approximately post-natal day 21 at which time they show the characteristic
ataxia and tremor phenotype. The mice then lose weight and develop progressive
paralysis before dying at round 28 days. Atrophy of the spleen and thymus is also
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observed in wst/wst mice, resulting in a decrease in the levels of circulating
lymphocytes (Shultz et ah, 1982).
The wasted phenotype was shown to be caused by a 15.8kb deletion in the Eefla2
gene. This mutation is a deletion of the promoter region and first non-coding exon of
eEFlA2, resulting in the abolition of transcription of the gene (Chambers et al.,
1998). Analysis of the expression of eEFlA2 in wasted and normal control mice
indicated that eEFlAl maintains a normal pattern of expression, whereas eEFlA2
expression is absent in 21-day-old mice. Analysis of eEFlAl and eEFlA2
expression analysis in wild-type mice between 2 days and 45 days of postnatal
development using RT-PCR showed that in skeletal muscle and heart, from 21 days
onwards, there is a gradual increase in eEFl A2 levels with a concomitant decrease in
eEFlAl expression. In the brain of mice both isoforms are expressed throughout
postnatal development (Chambers et al., 1998). Khalyfa et al also determined the
expression pattern of eEFlAl and eEFlA2 in wild-type (+/+), heterozygous (+/wst)
and homozygous (wst/wst) mice at the protein level using eEFlAl and eEFlA2
specific antibodies. They observed that in wasted mice a decrease in eEFlAl is
observed in heart, brain and muscle tissues during postnatal development, despite the
absence of eEFlA2, and confirmed the loss of eEFlA2 expression in neurons, heart
and skeletal muscle (Khalyfa et al., 2001). More recent analysis of expression levels
of eEFlAl and eEFlA2 in the developing wasted and wild-type littermate mouse
brain by immunohistochemical and immunofluorescent analysis demonstrated that in
wild-type mouse brain eEFlAl is present in the perikaryon of neurons early in
postnatal development and that by day 20 eEFlAl expression has completely
disappeared to be replaced by eEFlA2. In wasted mice this decrease in eEFl Al
expression occurs but the concomitant increase in eEFl A2 is not observed (Pan et
al., 2004).
How much of the phenotype of the wasted mouse can be explained by the loss of the
translational function of eEFlA2? It is plausible to hypothesize that the wasted
muscle phenotype can be attributed to the loss of protein translation in the tissue after
the expression of eEFlAl is switched off. The loss of protein synthesis following
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the down-regulation of eEFlAl in neurons can be used to explain the neurological
defects observed in the wasted mouse. Equally, eEFlA2 may be involved in
synaptogenesis, as the expression of eEFlA2 coincides with the pattern of
synaptogenesis in the rat (Chambers et ah, 1998). The mechanism by which ablation
of eEFl A2 expression may cause the immune system defects in the wasted mouse is
less apparent as expression of eEFlA2 has not been identified in wild-type mouse
spleen or thymus. However, there is evidence that the thymus from wasted mice
shows an increase in thymocyte apoptosis in situ and thymocytes from these mice are
more sensitive to apoptotic induction by gamma radiation, heat shock, and
dexamethazone. This, the authors suggest, implies that eEFlA2 may be a regulator
of apoptosis in thymocytes (Potter et ah, 1998).
1.5 Translation and eEF1A in aging and senescence
A decrease in the activity and levels of eEF 1A has been associated with the onset of
senescence in human fibroblasts (Cavallius et ah, 1986). In Drosophila melangaster
a similar observation has been made whereby elongation factor 1 (EF1) mRNA and
protein levels decrease followed by a decrease in protein synthesis during aging. The
rate of initiation and termination in the flies did not decrease during the 70%
decrease in protein synthesis, however the rate of elongation declined markedly
during aging (Webster and Webster, 1983; Webster and Webster, 1984). In
C57BL/6 mice the rate of protein translation is thought to decrease upon aging. The
rate of peptide chain elongation, but not initiation, declined substantially in brain,
liver, skeletal muscle and kidney in senescent mice compared to young mice
(Blazejowski and Webster, 1984). Therefore evidence exists to suggest that a
decrease in translation elongation, and eEFlA activity and abundance, could be
involved in aging and senescence.
1.6 Translation, eEF1A and cellular proliferation
Insulin is known to stimulate cell cycle progression and rapidly upregulate protein
synthesis. Insulin stimulation activates many protein kinases including the
multipotential S6 kinase, which has been shown to phosphorylate eEF la, (3, and y
from rabbit reticuloctyes and thereby increase the rate of elongation. Serum-
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deprived 3T3-L1 cells showed a 50% reduction in elongation activity compared to
serum fed cells and upon insulin administration the elongation activity increased 2-
fold (Chang and Traugh, 1997). Phorbol 12-myristate 13-acetate (PMA) is a
mitogen and protein elongation activator. PMA activation of cell proliferation
results in activation of the protein kinase C family. PKC y has been shown to
phosphorylate eEFIA on threonine 431, as well as the other eEFl subunits p, and y,
increasing the activity of eEFl (Venema et ah, 1991a). This increase in eEFl
activity is thought to be due to an increase the GDP/GTP exchange activity following
phosphorylation by protein kinase C (Peters et ah, 1995). Therefore it appears that
mitogenic activators upregulate elongation through signalling cascades resulting in
the phosphorylation of eEFIA and other eEFl components.
1.7 The non-canonical functions of eEFIA
As well as its role in translation eEFIA has been shown to perform roles, so called
non-canonical functions, in many other diverse cellular processes.
1.7.1 Cytoskeletal remodelling
eEFIA has been shown to bind and bundle actin (Dharmawardhane et ah, 1991;
Edmonds et ah, 1995; Owen et ah, 1992) and to sever microtubules (Shiina et ah,
1994) and therefore may have a role in the organisation of the cytoskeleton. This
interaction with the cytoskeleton may also be important for the compartmentalisation
of protein synthesis in the cytoplasm and aminoacyl tRNA channelling (Negrutskii
and Deutscher, 1991; Negrutskii et ah, 1994). The interaction of eEFIA with the
cytoskeleton is further detailed in Chapter 6.
1.7.2 Cell signalling
eEFIA (named PIK-A49 in this assay) can activate phosphatidylinositol 4-kinase in
carrot cells (Yang et ah, 1993) and phosphatidylinositols regulate many cellular
processes including cytoskeletal organisation and membrane trafficking. eEFIA has
also been found to interact with the zinc finger protein, ZPR1 by an in vitro binding
assay using human A431 epidermoid carcinoma cell extract and immobilized GZT-
ZPR1 fusion proteins and coimmunoprecipitation. Additionally, immunofluorescent
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analysis of subcellular localisation of the proteins in mammalian cells showed that
ZPR1 and eEFlA translocated to the nucleus upon mitogenic stimulation with EGF
and disruption of this interaction in S. cerevisiae leads to the accumulation of the
cells in G2/M of the cell cycle (Gangwani et ah, 1998). eEFlA has also been
identified as a potential binding partner of Akt2 using a GST-Akt2 tail screen of
CHOT cell lysates and shown to contain a minimal Akt2 phosphorylation motif,
suggesting it could be a substrate of the kinase. This minimal phosphorylation motif,
RXRXXT, is located at residues 67-72 of eEFlA and this region is completely
conserved between eEFlAl and eEFlA2 suggesting both variants could be
substrates of Akt2. The c-terminal tail of Akt2 was used in the screen to identify
binding partners of this isoform and not Aktl and 3 because this region is an area of
variability between the isoforms. P tubulin was also identified as a binding partner
of Akt2 in this screen and the authors suggest that eEFlAl, p tubulin and Akt2 may
form a complex at sites of cell activity, such as the protrusions of crawling cells (Lau
et ah, 2006). In a screen for genes whose expression is modulated by blocking the
EGFR and Her2 receptors with antibodies on the highly invasive breast cancer cell
lines MDA-MB435 and MDA-MB231, eEFlAl was identified as being down
regulated using differential display screening. Talukder et al. also observed an
increase in eEFl Al mRNA and protein levels in a variety of cell lines when they
were treated with epidermal growth factor (EGF) and heregulin-pi (E1RG) and this
activation of eEFlAl expression by E1RG required the SP1 site in the EEFlAl
promoter and results in promoter histone acetylation (Talukder et al., 2001).
1.7.3 Susceptibility to transformation
Another interesting property of eEFlAl is that it has been shown to determine the
susceptibility of fibroblasts to transformation induced by 3-methylcholanthrene and
ultra violet light. Taksuka et al. isolated a cDNA clone of eEFl Al from a BALB/c
3T3 A31 clonal variant that was highly susceptible to transformation. They
attributed this effect to eEFlAl causing the cells to be competent for growth rather
than hypersensitive to UV or carcinogens. They also suggested that the ability of
eEFlAl to remodel the actin cytoskeleton may be involved in its ability to increase
susceptibility to transformation as fibroblasts showed altered actin organisation.
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Additionally, eEFlAl may simply make these cells growth competent by increasing
the rate of translation of genes essential for growth (Tatsuka et al., 1992).
1.7.4 Apoptosis
There is evidence to suggest that eEFlAl may play a role in apoptosis. Duttaroy et
al. observed that high levels of eEFl Al in mouse fibroblasts caused the cells to
become pro-apoptotic upon serum starvation. Conversely, when levels of eEFlAl
were low in these cells they were in the mode of anti-apoptosis. Additionally,
fibroblasts overexpressing eEFlAl did not show an altered rate of protein synthesis
suggesting that the potential role of eEFlAl in apoptosis is independent of its
function in protein synthesis (Duttaroy et al., 1998). The pro-apoptotic activity of
eEFl Al has also been observed in a rat embryonic heart cell line, where hydrogen
peroxide-induced apoptosis resulted in an increase in the level of eEFlAl and anti-
sense eEFl Al cDNA protected these cells from apoptosis, suggesting eEFlAl
upregulation is required for the execution of apoptosis induced by oxidative stress.
This rapid increase in eEFl Al levels upon hydrogen peroxide treatment was shown
to be mediated by an increase in translation and not transcription of eEFlAl. The
authors suggest that the 5'TOP sequence in eEFlAl may play a role in this rapid
translational upregulation, by directing the mRNA into an inactive mRNA-
ribonucleoprotein pool or into a translationally active polyribosome pool (Chen et al.,
2000). A mouse erythroleukemic cell line that expresses temperature-sensitive p53
and goes into apoptosis when cultured at 32°C was used in a screen of genes
associated with p53-mediated apoptosis. Expression of eEFl Al was identified as
being upregulated by p53 activation and EEFlAl was shown to contain three
conserved and functional p53-response elements. They suggest that it could be the
microtubule severing activity of eEFlAl that mediates apoptosis in this model (Kato
et al., 1997). More recently, eEFlAl has been identified as having a role in lipotoxic
cell death. Mutant eEFl Al was identified to confer resistance to palmitate-induced
cell death using a random insertional mutagenesis assay in palmitate-sensitive CHO
cells. CHO cells containing mutant eEFlAl were also resistant to hydrogen
peroxide-induced cell death. Interestingly, they also observed no change in the rate
of protein synthesis in cells containing mutant eEFl Al and polymerisation of actin
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in cells treated with hydrogen peroxide was not observed in eEFl A1 mutant cells
suggesting eEFlAl exerts its role in apoptosis through cytoskeletal remodelling
(Borradaile et al, 2006). Therefore, it appears that eEFlAl is a pro-apoptotic factor
in vitro and that it could possibly exert this function through its ability to remodel the
cytoskeleton rather than any translational function.
1.7.5 Protein degradation
There is evidence to suggest that eEFlA may be involved in the co-translational
proteasome-mediated degradation of ubiquitinated cellular proteins in
Saccharomyces cerevisiae (Chuang et ah, 2005). eEFlAl has also been identified as
essential for the degradation of certain Na - acetylated proteins. Gonen et al.
identified eEFlA to be required for proteolysis of the core nucleosomal histone H2A,
actin and a-crystallin. In this function eEFlAl may be acting as an enzyme, or as a
chaperone protein that binds to and changes the conformation of certain proteins
rendering them susceptible to degradation (Gonen et al., 1994). The dual role of
eEFlAl in both protein degradation as well as protein synthesis may allow the cell to
regulate the overall level of protein present.
The identification ofmultiple roles of eEFl Al suggests it may be important in co¬
ordinating many processes within the cell. This might explain why eEFlAl is found
in such a high excess over other components of the translation machinery.
1.8 The non-canonical functions of eEF1A2
The similarity in amino acid sequence between eEFlAl and eEFlA2 may suggest
that any non-canonical functions exhibited by eEFlAl would also be performed by
eEFlA2. However, the similarity in function in translation between the two proteins
suggests that the significance of the developmental switch in expression of the two
isoforms could be explained by a difference in the non-canonical roles of eEFlA2.
To date not much data exists on the non-canonical functions of eEFlA2 however
work by Ruest et al. suggests that eEFlAl and eEFlA2 could in fact play opposing
roles in apoptosis. Ruest et al. observed the expression of eEFlAl and eEFlA2 in
cultured myoblasts during both muscle differentiation and serum deprivation-induced
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apoptosis. They observed an increase in eEFlA2 expression upon differentiation of
L6 and C2C12 myoblast cells and that upon serum deprivation differentiated
myoblasts decrease the expression of eEFlA2 and increase expression of eEFlAl.
Overexpression of eEFlA2 was protective against apoptosis whereas overexpression
of eEFl A1 accelerated cell death (and eEFl A1 antisense rescues the cells),
suggesting that eEFlA2 is anti-apoptotic and eEFlAl is pro-apoptotic in myoblasts
(Ruest et ah, 2002). The pro-apoptotic function of eEFl A1 could be attributed to its
microtubule severing ability, which would lead to apoptosis if this occurred in the
cells (Wang et al., 1999a). It is unknown whether eEFl A2 is also capable of
cytoskeletal remodelling but the regions in eEFlAl thought to be important for
cytoskeletal interactions are not highly conserved in eEFlA2.
Mouse eEFlA2 has also been shown to be protective against oxidative stress-induced
apoptosis. In a yeast two-hybrid screen using eEFl A2 as bait, 23 proteins were
identified as interactors and peroxiredoxin-1 (Prdxl) had the most hits. Expression
of eEFl A2 or Prdxl in mouse NIH 3T3 fibroblasts conferred partial resistance to
oxidative stress-induced apoptosis however co-expression of both proteins lead to
substantial resistance. Co-expression of eEFl A2 and Prdxl also resulted in an
elevation in the expression level of Akt especially under oxidative conditions (Chang
and Wang, 2006). Akt is a serine/threonine kinase in the phosphatidylinositol 3'-
kinase (PI3-K)-Akt signalling pathway. Akt signalling plays a role in the control of
cell proliferation and apoptosis and is frequently disrupted in human cancers.
Interestingly, Akt has been shown to enhance protein synthesis through
phosphorylation ofmTOR. mTOR is a serine/threonine kinase that activates
ribosomal protein S6 kinase (P70S6K1) and inhibits eukaryotic initiation binding
factor 4E-binding protein 1, enhancing the translation ofmRNAs containing a 5'TOP
sequence and releasing inhibition of translation ofmRNAs with a 5' CAP structure.
However, recent evidence suggests that mTOR phosphorylation may not effect these
translational regulators (Osaki et al., 2004). Other proteins have been identified from
the yeast two-hybrid screen as eEFl A2 interactors and these include cytoskeletal
proteins, vesicular transport/signalling proteins, and proteins involved in
transcription/translation, metabolism and protein maturation (Chang and Wang,
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2006). This suggests that eEFlA2 may play a role in diverse cellular functions, as
has been suggested for eEFlAl. What is not clear, however, is whether eEFlAl and
eEFlA2 perform analogous or distinct non-canonical functions.
1.9 Breast cancer
Epidemiology, incidence and risk factors
Breast cancer is the most common malignancy in women, worldwide there are 1
million new cases of breast cancer diagnosed each year with approximately 200,000
cases in the United States and 320,000 in Europe (Parkin, 2004). Although the
annual incidence of breast cancer is increasing in the United States, improved
screening and treatment mean that the mortality rate has declined by 2.3% per year
(Stewart et al., 2004). The incidence and mortality rates of breast cancer differ
greatly in different geographical locations: low risk locations include the Far East,
Africa and South America and high risk areas include North America and Northern
Europe (Parkin et al., 1999). Other risk factors for breast cancer include age, with
the incidence of breast cancer doubling about every 10 years. Lifetime exposure to
endogenous sex hormones has been studied in relation to breast cancer risk. Early
menarche (<12 years of age vs. > 14 years of age) and late menopause both increase
the risk of breast cancer. Early age at first pregnancy (<20 years of age) and higher
parity decrease the risk of breast cancer by 50% compared to nulliparous women.
Interestingly in women having their first child at over 35 years of age the risk of
developing breast cancer is actually higher than in nulliparous women. Prolonged
lactation is protective from breast cancer, giving a 4.3% decrease in the relative risk
of breast cancer for every 12 months of breast feeding. Hormone replacement
therapy and oral contraceptive use increase breast cancer risk. Alcohol consumption
in pre- and postmenopausal women results in an overall risk of 1.6 for developing
breast cancer. Postmenopausal obesity is associated with an increase in risk whereas
physical exercise is associated with a decrease in risk of breast cancer. In
postmenopausal women the main source of oestrogen is from lipid therefore an
overweight postmenopausal woman would have a higher levels of circulating
oestrogen than slimmer postmenopausal women. Physical exercise can cause
amenorrhea and this would therefore decrease the levels of circulating oestrogen and
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hence could decrease risk of breast cancer in women who exercise. Other factors
that increase breast cancer risk include: high mammographic breast density, a history
of benign breast disease and increased bone density. Additionally the risk ratios
increase with increasing number of affected first degree relatives demonstrating that
family history increases breast cancer risk. For a review of breast cancer risk see
(Dumitrescu and Cotarla, 2005).
Low and high penetrance breast cancer susceptibility genes
There are very few high-penetrance breast cancer susceptibility genes that confer a
high risk to the development of hereditary breast cancer. These include BRCA1 and
BRCA2, TP53, ATM, PTEN, NBS1 and LKB1. Mutations in these genes account for
only 5-10% of breast cancer cases. Hereditary breast cancers are distinct from
sporadic cases of the disease because they usually arise in younger individuals and
are often multifocal or bilateral. See review by Bennett et al. (Bennett et al., 2000)
BRCA1 was first identified by positional cloning in 1994 (Miki et al., 1994) but this
gene only showed linkage to about 45% of familial breast cancers. BRCA2 was then
identified by linkage analysis in high risk families not linked to BRCA1 in 1995
(Wooster et al., 1995; Wooster et al., 1994). Mutations in BRCA1 and 2 (Breast
Cancer 1 and 2) are thought to be involved in 80-90% of all hereditary breast cancers
but are infrequently found in sporadic cases of the disease (Futreal et al., 1994;
Lancaster et al., 1996). However, decreased expression levels of BRCA1 and
BRCA2 have been observed in sporadic breast cancers. LOH at 13q 12-13 (BRCA2
locus) has been observed in approximately one-third of sporadic breast cancers
(Cleton-Jansen et al., 1995). BRCA1 expression has been observed to be decreased
in sporadic breast cancers (Thompson et al., 1995) and this decrease in expression
has been shown to be mediated by promoter methylation in some cases (Dobrovic
and Simpfendorfer, 1997). BRCA1 and BRCA2 are tumour suppressor genes
implicated in many cellular processes including maintenance of genomic stability.
BRCA2 is involved in the regulation of RAD51 during homologous recombination in
DNA repair. BRCA1 is involved in many aspects of DNA repair such as the
transcriptional regulation of genes involved in repair and S-phase and G2/M
Chapter 1 Introduction 19
checkpoints in response to DNA damage (Gudmundsdottir and Ashworth, 2006;
Yoshida and Miki, 2004).
Germline mutations in the tumour suppressor gene TP53 are found in patients with
Li-Fraumeni cancer susceptibility syndrome, which manifests as an increase in
susceptibility to breast cancer as well as other types of cancers (Garber et ah, 1991).
The p53 protein is a transcription factor important in cell cycle arrest, apoptosis,
DNA repair and genomic stability, and angiogenesis (Lacroix et ah, 2006). Germline
mutations in the tumour suppressor gene PTEN are commonly found in patients with
Cowden syndrome, a disease associated with a 25-50% lifetime risk of breast cancer,
but are rarely observed in sporadic breast cancer cases (Ueda et al., 1998). Germline
missense mutations in the ataxia-telangiectasia mutated kinase (ATM) protein result
in the disease ataxia-telangiectasia (A-T), which among other symptoms including
cerebellar ataxia. Patients with A-T are thought to have an 11% risk of developing
breast cancer by the age of 50 and 30% by the age of 70 (de Jong et al., 2002). ATM
phosphorylates BRCA1 in response to ionising radiation leading to the activation of
DNA repair (Yoshida and Miki, 2004).
BRCA1 and BRCA2 mutations and the rare syndromes associated with breast cancer
do not account for all hereditary breast cancers. Low penetrance genetic
polymorphisms common within the population acting together with environmental
factors are also thought to be important in breast cancer risk. Research on low
penetrance breast cancer genes in still in its infancy, however de Jong et al. have
conducted a pooled analysis with the aim of finding polymorphisms that could be
causative in breast cancer or those in linkage disequilibrium with cancer causing
variants. Candidate genes include those involved in metabolism of oestrogen or
carcinogens, DNA repair and cell signalling (de Jong et al., 2002). Thirty-four
polymorphisms in 18 different genes were examined and 13 polymorphisms in 10
genes showed an association with breast cancer. These include polymorphisms in:
HRAS1 (involved in cell growth and differentiation), GSTM1 (detoxification of
xenobiotics), GSTP1 (detoxification of chemicals), CYP1B1 (metabolism), CYP2D6
(drug metabolism), and VDR (cell differentiation). Surprisingly little research as
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been carried out on combinations of polymorphisms and breast cancer risk (de Jong
et al., 2002).
Breast cancer pathology and molecular progression
The historical model of breast cancer progression based on morphological features
and epidemiological studies suggested that breast cancer followed a multi-step
process in its formation, much like the model proposed by Vogelstein for colon
cancer (Vogelstein et ah, 1988). The rather simplistic breast cancer progression
model argued that normal breast tissue underwent progressive changes to form a
hyperplasia with and without atypia, which then developed into an in situ carcinoma
and onto invasive carcinoma and metastasis. At each step an important genetic
alteration is thought to occur giving the cell a clonal selective advantage (Lakhani,








► ductal ► carcinoma ► ductal
hyperplasia in situ carcinoma
Atypical Lobular Invasive
lobular ►i carcinoma ► lobular
hyperplasia in situ carcinoma
Figure 1.3 Multi-step model of breast cancer progression, redrawn from
(Simpson et ah, 2005)
Both lobular and ductal carcinomas are thought to arise from terminal duct-lobular
units (TDLU) and the terms ductal and lobular simply reflect their different cell
morphology. Ductal hyperplasia is characterised by the uneven proliferation of
epithelial cells and alterations in nuclei shape and chromatin pattern. There is then a
transition from hyperplasia to atypical hyperplasia which is a small clonal outgrowth
of low grade malignant epithelium and is associated with an increased risk of breast
cancer. Ductal or lobular carcinoma in situ formation is the next step upon which
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cells acquire cytological characteristics of malignancy but the proliferating cells do
not breach the basement membrane but extend the ductal and lobular spaces (Allred
and Mohsin, 2000). The detachment from the basement membrane and stromal
invasion signifies the progression to an invasive tumour. The majority of invasive
breast carcinomas are ductal.
Advances in immunohistochemistry and molecular genetics have changed the multi-
step model of breast cancer progression from being perceived as a single pathway to
multiple parallel running pathways. This model is based on the identification of
distinct molecular genetic features in the invasive tumour being mirrored in pre¬
invasive lesions of comparable morphology. In the multi-pathway model there are
two major arms: one is the development of poorly differentiated ductal carcinoma
arising from grade III DCIS with both lesions showing amplifications in 17ql2 (the
high grade arm) and the other is the development of well differentiated ductal
carcinoma from grade I DCIS (low grade arm) with both of these lesions exhibiting a
loss at 16q (the locus of the E-cadherin gene). In the arm of the model leading to low
grade IDC tumours, as well as harbouring 16q loss, these tumours are usually
oestrogen (ER) and progesterone receptor (PgR) positive, HER2 negative, do not
express basal markers and have low genetic instability. In the opposing high grade
arm tumours frequently express Her2 but not the hormone receptors ER and PgR and
show many genetic losses, gains and amplifications including loss of 8p, 1 lq, 13q
and 14q; gains of lq, 5p, 8q, 17q; and amplifications on 6q22, 8q22, 11 q 13, 17ql2,
17q22-24 and 20ql3. Invasive lobular carcinoma (LIC) and the lobular carcinoma in
situ (LCIS) from which it arises both show loss of 16q and lq, which is highly
similar to the situation observed in well differentiated DCIS. There is however one
major difference between LCIS and LIC and low grade IDC/well differentiated DCIS
and that is lobular tumours lack E-cadherin expression due to alterations in the
CDH1 gene. A pleomorphic variant of lobular carcinoma (PLC) has recently been
identified and differs from classical lobular lesions by being high grade and
exhibiting features of apocrine differentiation. PLC appears to have genetic features
that overlap between the high and low grade arms of the multiple pathway model.
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For reviews of the molecular progression of breast cancer see (Kenemans et al.,
2004; Simpson et al., 2005).
Genes commonly involved in breast carcinogenesis
Many genes have been implicated as having a role in sporadic breast cancer. These
can be divided into functional groups: oncogenes; tumour suppressor genes; genes
involved in apoptosis, invasion, cell adhesion, and angiogenesis; and genes encoding
steroid receptors.
ERBB2/neu is an oncogene that is overexpressed in 25-30% of invasive breast
cancers, usually due to gene amplification, and this overexpression is associated with
poor prognosis (King et al., 1985; Simpson et al., 2005). Her2 is a transmembrane
receptor tyrosine kinase and a member of the epidermal growth factor receptor
(EGFR) family of receptor tyrosine kinases. This family also includes Herl, Her3
and Her4 and these receptors are known to have at least 25 ligands including
epidermal growth factor (EGF), TGF-a and neuregulin. Epidermal growth factors
are known to stimulate cell cycle progression, inhibit apoptosis, and stimulate
angiogenesis and metastasis through stimulation of intracellular signalling pathways
involving phospholipase C, ras and raf. A ligand that directly binds Her2 has not
been identified but Fler2 heterodimerises with one of the three other Eler proteins and
is thereby activated by their ligands (Warren and Landgraf, 2006). Overexpression
of ERBB2 in breast cancer cell lines has been shown to increase the invasive and
metastatic properties of the cell (Tan et al., 1997) and in mouse models
overexpressing Her2 in mammary epithelium under the control of the mouse
mammary tumour virus (MMTV) promoter develop mammary tumours after a long
latency (Guy et al., 1992). In contrast, transgenic mice expressing activated Eler2
with an activating mutation in the transmembrane domain develop multifocal
mammary carcinomas with a significantly shorter latency (Muller et al., 1988). Her2
is the target for Herceptin or Trastuzumab, a humanised monoclonal antibody that
binds the extracellular domain of the receptor.
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The tumour suppressor gene, TP53, appears to play an important role in sporadic
breast cancer development and progression. p53 induces or represses the expression
of a diverse range of genes involved in cell cycle arrest, DNA repair, apoptosis,
angiogenesis and senescence. Mutations tend to be point mutations rendering the
protein inactive but stabilised so an increase in the protein that can be identified
using IHC. The majority of p53 mutations are found in the DNA-binding domain.
(Lacroix et al., 2006; Levine, 1997). It is found to be mutated in approximately 30%
of invasive breast carcinomas and is associated with poor prognosis and aggressive
tumours (Mazars et al., 1992). Mammary tumours, however, are infrequently
observed in p53nu" mice (Donehower et al., 1992). Overexpression of the oncogenes
ras or wnt-1 in p53-deficient mice leads to the development ofmammary tumours
with aggressive features (Donehower et al., 1995; Hundley et al., 1997).
Bitransgenic mice carrying MMT\-ERBB2 and mutant p53 172Arg-to-His under the
control of the WAP promoter develop mammary tumours with a shorter latency than
MMTV-ERBB2 mice, suggesting co-operativity between the two genes (Li et al.,
1997a).
In the regulation of apoptosis the anti-apoptotic BCL2 gene is abnormally expressed
in 30-45% of breast cancers. Those genes involved in the alteration of adhesion and
invasion important in breast cancer metastasis include N-CAM, integrins, E-cadherin
cathespinD and metalloproteinases. Finally, the angiogenesis observed in breast
cancer can involve an increase in vascular endothelial growth factor (VEGF) as well
as fibroblast growth factor and platelet-derived growth factor (Kenemans et al., 2004;
Lerebours and Lidereau, 2002). In addition overexpression of the oestrogen receptor
a (ERa) is frequently observed in breast cancer and its role is discussed in Chapter 3:
eEFlA2 is overexpressed in two-thirds of breast tumours.
Genomic regions most frequently altered in breast cancers
Gains or losses in chromosomes in cancers are often identified using comparative
genomic hybridisation and have been shown to be commonly found within certain
cancers and between cancer types. In breast cancer, whole chromosome arm gains
are observed at lq and 8q. As well as whole arm gains in chromosomes 1 and 8,
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amplifications are also seen at lq21, lq32, lq41 and 8q24. Other frequently
amplified regions of the breast cancer genome include 1 lql 3, 16pl 1, 17ql 1.2, 17q24
and 20q 13 (Knuutila et al., 1998). 1 lql3 contains the locus encoding the oncogene
CCND1 and 17ql2 contains the ERBB2 gene however the putative oncogenes in
many of these amplified chromosomal regions are yet to be found. Gains on 8q,
17ql2 and 20ql3 are associated with decreased survival (Isola et ah, 1995; Tanner et
ah, 1995). Regions of loss of heterozygosity (LOH) in breast cancers point to the
genetic loci containing tumour suppressor genes. LOH is found at lp, 3p, 6q, 8p, 9p,
1 lp, 13q, 16q, 17p in more than 15-20% of breast tumours (Kerangueven et ah,
1997).
Subtypes of breast cancers based on distinct gene expression
signatures
Large scale gene expression analysis using microarrays has identified the existence
of five clinically relevant subgroups of breast cancer based on the expression pattern
of over 500 genes in 115 carcinomas and 7 non-malignant tissues. The main group
identified was the luminal subtype that expressed genes characteristic of luminal
epithelial cells including the oestrogen receptor (ER). This group was itself divided
into two subgroups: the luminal A subtype showing the highest expression of ER,
oestrogen-regulated protein LIV-1, the transcription factors hepatocyte nuclear factor
3, alpha (HNF3A), X-box binding protein 1 (XBP1) and GATA-binding protein 3
(GATA3). Conversely, the luminal subtype B exhibits lower expression ofER and
the oestrogen-regulated genes listed for subtype A and high expression of GGH,
LAPTMB4, NSEP1 and CCNE1. The basal epithelial-like subset of tumours express
genes characteristic of basal epithelial cells of the normal breast including KRT 5 and
KRT17, annexin 8, CX3CL1 and TRIM29. The ERBB2+ subtype of breast cancer
expresses many of the genes in the 17ql2 amplicon including ERBB2, GRB7 and
TRAP100. Finally, a normal like breast tumour group was identified that expresses
genes characteristic of the normal breast adipose tissue and other non-epithelial
components. The basal-like and ERBB2+ subtypes have been associated with the
shortest survival time. The luminal B subtype also appears to be a clinically distinct
group that has a higher propensity to relapse and does not respond to hormone
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therapy (Sorlie, 2004; Sorlie et al., 2001; Sorlie et al., 2003). In a recent study by
Bergamaschi et al. array CGH was used to identify distinct copy number alterations
that are associated with these gene expression subtypes. As would be expected the
ERBB2+ subtype showed more frequent amplification at 17ql2-q21 (the ERBB2
locus) than the other subtypes. Luminal A tumours were associated with gain at
1 q 12-q41 and 16pl2-13. Interestingly, Luminal B subtypes showed an association
with high level amplification at 20ql3 (EEF1A2 locus) (Bergamaschi et al., 2006)
suggesting eEFlA2 expression might be associated with this subtype and its
clinicopathological features. Importantly, there are a large number of genes on
chromosome 20ql3 and a great number of potential oncogenes.
1.10 Ovarian Cancer
Epidemiology, incidence and risk factors
Women have a 1 in 70 lifetime risk of developing ovarian cancer and it is the fifth
most common female cancer. Ovarian cancer is the most common cause of death
from gynaecological malignancy. In Europe there are 27,000-30,000 cases of
ovarian cancer diagnosed each year. The majority of cases of the disease are
sporadic, with only 5-10% having a hereditary genetic cause. Due to the
asymptomatic nature of ovarian cancer 70% of cases are diagnosed in the advanced
FIGO stage III or IV. The overall 5-year survival rate is 40% however this is directly
related to the stage of the disease, for example patients with stage I disease have an
89% 5-year survival whereas those with stage IV have a 5-year survival rate of just
11% (Runnebaum and Stickeler, 2001).
Ovarian cancer is more prevalent in the industrialised countries of Northern and
Western Europe as well as the United States. In contrast countries in Africa and Asia
have a low incidence of the disease. Ethnicity appears to play an important role in
ovarian cancer incidence as in the United States white women are at the most risk,
African American, Hispanic and Asian American at an intermediate risk while
Native American women are at the lowest risk (Runnebaum and Stickeler, 2001).
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Dietary factors may play a role in the higher incidence of epithelial ovarian cancer in
the western world, as diets high in saturated animal fats and meat have been
associated with increased risk. Japanese women have an increased risk of ovarian
cancer when they have migrated to the United States suggesting diet may play a role.
Obesity may also increase ovarian cancer risk. Asbestos and talcum powder use
have also been implicated in conferring an increase in ovarian cancer risk
(Runnebaum and Stickeler, 2001).
Reproductive and hormonal factors have also been implicated in epithelial ovarian
cancer risk. Pregnancy seems to be protective against ovarian cancer with each
pregnancy resulting in a 15-20% reduction in risk. The use of oral contraceptives for
5 years or more decreases the risk by 50% over non-users. Breast feeding also
appears to reduce ovarian cancer risk in women while early menarche and late
menopause may increase risk but this has not been shown reliably. Tubal ligation
and hysterectomy have been shown to decrease ovarian cancer risk by up to 80%.
Tubal ligation is thought to prevent the retrograde movement of inflammatory
substances to the ovary and therefore this may be the mechanism by which it results
in a decrease in ovarian cancer risk. Tubal ligation results in a decrease in ovarian
cancer risk of up to 80% suggesting that inflammation may be an important cause of
epithelial ovarian cancer. Polycystic ovarian syndrome, pelvic inflammatory disease
and endometriosis all appear to increase risk. Prolonged use of hormone replacement
therapy also leads to an increase in risk of ovarian cancer of 50% over non-users
(Riman et ah, 2004).
Pathology of ovarian cancer
Ovarian cancers have three distinct histological and biological types: benign
(adenoma), borderline (low malignant potential) and malignant (carcinoma) based on
the extent of epithelial proliferation and stromal invasion. The common histological
subtypes of epithelial ovarian carcinomas are serous, mucinous, endometrioid and
clear cell. Epithelial ovarian cancers (EOC) are thought to arise from the ovarian
surface epithelium (OSE). The OSE is a simple epithelium that exhibits some
stromal rather than epithelial features. EOC constitutes 90% of ovarian cancers and
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the more rare types of ovarian cancer arise from granulosa, stromal and germ cells.
Epithelial ovarian cancers are complex histologically, and undergo metaplasia to
acquire characteristics of the Mullerian duct-derived epithelium. This is the basis for
classification of the tumours, serous resembles the fallopian tube, endometrioid the
endometrium and mucinous the endocervix. Serous adenocarcinomas constitute 80%
of all epithelial ovarian cancers. The less common clear cell carcinoma has
mesonephros-like features. This Mullerian differentiation can be seen as a change in
cell shape, E-cadherin, junctional complexes, epithelial membrane antigens, as well
as secretory products such as mucins and CA125 (reviewed by (Auersperg et al.,
2001) and (Murdoch and McDonnel, 2002)). Currently CA125 is the only marker
commonly used in ovarian cancer. It is a reliable marker for the response to or
progression on various treatments however it has no role in diagnosis or prognosis
(Meyer and Rustin, 2000).
The cell of origin of epithelial ovarian cancers
There is debate over the origin of epithelial ovarian cancer. It is thought that most
epithelial ovarian tumours arise from the OSE or from inclusion cysts that form from
invaginations of OSE into the ovarian cortex (Feeley and Wells, 2001; Radisavljevic,
1977) . Evidence for this is the observation of atypia in the OSE adjacent to invasive
carcinoma; increased inclusion cysts in apparently normal ovaries contralateral to
ovarian cancer compared to age-matched controls; OSE adjacent to ovarian
carcinoma showing metaplastic and hyperplastic change; and ovaries removed
prophylactically from women with a family history of ovarian cancer showing
cortical inclusion cysts with abnormalities in the epithelial lining. Additionally, the
OSE and the epithelium of the Mullerian ducts have a common developmental origin
and the OSE undergoes mullerian metaplasia during adult life. The epithelial lining
of inclusion cysts has also been shown to have differentiated to a Mullerian, or to be
more exact, serous epithelium and to overexpress p53, an observation frequently
made in serous carcinomas (Feeley and Wells, 2001; Fleming et al., 2006).
An alternative hypothesis is that EOC arises from the epithelium of the secondary
Mullerian system. This system includes the rete ovarii and paraovarian/paratubule
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cysts that represent embryological remnants of the Mullerian ducts. This would
mean that the "differentiating up" into Mullerian-like histology would not be
necessary in EOC formation and would explain the histological similarity between
the subtypes of EOC and Mullerian epithelial tumours. Additionally, Dubeau argues
that small benign cysts that are morphologically indistinguishable from ovarian
cystadenomas are common in the paratubal/paraovarian area and that ovarian
epithelial tumours in rodents arise from dilation of the rete ovarii (Dubeau, 1999).
However, it is argued that atypia has not been observed in these secondary Mullerian
components and early ovarian carcinoma is commonly observed close to the ovary
surface where cortical cysts form (Feeley and Wells, 2001). Additionally there is
evidence that the mouse and human OSE can give rise to tumours resembling serous,
endometrioid and mucinous-like tumours. Cheng et al. stably expressed the HOX
genes Hoxa9, HoxalO and Hoxall in the mouse OSE cell line MOSEC or the human
OSE cell line T80H and subsequently injected the cells intraperitoneally into female
nude mice. Cells transgenically expressing HOXA9 gave rise to tumours with a
serous-like histology, HOXA10 expression gave rise to endometrioid-like tumours
and HOXA11 expression induced the formation ofmucinous-like tumours
suggesting that inappropriate expression of these genes, that are involved in normal
patterning of the reproductive tract, can give rise to the distinct histological subtypes
seen in EOC (Cheng et ah, 2005).
There is also some evidence that endometrioid and clear cell carcinoma could arise
from the precursor lesion endometriosis. Endometriosis is common in women in
their reproductive years and results from the retrograde implantation of tissue similar
to endometrium at sites outside the uterine cavity, most commonly the ovary, during
menstruation. Endometrioid and clear cell carcinomas are frequently associated with
endometriosis in 28% of endometrioid and 49% of clear cell carcinomas (Russell,
1979). Additionally, Jiang et al. observed LOH at candidate ovarian tumour
suppressor loci in endometriosis and identified genetic lesions common to
endometriosis and the endometrioid or clear cell carcinoma within or adjacent to it
(Jiang et al., 1996; Jiang et al., 1998).
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Hypotheses of how EOC arises from the OSE
The OSE, from which ovarian cancer is thought to arise, is a single layer of
epithelium that covers the ovary. It functions in cyclical ovulatory ruptures and in
the exchange of materials between the ovary and peritoneal cavity. Between the
OSE and the ovary lies the basement membrane and tunica albuginea (Auersperg et
al., 2001). There are differing models on how epithelial ovarian cancers arise from
the OSE. The first, formulated by Fathalla in 1971, is called the "incessant ovulation
hypothesis". Fathalla suggested that repeated ovulations lead to malignant
transformation of the OSE due to repeated rupture and repair introducing genetic
aberrations (Fathalla, 1971). The incidence of epithelial ovarian cancer has been
increasing over the last century. The number of ovulations a woman experiences has
also increased as women have less children lending support for the incessant
ovulation hypothesis. Additionally, when the total number of ovulations in women
with EOC was calculated and compared to those whom had not had EOC a
significant correlation between high number of ovulations and EOC was found
(Purdie et al., 2003). Another line of evidence is that in hens, unlike in other
animals, EOC does exist and these animals are frequent ovulators (Fredrickson,
1987). Further, epidemiological studies have identified lactation, parity and the oral
contraceptive, that all inhibit ovulation, as protective against the development of
ovarian cancer (Cramer et al., 1983). However, there is evidence that this model
may be too simplistic. For example, the progestin-only contraceptive pill (which
does not suppress ovulation) has been shown to be more effective than the combined
oral contraceptive against EOC (Risch, 1998). Also women with polycystic ovarian
syndrome are at increased risk ofEOC despite the anovulatory nature of this disease
(Schildkraut et al., 1996).
The second hypothesis is the pituitary gonadotrophin hypothesis that states that
excessive gonadotrophin exposure leads to an increase in oestrogen exposure to the
OSE and this can lead to malignant transformation (Cramer and Welch, 1983).
Gonadotrophins could directly stimulate transformation of the OSE directly or
indirectly through the stimulation of oestrogen levels. Pregnancy and oral
contraceptive pill use lower levels of pituitary gonadotrophins but during pregnancy
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there are high levels of oestrogen and human chorionic gonadotrophin (Risch, 1998).
Women with polycystic ovarian syndrome can have high levels of lutenising
hormone (LH) compared to follicle stimulating hormone (FSH) and a high risk of
developing EOC (Schildkraut et al., 1996). However, breast feeding has been shown
to be protective against EOC but during breast feeding there are high levels of
circulating FSH. Also low levels of gonadotrophins have been observed in women
with EOC (Risch, 1998).
A further hypothesis is called the hormonal hypothesis and states that excess
androgen stimulation of the OSE could lead to the development ofEOC and that
progesterone stimulation of the OSE is protective. Androgens are produced by
developing follicles in the ovary and it is proposed that inclusion cysts lined with
OSE adjacent to developing follicles may be exposed to this hormone (Risch, 1998).
Androgen receptors have been identified on human OSE cells and Mibolerone, a
synthetic androgen has been shown to stimulate proliferation of these cells
(Edmondson et al., 2002). This effect of androgen administration on human OSE
proliferation in culture is not always observed however (Karlan et al., 1995).
Patients with polycystic ovary syndrome have high levels of androgens and this may
contribute to the increased risk of EOC in these patients (Schildkraut et al., 1996).
The oral contraceptive pill has been shown to decrease testosterone production and
cause high levels of progestins. Progesterone levels are also very high in pregnant
women (Risch, 1998).
The final model is called the inflammation hypothesis. The ovulatory process
involves an inflammatory reaction in which there is an infiltration of leukocytes and
production of inflammatory cytokines and nitric oxide, vasodilation, DNA repair and
tissue remodelling. The genetic damage induced by inflammation may be a factor in
the development of EOC from the OSE (Ames et al., 1995). The use of anti¬
inflammatory medication reduces the risk of colon and breast cancer and exposure to
factors causing epithelial inflammation including asbestos, talc, endometriosis and
pelvic inflammatory disease have been implicated in causing epithelial ovarian
cancer (Ness and Cottreau, 1999).
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A model of ovarian cancer disease progression
The pathogenesis of ovarian cancer is unknown and no definitive model exists. Shih
and Kurman proposed a dualistic progression model based on genetic and
pathological evidence. There are two pathways of progression in this model and this
divides ovarian tumours into type I and type II. Type I tumours include low grade
serous carcinoma, mucinous carcinoma, endometrioid carcinoma, clear cell
carcinomas and malignant Brenner tumours. Type II tumours are moderately and
poorly differentiated serous carcinoma (high grade serous carcinoma), malignant
mixed mesodermal tumours (carcinosarcomas) and undifferentiated carcinoma. The
pathway for the progression of type I tumours has clear precursors called
cystadenoma, and atypical proliferative tumour and non-invasive carcinoma (both
referred to as borderline). Type I tumours progress slowly and commonly exhibit
KRAS mutations in serous tumours and BRAFmutations in mucinous tumours as
well as fi-catenin and PTEN mutations in endometrioid tumours. Type II tumours
show a very different progression: they arise directly from the OSE or from inclusion
cysts and metastasise early. The type II characteristic molecular alterations are less
well known but p53 is frequently mutated in type II tumours. Additionally, high
grade serous carcinomas also have been shown to exhibit overexpression of HER2
and Akt2 (Shih Ie and Kurman, 2004). This model is depicted in figure 1.4.
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Figure 1.4 Shih and Kurman proposed model of ovarian tumourigenesis,
redrawn from (Shih Ie and Kurman, 2004). Abbreviations: MPSC micropapillary
serous carcinoma (low grade serous carcinoma), CIN chromosomal instability, HLA-
G human leukocyte antigen-G, SBT serous borderline tumour, APST atypical
proliferative serous tumour.
The genetics of epithelial ovarian cancer
Familial ovarian cancer
Familial ovarian cancer refers to ovarian cancer associated with highly penetrant
autosomal dominant genetic predisposition. There are three clinical types of
hereditary ovarian cancer: "site-specific" ovarian cancer, breast and ovarian cancer
syndrome and hereditary nonpolyposis colorectal cancer (HNPCC; Lynch II)
syndrome. Site-specific and breast and ovarian cancer syndrome are both associated
with germline mutations in BRCA1 and BRCA2. HNPCC ovarian cancer syndrome
is associated with germline mutations in the DNA mismatch repair (MMR) genes
hMLHl and hMSH2. 10% of ovarian cancers are hereditary and of these 90%
harbour germline mutations in the BRCA genes, and 10% mutations in MMR genes.
Hereditary ovarian cancers are distinct from sporadic forms of the disease in there
clincopathologic features. BRCA1 mutant carriers have a cumulative lifetime risk of
ovarian cancer of 40-50%; BRCA2 mutant carriers have a 20-30% risk. Individuals
with HNPCC syndrome have a 12% cumulative lifetime risk of developing ovarian
cancer (Prat et al., 2005).
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Few low penetrance germline disease polymorphisms have been reliably identified
however a SNP in the promoter of the progesterone receptor and an association with
risk of developing endometrioid and clear cell carcinoma has been found (Berchuck
et al., 2004).
Sporadic ovarian cancer
ERBB2 is amplified in 5-7% of ovarian carcinomas and overexpressed in 17-20%
(Mano et al., 2004; Singleton et al., 1994). Increased copy number ofERBB2 is
associated with aggressive disease characteristics and is an independent prognostic
factor for overall survival (Lassus et al., 2004). The tumour suppressor gene TP53 is
also found to be inactivated in 30-40% of ovarian carcinomas. Amplification of c-
myc has been reported in 40% of ovarian cancers (Wang et al., 1999b). Activation of
the phosphatidylinositol 3-kinase/Akt pathway has been detected in 30% of ovarian
carcinomas and k-ras mutations have also been observed in ovarian carcinomas
(Mok et al., 1993; Yuan et al., 2000). In a mouse model of induction of ovarian
cancer Orsulic et al used ovarian cells from transgenic mice expressing the avian
receptor TVA and deficient for p53 to show that the addition of any two of the
oncogenes c-myc, k-ras or Akt resulted in induction of ovarian tumour formation
when the cells were injected into various sites in a recipient mouse (Orsulic et al.,
2002). Kusakari et al. used immortalised human OSE cells and expressed either
ERBB2 or mutant Ha-ras in them, which lead to anchorage independent growth and
tumour formation in nude mice suggesting these oncogenes have a role in ovarian
cancer (Kusakari et al., 2003).
Specific histological types exhibit specific genetic alterations, as eluded to in the
model of ovarian cancer progression proposed by Shih and Kurman (Shih Ie and
Kurman, 2004). K-ras activation is specifically observed in mucinous tumours
including all three histological types: adenomas, borderline and carcinomas,
suggesting k-ras is involved in mucinous differentiation. TP53 mutations are most
common in serous carcinoma but not in the benign or borderline types suggesting it
is involved in malignant transformation. TGF/3-2 mutations are mainly found in
endometrioid carcinoma. Deleted in Colorectal Cancer (DCC), a tumour suppressor
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gene, shows a loss of expression in 50% of serous carcinomas but not in the
premalignant forms of the tumour. Microsatellite instability is significantly more
frequent in endometrioid-type tumours than the other histological subtypes, being
observed in 50% of endometrioid cancers (Fujita et ah, 2003). Genetic alterations
specific to histological subtypes is perhaps to be expected due to their distinct
histological and biological characteristics.
1.11 Translation, translational control and cancer
Initiation factor EIF4E is involved in the initiation of translation, where it is an
mRNA cap binding protein, and has been identified as an oncogene. Overexpression
of eIF4E has been shown to transform NIF1 3T3 cells and enables them to grow as a
tumour when injected into mice (Lazaris-Karatzas et ah, 1990). Overexpression of
eIF4E has also been observed in breast, colorectal, head and neck, bladder and lung
tumours (Berkel et ah, 2001; Crew et al., 2000; Flaydon et ah, 2000; Li et al., 1997b;
Rosenwald et ah, 2001). The EIF4E locus has also been found to be amplified in
non-small-cell lung cancers and breast tumours (Balsara et ah, 1997; Sorrells et ah,
1999). Elevated expression of the initiation factor has been correlated with poor
survival in breast cancer (Li et ah, 1997b). There is evidence to suggest that eIF4E
activates the Ras oncogene and may be part of this oncogenic pathway (Lazaris-
Karatzas et ah, 1992).
Members of the eEFIB protein complex involved in nucleotide exchange on eEFIA
have also been implicated in cancer. In a screen for genes specifically upregulated in
cadmium transformed BALB/c-3T3 fibroblasts eEFlB|3 was identified and
overexpression in NIH 3T3 cells resulted in a transformed phenotype (Joseph et ah,
2002). eEFlBa and P have not been shown to be overexpressed in cancer. eEFlBy
on the other hand has been shown to be overexpressed at the RNA level in
hepatocellular carcinoma, gastric carcinomas, 15% of esophageal carcinomas and
50% of colorectal adenomas (Mimori et ah, 1996; Mimori et ah, 1995; Shuda et ah,
2000). It has not been assessed whether eEFlBy is capable of transforming rodent
fibroblasts.
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The role of eEF1A1 and eEF1A2 in tumourigenesis
There is evidence of overexpression of both eEFlAl and eEFlA2 in cancers
however only EEF1A2 has been shown to be an oncogene. For a gene to be
classified as an oncogene two criteria have to be met: the gene has to be found to be
hyper-activated or hyper-expressed in primary human cancers and the gene has to be
capable of transforming rodent cells cultured in vitro. The rodent cell lines, NUT 3T3
or Rati, are often used to identify a potential oncogene by overexpressing the protein
in them and looking for oncogenic properties. eEFl A2 was shown to have
oncogenic properties when expressed under the control of a CMV promoter in NUT
3T3 cells. It enhanced focus formation, allowed anchorage-independent growth and
decreased doubling time of the fibroblasts (Anand et ah, 2002). EEF1A2 maps to
chromosome 20ql3.3, and an increase in copy number at this locus has been
identified in breast (Kallioniemi et ah, 1994) and ovarian (Suehiro et ah, 2000)
cancers by comparative genomic hybridisation. In addition, the increased copy
number at this region is associated with poor clinical prognosis and is often
associated with more aggressive tumours (Isola et ah, 1995; Tanner et ah, 2000). In
a microarray analysis of gene expression in 113 epithelial ovarian carcinomas,
upregulation of eEFl A2 was identified in clear cell carcinomas, a particularly poor
prognosis ovarian carcinoma (Schwartz et ah, 2002). Anand et al. found EEF1A2 to
be amplified in 25% of primary ovarian tumours and to be highly expressed, at the
RNA level, in 30% of ovarian tumours and ovarian carcinoma cell lines. They also
demonstrated that eEFl A2 increased the growth rate of ES-2 ovarian carcinoma cells
when xenografted in nude mice (Anand et ah, 2002). Kulkarni et al. recently showed
expression of eEFlA2 in 60% of primary breast cancers and this expression was
associated with an increased probability of 20-year survival. Patients with tumours
expressing eEFlA2 at moderate to strong level had a cumulative 20-year survival of
approximately 75%, whereas only 55% of those patients with tumours showing low
to negative expression of eEFlA2 were alive after 20 years (Kulkarni et ah, 2006).
Amplification of 20ql3 and overexpression of eEFlA2 have been observed in lung
cancer as well as breast and ovarian cancers. Zhu et al. used array CGH and FISH to
identify regions of genomic aberrations in lung adenocarcinoma cell lines and found
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frequent gains at 20ql3. They then analysed the expression of eEFlA2 by
quantitative RT-PCR in normal lung tissue and compared this to its expression in 27
primary lung adenocarcinomas and found eEFlA2 RNA expression was on average
127.9 fold higher in the cancers than in normal lung tissue and was more than 2-fold
higher in 70% of the 27 primary lung adenocarcinomas than in normal tissue (Zhu et
al., 2006). A second study of DNA copy number, mRNA and protein expression in
lung adenocarcinoma cell lines using CGH, transcript microarray and mass
spectrometry identified EEF1A2 as one of only 4 genes in which elevated protein
levels correlated with mRNA and DNA copy number. RNA interference of eEFlA2
in these 4 lung adenocarcinoma cell lines resulted in a decrease in proliferation and
induction of apoptosis suggesting that eEFl A2 is required for viability and/or growth
of these cells. Additionally, immunohistochemical analysis of eEFlA expression in
a tissue microarray containing stage I non-small-cell lung cancer showed that the
elongation factor was expressed in 28% of these cancers and this expression was
associated with short overall survival time, however this analysis was carried out
using a non-specific antibody that recognises both eEFlAl and eEFlA2 (Li et al.,
2006). Interestingly, peroxiredoxin-1 (Prdxl) was one of the other three genes
shown to be amplified and overexpressed in this analysis of lung cancers (Li et al.,
2006) suggesting that eEFlA2 and Prdxl may be playing a synergistic role in
resistance to apoptosis perhaps through modulation of Akt, as previously described
by Chang et al. in mouse fibroblasts (Chang and Wang, 2006).
Amplification at 6ql4 (the site of the EEFlAl locus) has only been identified in
some childhood brain tumours (Shlomit et al., 2000), in fact a loss in this region is
more frequently observed in cancer (Verhagen et al., 2002). Overexpression of
eEFlAl has however been identified in breast, lung, prostate and colon cancers (de
Wit et al., 2002; Grant et al., 1992; Mohler et al., 2002; Xie et al., 2002). Again
overexpression of eEFlAl in these cancers was often investigated using a
commercially available non-specific eEFlA antibody and therefore it is not always
clear if it is eEFl Al or eEFl A2 that is being identified. Furthermore, it is often
stated that eEFlAl has been shown to be more highly expressed in the highly
metastatic cell rat mammary adenocarcinoma cell line MTLn3 cells than in the
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weakly metastatic MTC cell line (Edmonds et al., 1996). However, this analysis was
carried out using an antibody raised against a peptide corresponding to the carboxyl
terminus ofmouse eEFlAl, which has only one amino acid difference to mouse
eEFlA2 and is therefore likely to recognise both variants of eEFlA. It is therefore
unclear whether it is eEFlAl or eEFlA2 that is more highly expressed.
The translationally controlled tumour protein (TCTP) gene has been identified as a
gene whose expression is down regulated during tumour reversion/suppression and
by p53 and Siah-1 activation (Tuynder et al., 2002). eEFlA and eEFIB were
identified as TCTP interactors using a yeast-two hybrid screen and interaction
between eEFlA and TCTP stabilised eEFl A in its GDP bound form. It is not known
whether it is eEFlAl and eEFlA2 or just one of the 2 elongation factors that
interacts with TCTP (Cans et al., 2003). TCTP has been shown to associate with
microtubules in a cell cycle dependent manner, to be involved in the progression of
cytokinesis and apoptosis. Therefore interaction of eEFlA with TCTP might have a
role in cancer.
Shen et al. used differential RNA display technology to identify a 2kb transcript they
called prostate carcinoma tumour inducing gene 1 (PTI-1) (Shen et ah, 1995). This
transcript constitutes a 630bp region with 87% sequence similarity to Mycoplasma
hyopneumoniae 23S rRNA fused to a truncated mutated form of eEFlA and is
preferentially expressed in prostate carcinomas but not normal tissue. It was also
identified in cell lines derived from breast, lung and colon cancers. In vitro
translation demonstrated the protein produced from the PTI-1 transcript was 46kDa
in size (Shen et al., 1995). PCR to amplify the 5'UTR ofPTI-1 in human tumour
cell lines suggest that the gene is part of the human genome (Sun et al., 1997).
Expression of full length PTI-1, but not the 5' UTR or truncated eEFlA alone, in
CREF-Trans 6 cells and injection into nude mice induced tumour formation and this
could be reversed by expression of full length anti-sense PTI-1 (Su et al., 1998).
Mansilla et al. could detect PTI-1 protein expression using anti-eEFlA antibodies in
human cell lines overexpressing PTI-1 but not in the LNcap cell line, the cell line
from which PTI-1 was originally isolated, suggesting the oncogenicity of PTI-1
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could be related to the transcript and not the protein product (Mansilla et al., 2005).
The role of an RNA transcript in cancer seems unlikely, however RNA is thought to
play a role in cancer. MicroRNAs (miRNAs) are small non-coding RNAs that
mediate negative regulation of gene expression at the post-transcriptional level and
have been shown to play a role in development, proliferation and apoptosis.
MicroRNAs either bind to complementary sequences in the 3'UTR of target mRNAs
resulting in endonucleolytic cleavage of the mRNA or the miRNA binds to imperfect
complementary sites and interfere with protein synthesis. MicroRNAs are often
aberrantly expressed in tumours and are thought to interrupt the cell cycle and
interact with signalling oncogenes (Liu et al., 2006). Retroviruses are also thought to
play a role in cancers such as leukaemias, breast cancer and skin cancer (Talbot et
al., 2004). However there is no evidence that full length coding RNAs, and not the
protein, play a role in cancer.
A test of the oncogenic potential ofEEF1A1 in NIH 3T3 cells has not been carried
out; this would answer the question ofwhether both eEFIA variants are capable of
transforming rodent fibroblasts.
1.12 Hypothesis: EEF1A2, but not EEF1A1, is an oncogene and the
oncogenic properties of eEF1A2 lie in its unique non-canonical
functions.
There is evidence that EEF1A2 is an oncogene but less evidence supporting the role
of EEFIA J in oncogenesis. The restricted developmental expression of eEFlA2
(Knudsen et al., 1993) and the high evolutionary conservation of the protein (Lee et
al., 1994) suggest that eEFlA2 performs functions that are distinct from those
performed by eEFlAl. It is not clear whether this difference in eEFl A2 is in its role
in translation or whether eEFl A2 exists to perform a non-canonical function that
eEF 1A1 cannot. The fact that both proteins have been shown to have comparable
functions in translation (Kristensen et al., 1998) suggests that it is perhaps a non-
canonical function of eEFlA2 that is responsible for its existence in terminally
differentiated long-lived cells in mammals and this non-canonical function could
perhaps play a role in oncogenesis when eEFlA2 is inappropriately expressed. It is
Chapter 1 Introduction 39
also possible that overexpression of eEFl A2 results in an increase in the global
levels of translation in cancer cells and that this drives the faster proliferation of
cancer cells. This is unlikely as the rate limiting step of translation generally
considered to occur at initiation (Hershey, 1991) and eEFlAl is already in vast
excess over the other components of the translational machinery, constituting 3-5%
of the total cellular protein. Additionally, most cells are thought to be functioning
near the maximum rate of elongation (ca. 5 amino acids/ribosome/sec) and therefore
large increases in the rate of elongation are not possible (Hershey, 1991). If, in fact,
overexpression of eEFlA2 in cells already expressing eEFlAl does result in an
increase in the global rate of translation this may result in the introduction of errors
in the protein sequence (overexpression of eEFlA has been linked to increased
translational infidelity in Saccharomyces cerevisiae (Song et al., 1989)) leading to
potentially oncogenic proteins being produced, however it is difficult to see how this
would be heritable. It has also been suggested that eEFl Al and eEFl A2 may differ
in the proteins they translate and that this may contribute to the role of eEFlA2 in
oncogenesis due to the preferential translation of proteins that enhance oncogenesis,
such as those involved in promoting proliferation or inhibiting apoptosis. This is
also unlikely as the elongation and termination phases are thought to occur by the
same mechanism for all proteins and to be insensitive to mRNA sequence or
structure (Hershey, 1991). On the other hand, this is thought to be the mechanism by
which EIF4E is oncogenic: through the translation of oncogenesis-related mRNAs
that contain a specific secondary structure in the 5' UTR such as VEGF, c-myc and
Bcl-2 (Graff and Zimmer, 2003).
Despite the amino acid similarity (96%) between eEFlAl and eEFlA2 (Knudsen et
al., 1993) it could be possible that eEFlA2 performs different non-canonical
functions to eEFlAl. This could be due to post translational modifications found
only on eEFlA2 and not eEFlAl, which alter function. For instance eEFlA2 has
predicted phosphorylation sites that are not present in eEFlAl (Newbery et al., in
preparation). eEFlA2 may interact with and remodel the cytoskeleton, as has been
demonstrated for eEFlAl (Gross and Kinzy, 2005), but in a different manner that
enhances tumourigenesis is some cell types. The finding that eEFlA2 is protective
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against oxidative-stress induced apoptosis through modulation ofAkt may also offer
a clonal advantage to a cell. In a yeast two-hybrid screen, eEFlA2 was shown to
interact with proteins involved in many diverse cellular functions suggesting that an
unknown non-canonical function may be behind the oncogenic properties ofeEFlA2
(Chang and Wang, 2006).
Therefore I hypothesise that eEFl A2 but not eEFlAl is an oncoprotein and that it is
the potential non-canonical functions of eEFlA2 that mediate its role in cancer.
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1.13 Project aims
The aim ofmy PhD was to investigate the expression of eEFlA2 in breast and
ovarian cancers using commercial tissue arrays, as well as locally made arrays and a
panel of ovarian tumours for which DNA, RNA and protein were available. This
expression analysis data could then be used to look for any clinical associations that
could give insight into the potential role of eEFlA2 in these cancers. The
mechanism by which eEFl A2 is overexpressed was also to be determined using
DNA sequencing, copy number analysis and methylation analysis. The final aim
was to use RNA interference in cancer cell lines to investigate the potential role of
eEFlA2 in oncogenesis.
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Chapter 2: Materials and methods
2.1 Materials
General laboratory chemicals were purchased from Sigma, unless otherwise
indicated. All PCR primers were purchased from Invitrogen and cell culture medium
was obtained from Invitrogen.
2.1.1 Buffers and solutions
Buffer and solution recipes that are not detailed in Methods are shown in table 2.1.
Table 2.1 buffers and solutions
2X Laemmli
Loading Buffer




250nM Tris HCL (pH8.3), 1.9M glycine, 10% SDS
Mowiol 7.5g Mowiol 4-88 was mixed with 10ml glycerol in a 250ml
flask. 25ml distilled water was added and the flask covered
and incubated at room temperature overnight. 50ml of 0.2M
Tris HCL pH8.5 was added and the mixture heated in a
boiling water bath for 20 minutes. The mixture was allowed
to cool before adding DAPI.
PBS (Phosphate
Buffered Saline)






As above but also containing 0.1% (v/v) Tween-20 added
post autoclaving.
RIPA 150mM NaCl, l%NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, 50mM Tris HCL pH8
TBE (Tris
Borate-EDTA)
108g Tris, 55g Boric acid and 9.3g ofNa4EDTA in 1L of
distilled water, pH8.3
Citric acid 1,05g citric acid per 500mls distilled water, pH to 6.0
Lithium
carbonate




1.0% Tryptone, 0.5% Yeast Extract, 1.0% NaCl, pH7.0.
Medium was autoclaved and allowed to cool to
approximately 55°C before antibiotic was added.
LB agar plates LB was prepared as above but 15g/L agar was added before
autoclaving. After cooling to approximately 55°C antibiotic
was added and plates poured and allowed to harden.
Low salt LB lOg Tryptone, 5g NaCL, 5g Yeast extract
15g agar if plates, in 1L distilled water, pH 7.5
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2.2 Methods
2.2.1 Patient samples
2.2.1.1. Breast cancer samples
Specimens of normal and cancerous breast tumours were obtained with informed
consent and local ethical committee approval from patients undergoing surgical
treatment at the Lothian University Hospitals NHS Trust.
2.2.1.2 Ovarian cancer samples
Primary ovarian (HOV) tumour material and non-malignant tissues were obtained
from patients having undergone gynaecological surgery in the Lothian University
Hospitals NHS Trust. Institutional ethical approval was granted for this work by the
Lothian University NHS Trust Medicine/Clinical Oncology Research Ethics
Subcommittee.
2.2.2 Production and validation of the anti-eEF1A1 and eEF1A2
antibodies
2.2.2.1 Design, generation and characterisation of antibodies
Anti-peptide antibodies were designed in order to specifically recognise each eEFl A
variant. Three peptide sequences were selected in regions of the two variants
showing amino acid differences (see figure 3.1) these are called 1A1-1, 1A1-2, 1A1-
3 and 1A2-1, 1A2-2 and 1A2-3. These peptides were also selected to regions
showing no amino acid differences between human and mouse proteins to allow use
of the antibodies in the recognition of the eEFl A variants in the two species. Finally
the peptides were chosen from regions of the protein thought to be accessible by the
antibody based on the structure of the bacterial protein EF-Tu resolved by X-ray
crystallography (Song et al., 1999). The peptide were linked to keyhole limpet
hemocycanin, KLH, to increase antigenicity of the peptide. All of the antibodies
were raised in sheep and 1A2-3 was also raised in rabbit. The serum from each bleed
was used to test for the recognition by each antibody of the peptide to which it was
raised by EL1SA.
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The antibodies were purified using ammonium sulphate precipitation and
immunoaffinity purification against the peptide to which it was raised. This resulted
in the abolition of non-specific bands on Western blots.
2.2.2.2 Validation of eEF1 A1 and eEF1 A2 antibody specificity
The specificity of the eEFlAl and eEFlA2 anti-peptide polyclonal antibodies was
determined using Western blotting by Helen Newbery. Antibodies 1A2-1, 1A2-2
and 1A2-3 all recognised a band of approximately 50kDa in protein extract from the
brain ofwild type mice that is known to express both eEFlA variants (Lee et al.,
1993). No band was present when extracts from the brain ofwasted mice was used
in Western blotting and probed with the anti-eEFlA2 antibodies, confirming the
specificity of the antibody. In heterozygous wasted mice carrying only one
functional Eefla2 allele a band of half the intensity to that seen in wild type mice
was identified on Western blots.
The specificity of the eEFlAl antibodies were also determined using Western blot.
eEFlAl is known not to be expressed in mouse skeletal muscle at 25 days
(Chambers et ah, 1998) and this was used as a negative control. The 1A1-1 and
1 Al-3 antibodies recognised a band of approximately 50kDa in all mouse tissues
apart from skeletal muscle from 25 day wild type mice. Examples of these Western
blots can be found in figure 3.2.
2.2.3 Immunohistochemistry (IHC)
2.2.3.1 Tissue Micro Arrays (TMAs)
A breast tumour histoarray (CB2) and an ovarian cancer tissue array (CJ1) produced
by SuperBioChips (AMS Biotechnology) were obtained. An ovarian tumour TMA
was produced by Alistair Williams and a breast tumour tissue array was produced by
Dana Faratian at the New Royal Infirmary, Edinburgh.
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2.2.3.2 IHC on commercial tissue arrays
Formalin fixed, paraffin embedded sections of human normal tissue and tumour
tissue were deparaffmized with xylene, rehydrated, treated with picric acid and
microwaved in citric acid pH6. Slides were then washed in water and PBS and
loaded into a Sequenzer. Slides were blocked in a 1:5 dilution in PBS of
sheep/rabbit serum for 30 minutes at room temperature. Primary anti-eEFlA2 rabbit
and sheep antibodies were used at a concentration of 1:10 to 1:75 diluted in PBS, for
30 minutes at room temperature and secondary goat anti-rabbit IgG Biotin
conjugated antibody (Dako Cytomation) or rabbit anti-goat IgG biotinylated (Dako
Cytomation) were used at 1:200 to 1:500, at room temperature for 30 minutes.
Slides were incubated with StreptABC complex/HRP (Dako Cytomation) at room
temperature for 30 minutes and in diaminobenzidene (Sigma Fast DAB, Sigma) for 2
minutes at room temperature. Finally slides were counterstained in haematoxylin,
dehydrated, cleared in xylene and mounted in pertex.
2.2.3.3 IHC Envision method on in-house tissue arrays
An alternative method of IHC was recommended by a Pathologist to decrease the
background staining observed using the previous IHC method. This should make the
interpretation of the results easier as there should be less background staining. The
results using this protocol for IHC and the previous technique should be comparable
as the same antibodies are used and controls to ensure specificity are used in both
techniques. The kit used for the Envision technique was the ChemMate DAKO
EnVision Detection Kit, Peroxidase/DAB, Rabbit/Mouse (DAKO Cytomation).
Deparafinization, rehydration and antigen retrieval and were carried out as 2.1.
Peroxidase blocking was carried on slides in the Sequenzer using peroxidase
blocking solution containing 6% hydrogen peroxide and 10% sodium azide for 5
minutes. Slides were then washed in PBS and blocking carried out as described in
Materials and Methods section 2.2.3.2. Primary rabbit anti-eEFlA2 1A2-3 antibody
was then added to the slides at a concentration of 1:10, diluted in antibody diluent
(DAKO Cytomation), for 30 minutes at room temperature. Slides were then washed
in PBS and three drops of ChemMate DAKO EnVision/HRP Rabbit/Mouse
secondary antibody (DAKO Cytomation) were added to each slide and incubated for
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30 minutes at room temperature. Slides were again washed in PBS then removed
from the Sequenzer. The DAB-containing Substrate Working Solution was prepared
by mixing 50 parts ChemMate Substrate Buffer withl part ChemMate DAB +
Chromogen (DAKO Cytomation). 1 ml of this solution was added to each slide and
incubated for 5 minutes. Slides were then stained with haematoxylin, counterstained
with lithium carbonate and dehydrated in alcohol, cleared in xylene and mounted in
pertex.
2.2.3.4 Immunohistological scoring methods
Different scoring methods were used depending on the section type being scored.
For instance, tissue arrays comprising ofmultiple, small tissue cores on a single slide
were scored as negative, weak, moderate or strong for eEFlA2 expression. This
included the breast tumour sections and normal breast sections tissue array (CB2,
SuperBioChips, AMS Biotechnology) and the commercial ovarian cancer tissue
array (CJ1 produced by SuperBioChips AMS Biotechnology) and in-house ovarian
TMA when scored manually. Large single tumour sections were histoscored using a
score of 1-3 for staining intensity multiplied by the percentage of tumour tissue
staining, giving a maximum score of 300. Blind scoring was carried out by two
independent researchers and all ovarian cancer sections were scored by a pathologist.
All breast tumour sections were observed by a pathologist for analysis of tissue
types.
Automated scoring of the in-house ovarian TMA was carried out by Alistair
Williams using a modification of the method ofTolivia et al. (Tolivia et ah, 2006).
Briefly, each core is photographed at 200x magnification, occupying the entire field
of view. All cores are photographed without altering the camera or microscope
settings. The area of the image occupied by viable carcinoma cells is recorded. The
colour range is set by using an unequivocal positive core. The intensity of staining is
then measured for each core using Photoshop (Adobe) and the volume adjusted score
calculated.
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2.2.4 Statistical methods
A two sample t-test (equal variance, unpaired, two-tailed) was used to test for a
difference in the average eEFlA2 expression histoscore between the oestrogen
receptor negative and oestrogen receptor positive tumours. For breast tumour
Quantitative Real-time RT-PCR data, a two-sample t-test allowing for difference in
variance between the two samples was used to test the difference between the mean
standardised quantity ofRNA for the ER-positive and ER-negative groups. Fisher's
exact test was used to test for an association between oestrogen receptor positive and
p53 wild-type tumours. A one-way, repeated measures ANOVA for 3 correlated
samples was used to test for a difference in the percentage of cells in S-phase
following RNA interference treatments. P values that were less than or equal to 0.05
were considered significant. To test the inter-rater reliability in histoscoring of the
breast TMAs an intra-class correlation coefficient (ICC) was performed. This allows
the evaluation of the agreement ofmeasurements made by multiple raters, where the
measurements are parametric or interval. Model 2 and individual measurements
were selected in the analysis. The coefficient gives a measurement of concordance,
where 1 is perfect agreement and 0 is no agreement.
2.2.5 RT-PCR
2.2.5.1 RNA extraction from breast tumour biopsies
Biopsies from normal breast tissue and breast tumour samples obtained from patients
undergoing treatment at Royal Infirmary of Edinburgh and Western General
Hospital, Edinburgh were snap frozen and stored in liquid nitrogen until RNA
extraction.
2.2.5.2 RNA extraction from cell lines
MCF-7 cells transfected with shRNA vectors T1B1 and NEGT1B1 were trypsinised
and pelleted at 24 and 48 hours post transfection. The cell pellets were stored at
-70°C until use. RNA was extracted from cells using the RNeasyMini Kit (Qiagen)
according to manufacturer's instructions. The RNeasy system involves the use of a
silica-based membrane column. The cells or tissue from which the RNA is to be
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extracted is lysed and homogenised in a denaturing guanidine-containing buffer,
which inactivates any RNase present in order to ensure high yield ofRNA. Ethanol
is then added to the lysed RNA sample in order to allow binding to the column.
Only RNA of over 200 nucleotides binds to the silica-based column therefore
enriching for mRNA and excluding rRNA. Contaminants are washed away using
wash buffers and finally the RNA is eluted from the column.
2.2.5.3 DNase I treatment of RNA
RNA was treated with DNase I to ensure the removal of any contaminating DNA
using DNA-free Kit (Ambion) according to manufacturer's instructions.
2.2.5.4 First strand cDNA synthesis
cDNA was prepared from RNA using the Retroscript Kit (Ambion) following
manufacturer's instructions.
2.2.6 Taqman quantitative real-time RT-PCR
2.2.6.1 Taqman assay of eEF1A2 expression in breast and ovarian cancers
TaqMan Assay-on-Demand gene expression pre-designed and optimised primer and
probe sets from Applied Biosystems, were used for EEF1A2 (Assay # Els 00157325
ml) and glyceraldehyde-3-phosphate dehydrogenase quantification (GAPDH;
control; Hs 99999905 ml). The sequences of these primers are not supplied by the
manufacturer. In a lOpl reaction volume per well of a 394-well plate, 0.5pl of
primers, 5pl of TaqMan PCR Master Mix, no AmpErase UNG lOx (Applied
Biosystems), and 4.5pi of diluted cDNA were added. Each sample was run in
triplicate. Real-time RT-PCR and the quantification ofRT-PCR products were
performed and the products analyzed using an ABI Prism 7900HT Sequence
Detection System, and the appropriate software (SDS3.1) (Applied Biosystems).
Minus cDNA and RNA only controls were included to check for contamination of
RNA or PCR reagents.
Chapter 2 Materials and Methods 49
2.2.6.2 Measurement of PCR efficiency
The PCR efficiency was measured by constructing a serial dilution of cDNA and
measuring the cycle threshold of the product produced at each dilution of cDNA. If
the PCR efficiency is close to 100%, then the amount of product at each dilution will
be proportional to the dilution, i.e. there will be one-tenth of the product in a 1:100
dilution of cDNA compared to the 1:10 dilution. The cycle threshold is plotted
against the log of the quantity of cDNA and should be a straight line. The slope of
the line is equal to 3.3, giving 100% PCR efficiency. A deviation of the slope to
more than 3.3 represents a PCR efficiency of less than 100% and a slope of less than
3.3 represents a PCR efficiency ofmore than 100%. A PCR efficiency ofmore than
100% simply implies that there is contamination in the PCR resulting in the amount
ofDNA produced being more than expected from the relative cDNA amount.
2.2.6.3 Real-time RT-PCR standard curve method of analysis
The standard curve method of analysis - with housekeeper and gene of interest
amplification in separate tubes - was used for analysis of eEFl A2 mRNA levels in
breast and ovarian samples. For analysis of the expression of eEFlA2 in breast
cancer and normal breast RNA, a standard curve was created by conducting 4 serial
dilutions of the sample F14 from 1:10, 1:50, 1:100, to 1:1000. Primers amplifying
both eEFlA2 and GAPDH were used for amplification at each dilution. Results of
the analyses were only used if the standard curves had a correlation coefficient of
0.99 or more and a slope of -3.3 (i.e. a PCR efficiency of 100%). The breast tumour
RNA samples were run on the same plate at a dilution of 1:10. The average quantity
mean of eEFlA2 was then normalised against the average quantity mean for
GAPDH for each tumour sample and this value was standardised against the average
quantity mean of the two normal breast RNA samples (=1). The standard deviation
(S) was calculated using the following equation: S = (cv) (X) where X is the mean
normalised quantity and cv = V(cvl + cv2), where cvl is the standard deviation of
the measurement of eEFlA2 in each triplicate and cv2 is the standard deviation of
the measurement ofGAPDH in the triplicates. For the analysis of ovarian tumour
and cell line eEFl A2 expression, RNA from the ovarian cancer cell line OVCAR3
was used for standard curve construction in the same manner as for the breast cancer
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samples. Analysis was also carried out in the same way, however the samples were
expressed as normalised and not standardised data as normal ovarian surface
epithelium RNA was not available.
2.2.7 SYBR Green method of quantitative real-time PCR
2.2.7.1 EEF1A2 DNA copy number analysis
2.2.7.1.1 DNA preparation from ovarian cancer tissues and normal human
blood
Control normal human DNA was extracted from human blood obtained from the
National Blood Transfusion service. DNA was extracted from primary ovarian
tumours and normal whole ovary by Diane Scott, Cancer Research Centre,
University ofEdinburgh.
2.2.7.1.2 Primers used for EEF1A2 and reference gene amplification
Two sets of primers were designed in the introns ofEEF1A2, called EEF1A2FR2-3
and EEF1A2FR3-4, to give a product of approximately 1 OObp. For normalisation of
the total amount ofDNA present 3 sets ofmicrosatellite primers were used. These
were D5S643, D10S586, D11S1315, and have been used for copy number analysis
by (Ginzinger et al., 2000). These primers were selected by Ginzinger et al. because
they amplify regions of chromosomes that have not been shown not to harbour copy
number alterations frequently in ovarian cancers. The regions of the chromosomes
amplified by the control primers were confirmed to be stable in ovarian cancer by
completing a literature search of studies into chromosome copy number in ovarian
cancer. As a control for chromosome 20 copy number microsatellite primers on 20p
was used, a pericentromeric marker region was not used as it would be difficult to
get specific PCR product from this GC-rich repetitive region. The primer
information is given in the table 2.2.
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D5S643 fwd TGGGCGACAGAGCCATC 134-
D5S643 rev TGTGGTGTGCCATTTATTGACT 138bp
D10S586
D10S586 fwd TATTATACTCCAGCCGGGG 124-
D10S586 rev GGAGACTATTTACTTTGTGTCCTTG 132bp
D11S1315
DllS1315fwd AAAGGCACAAAAACTAAAACTCTGG 158-
D11S1315 rev CCGTCAGTGTGATAAAAGCCAG 162bp
2.2.7.1.3 Primer concentration optimisation for optimisation of PCR efficiency
Standard curves were created using lOOng of normal genomic blood DNA serially
diluted 1:2, 1:4 1:18, 1:16 and 1:32. Primers that amplify EEF1A2 and the three
microsatellite markers were used at 50nM, 200nM and 900nM. The concentration of
primers giving the optimal PCR efficiency (between 90-110%) was used in the
quantitative real-time PCR. The optimised standard curves were repeated three times
and the average PCR efficiency for each primer set was used in subsequent analysis.
2.2.7.1.3 Quantitative real-time PCR determination of EEF1A2 copy number
12.5ul of iQ SYBR Green Supermix (2x) (BioRad), 200nM of forward and reverse
primers and lOOng of genomic DNA was used in a 25ptl reaction. Each reaction was
run in duplicate. For real-time detection a MyiQ Single-Color Real-Time PCR
machine was used (BioRad). A melt curve was carried out to confirm specificity of
the PCR primers; a sharp peak in fluorescence indicates a single-sized specific
product.
The PCR cycling programme used is shown below, collection refers to the cycle and
step at which fluorescent signal was detected by the camera and recorded.
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PCR cycling programme:
Cycle 1 (lx) Step 1 95°C 8.5 minutes
Cycle 2 (40x) Step 1 95 °C 30 seconds
Step 2 62 °C 30 seconds
Step 3 72 °C 30 seconds collection
Cycle 3 (lx) Step 1 95 °C 1 minute
Cycle 4 (lx) Step 1 60 °C 1 minute
Cycle 5 (80x) Step 1 60 °C 10 seconds collection
Increase setpoint temperature in cycle 5 step 1 by 0.5°C for melt curve.
2.2.7.1.4 Analysis of EEF1A2 copy number
In order to analyse the copy number ofEEF1A2 the Plaffl method (Pfaffl, 2001) was
used and the mathematical model is represented below:
ratio = (E, et JACt target (control-treated)
| ^ JACt ref (control-treated)
The copy number ofEEF1A2 was determined for 5 different normal genomic DNA
samples and averaged. The amount ofEEF1A2 amplified was normalised by each of
the amplification at each of the microsatellite loci and the geometric mean of these
ratios was taken for each cancer. The final geometric means for each sample were
doubled to give a diploid DNA content.
2.2.7.2 Real-time PCR analysis of chromosome 20p copy number analysis
2.2.7.2.1 Primers and optimisation of PCR efficiency
In order to determine the copy number at chromosome 20p two microsatellite
primers D20S804 and D20S819 that amplify loci at 20pl 1.23 and 20pl2.3 were
used, the primer information is given in table 2.3. The primer concentration at which
the PCR efficiency was between 90% and 110% was determined by the method
outlined in Materials and Methods section 2.2.7.1.3.
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2.2.7.2.2 Real-time PCR protocol
12.5/rl of iQ SYBR Green Surpermix (2x) (BioRad), 500nM of forward and reverse
primers and 200ng DNA was used in a 25/xl reaction and each DNA sample was run
in duplicate. The MyiQ Single-Color Real-Time PCR machine was used (BioRad)
for PCR detection. Melt curves were run to ensure specificity ofPCR product.
Normal genomic DNA was again DNA extracted from blood obtained from the
National Blood Transfusion Service.
2.2.7.2.3 Analysis of 20p copy number by standard curve method
The amount of D20S804 or D20S819 PCR product was normalised to amount of
product from the control microsatellite D5S643 amplification (known to be diploid
from previous analysis in all ovarian cancer DNA investigated). For this analysis the
standard curve method was used. A standard curve of normal gDNA was
constructed by serial dilutions of 1:10, 1:100, 1:1000, 1:10000 and 1:100000. For
each primer pair a standard curve was run and analysis was carried out as detailed in
Materials and Methods section 2.2.7.1.3. Minus DNA controls were included to
check for PCR reagent contamination and again a melt curve analysis was included
to check for PCR reagent contamination.
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2.2.8 Alterations of oestrogen receptor alpha activity and measurement
of eEF1 A2 levels
2.2.8.1 Oestrogen receptor alpha RNA interference protocol - Catherine
Naughton
RNA interference, estradiol treatment and assessment of oestrogen receptor levels in
MCF-7 cells was carried out by Catherine Naughton, Cancer Research Centre,
University of Edinburgh.
2.2.8.2 Real-time PCR measurement of eEF1A2 expression
2.2.8.2.1 Primer design and optimisation
Primers used to quantify eEFlA2 expression levels were designed using San Diego
Supercomputer Center Biology Workbench 3.2, Primer 3 program and called
EEF1A2 left and EEF1A2 right. These were designed to be less than 150bp apart
(spanning an intron) in order to reduce the likelihood of the product forming
secondary structure that would inflate the SYBR green fluorescent signal. The
reference genes used were pumilio homolog 1 (Drosophila) (PUM1) taken from
(Szabo et ah, 2004) and identified as a suitable housekeeping gene in breast cancers
and TATA box binding protein (TBP) taken from (Dallol et ah, 2002). Both of these
primers also amplify small regions of the cDNA. Details of the primers are shown in
table 2.4. Personal communication with Alexey Larionov suggested that expression
of these reference genes were unlikely to be altered by oestrogen treatment ofMCF-7
cells. Optimisation was carried out as previously detailed.




Primer sequence (5'-3') Size of
amplified
product




PUM1 PUM1 fwd TGAGGTGTGCACCATGAAC 187bp
PUM1 rev CAGAATGTGCTTGCCATAGG
TBP TBP fwd TGCACAGGAGCCAAGAGTGAA 132bp
TBP rev CACATCACAGCTCCCCACCA
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2.2.8.2.2 Real-time PCR protocol
A standard curve ofMCF-7 cells treated with estradiol only was constructed by serial
dilutions ofcDNA 1:10, 1:100, 1:1000, 1:10000 and 1:100000. All three sets of
primers were used at 200nM. 12.5/u.l of SYBR Green iQ Supermix 2x (BioRad),
200nM of forward and reverse primers and 2/xl of cDNA was used in a 25/i\ reaction.
Each reaction was carried out in duplicate. The PCR cycling programme is shown
below, collection refers to cycles at which the camera is detecting the fluorescent
signal. PCR was carried out using the MyiQ Single-Color Real-Time PCR machine
(Biorad). Minus cDNA and RNA only controls were included and melt curve
analysis confirmed product specificity.
PCR cycling programme:
Cycle 1 (lx) Step 1 95°C 3 minutes
Cycle 2 (40x) Step 1 95 °C 20 seconds
Step 2 60 °C 20 seconds
Step 3 72 °C 30 seconds collection
Cycle 3 (lx) Step 1 95 °C 1 minute
Cycle 4 (lx) Step 1 60 °C 1 minute
Cycle 5 (80x) Step 1 60 °C 10 seconds collection
Increase setpoint temperature in cycle 5 step 1 by 0.5 °C for melt curve.
2.2.8.2.3 Analysis of eEF1A2 expression levels
Data analysis was carried out using the excel macro supplied with the MyiQ Single-
Color Real-Time PCR machine (BioRad) based on the method of (Vandesompele et
ah, 2002).
2.2.9 Determination of OAS1 levels in MCF-7 cells transfected with
shRNA vectors using real-time RT-PCR.
2.2.9.1 Primer design
Primers for amplification ofOAS1 cDNA were taken from (Bridge et ah, 2003) and
are shown in table 2.5. GAPDH cDNA levels were used for normalisation and the
primer sequences for GAPDH amplification are also listed in table 2.5.
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Table 2.5 Sequences ofprimers used in real-time RT-PCR to amplify 0AS1 and
GAPDH
Gene Primer name Primer sequence (5'-3')
OAS1 OAS1 fwd AGGTGGTAAAGGGTGGCTCC
OAS1 rev ACAACCAGGTCAGCGTCAGAT
GAPDH GAPDH left CATCAATGGAAATCCCATCAC
GAPDH right GGTTTTTCTAGACGGCAGGTC
2.2.9.2 Real-time PCR
For analysis ofOAS1 expression levels the SYBR green method of real-time PCR
was used as described in Materials and Methods section 2.6.2.2. The annealing
temperature was 58°C. Analysis was also carried out as described in Materials and
Methods section 2.2.7.2.3.
2.2.10 Western blots
2.2.10.1 Preparation of protein lysates
Protein lysates from RNAi treated cells were prepared from cell pellets frozen at -
20°C. Cell pellets were thawed and resuspended in 50-100/xl ofRIPA buffer and
Complete Protease Inhibitor Cocktail (Roche) was added to protect against protein
degradation. Cell lysates were then sonicated to break up DNA. Protein lysates
from MCF-7 cells treated with siRNA to ERa were obtained at a concentration of
2pg/p\ from Catherine Naughton. Protein lysates from cell lines were prepared using
previously published protocols (Gilmour et al., 2002); the same method was used for
primary tumour samples, but in these cases tissue was initially homogenised in
extraction buffer prior to determination of protein content.
2.2.10.2 Protein Quantification
Protein quantification was carried out using the BioRad DC Protein Assay Kit
following manufacturer's instructions.
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2.2.10.3 Preparation of SDS-PAGE gel and protein loading
The BioRad Mini PROTEAN 3 mini-gel apparatus was used according to
manufacturer's instructions. A 12% acrylamide separating SDS-PAGE gel was
poured as follows:
30% acrylamide 5.2ml





The separating gel was overlaid with isopropanol to disperse bubbles. The gel was
allowed to set for 45 minutes. The isopropanol was removed and the stacking gel
prepared as follows:
30% acrylamide 1.45ml





The stacking gel was poured on top of the separating gel and combs inserted into the
liquid. This gel was allowed to set for 10 minutes.
The plates were then placed in the gel tank apparatus. The chamber and tank were
filled with IX Laemmeli running buffer. The combs were then removed from the gel
and the wells washed out using a pipette. lOjUg of protein was mixed with 2X
Laemmeli loading buffer and 1/rl of 1M DTT/lOpil sample. The protein was then
boiled for 5 minutes and briefly centrifuged. The protein samples were then loaded
into the wells of the SDS-PAGE gel together with a pre-stained SDS-PAGE standard
Broad Range (BioRad) marker ofprotein size. The protein was run at 100V through
the stacking gel and then at 150V through the separating gel.
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2.2.10.4 Western blotting
The BioRad Mini Trans-Blot Electrophoretic Transfer cell was used for Western
blotting. Hybond-P membrane (Amersham Pharmacia Biotech) was first soaked in
methanol. Filter paper, sponges and SDS-PAGE gel as well as the Hybond-P
membrane were then soaked in a transfer buffer containing the following:
IX Laemmli running buffer 200mls
100% Methanol 200mls
dH20 600mls
The sponge, filter paper and membrane were then stacked and assembled into the
apparatus. The apparatus was filled with the transfer buffer and run at 350mA for
one hour at 4°C. After one hour the blots were removed and the non-specific sites on
the membrane were blocked in 5% powdered milk in PBS-T overnight at 4 °C.
2.2.10.5 Antibody probing of Western blot membrane
The blots were incubated for two hours at room temperature with primary anti-
eEFlA2 rabbit antibody and primary anti-eEFlA1 sheep antibody diluted 1:200 in
blocking solution, as well as primary anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) polyclonal mouse antibody (Chemicon International)
diluted 1:10000. Primary rabbit anti-Hsp70 (Hsp72) (Stressgen) was used at a
concentration of 1:30000. Blots were then incubated in the appropriate Horse Radish
Peroxidase conjugated secondary antibody (Dako Cytomation) at 1:500. Detection
was performed using enhanced chemiluminescence detection kit (Amersham
Biosciences).
2.2.11 RNA interference
2.2.11.1 Dharmacon pooled oligos
A set of four siGENOME SMARTPOOL human oligos targeted to EEF1A2 (M-
003882-00-0010) and a negative control-pool of non-targeting siRNAs (D-001206-
13-05) were purchased from Dharmacon.
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2.2.11.2 Transfection of cells with siRNA using Oligofectamine (Invitrogen)
24 hours before transfection, 4xl04 Hela or MCF-7 cells were plated in a 24 well
plate in 500/d ofmedium. In a transfection tube, 2.5/xl of a 20/xM stock of
oligonucleotide was diluted in 40/xl ofOptimem (Invitrogen). In a separate tube 2/d
ofOligofectamine (Invitrogen) was diluted in 7.5/d of Optimem. These solutions
were mixed gently by pipetting. After five minutes the diluted oligonucleotide was
combined with the diluted Oligofectamine and mixed by tapping and allowed to
stand for 20mins. During this time the medium was removed from the plated cells,
the cells washed with PBS, and replaced with 200/xl ofOptimem. After the 20
minute incubation, 52/d of the complex was added to the appropriate well. After 4
hours the medium in each well was supplemented with 125/xl of growth medium
containing 30% fetal calf serum. Untransfected and mock transfected controls were
included. At 24, 48 and 72 hours post-transfection the cells were trypsinised,
pelleted and stored at -20°C or -70°C.
2.2.11.3 shRNA design
The BLOCK-iT U6 RNAi Entry Vector Kit was purchased from Invitrogen. shRNA
oligos were designed following manufacturer's instructions, see table 2.6
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Table 2.6 Details ofthe shRNA constructs targeted to eEF!A2
Name Region targeted to Length Loop sequence






























2.2.11.4 shRNA treatment of cells
MCF-7 and HeLa cells were transfected with the shRNA detailed in Materials and
Methods section 2.2.11.3 by two different protocols: lipofectamine and
nucleofection. Transfected cells were pelleted at the appropriate time point and
frozen at -20°C or -70 °C until Western blot or RT-PCR analysis.
2.2.11.5 RNA interference using Ambion pre-designed siRNAs
The siRNAs used for the ablation of eEFlA1 or eEFlA2 expression are detailed in
table 2.7: the Ambion catalogue number of these siRNAs is 16704. The non-
targeting siRNA was also supplied by Ambion, catalogue number 4611.
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Table 2.7 Sequences ofthe Ambion pre-designed siRNAs to eEFlAl and eEFlA2
Gene siRNA name siRNA ID # Sequence (sense) Effective
EEFlAl 1A1-1 2991 GGAUGUCUACAAAAUUGGUTT Yes
EEFlAl 1A1-2 2898 GGGAUGGAAAGUCACCCGUTT Yes
EEFlAl 1A1-3 289305 CAUCUAAUUCUGGUUUUACTT No
EEF1A2 1A2-1 10976 GGUCCAGUGGAAGUUCUUCTT Yes
EEF1A2 1A2-2 10884 GGACCAUUGAGAAGUUCGATT Yes
EEF1A2 1A2-3 10789 GGUAUUGACAAAGGACCATT No
Each of the siRNAs was resuspended to a concentration of 50/xM and aliquoted for
storage at -70°C.
2.2.12 Transfection protocol
2.2.12.1 Transfection of DNA using Lipofectamine 2000
HeLa cells were plated at a density of4xl04 per well of a 24 well plate 24 hours
before transfection. Lipofectamine 2000 (Invitrogen) was used following
manufacturer's protocol.
2.2.12.1.1 Transfection of siRNA using Lipofectamine 2000
HeLa cells were plated at a density of4xl04 in 500ml ofmedium in a 24 well plate.
After 24 hours the cells in each well were transfected with 20nM of siRNA with 1pi
of Lipofectamine 2000 following manufacturer's protocol (Invitrogen).
2.2.12.2 Transfection using a Nucleofector
A Nucleofector (Amaxa Biosystems) was used for transfections into MCL-7 cells
and PEOl cells. MCL-7 and PEOl cells were plated 3 days prior to transfection in
large T175 flasks. When they reached 70-80% confluency the cells were trypsinised
and counted using a Coulter counter (Beckman Coulter). 1x10s cells were then
centrifuged at lOOOxg for 5 minutes and the pellet resuspended in 100/d of the
appropriate nucleofector solution (Amaxa Biosystems). MCL-7 cells were
resuspended in solution V and PEOl cells were resuspended in solution L. 3/rg of
DNA vector was added to each and the solution transferred to a cuvette. Cells were
then electroporated in the nucleofector using the appropriate programme. For MCF-
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7 programme P-20 was used, for PEOl cells programme U-20 was used. The
cuvette was removed from the machine immediately following electroporation and
500pil ofwarmed medium was added to the cells. The cells were then transferred
into a well of a six well plate containing 1ml ofmedium using the pipettes provided.
Controls include cells with DNA and nucleofector solution but no electroporation
and cells plus solution and electroporation but lacking DNA.
2.2.13 Immunocytochemistry
Transfected cells were washed in warmed IX PBS, and fixed in 2-4%
paraformaldehyde for 10 minutes. Cells were then washed once in PBS containing
0.2% Triton X-100 and once in PBS. Cells were then blocked in PBS containing 5%
Bovine Serum Albumin and 0.2% Tween for 30 minutes at room temperature,
shaking gently. Cells were then washed once (except secondary only controls) in
PBS-T (0.2% Tween-20) and incubated in primary antibodies diluted in PBS-T for
one hour at room temperature, shaking gently. Goat anti-V5 (Abeam) was used at a
concentration of 1:1000, mouse anti-a-tubulin (Sigma) was used at a concentration of
1:4000 and Alexa Fluor 594 phalloidin (Invitrogen) at 1:400. Cells were then
washed twice in PBS-T and incubated in secondary Alexa Fluor conjugated
antibodies (Molecular Probes, Invitrogen) for 30 minutes at room temperature.
Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor 594 goat anti-mouse IgG and
Alexa Fluor 594 donkey anti-sheep IgG were used at a concentration of 1:1000
diluted in PBS-T. Cells were finally washed in PBS-T and mounted on a glass slide
in Mowiol (Sigma) containing DAPI and viewed under a fluorescent microscope.
2.2.14 Microscopy
Immunofluorescently stained cells were viewed on an Axioskop 2 fluorescent
microscope (Zeiss) and using Smart Capture software. Sections stained by
immunohistochemistry were viewed by light microscopy on an Olympus BX51 using
DP software (Olympus).
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2.2.15 Mutation screening of EEF1A2
2.2.15.1 EEF1A2 exon PCR primer sequences
PCR amplification of each exon ofEEF1A2 was carried out prior to sequencing. In
some case two separate primer pairs were used to amplify one exon. The primer
sequences are shown in table 2.8, those marked with a * were designed by Helen
Newbery.
Table 2.8 Sequences ofprimers used to amplify EEF1A2 exons
Exon of
EEF1A2
Primer name Primer sequence (5'-3')
1 Exon 1 fwd ATTAGGGAGAGCCCCTCAGA

















8 Exon 8 fwd TAAGCGTGTTCCGAGGACAT
Exon 8 rev TCTCTGCCCTGAGTAGCCAT
2.2.15.2 PCR conditions for amplification of EEF1A2 exons
The conditions used for each primer set to amplify the EEF1A2 exons are outlined in
table 2.9. In the majority of cases the Taq polymerase used was purchased from
Invitrogen however PCR of exons 1 and 8 required the used ofDyNazyme EXT
DNA polymerase (Finnzymes, NEB), a DNA polymerase specifically designed for
use in the amplification of long, difficult to PCR, sequences. Due to the GC rich
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sequence around exons 1 and 8 ofEEF1A2 it was necessary to design primers that
amplified a large fragment that encompassed the exonic sequence.



























































For PCR using Invitrogen Taq DNA polymerase the following were added to a
sterile eppendorf tubes/plates on ice. Appropriate master mixes were used.
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10X Invitrogen PCR buffer 2.5 fil
dNTPs lOmM 1.0/xl
Forward primer 100ng//xl 1.0/xl
Reverse primer 100ng//zl 1.0/xl
DNA 50ng//xl 4.0/xl
DMSO 2.5/xl
Taq DNA polymerase 5U//xl 0.25/xl
Betaine 5.5M 7.03/xl
ddH20 Up to 25/xl
The PCRs were then placed in a PTC-225 thermal cycler (MJ Research) and the
following programme run:
Step 1: 94°C 5 mins
Step 2: 94 °C 30secs
Step 3: Annealing temp 30secs
Step 4: 72 °C 30secs
Repeat steps 2-4 32 more times
Step 5: 72 °C lOmins
The following was added to a sterile PCR tube/plate for PCR amplification of exons
1 and 8 using DyNazyme EXT.
10X DyNazyme EXT reaction buffer 2.5/xl
dNTPs lOmM 1.0/xl
Forward primer 100ng//xl 1.0/xl
Reverse primer 100ng//d 1.0/xl
DNA 50ng//xl 4.0/xl
DyNazyme EXT DNA polymerase lU//xl 1.0/xl
DMSO 2.5/xl
ddH20 Total to 25/xl
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The following PCR cycling programme was used:
Step 1: 94°C
Step 2: 94 °C
Step 3: 60 °C





Repeat steps 2-4 37 more times
Step 5: 72 °C 1Omins
Following amplification 5/xl of each PCR product was run on a 1% agarose gel to
check the size.
2.2.15.3 Agarose gel electrophoresis
PCR products were assessed by agarose gel electrophoresis. 1% to 2% (w/v) agarose
solution in 0.5X TBE was heated until dissolved in a microwave. Melted agarose
was allowed to cool slightly and 0.003% ethidium bromide was added to the
solution. The agarose solution was then poured into a casting tray and combs placed
in the liquid. The agarose was then allowed to set and the combs removed. The tray
was then placed in an electrophoresis tank and covered in 0.5x TBE. Ready Load
1 kb DNA ladder (Invitrogen) was used as a molecular weight marker. PCR products
were mixed with 2x loading buffer and added to the wells of the agarose gel
alongside the molecular weight marker. The gel was then run at 100V for one hour
and viewed under UV light.
2.2.15.4 Sequencing EEF1A2 PCR products
2.2.15.4.1 Clean up of PCR product
ExoSAP-IT (USB, GE Healthcare Biosciences) was used to clean up the PCR
product for sequencing. 2/d ofExoSAP-IT was used per 5/zl PCR product and the
reaction was incubated at 37°C for 15 minutes and 80°C for 15 minutes.
2.2.15.4.2 Sequencing primer design
Sequencing was either carried out either using the PCR primers used to amplify the
exon or using internal primers as indicated in table 2.10. The prefix INT in the
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primer name refers to a sequencing primer designed 3' to the PCR primer and the
sequence of these is also indicated in table 2.10.
Table 2.10 Sequences ofprimers used to sequence EEF1A2








2 2FC 2RC Int2FC
2RC
CACAGAATCACTGCAG

































Sequencing was carried out using BigDye v3.1 (Applied Biosystems). 6.5/xl of PCR
product was added to 1/d of BigDye v3.1, 1.5/rl of 5x BigDye Buffer (Applied
Biosystems), 1/rl of sequencing primer and the reaction was made up to 10/xl with
distilled water in a sterile 96 well plate. The following programme on an MJ
Research machines PCR block was carried out:
lx: 96°C 1 min
24x: 96°C 30 sec
50°C 15 sec
64°C 4 min
lx 4 °C HOLD
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The sequencing product was then precipitated using ethanol. 2.5/xl of 125mM EDTA
was added to 10/xl sequencing reaction. Following this, 30/xl of 100% ethanol was
added to each well and the contents mixed by inversion 4 times. The plate was then
spun in a sigma centrifuge at 1238xg for 30 minutes. After centrifugation the plate
was inverted over tissue paper to remove the ethanol from the wells. To remove any
remaining ethanol the plate was spun up-side-down on tissue paper to 700xg. 30/xl
of 70% ethanol was then added to each well and the plate centrifuged at 1238xg for
15 minutes. The above process of removing the ethanol was repeated and when the
wells were entirely dry the plate was submitted for sequencing. Sequencing was
carried out at the Wellcome Trust Clinical Research Facility, Western General
Hospital and analysed using Chromas version 1.45, Griffith University, Australia.
2.2.16 Bisulphite sequencing
2.2.16.1 Bisulphite conversion of DNA
The first step in bisulphite sequencing is the bisulphite conversion ofDNA. This
involves the conversion of unmethylated cytosines to uracil so they can be
distinguished from methylated cytosines of CpG dinucleotides by sequencing. This
was achieved using the EZ DNA Methylation Kit (Zymo Research). 1 /xg ofDNA
from ovarian tumours HOV 104, 179, 548 and 557 as well as normal whole ovary
DNA 440 and 470 was converted following the manufacturer's protocol.
2.2.16.2 PCR of the 5'CpG island of EEF1A2
The 5'CpG island ofEEF1A2 was amplified from the converted DNA extracted from
normal and cancerous ovarian tissues by PCR. The primers hF6 and hR4 amplify a
548bp fragment including the 5' 50% of the EEF1A2 CpG island.
Table 2.11 Sequences ofprimers used to amplify the 5'CpG island ofEEF1A2
Primer name Primer Sequence (5'-3')
hF6 AGGGATTGGAAATTAGTAGATTT
hR4 AAAAAAAATCCACCTATTAA
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For PCR the Roche Fast Start Taq DNA polymerase was used as detailed in the table
below:
1 OX FS Bfr/MgCh reaction buffer 2.5/xl
dNTPs 2.5mM 8.0/xl
Forward primer 5/xM 3.0/ul
Reverse primer 5/xM 3.0/xl
DNA 3.0/xl
FS Taq DNA polymerase lU//d 0.2/xl
ddH20 Total to 25/xl
PCR cycling programme:
Step 1 95°C 5 minutes
Step 2 95 °C 30 seconds
Step 3 52 °C 30 seconds
Step 4 72 °C 1 minute 30 seconds
Repeat steps 2-4, 44 times
Step 5 72 °C 10 minutes
Step 6 10°C HOLD
10/xl of PCR product was run on a 1% agarose gel to check the product size.
2.2.16.3 TA cloning of bisulphite converted EEF1A2 PCR products
The EEF1A2 PCR products were then ligated into the pCR2.1 vector using the TA
Cloning Kit (Invitrogen) following manufacturer's protocol. 2/xl ofPCR product
was ligated into the vector and transformed into Chemically Competent TOP 10
E.coli (Invitrogen). The transformed cells were then plated on LB-agar containing
100/xg/ml Kanamycin and 20/xg/ml of X-gal (Invitrogen) for blue/white selection and
incubated at 37°C overnight. White colonies were picked using a sterile cocktail
stick and swirled in sterile water in a 0.5ml Eppendorf tube and streaked onto a
reference plate that was then placed at 37 °C. The sterile water containing bacterial
cells from positive colonies was heated to 95 °C for 10 minutes to break up the
bacteria and release the DNA. Following heating the tubes were centrifuged at
3000rpm for 10 minutes. Colony PCR to identify EEF1A2 inserts was carried out
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and positive colonies were cultured and the pCR2.1 vector containing EEF1A2 PCR
product was extracted using a DNA Miniprep Kit (Qiagen).
2.2.16.4 Colony PCR
PCR was carried out on DNA isolated from bacterial colonies using the following
reagents.
1 OX Invitrogen PCR buffer 2.5/xl
dNTPs lOmM l.O/il
Ml3 forward 5/jlM 2.5/xl
Ml3 reverse 5/xM 2.5/xl
Bacterial DNA 2.0/xl
Taq DNA polymerase 5U//U.1 0.125/xl
ddH20 Up to 25/xl
PCR cycling programme:
Stepl 95°C 2 minutes
Step 2 95 °C 30 seconds
Step 3 50 °C 30 seconds
Step 4 72 °C 2 minutes
Repeat steps 1 to 4, 35 times
Step 5 72 °C 7 minutes
Step 6 10°C HOLD
lO/xl ofPCR product was then run on a 1% agarose gel to check the fragment is the
expected 748bp in length.
2.2.16.5 Sequencing of bisulphite converted EEF1A2 5'CpG clones
Sequencing was carried out as described in Materials and Methods section 2.2.12.5
using the Ml3 forward and reverse primers and 2/A of plasmid DNA obtained from
DNA Miniprep isolation. Analysis of bisulphite sequence results was carried out
using BiQ Analyzer software (Bock et al., 2005).
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2.2.17 Cloning
In order to create N-terminal Green Fluorescent Protein (GFP) tagged eEFl A1 and
eEFl A2 constructs I used the Gateway cloning system (Invitrogen) to clone the full
length cDNA sequences into the destination vector pcDNA-DEST53.
2.2.17.1 Gateway attB flanked PCR primer design
Primers were designed according to manufacturer's instructions to amplify human
eEFl A1 cDNA sequence and also incorporate the attB sites required for site-specific
recombination into vectors. The sequence of the primers can be found in the table
below. Human eEFlA2 cDNA sequence in the Gateway entry vector pENTR221
(Ultimate ORF clones) was purchased from Invitrogen and could therefore be cloned
directly without the PCR step.










2.2.17.2 PCR with attB site containing primers
The full length human eEFl A1 IMAGE clone, accession number BC028674, image
ID 4107346 was used to PCR the eEFlAl insert from. DyNazyme EXT DNA
polymerase (Finnzymes, NEB) was used in the following PCR:
10X DyNazyme EXT reaction buffer 5.0pi
dNTPs lOmM 1.0/il
Forward primer 100ng//xl 2.0/xl
Reverse primer 100ng/jUl 2.0p\
Miniprep IMAGE clone 50ng//d 5.0/xl
DyNazyme EXT DNA polymerase lU/jul 1.0/il
ddH20 Total to 50/xl
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PCR programme:
Step 1 94°C
Step 2 94 °C
Step 3 60 °C





Repeat steps 2-4 29 times
Step 5 72 °C 5 minutes
5/xl ofPCR product was run on an agarose gel to check the size, which should be
approximately 1,4kb.
2.2.17.2 BP recombination reaction
In order to clone the EEF1A1 cDNA sequence into the Gateway entry vector
pDONR221 a BP reaction was carried out between the attR containing PCR product
of EEF1A1 and pDONR221, following manufacturer's protocol. This leads to the
production of the EEF1A1 cDNA sequence cloned into an entry vector.
2.2.17.4 LR recombination reaction
EEF1A1 was then cloned from the entry vector pDONR221 into the destination
vector pcDNA-DEST53 for expression as an N-terminal GFP tagged protein. The
human EEF1A2 cDNA was purchased from Invitrogen in the entry vector
pENTR221 (Ultimate ORF clones) and cloned into the destination vector pcDNA-
DEST53 using the LR recombination reaction. The LR reaction was carried out
following manufacturer's protocol. Destination clones were sequenced to check for
sequence alterations in the eEFlAl and eEFl A2 cDNA sequences.
2.2.17.5 Transformation of competent E.coli cells
One Shot TOP 10 Chemically Competent E.coli (Invitrogen) was transformed with
plasmid DNA following manufacturer's protocol. The pUC19 control DNA plasmid
(Invitrogen) was used as a positive transformation control.
2.2.17.6 Bacterial culture and selection
Transformed TOP 10 Chemically Competent E.coli cells were plated on Luria-
Bertani (LB) agar at 37°C or cultured in liquid LB at 37°C with shaking at 200rpm
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containing the appropriate selective antibiotic. Kanamycin was used at 100/ig/ml,
Ampicillin was used at 50/xg/ml and chloramphenicol (diluted in methanol) was used
at 25/rg/ml and these antibiotics were supplied by Sigma. Zeocin (Invitrogen)
selection was carried out in low salt liquid broth at a concentration of 25/xg/ml.
2.2.17.7 Plasmid preparation
Plasmids preparations from transformed E.coli cells were produced using the Qiagen
Miniprep or Maxiprep kits or the ENDOfree maxiprep kit following the
manufacturer's protocol.
2.2.18 Maintenance of cell lines
2.2.18.1 Subculturing of cells
All reagents for tissue culture were obtained from Invitrogen. HeLa cells were
cultured in DMEM containing 10% fetal calf serum (FCS) and
Penicillin/Streptomycin (Pen/Strep). MCF-7 cells were cultured in MEM containing
Earle's salts, 10% FCS and Pen/Strep. PEOl cells were maintained in RPMI 1640
containing 10% FCS and Pen/Strep. Cells were cultured in T75 flasks in 25mls of
medium at 37 °C and 5% CO2. To passage cells medium was aspirated and 5mls of
trypsin:versene (1:1) was added to the cells. Cells were placed at 37 °C, 5%CC>2 until
trypsinised. 5mls ofmedium was then added to the cells and the cells removed into a
15ml falcon tube. Cells were centrifuged at lOOOrpm for 5 minutes and medium was
aspirated. Cells were then resuspended in lOmls of medium and 1ml was added to a
new T75 flask containing 25ml of fresh medium. Cells were passaged 1:10
approximately twice weekly.
2.2.18.2 Counting cells
Cells were diluted 1:100 in isotone and counted using the Coulter Counter Z series
(Beckman Coulter).
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2.2.18.3 Cryopreservation of cell lines
Cells in a T75 flask were trypsinised and pelleted as described in 2.15.2. Cells were
then resuspended in 6mls ofmedium supplemented with 5% DMSO and placed into
lml screw cap cyropreservation vials. These vials were then wrapped in tissue,
placed in a polystyrene box and put at -70 °C. After 24 hours at -70 °C the vials were
placed in liquid nitrogen.
2.2.19 Assays on cell lines
2.2.19.1 Analysis of the interferon response
MCF-7 cells were plated in a 24 well plate at a density of4xl04 cells per well, 24
hours before transfection. Cells were plated both for analysis of OAS1 expression
and cell viability. T1B1 and NEGT1B1 were transfected into the cells using
Lipofectamine 2000 (Invitrogen). 0.1/rg ofplasmid was transfected with 1.25/xl of
Lipofectamine 2000, 0.2/xg was transfected with 3/xl of Lipofectamine, 0.4/xg was
transfected with 6/xl of Lipofectamine 2000 and 0.8/rg was transfected with 12/il of
lipofectamine in serum free medium according to manufacturer's protocol.
Untransfected and mock transfected (Lipofectamine 2000 only) controls were
included.
2.2.19.2 Cell viability assay
MCF-7 cells transfected with shRNA vectors were trypsinised and pelleted 24, 48
and 72 hours post transfection. Cells from each well were trypsinised, pelleted and
resuspended in 50/xl ofmedium. 10/rl of resuspended cells were mixed with 10/rl of
Trypan Blue stain (Invitrogen). lOjid was pipetted between a coverslip and the slide
of a haemocytometer and examined under a microscope. The number of cells within
the central square was counted and multiplied by x 104/ml to give the concentration
of cells. Those stained blue were unable to exclude the dye and were therefore
classified as dead or unviable.
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2.2.19.3 BrdU assay
2.2.19.3.1 5-Bromo-2'-deoxy-uridine (BrdU) incorporation and
immunofluorescent staining of cells
Analysis of cell proliferation in MCF-7 cells transfected with siRNA against
EEF1A2 was carried out using the 5-Bromo-2'-deoxy-uridine (BrdU) Labelling and
Detection Kit I (Roche). MCF-7 cells were plated on 13mm glass coverslips in a 24
well plate and transfected with siRNA as described in Materials and Methods section
2.2.8.2. Each treatment was carried out in duplicate. At 24 and 48 hours post
transfection the medium was removed from the cells and replaced with medium
containing 10/xM BrdU labelling reagent. Cells were then incubated in BrdU at 37°C
5%C02 for 30 minutes. Cells were then washed fixed and stained with a primary
anti-BrdU and secondary fluorescent conjugated antibody following manufacturer's
protocol. Coverslips were finally mounted in Mowiol (Sigma) containing DAPI on
glass slides and viewed by fluorescent microscopy.
2.2.19.2.2 Analysis of the percentage of cells in S phase (proliferating)
Two representative fluorescent microscope images of each slide were taken at X40
magnification. Images of cells were then viewed using Adobe Photoshop software
(Adobe) and the number of green (BrdU labelled) and blue (DAPI stained) cells were
counted.
2.2.19.3 Propidium iodide cell cycle analysis
The following solutions were prepared and the constituent reagents were obtained
from Sigma.
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Citrate
buffer
85.5g sucrose and 11.76g trisodium citrate dissolved in 800ml
dH20








dissolved in dH20 to 2000ml
pH7.6
Solution A 15mg trypsin in 500ml stock solution
pH7.6
Solution B 250mg trypsin inhibitor and 50mg ribonuclease A in 500ml stock
solution
pH7.6
Solution C 208mg propidium iodide and 500mg spermine
tetrahydrorochloride in 500ml stock solution
pH 7.6
MCF-7 cells transfected with shRNA plasmids and plated in 6 well plates were
trypsinised 48 hours post transfection in 500/xl of trypsin:versene. Following
trypsinisation 500yu,l ofmedium was added to the cells. One half of the cells were
pelleted for protein analysis while the other halfwas pelleted for cell cycle analysis.
MCF-7 cells for cell cycle analysis were resuspended in 50/d of citrate buffer. 225yu.l
of solution A was added and the cells were incubated at room temperature for ten
minutes. 162 fi\ of solution B was then added to the cells and a further incubation of
ten minutes at room temperature was carried out. Finally 125/d of solution C was
added and the cells incubated on ice for 10 minutes. Propidium iodide stained cells
were then analysed by flow cytometry. A two-parameter dot-plot ofForward Light
Scatter (FLS) vs. Side Scatter (SS) was plotted. A single parameter FL3 histogram
plot (area) with a linear x axis was used to visualise the DNA content in the cell
population. The voltage of the FL3 laser was adjusted so that the G1 peak was at a
mean of 200 on the x axis. No compensation was required as only one fluorochrome
(propidium iodide) was used. 10,000 ungated events were collected in total for each
sample. Flow cytometry was carried out using a Coulter EPICS XL flow cytometer
(Beckman Coulter). Apoptotic, Gl, S and G2/M cells were gated using the EXPO
ADC analysis software (Beckman Coulter) and the percentage of cells in each region
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was recorded. Analysis was carried out on the FL3 histogram data using Multicycle
AV for Windows software (Phoenix Flow Systems).
2.2.19.4 Heat shock
In order to test the specificity of the rabbit anti-Hsp70 antibody (Stressgen) HeLa
cells were seeded into small flasks and incubated at 37°C, 5% CO2. Twenty-four
hours later the flasks were removed from the incubator and the lids sealed with
parafilm. The flasks were then either returned to 37°C or placed in a 40°C or 42°C
waterbath for one hour. The flasks were then removed from the waterbath and the
parafilm removed from the lids of all the flasks including those at 37°C. The cells
were then placed in the 37°C incubator for 2 hours, 7 hours or 24 hours. Following
this the cells were pelleted and protein lysates produced and Western blots run to
analyse Hsp70 expression. RNA interference was carried out as described in
2.2.11.5 and 2.2.12.1.1 in this chapter. All transfections were carried out in duplicate
wells and duplicate plates. Forty-eight hours post-transfection the 24 well plates
were removed from the 37°C, 5% CO2 incubator and sealed using parafilm. One of
the duplicate plates was placed at 37°C and the other was heat shocked at 42°C in a
waterbath for one hour. The parafilm was removed from the plates and the cells
incubated at 37°C, 5% CO2 for 2 hours to allow protein synthesis. This method is a
modified version of the protocol used by Shamovsky et al. (Shamovsky et ah, 2006).
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Chapter 3: eEF1A2 is overexpressed in two-thirds of breast
cancers
3.1 Introduction
Oestrogen receptor (ER) positive breast cancers and their treatment
Oestrogens are a group of steroid hormones that perform roles in many processes
within the cell, from growth and differentiation to specific organ functions. The
classical mechanism ofER activation of transcription of target genes is through
ligand-occupied receptor binding to specific elements in target genes. Upon
oestrogen binding to the ER in the nucleus the receptor dimerises leading to an
activation of its transcriptional activity by binding to the Oestrogen Response
Element (ERE), a specific 15 nucleotide inverted palindromic sequence found in the
promoter region of certain genes, (see review by (O'Lone et ah, 2004). Alternatively,
the ER can indirectly activate transcription through association with other DNA-
binding transcription factors such as activating protein-1 (AP-1) (Kushner et al.,
2000) and Spl (Safe, 2001). Both of these mechanisms involve the recruitment of
co-activators and components of the basal transcriptional machinery to promote
transcription of specific genes. In addition to nuclear ERs there are also plasma
membrane associated ERs that mediate gene regulation (Wong et ah, 2002). Lastly,
the oestrogen receptor can also influence gene expression via the sequestration of
common transcriptional components (Speir et ah, 2000). Examples of oestrogen-
responsive genes include the progesterone receptor (May et ah, 1989), pS2 (Brown et
ah, 1984) and heat shock protein 27000 (Hsp27) (Moretti-Rojas et ah, 1988).
There are known to be two ER isoforms, ERa and ER/3. The predominant form of
ER in human reproductive tract and mammary tissue is ERa. The incidence ofER
positive cancers increased by 344% between 1978 and 2003, with ER receptor
positive ductal cancers constituting 80% of all breast cancers in 2003 (Glass et ah,
2005). Most tumours that express the ERa are low grade, and those that do not are
frequently poorly differentiated (Millis, 1980). ER/3 is also expressed in breast
cancers, in particular it is found in ERa positive breast cancers, and there are cancer
cells that express both of the isoforms simultaneously. ER/? is thought to be
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important in regulating oestrogen signalling pathways and its expression is an
indicator of good prognosis in breast cancer (Omoto et al., 2002).
Oestrogen receptor positive cancers are good candidates for treatment with endocrine
therapy. This can be in the form of anti-oestrogen drugs such as tamoxifen, or
aromatase inhibitors. Tamoxifen is thought to work by binding to the ER and
rendering it non-functional. Aromatase inhibitors, on the other hand, reduce levels of
oestrogen itself. This class of drugs inhibit the biosynthesis of the most potent form
of oestrogen, estradiol, from androgens by the cytochrome P450 enzyme complex
called aromatase. High levels of this enzyme complex can be found in the ovaries of
pre-menopausal women, the placenta of pregnant women and adipose tissue of post¬
menopausal women, as well as breast tissue and sites surrounding breast tumours.
Examples of aromatase inhibitors include Aminoglutethimide, 4-
Hydroxyandrostenedione and the third generation aromatase inhibitors Anastrozole,
Exemestane and Letrozole, see review (Brueggemeier et al., 2005).
Oestrogen receptors (a and /3) are known to bind the following 15bp palindromic
sequence in target genes with highest affinity in vitro, where the N represents
variable nucleotides (Klein-Hitpass et al., 1986).
-6 -5-4-3-2-1 +1 +2 +3 +4 +5 +6
5'PuGGTCA NNN T G A C C Py 3'
There are few characterised EREs in the human and mouse genomes, in fact only
three consensus EREs have been identified in human oestrogen-regulated genes:
EBAG9, COX7A2L and EFP/ZNF147 (Ikeda et al., 2000; Inoue et al., 1993;
Watanabe et al., 1998). Near consensus EREs have also been identified in oestrogen
responsive genes and these show a base pair diverging from the consensus at one or
two nucleotides. It has been shown that some base alterations are better tolerated
than others, for instance -5C, -4C and -2A result in a large decrease in ER binding
affinity in vitro. Symmetrical changes in both arms of the palindrome affect the
binding more substantially than non-symmetrical changes. It was also noted that
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many natural elements show one change with a small effect on affinity, -6Py+6Pu or
-1G/+1C together with another variation. In a genome wide search for near
consensus EREs, containing one nucleotide variation or two where one is -6Py+6Pu
or -1G/+1C, 71,119 elements were found in the human genome and 65,012 in the
mouse genome; the distribution of these EREs was generally consistent with
chromosome size. Although many previously characterised EREs are mainly located
within 0.5Kb of transcriptional initiation sites, this study found that the ERE was
more abundant in the 0 to + 1Kb region of genes in both mouse and human genomes.
In general they found a random distribution of EREs with enrichment around
transcriptional start sites. EREs are less represented and conserved further from the
start site (i.e. -1 to -10Kb) (Bourdeau et ah, 2004).
Field cancerization
The concept of "field cancerization" was first proposed for oral cancer by Slaughter
et al. in 1953 (Slaughter et ah, 1953). This concept was proposed to explain the local
recurrence ofprimary tumours (so called second primary tumours) following tumour
resection, as well as the observation ofmultiple primary tumours. Most studies in
this field have been done on head and neck squamous cell carcinomas (PINSCC).
The model proposed, based on evidence from extensive studies on HNSCC, fits into
the model ofmultistep carcinogenesis. In multistep carcinogenesis the accumulation
of genetic mutations leads to the progression of a normal cell into a cancer (Fearon
and Vogelstein, 1990). Field cancerization proposes that a stem cell acquires genetic
alterations and forms a patch of genetically identical daughter cells. An additional
genetic hit that confers a growth advantage to a cell then causes the development of
an expanding clone that laterally displaces normal epithelium. The patch of
genetically altered cells has now given rise to a field of cells derived from a
genetically altered clone. Subsequent genetic hits give rise to sub clones within this
field that share a common clonal origin but have divergent genetic alterations. A sub
clone then eventually forms an invasive cancer. To summarise, there are two
important steps in this model, (1) the emergence of a group of stem cells with
superior proliferative capacity from the patch of genetically altered stem cells and (2)
the transforming event that leads to the formation of an invasive cancer. Of clinical
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importance is the fact that fields may remain after surgery that appear normal
histologically but then give rise to local recurrence in the future, see reviews
(Braakhuis et ah, 2003) and (Garcia et al., 1999).
Common genetic lesions identified in "normal" cells proximal to a cancer include
loss of heterozygosity, microsatellite alterations, chromosome instability and
mutations in TP53, as well as aberrant DNA methylation patterns (Braakhuis et al.,
2003). In breast cancer Heaphy et al. completed a study of the telomere DNA
content and allelic imbalance in normal tissue adjacent to breast tumours. They
showed that shortened telomeres and allelic imbalances were present at sites at least
lcm away from the tumour and in a substantial number of the cells present in this
apparently normal tissue. Additionally they demonstrated that genomic instability
decreased the further away from the tumour the cells were isolated (Heaphy et al.,
2006).
Invasion and metastasis in breast cancer
It is well known that particular cancers metastasize to certain sites in the body.
Breast cancer shows a distinct metastatic pattern involving the regional lymph nodes,
bone marrow, lung and liver. There are two proposed mechanisms mediating this,
firstly the cancer cells may differentially survive and proliferate at these sites, or
alternatively they are selectively trapped with or without preferential homing
(Moore, 2001). In breast cancer, expression of the chemokine receptors CXCR4 and
CCR7 on the breast cancer cells and the concomitant expression of their ligands at
sites to which these cells metastasize, suggests that the cells are preferentially
homing to these sites. Therefore the migration of these breast cancer cells is directed
from the primary tumour site through the circulation to the preferential metastatic
regions (Muller et al., 2001).
20q amplification and breast cancer
Regions of chromosomes showing frequent alteration in a certain cancers are likely
to contain genes important for the genesis of that disease. EEF1A2 maps to 20ql 3.3
(Lund et al., 1996) and amplifications in 20ql3 are commonly observed in breast
Chapter 3 eEFlA2 is overexpressed in two-thirds of breast cancers 82
cancers. 20ql3 amplification has been associated with more aggressive breast
tumours with lymph node involvement (Courjal et al., 1996). Additionally, 20ql3
amplification has been associated with high grade breast tumours, aneuploidy and
short disease-free survival (Tanner et al., 1995). Cingoz et al. identified 20ql3
amplification by CGH in breast cancers and found that this amplification was more
frequent in ER positive cancers. High level DNA amplifications were mapped to
20ql2-qter and 20ql3-qter (Cingoz et al., 2003). Amplification at 20ql3.2 is
frequently observed in breast cancers (Kallioniemi et al., 1994; Tanner et al., 1994;
Tanner et al., 1996); this amplicon is proximal to the EEF1A2 locus.
Evidence that eEF1A2 is involved in breast cancer
There are multiple lines of evidence to suggest that eEFl A2 may be involved in
breast cancer. EEF1A2 maps to 20ql3 and amplifications in this region are
frequently observed in breast cancer, as detailed above. Furthermore, analysis of
expression data in the NCBI SAGE database suggests that eEFlA2 is more highly
expressed in breast tumours than in normal breast tissue. Finally, the expression of
eEFl A was identified by microarray and immunohistochemical analyses to be more
highly expressed at the invasive edge ofbreast tumours (Zhu et al., 2003). However,
the immunohistochemical analysis of breast tumours was carried out using an
antibody that recognises both eEFlAl and eEFlA2 and therefore it is not clear
which form of eEFlA may be involved. Helen Newbery developed eEFl Al and
eEFl A2 antibodies (Newbery et al., in preparation) and I have utilised these to
investigate the expression of eEFl A2 in breast cancer.
eEF1A1 and eEF1A2 specific antibodies
The specificity of the eEFlAl and eEFl A2 antibodies was determined by Western
blotting ofmouse tissue protein lysates. These antibodies are polyclonal anti-peptide
antibodies and the mouse peptides to which they were raised are shown in figure 3.1.
The Western blots showing specificity of the antibodies is shown in figure 3.2. The
eEFlAl antibodies 1A1-1 and 1 Al-3 give a band of approximately 50kDa in adult
mouse brain and liver but not in skeletal muscle where only eEFlA2 is expressed.
The eEFlA2 antibodies 1A2-1, 1A2-2 and 1A2-3 give a band of approximately
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50kDa in adult mouse brain and skeletal muscle but not in the brain ofwasted mice,
which is null for eEFlA2. These Western blots were produced by Helen Newbery
(Helen Newbery, PhD thesis 2002).
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Figure 3.1 eEFlAl and eEFlA2 protein sequence alignment showing the
peptide sequences used to produce eEFIA variant-specific antibodies
The sequences of the peptides used to raise variant-specific antibodies are underlined
in green. These regions were chosen because they display amino acid differences
between eEFlAl and eEFlA2 and are conserved between human and mouse eEFIA
proteins.
eEFlAS ErEF 1A1
Figure 3.2 Validation of the specificity of the eEFlAl and eEFlA2 antibodies by
Western blot
The eEFlA2 specific antibodies recognise a band at approximately 50kDa in
wildtype mouse brain and muscle but not liver. The eEFlAl specific antibodies
recognise a 50kDa band in adult mouse brain and liver but not in skeletal muscle.
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3.2 Results
3.2.1 Expression of eEF1A2 in normal breast tissue
Breast cancers are thought to arise from the epithelial cells of the terminal duct-
lobular units. It was therefore necessary to first determine the expression of eEFlA2
in these cells in normal breast. I stained seven normal breast sections by
immunohistochemistry with two different anti-eEFlA2 antibodies, 1A2-1 and 1A2-
3. These antibodies were raised to two different synthetic eEFl A2 peptides, selected
from protein regions that show amino acid differences between eEFl A1 and eEFlA2
(Newbery et al., in preparation). The stromal and adipose tissue in normal breast was
negative for eEFl A2 expression. Low levels of eEFlA2 expression could be seen in
the cytoplasm of the luminal epithelium and no eEFl A2 was present in the
myoepithelial cells, shown in figure 3.3. Therefore, eEFlA2 appears to be expressed
at negligible levels in the luminal epithelial cells of the normal breast ducts. It is
important to note that this normal breast is most likely to have originated from
material removed from around a cancer in a patient and is therefore not necessarily
completely "normal".
3.2.2 Expression analysis of eEF1A2 in breast cancers by
immunohistochemistry
In order to determine whether eEFl A2 is overexpressed in breast cancers a tissue
array containing cores from 46 different breast tumours was stained
immunohistochemically using the variant-specific anti-eEFlA2 antibody, see figure
3.3. This tissue array was obtained from Super Biochips and detailed clinical
information is not available with it. The limited clinical data available with the TMA
is represented in table 3.1.
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Figure 3.3 Immunohistochemical analysis of eEFlA2 expression in normal breast and
breast cancers.
Normal breast (N) shows low levels of staining for eEFlA2 in the ductal epithelium (D).
The stroma (S) and adipose tissue (AT) are negative for eEFlA2 expression. T1-T5 show
expression of eEFlA2 in the cancerous epithelial cells of five different tumour cores. NEG
shows the secondary-only control on a normal breast section and SOI and S02 are examples
of secondary antibody-only controls, on breast tumours T3 and Tl.
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Table 3.1 Clinical data available with the commercial TMA


















Infiltrating ductal carcinoma 31




Signet ring carcinoma 1





Patient age Minimum 26
Maximum 80
The cancerous cells stain cytoplasmically and the stroma and adipose tissue are
negative for expression of eEFl A2: the staining on each core is mainly
homogeneous. In order to control for heterogeneity in the tumour from which the
cores were taken two cores from each tumour were stained with two different
antibodies to eEFlA2. The cores were then scored by two researchers and one
pathologist for expression level of eEFlA2 using a histoscore method. This method
involves scoring the intensity of staining on a level of 1-3, multiplied by the
percentage of tumour cells staining at that level, giving a maximum score of 300.
Of the 46 cancers, 5 (11%) tumours expressed eEFlA2 strongly, a histoscore of
between 200 and 300, and 22 (48%) expressed eEFl A2 at a moderate level, a
histoscore of between 100-200. The remaining tumours showed eEFlA2 levels
similar to that found in normal breast epithelium. The inter-rater agreement or
reliability was tested using the intra-class correlation coefficient (ICC) and this gave
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a correlation coefficient of 0.8244, suggesting there is little variation between the
scoring of each tumour by the raters. None of the three lobular carcinomas showed
expression of eEFlA2. Twenty-two of the 46 cancers were oestrogen receptor
negative and 24 were oestrogen receptor positive. Only 4 of the 22 oestrogen
receptor negative cancers showed anything more than weak expression of eEFlA2
whereas 18 of the 24 oestrogen receptor positive cancers showed moderate to strong
expression of eEFlA2. The oestrogen receptor status was assessed using multiple
antibodies by immunohistochemistry (SuperBioChips).
Interestingly in tumour T1 there appears to be some nuclear staining of eEFlA2 as
well as cytoplasmic localisation. eEFlA1 has been shown to translocate to the
nucleus when bound to ZPR1 in mitogen-stimulated S. cerevisiae and human A431
epidermoid cells (Gangwani et al., 1998). The role of ZPR1 has not been determined
however eEFl A2 was also shown to bind ZPR1 in a yeast two-hybrid screen (Chang
and Wang, 2006) and this may explain the localisation of eEFl A2 in the nucleus of
the T1 tumour cancer cells in which a mitogenic signalling pathway could be
activated.
3.2.3 Statistical analysis shows eEF1A2 expression is associated with
oestrogen receptor-positive cancers
The tissue microarray used in the above analysis was obtained from SuperBioChips.
As such, detailed clinical information on each patient was not available with these
cores and this is a major drawback of using these readily available tissue
microarrays. However, the expression status of the oestrogen and progesterone
receptors as well as lymph node status and p53 mutation status was given for each
cancer. It appeared that eEFlA2 was preferentially expressed in oestrogen receptor
positive cancers and therefore to test the statistical significance of this observation
eEFlA2 expression was grouped as [negative and weak], and [moderate and strong]
and tested against oestrogen receptor expression status using the Fisher's exact test.
This analysis showed an association between oestrogen receptor-positive cancers and
cancers showing moderate/strong expression of eEFlA2 (p=0.016, Fisher's exact
test). There was an apparent association between eEFlA2 expression and p53 status
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but this was not statistically significant. This may be due to the significant
association between oestrogen receptor positive and wild type p53 cancers (p=0.012,
Fisher's exact test). A negative association between mutant p53 and the oestrogen
receptor has previously been observed by Levesque et al. (Levesque et ah, 1994).
In order to look further into the association between oestrogen receptor-positive
cancers and moderate to high expression of eEFlA2 we obtained 16 sections from
oestrogen-receptor positive cancers of patients at the Western General Hospital. Of
these, 13 (81%) showed moderate to high expression of eEFlA2, see figure 3.4.
This is higher than the 59% of cores that stained moderate to high for eEFlA2
expression on the commercial tissue array. This is likely to be due to the fact that all
of these sections are all from ER-positive tumours. In total, 40 of the 63 breast
tumours (63%) examined by immunohistochemistry showed moderate to high
expression of eEFlA2.
3.2.4 eEF1A2 expression in a panel of 250 breast cancers using the
DAKO Envision immunohistochemical staining technique
In order to extend the analysis of eEFlA2 expression in breast cancers we obtained a
larger TMA containing 250 breast cancers. Staining of this in-house TMA with
eEFl A2 using the IHC protocol used to stain the commercial TMA resulted in a
great deal of background staining when used on this large TMA. In order to increase
specificity and decrease background on cancer sections stained with the anti-eEFlA2
antibody I employed a more contemporary immunohistochemistry technique that is
standard protocol at the New Royal Infirmary Pathology Department, Edinburgh.
This technique involves the use of a different antigen retrieval method and the
Envision secondary antibody system from DAKO Cytomation, details ofwhich can
be found in Chapter 2: Materials and Methods. This technique utilises an antigen
retrieval technique in which the tumour section is pressure cooked in EDTA solution,
rather than microwaved in Citric acid, resulting in antigen retrieval taking place at a
different pH. The main difference between this and the previous technique is the
secondary antibody, which has a HRP labelled polymer conjugated to it. This
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Figure 3.4 Expression of eEFlA2 in oestrogen receptor-positive breast cancers
from patients at the Western General Hospital.
The majority of the cancers expressed eEFlA2 at a moderate to high level. The
staining was mainly homogeneous on each section.
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labelled polymer does not contain avidin or biotin and therefore this reduces non¬
specific staining. I applied this technique to stain a tissue array containing 250 breast
cancer cores with 30 years' of follow-up clinical data. This is a far more powerful
tool than the commercial tissue array used in previous expression analysis because of
the large amount of clinical data available with it. The clinical data available for the
TMA is shown in table 3.2.
Table 3.2 Clinical data available with the in-house TMA





















The eEFlA2 staining pattern was markedly different from that observed with the
previous IHC protocol carried out on the commercial tissue array. The staining was
homogeneous within cores as previously noted; however the staining was found to be
either very strong or negative and there were not many cancer sections staining at
intermediate levels for eEFl A2, see figure 3.5. 201 of these cores were then
included for analysis, many cores were excluded on the basis of a lack of tumour
present or the core lifting off of the slide and being lost. Two researchers and a
pathologist independently scored the staining level using the histoscore method. Of
the 201, 10 scored highly (200-300 histoscore) and 14 stained moderately (100-200)
for eEFl A2. The inter-rater reliability was tested using the intra-class correlation
coefficient (ICC). The ICC for this IHC scoring was 0.7538, suggesting that there
was high agreement or concordance between the raters.
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Figure 3.5 eEFlA2 expression in breast cancer cores on a large TMA.
The majority of cores were negative for eEFlA2, however, 11% stained moderately
or highly for eEFlA2. In approximately 5% of the cores the expression of eEFlA2
was impressively high (histoscore of 300). Antibody controls show the Islets of
Langerhans in the pancreas staining strongly (positive control), and the liver showing
no eEFl A2 expression (negative control).
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Approximately 5% of the cancers showed high levels of eEFlA2 expression and 7%
stained moderately for eEFlA2. This is compared to 11% exhibiting high expression
levels of eEFlA2 and 48% exhibiting moderate expression of eEFlA2 in the
commercial tissue array. In addition there was no apparent association between
eEFl A2 expression and histological type, grade, stage or oestrogen receptor status.
3.2.5 Expression of eEF1A2 at the RNA level in breast cancers
In order to investigate the expression of eEFl A2 at the RNA level we obtained RNA
from oestrogen receptor positive (n=21) and negative breast cancers (n=8), as well as
normal breast tissue (n=2) and benign breast tumour tissue (n=l) and I conducted
quantitative real-time RT-PCR on the samples. These samples were collected and
RNA extracted from them by Professor W. Miller and Dr. Alexey Larionov at the
Western General Hospital. The RNA was extracted from total tumour tissue and not
laser dissected material, however the relative amount of epithelial:stromal
components are known. No tumours in which there was less than a 20% epithelial
component were used in the analysis. Most cancers showed an epithelial percentage
ranging from 40-60%.
I conducted real-time RT-PCR on cDNA samples from the tumours and normal
breast using eEFlA2-specific primers and GAPDH primers as a reference gene.
These primers were obtained from Applied Biosystems and are pre-designed and
optimised, consisting of a primer pair and a FAM-labelled probe.
I confirmed the specificity of the eEFlA2 primers using cDNA obtained from
lymphoblastoid cells that are known not to express eEFlA2; no eEFl A2 PCR
product formed but a GAPDH transcript was present in this sample. Minus cDNA
and RNA only controls were included to check for contamination. In the breast
tissue analysed, levels of eEFlA2 were normalised to GAPDH levels to correct for
differences in cDNA amounts. The normalised level of eEFlA2 in the two normal
breast tissue samples was averaged to give an average expression level in normal
breast. Levels of eEFlA2 in all other tumours were then standardised to the average
level of eEFl A2 expression in normal breast.
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Levels of eEFlA2 were very low in normal breast and benign breast tumour tissue
compared to expression in tumours. The majority of breast cancers showed higher
levels of eEFl A2 than normal and benign tissue; in fact in the extreme this level was
up to 30 times higher than that seen in normal tissue. The expression levels of
eEFlA2 in oestrogen receptor-negative cancers compared to the expression in
normal breast tissue ranged from 0.01 to 4.53. In oestrogen receptor-positive cancers
the eEFlA2 expression levels compared to that in normal breast ranged from 0.1 to
29.35. This is represented in figure 3.6. In oestrogen receptor-negative cancers the
average expression level of eEFlA2 was 1.2 times higher than that seen in normal
breast. Interestingly, the levels of eEFlA2 were higher in oestrogen receptor-
positive breast cancers, showing an average level 8.4 times higher than in normal
breast epithelium. This difference in eEFlA2 expression is 7.2 units (p=0.0087, t-
test, 95% confidence interval 2.0 to 12.5 units), see figure 3.7, where 1 unit is the
level of eEFlA2 in normal breast. A comparison of the expression level of eEFlA2
and the malignant component of the breast tumours (where the data is available) is
shown in figure 3.8. There does not appear to be a consistently higher expression of
eEFl A2 in tumours that also have a high malignant cell content suggesting that the
eEFlA2 expression levels measured using this technique are representative of the
levels in the tumour and not simply a consequence of the amount of stroma in each
sample.
The observation of higher eEFl A2 RNA expression levels in the oestrogen receptor
positive breast tumours together with the results of immunohistochemical analysis of
breast cancer cores on the commercial tissue array suggests that EEF1A2 may be an
oestrogen-responsive gene or indeed may regulate oestrogen receptor expression by
an unknown mechanism.








Figure 3.6 Expression of eEFlA2 at the RNA level in oestrogen receptor positive
and negative breast cancers, analysed by real-time RT-PCR.
eEFlA2 expression at the RNA level in normal breast and benign breast tissue
(grey), oestrogen receptor negative (white) and positive (black) cancers. Expression
of eEFlA2 is low in the normal breast tissue and benign breast tumour tissue. The
majority of the cancers analysed overexpressed eEFlA2, the highest showing a 30-
fold increase in expression compared to normal breast tissue. Error bars represent 1

































Figure 3.7 Levels of eEFlA2 expression are higher in oestrogen receptor
positive (ER+) than negative (ERO) breast cancers.
Horizontal bars show mean eEFlA2 expression level for each group. This difference
in eEFlA2 expression is 7.2 units (p=0.0087, t-test, 95% confidence interval 2.0
to 12.5 units).
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3.2.6 Does the EEF1A2 promoter region contain an Oestrogen
Response Element (ERE)?
The results from analysis of expression levels of eEFl A2 in breast cancers showed
that eEFlA2 expression is significantly higher in ER-positive cancers. This in turn
suggests that eEFlA2 expression may be switched on by the activation of the
oestrogen receptor or by an indirect mechanism resulting from oestrogen receptor
overexpression. Hence, EEF1A2 may be transcriptionally regulated by the oestrogen
receptor or may be co-ordinately regulated with the oestrogen-receptor. I completed
bioinformatical analysis using the Dragon ERE finder program 2.0 (Bajic et al.,
2003) to identify possible EREs in the EEF1A2 genomic sequence EMBL/Genbank
Accession no. AF163763. The sensitivity of the program was set at the default level,
which is 83%, and at this level the program predicts one ERE per 13 300nts based on
analysis of chromosome 21 (Bajic et al., 2003). The input EEF1A2 sequence (12kb)
includes approximately 2kb upstream of the transcription start site (TSS). The first
near consensus ERE identified in EEF1A2 is on the forward strand at position 11299,
located between exons 7 and 8, and is CA-GGTGA-CCC-TGCCC-AG, the divergent
nucleotides being -2G and +3G. Two putative sequences were also identified on the
reverse strand at positions -6334 and -2680 and were AA-GGGCA-CGG-TGGCC-
GG and CA-GGTGG-AGA-TGCCC-TC respectively. None of the putative EREs
are in the promoter region ofEEF1A2 on the forward strand and none of the putative
ERE sequences in the human EEF1A2 sequence are conserved in the mouse. The
position of the predicted human EEF1A2 EREs well outside the promoter region of
the gene and the lack of conservation of these sequences between human and mouse
suggests that they are non-functional.
3.2.7 eEF1A2 levels are not altered by the knockdown of ERa in MCF-7s
To further investigate whether EEF1A2 is oestrogen responsive we obtained RNA
and protein from MCF-7 cell lines that had ERa expression ablated by RNA
interference. MCF-7 cells are breast cancer cells that overexpress the oestrogen
receptor and are therefore appropriate to use for investigation of oestrogen-
responsive genes. This experiment was carried out by Catherine Naughton under the
supervision of Simon Langdon at the CRUK Laboratories, Edinburgh University. In
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this experiment MCF-7 cells were transfected with 3 different oligos targeting the
ERa sequence, called RNAi 1 RNAi 17 and RNAiERS 1, and the levels of the
oestrogen receptor measured by Western blot and quantitative real-time RT-PCR. In
addition to this, the MCF-7 cells were also first treated with 17/3 estradiol and then
subjected to RNA interference to ERa. Controls include untransfected MCF-7 cells
treated and not treated with 17/3 estradiol, as well as cells transfected with a non-
targeting oligo. 48 hours after transfection the cells were harvested for protein and
RNA analysis. Catherine Naughton has confirmed knockdown of the oestrogen
receptor alpha using this system (see figures 3.9 and 3.11). The highest level ofERa
knockdown, at both the RNA and protein level, was seen after 17/3 estradiol
stimulation and subsequent treatment with RNAi 17. This experiment could
potentially allow us to determine whether EEF1A2 is an estradiol-responsive gene as
opposed to being coordinately regulated with the ERa.
Using Western blot analysis I measured the levels of eEFl A2 in cells subjected to
the above treatments. The results are shown in figure 3.9. The levels of eEFlA2
were normalised to the levels ofGAPDH using image analysis software. eEFlA2
expression does appear lower in MCF-7 cells treated with siRNAs to ERa,
particularly those treated with RNAiERS 1. The expression of eEFl A2 in cells
treated with non-targeting oligo (Neg) is also lower than untreated cells however. In
addition, the expression of eEFlA2 does not increase in MCF-7 cells treated with
estradiol compared to untreated cells suggesting that eEFl A2 is not oestrogen
responsive.
I also analysed the expression of eEFl A2 at the RNA level using real-time RT-PCR
by the SYBR green method. In this assay the reference genes pumilio homolog 1
(PUM1) and TATA box binding protein (TBP) were used. These genes are known
not to be altered by changes in oestrogen receptor activity in breast cancers (Alexey
Larionov, personal communication). The use of two housekeeping genes results in a
more accurate normalisation of the expression level of the gene of interest, in this
case EEF1A2. RNA only and -cDNA controls were included to rule out the
possibility of contamination. Melt curves were used to confirm specificity of the
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Figure 3.9 Western blot analysis of eEFlA2 protein levels in MCF-7 cells
treated with siRNAs against the ERa.
(a) Western blot carried out by Catherine Naughton showing the knockdown of ERa
in MCF-7 cells following various treatments (b) Western blot showing eEFlA2
expression in MCF-7 cells treated with siRNAs to ERa and/or treated with estradiol,
(c) eEFlA2 expression levels normalised to GAPDH. eEFlA2 protein levels appear
to be lower in cells treated with RNAi against the ERa than in untreated cells
(treatments 2-4 compared to 1). Treatment of MCF-7 cells with estradiol does not
appear to result in an increase in eEFlA2 expression however (treatments 5-8).
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PCR products. A standard curve was run for each pair of gene-specific primers, on
cDNA from oestrogen-stimulated untreated MCF-7 cells, to determine PCR
efficiency, see figure 3.10. Each of the genes did not have the same PCR efficiency
and therefore the delta delta Ct method of analysis could not be used. Instead, the
results were analysed using the Excel macro available with the real-time PCR
machine that uses algorithms detailed in Vandesompele et al. (Vandesompele et al.,
2002). This algorithm allows the normalisation of a gene using multiple reference
genes with different PCR efficiencies. Results of the quantitative analysis of
eEFlA2 expression are shown in figure 3.11 as well as results obtained from
Catherine Naughton showing the ERa expression at the RNA level. It appears that
levels of eEFl A2 actually increase, relative to the level in untreated MCF-7 cells,
upon ERa knockdown. Additionally, eEFlA2 expression appears to decrease upon
estradiol treatment ofMCF-7s. This suggests that eEFl A2 is not positively
oestrogen responsive; it even appears in this system to be negatively regulated by
ERa at the RNA level. There appears to be some indication that eEFlA2 expression
may decrease upon ERa knockdown by RNAi but this is by no means conclusive.
Interestingly, ERa levels are only knocked down by the siRNA ERS1 following pre-
treatment of the cells with estradiol. This suggests that the siRNA is not effective
unless the ERa mRNA levels are high and therefore that the affinity of the siRNA is
not high enough to trigger the RNA interference process when there is not much ERa
message present.
3.2.8 eEF1 A2 expression levels do not decrease in Letrozole treated
breast cancers
In order to investigate the apparent association between ER positive tumours and
high eEFl A2 expression levels in vivo we have obtained sections of tumours from
patients that had been given neo-adjuvant hormone therapy with Letrozole (Femara),
from Mike Dixon at the Western General Hospital. Letrozole is an aromatase
inhibitor; inhibiting the conversion of androgens produced in lipid to oestrogen and
is prescribed to patients with ER positive tumours. Therefore post treatment the
levels of activated ER should decrease and concomitantly the levels of oestrogen
responsive gene expression should decrease. Biopsies were taken before treatment,
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Figure 3.10 Amplification, melt and standard curves for determination of
eEFlA2 levels in ERa RNAi-treated MCF-7 cells.
(a) The amplification and melt curves of eEFlA2, TBP and PUM1. Strong specific
peaks in the melt curve for each PCR product show the primers anneal specifically.
In blue is the eEFlA2 PCR product, in green PUM1 and in red TBP. Standard
curves all have a correlation coefficient of more than or equal to 0.99. (b) Standard
curve for eEFlA2 PCR, (c) standard curve for PUM1 (d) standard curve TBP
product. Blue circles denote the standards, red squares the samples being quantified.
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Figure 3.11 eEFlA2 levels in ERa RNAi treated MCF-7 cells.
(a) Real-time RT-PCR quantification of ERa expression levels in MCF-7 cells
treated with an ERa targeted siRNA, and/or estradiol - Catherine Naughton. (b)
eEFlA2 levels are shown normalised to PUM1 and TBP and standardised to levels in
untreated MCF-7 cells (*). Cells in which ERct expression has been ablated show a
small increase in eEFlA2 expression compared to controls. Cells treated with
estradiol and then subjected to ERa RNAi show a small decrease in eEFlA2
expression. These fluctuations in eEFlA2 levels are not large - no increase or
decrease in eEFlA2 levels is greater than approximately 1.2 times the level seen in
untreated MCF-7 cells. Levels of eEFlA2 expression do not appear to correlate to
the levels ofERa expression.
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slides marked with an A, 10-14 days into treatment (B), 3 months into Letrozole
treatment (C) (Miller et ah, 2006). The sections of biopsies taken during neo¬
adjuvant treatment and at surgical resection were stained for eEFl A2 expression and
secondary antibody only controls were included. Additionally, a tissue array
containing normal human liver (negative for eEFlA2) and pancreas (positive for
eEFlA2) was also stained with 1A2-3 as antibody controls. Examples of the staining
can be seen in figure 3.12.
The sections were examined by a pathologist, Dr Dana Faratian. He observed
heterogeneous staining within the cytoplasm of the cancer cell epithelium; eEFlA2
either showed a diffuse cytoplasmic subcellular localisation or was concentrated
around the nucleus i.e. in a perinuclear localisation. The expression pattern of
eEFlA2 across some sections was also heterogeneous, with some tumours showing
areas of cancer expressing high levels of eEFl A2 and concomitantly showing no
expression of the elongation factor in another area. It has been previously been
reported that eEFlA expression is higher at the leading edge ofbreast tumours (Zhu
et al., 2003) and this may explain the heterogeneity observed in these breast cancer
sections. An additional important observation is that in section WB01/12431 normal
ductal epithelium is staining positive for eEFlA2; examples of this can be found in
figure 3.13. This implies that there may be a field effect causing expression of
eEFl A2 and that eEFl A2 expression may be an early event in cancer progression or
neoplasia. Alternatively, the expression of eEFl A2 in normal adjacent breast tissue
could be induced by the secretion of an unknown factor by the surrounding
malignant cells. It would be necessary to obtain DNA from the normal breast tissue
in order to determine if there is an underlying genetic aberration in the normal cells
causing eEFl A2 expression and therefore the presence of a field effect. Importantly,
there appears to be no correlation between stage of aromatase treatment and
expression of eEFlA2, adding another argument against EEF1A2 being an oestrogen
responsive gene.
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Figure 3.12 Expression of eEFlA2 in breast tumours pre and post Letrozole
treatment.
eEFlA2 expression does not appear to decrease, compared to the levels in biopsies
taken before Letrozole treatment, in oestrogen receptor positive tumours at 10-14
days, or 3 months into treatment. Positive control for eEFlA2 is the pancreas (P)
and the negative control is the liver (L).




Figure 3.13 Normal adjacent breast tissue (NABT) staining positively for
eEFlA2
In section WB01/12431 no invasive breast cancer was present however hyperplastic
lesions (d + b) and normal breast tissue can be observed (a-c). eEFlA2 expression is
present in both the hyperplastic lesion and the normal adjacent breast tissue
suggesting that field cancerization may be at play.
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3.2.9 Is eEF1A2 preferentially expressed in lymph node positive cancers?
The heterogeneous expression pattern of eEFl A2 observed in some of the breast
tumours examined by immunohistochemistry and the evidence of a higher level of
eEFlA at the invading edge (Zhu et ah, 2003) lead us to investigate the possibility
that eEFl A2 may be more highly expressed in lymph node positive breast tumours,
due to a potential role of the protein in invasion. Ten lymph node positive and ten
lymph node negative breast tumour sections were stained using the 1A2-3 antibody
and the DAKO Envision secondary system. Only one of the ten sections showed
uniform staining of eEFl A2. This positive tumour was lymph node positive but due
to the small numbers of sections stained nothing could be concluded from this.
However, an interesting observation was that in many of these tumours eEFlA2
seemed to be expressed in precursor hyperplasic lesions and Ductal Carcinoma In
Situ (DCIS): examples of this staining pattern can be found in figure 3.14. In four of
the ten tumour sections DCIS staining positively for eEFl A2 was observed by the
pathologist, however the grade ofDCIS was not assessed and all tumour sections did
not contain DCIS. A more thorough analysis of the expression of eEFlA2 in DCIS
was not carried out.
This observation of eEFl A2 expression in DCIS implies that eEFlA2 may be
expressed early in breast cancer progression and therefore may be important for early
events in breast carcinogenesis. It may also suggest that eEFl A2 is important for
progression to an invasive phenotype in which the hyperplastic cells breach the
basement membrane and begin to invade the surrounding stroma. This is quite
nicely illustrated in figure 3.14, where eEFlA2 expression can be seen in cells that
have breached the basement membrane into the surrounding stroma. More analysis
on a larger set ofbreast tumours would be required to add validity to these
observations. Currently, an array ofmore than 400 node positive and negative breast
tumours is being produced by Dana Faratian at Edinburgh New Royal Infirmary and
this tool may further validate the results obtained from the limited investigation
carried out here. Additionally, examining the expression of eEFl A2 in a panel of
pre-malignant breast lesions would allow us to determine if eEFlA2 expression is
common in these early stages of breast cancer.
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Figure 3.14 Expression of eEFlA2 is often observed in hyperplastic pre-
malignant lesions in the breast, such as DCIS.
eEFlA2 expression is frequently found in pre-malignant lesions in the node positive
and negative, full face breast tumour sections. This observation suggests that
eEFlA2 expression may be an early event in breast carcinogenesis. The arrow
denotes eEFlA2 expressing cells that appear to have breached the basement
membrane.
Chapter 3 eEFlA2 is overexpressed in two-thirds of breast cancers 108
3.3 Discussion
Early analysis of eEFl A2 expression levels in breast cancers using commercial tissue
arrays and sections from ER positive breast cancer biopsies suggested that the
elongation factor was expressed in a large proportion of breast tumours (two-thirds)
at a moderate to high level (Tomlinson et al., 2005). Subsequent analysis of eEFlA2
levels in another array containing over 200 cores from breast cancers showed only
11% of the cores stained moderately to strongly for eEFlA2. This difference could
be due to the fact that only one tissue array (and therefore one core from each
tumour) had been scored with one antibody for the TMA obtained from Dana
Faratian whereas two cores from each tumour were stained with two different
antibodies on the commercial tissue arrays. The use of two different antibodies on
two cores per tumour is likely to give a more accurate representation of eEFl A2
expression in breast cancer as a whole. Additionally, the percentage of tumours
staining positive for eEFlA2 on the commercial TMA is more consistent with the
number of tumours expressing eEFlA2 at the RNA level. The observed
heterogeneity of eEFl A2 in the Letrozole treated and lymph node positive and
negative sections would also suggest that multiple cores from each tumour should be
stained to get an accurate picture of eEFl A2 expression.
Dana Faratian's TMA not only contained more cores but was stained using a
technique (Envision secondary antibody) that is thought to decrease non-specific
staining and this was the reason for using this alternative technique. Therefore of the
48% of cores that stained moderately positive for eEFlA2 on the commercial tissue
array a percentage may have been exhibiting non-specific staining. However, the
specific staining of eEFl A2 in the epithelium but not the stroma acts as an internal
control on the commercial TMA and suggests otherwise. Additionally, the
discrepancy between the percentages of cores staining positive for eEFl A2 between
the two tissue arrays may be due to the different antigen retrieval techniques used.
The pressure cooking in EDTA solution method used on the larger array may only
lead to partial antigen retrieval and therefore only those cores expressing eEFlA2 at
high levels would stain positively.
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The clinical and pathological information for the tumours on both the commercial
tissue array and the larger in-house array are presented in tables 3.1 and 3.2. For the
production of the commercial tissue microarrays the tissues were fixed in 4%
buffered neutral formalin for 12 to 24 hours, dehydrated with gradient ethanol,
cleared with xylene, and embedded in paraffin. The oestrogen receptor, progesterone
receptor and p53 expression was analysed using immunohistochemistry with
multiple antibodies. For the in-house TMA the tissues were fixed in formalin,
mercuric acid, or Bouin's fixative, the later two being different from the fixation
technique used in the production of the commercial TMA. This difference in the
method of fixation between the commercial and in-house array could be the reason
behind the differences in eEFlA2 expression observed between the two TMAs. The
histology of the tumours included on the commercial TMA and the in-house TMA
are homogeneous with the majority being ductal and not lobular. Additionally, there
is a lower representation ofER positive tumours on the commercial TMA (27/46,
60%) than on the in-house TMA (136/177, 77%), which would be expected to (based
on the association of eEFlA2 with ER positive cancers) result in higher percentage
of eEFlA2 positive tumours on the in-house TMA than the commercial TMA and
not the lower percentage that was observed, suggesting this is not behind the
difference in eEFl A2 expression.
A paper published recently by Kulkarni et al. suggests that the
immunohistochemistry technique used on the commercial tissue array gave a more
accurate representation of the actual expression pattern of eEFlA2. They found that
50-60% of primary breast tumours expressed eEFlA2 at a moderate to high level
(Kulkarni et al., 2006); a very similar level to that observed in the commercial tissue
array. In this array, only primary invasive breast carcinomas were included on the
TMA. The majority of the breast cancers on the commercial TMA for which I
investigated eEFl A2 expression were also invasive breast carcinomas. The median
age of the patients at diagnosis was 61.5 years (higher than the median age of 47 in
the cohort of patients on the commercial TMA), with the minimum age of 28.2 years
and maximum of 93.5 years. Kulkarni et al. used EDTA pH8.0 with heating for
antigen retrieval, which is different from the technique I used to immunostain the
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commercial TMA: citric acid pH6. Another obvious difference in the staining
protocol is the eEFlA2-specific antibody used by Kulkarni et al. The peptide used
by Kulkarin et al. corresponds to the peptide we used to generate the 1A2-2
antibody. I however did not use this antibody in any of the expression analysis
because it was less specific than the 1A2-1 and 1A2-3 antibodies. Therefore the
immunohistochemical protocols used in my analysis of the eEFlA2 expression on
the commercial TMA and Kulkarni et al.'s are quite different, however the results
seem similar in terms of the proportion of breast cancers expressing moderate to high
levels of eEFl A2. The tumours used in my analysis and Kulkarni et al. 's appear
fairly homogeneous in respect to histology however the proportion of the tumours
that are oestrogen receptor positive, lymph node positive and the stage of the
tumours is not detailed in the Kulkarni et al. manuscript and I am therefore unable to
compare these aspects of the different TMAs. The main difference between the
staining is that I used two antibodies raised to different regions of the mouse eEFl A2
sequence and I used a different antigen retrieval method.
The expression of eEFl A2 showed a significant association with oestrogen receptor
positive breast cancers (Tomlinson et al., 2005). Further investigations into the
possibility that EEF1A2 is an oestrogen responsive gene have not completely
resolved the question, however, they do suggest that eEFl A2 is not directly regulated
by ERa. The apparent absence of an ERE in the EEF1A2 promoter region implies
the ER does not directly bind to the gene to activate transcription; however the
sequence motifof the ERE is not as simple as previously described. For instance the
ER is also known to bind to half EREs in multiple copies and ERa can bind extended
half site sequences of the orphan nuclear hormone receptor steroidogenic factor 1
(SPREs). Half site binding can also take place in combination with the binding of a
nearby Spl site (O'Lone et al., 2004). There was an ERE identified in the intron
between exons 7 and 8 ofEEF1A2 on the forward strand, and it is possible that the
distant EREs may be functional as it has been suggested that EREs upstream of the
promoter could be active through the formation of chromatin loops to allow the
recruitment of the basal transcription machinery on to the start site (O'Lone et al.,
2004). However, the lack of conservation of the predicted ERE sequences between
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the human and mouse EEF1A2 suggests that they are in fact non-functional. At the
sensitivity level used (83%), the Dragon ERE program 2.0 is known to predict a
putative ERE motif every 13 300nts therefore it would be expected that one such
motifwould be identified in the 12Kb ofEEF1A2 sequence. The ability of these
putative EREs to bind the ER in vitro could be tested using CHiP analysis and gel
shift assays. It is important to note that the oestrogen receptor can activate the
transcription of a gene by mechanisms that do not involve direct interaction with the
DNA. As described previously the ER can associate with other DNA binding
transcription factors and indirectly mediate transcription (Kushner et al., 2000).
Therefore the apparent lack of a functional ERE in EEF1A2 does not completely rule
out the possibility that the ER may regulate its expression.
Further evidence suggesting EEF1A2 is not oestrogen responsive comes from the
results of the evaluation of the protein levels of eEFlA2 in MCF-7 cells in which the
ERahas been stimulated by 17/5 estradiol (E2) administration for 48 hours and/or
ablated by RNA interference. Upon E2 stimulation ofER-expressing cells the level
of an oestrogen-responsive gene would be expected to increase and to decrease upon
ER ablation by RNAi; RNA levels of eEFlA2 actually appear to decrease in MCF-7
cells 48 hours after estradiol exposure and increase upon RNAi ablation of the ERa.
This even goes as far as to suggest that eEFlA2 is negatively regulated by the ERa.
EEF1A1 on the other hand has been shown to be oestrogen responsive in MCF-7
cells. Charpentier et al. looked at global gene expression using SAGE in MCF-7
cells treated with E2 for 3 hours and 10 hours. They found eEFl Al to be upregulated
3.2 fold following 3 hours of 17/5 Estradiol treatment, increasing to 3.5 fold after 10
hours of treatment (Charpentier et al., 2000). Interestingly they did not identify
EEF1A2 in this screen. EEFlA1 and EEF1A2 have very similar coding regions but
divergent promoter regions, introns, and 5' and 3' UTRs (Knudsen et al., 1993),
therefore it is likely that the two genes are differently regulated. EEF1A1 is also
found in the ERGDB database of oestrogen responsive genes (Tang et al., 2004).
This database was compiled from a literature review of experimentally identified
oestrogen target genes and includes putative ERE sequences identified using the
Dragon ERE Finder 2.0 (Bajic et al., 2003). The location of the transcription start
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site (TSS) and promoter sequence was determined using FANTOM3 or UCSC's
Gene Sorter based on the Refseq ID/GenbankID BC028674. The TSS is listed as
position 96624443 on chromosome 6 and two putative EREs were identified; the first
at position 681 nucleotides (nts) upstream of TSS, TT-GGTCA-GGC-TGGTC-CT,
and the second 3687 nts upstream of the TSS, TT-GGTCT-TGA-TGTCT-CA (Tang
et al., 2004). Both of these potential EREs are fairly close to the TSS ofEEF1A1
and therefore are perhaps more likely to be functional than those identified in
EEF1A2. It has been shown that EREs up to 10Kb upstream from the TSS can be
functional (Bourdeau et al., 2004).
There are weaknesses in the way the association of eEFlA2 expression with ER
positive cancers was discovered. The commercial tissue array only contained cores
from 46 different breast tumours. This is a relatively small number of cores and this
may lead to the identification of a false association. Notably there were an
approximately equal number ofER positive and negative tumours on the array. The
ER association was reproduced when the levels of eEFlA2 mRNA were evaluated
by real-time RT-PCR in RNA obtained from a different group ofERa positive and
negative breast tumours. This analysis showed that eEFlA2 mRNA levels were
significantly higher in the ERa positive group than negative group (p=0.0087, t-test,
95% confidence interval 2.0 to 12.5 units). Similarly, this analysis was also carried
out on a small number of samples, (n=8 ERa negative cancers, n=21 ERa positive
cancers). This was due to the fact that only a limited number ofERa negative
tumour biopsies were archived because this tumour type was not relevant to the study
for which the samples were originally being collected. Additionally, as eluded to
previously, the RNA was extracted from whole tumour samples flash frozen in liquid
nitrogen following surgery and therefore contains both stromal and epithelial
components. As eEFlA2 is not expressed in stroma, samples with a higher total
stromal component will show a lower level of eEFl A2, even if it is expressed at high
levels in the epithelial component. There did not however appear to be any
correlation between the percentage epithelial content of the tumour samples and the
eEFlA2 expression level.
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Kuang et al. investigated the differential expression of cDNAs between the oestrogen
receptor positive cell line MCF-7 and the oestrogen receptor negative cell line MDA-
MB-231 and found eEFlA2 was expressed at a 25-fold higher level in MCF-7 cells.
However, they did not identify eEFl A2 as being estradiol-responsive (Kuang et al.,
1998). This observation together with my results showing eEFlA2 levels do not
increase upon estradiol treatment ofMCF-7 cells or decrease in tumours post-
letrozole treatment, suggests EEF1A2 may be co-ordinately regulated with the ERa
but not oestrogen-responsive. eEFl A2, for instance, may be stimulated by a
transcription factor that had its transcription directly activated by the ER. Evidence
against eEFl A2 being co-ordinately regulated with the ER comes from Kulkarni et
al. who did not find an association between eEFl A2 expression in breast cancers and
oestrogen receptor positive breast cancers. They did however find that eEFlA2 was
expressed almost exclusively in the luminal-like tumours, a tumour type that is
known to be mainly ER positive (Kulkarni et al., 2006).
An interesting observation is that eEFlA2 appears to be expressed in some normal
breast epithelium surrounding a cancer and was expressed in several hyperplastic
lesions and DCIS. In one tumour eEFlA2 expression was observed in both DCIS
and surrounding normal breast tissue. These observations suggest that eEFlA2
expression may be an early event in breast carcinogenesis. Interestingly, 20ql3
amplification (a potential mechanism of eEFl A2 overexpression) has been identified
by FISH and CGH to be present in the early stage of intraductal hyperplasia (Aubele
et al., 2002). The inappropriate overexpression of eEFlA2 in adjacent normal breast
tissue suggests that genetic alteration, by whatever mechanism it may be, early on in
the carcinogenic process has induced eEFlA2 and this would fit into the field
cancerization model. Work by Anand et al. showing that eEFl A2 is capable to
inducing a tumourigenic phenotype in NIH 3T3 cells and accelerated growth of
ovarian cells when xenografted into nude mice (Anand et al., 2002), suggests that
eEFlA2 expression could confer a growth advantage to the cells in a developing
field. An alternative hypothesis is that the cancer cells exert a transforming effect on
surrounding cells leading to the induction of expression of gene and this model has
been proposed in prostate cancer (Ozen et al., 1997). Nevertheless, field
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cancerization has been observed previously in breast cancer and may therefore be an
appropriate model to explain the presence of high amounts of eEFl A2 in
histologically normal adjacent breast tissue. Additionally, eEFlA2 expression could
be induced in the normal adjacent breast tissue by a secreted product from the nearby
malignant cells and this is another possible mechanism mediating eEFlA2
upregulation in normal breast.
Another interesting observation in breast tumour sections was the heterogeneity in
eEFlA2 staining. This together with the observation by Zhu et al. of eEFlA
expression being higher at the leading edge of breast tumours (Zhu et al., 2003)
suggests that eEFl A2 may be playing a role in tumour invasion and metastasis. In
order to attempt to investigate this, the expression of eEFlA2 in a panel of 5 full face
lymph node positive, i.e. invasive/metastatic breast tumours, and lymph node
negative non-invasive breast tumours was analysed by IFIC. I found that only one of
the 10 tumours showed expression of eEFlA2 and that there did not appear to be a
higher expression of the factor at the edge of the tumour. This suggests that the
heterogeneity seen in some breast tumours in the Letrozole study was not due to
higher expression at the invading edge. It also suggests that the Zhu et al. may have
been detecting an increase in expression of eEFl A1 and not eEFlA2 at the leading
edge of breast cancers. In order to investigate whether eEFlA2 is more highly
expressed in lymph node positive than negative breast tumours it would be necessary
to look at a larger cohort of samples. Dana Faratian is currently producing a TMA
containing cores from 400 lymph node status known tumours, which would be a very
powerful tool for finally drawing a conclusion on this hypothesis.
Another possible method to investigate the potential role of eEFlA2 in invasion and
metastasis would be to investigate whether eEFlA2 expression is associated with any
of the known markers for invasion and metastasis. These include N-CAM, integrins,
E-cadherin, uPA, cathespinD and metalloproteinases, to name but a few. An
association could suggest a mechanistic link between the marker and eEFl A2 and
could then be further investigated with in vivo and in vitro studies. One experimental
method commonly used to assess the invasive potential of a gene is a matrigel
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invasion assay. This involves plating cells in a chamber and adding some form of
chemoattractant below the chamber (e.g. FCS). Between the well and the chamber is
a synthetic basement membrane through which only invasive cells can travel. The
breast cancer cell line MBA-MD-231 is known to be highly invasive and we have
shown it to express eEFlA2 (data not shown). Performing RNAi and assaying for
changes in invasive potential by this method would allow the assessment of the role
eEFl A2 may be playing in invasion.
A recently published paper found that eEFlA2 expression in breast cancer is
associated with a significantly increased 20-year survival, meaning eEFlA2 may be
a useful prognostic marker. Additionally they found a weak but significant inverse
correlation between eEFlA2 expression and p53 and Ki67 leading them to suggest
that eEFl A2 drives oncogenesis via a mechanism other than an increase in mitosis
(Kulkarni et al., 2006). The suggestion that eEFl A2 expression may be a marker of
good prognosis is surprising given it has been shown to exhibit an oncogenic
phenotype when overexpressed (Anand et al., 2002). The authors suggest that this
may indicate that the potential oncogenic pathway driven by eEFlA2 is less
malignant than that induced by other oncogenes such as ERBB2. Finally, Kulkarni et
al. did not find an association between eEFlA2 expression and lymph node
involvement suggesting eEFl A2 is not involved in breast cancer metastasis to the
lymph nodes (Kulkarni et al., 2006).
In summary, eEFl A2 appears to be expressed in a large proportion of breast cancers
(almost two-thirds of tumours cores on one TMA), and this expression is associated
with oestrogen receptor positive cancers. EEF1A2 appears to be co-ordinately
regulated with the ER and not oestrogen responsive. Additionally, eEFl A2 does not
appear to be more highly expressed at the invading edge of the full face node-
positive and negative breast tumours analysed. Interestingly, high eEFlA2
expression was observed in normal adjacent breast tissue, early hyperplastic lesions
and DCIS, suggesting eEFlA2 may be important in the early stages ofbreast
carcinogenesis.
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Chapter 4: eEF1A2 is highly expressed in ovarian clear cell
ovarian carcinomas
4.1 Introduction
Ovarian clear cell carcinomas
Clear cell carcinoma (CCC) is a very distinct subtype of epithelial ovarian
carcinoma, often described as having a poor prognosis compared to serous carcinoma
(Tammela et al., 1998), partly due to its resistance to platinum-based chemotherapy
in advanced stages (Goff et al., 1996). It is a rare form of epithelial ovarian cancer,
accounting for only 10% of all cases. CCC is very distinct histologically and is
distinguished by the appearance of epithelial nests in a fibromatous mesh. Both CCC
and endometrioid carcinomas are thought to arise from the same precursor lesion,
endometriosis, and are often found intermixed within the same tumour (Feeley and
Wells, 2001). It is known that the expression profdes of endometrioid and clear cell
carcinomas differ, for instance CCC show no p53 mutations whereas endometrioid
adenocarcinoma show a 63% occurrence (Okuda et al., 2003). CCCs also show a
distinct pattern of loss of heterozygosity, exhibiting a prevalence at lp, 19p and 1 lq
(Okada et al., 2002). Additionally, CCC has been shown to express a unique pattern
of cell cycle regulatory molecules compared to the other histological types of ovarian
adenocarcinomas, expressing low levels of p53 and cyclin A and showing an
increased expression of p21 and cyclin E (Shimizu et al., 1999). Patients with CCC
tend to present with stage I disease (48.5%), whereas only 16.6% of patients with
serous carcinoma present at this stage (Sugiyama et al., 2000). Important to CCCs
resistance to chemotherapy, this histological type has been shown to express
glutathione peroxidase 3 (GPX3) (Hough et al., 2001). CCCs have also been shown
to overexpress the DNA repair genes ERCC1 and XPA more than two-fold higher
than the other histological subtypes and this may explain their resistance to DNA
damaging agents (Reed et al., 2003). Additionally, high expression levels ofHer2
has been shown to associate with ovarian clear cell carcinomas (Rubin et al., 1994).
Finally, a microarray study of gene expression in epithelial ovarian cancers showed
CCCs expressed the most distinctive gene expression profile of all the histological
types. This distinct molecular signature comprised 73 genes that were expressed
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two-fold to twenty nine-fold higher in CCC and known to perform roles in the stress
response, cell proliferation, differentiation and cell adhesion, to name but a few
(Schwartz et ah, 2002). Therefore it is apparent that clear cell carcinomas constitute
a distinct subtype of ovarian cancer.
Evidence for the role of eEF1 A2 in ovarian cancer
eEFl A2 maps to chromosome 20ql3.3, and an increase in copy number at this locus
has been identified in ovarian cancers (Suehiro et ah, 2000). In addition, the
increased copy number at this region is associated with poor clinical prognosis and is
often associated with more aggressive tumours (Suehiro et ah, 2000; Tanner et ah,
2000). In a microarray analysis of gene expression in 113 epithelial ovarian
carcinomas, upregulation of eEFl A2 has also been identified in clear cell ovarian
carcinomas (Schwartz et ah, 2002). Anand et al. found EEF1A2 to be amplified in
25% ofprimary ovarian tumours and to be highly expressed in 30% of ovarian
tumours and ovarian carcinoma cell lines. Finally, eEFlA2 has been shown to
increase the growth rate ofES-2 ovarian carcinoma cells xenografted in nude mice
and to transform NIH 3T3 cells (Anand et ah, 2002). Therefore a large amount of
data exists to suggest that eEFlA2 may be an oncogene in ovarian cancer.
I therefore sought to investigate the expression of eEFlA2 at both the RNA and
protein level (previous analysis has only been carried out at the RNA level), and to
look for any clinical associations that may give a clue to the role of the translation
factor in ovarian cancer.
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4.2 Results
4.2.1 Expression of eEF1 A2 in ovarian cancer cell lines
A panel of ovarian cancer cell line protein and RNA samples (plus two leukaemia
cell lines) were obtained from Hani Gabra of the Cancer Research Centre, Edinburgh
University. The expression of eEFl A2 at the RNA level was determined using
quantitative real-time RT-PCR and the results are shown in figure 4.1. Of the 16 cell
lines examined 3 did not express eEFlA2 and these were HL60, PEOl and PE04.
Using Western blot analysis the levels of eEFl A2 protein expression was
investigated in these cell lines. The results can be seen in figure 4.2. Of the 14
ovarian cancer cell lines examined only 2 cell lines were negative for eEFl A2 at the
RNA and protein level, these were PEOl and PE04. The cell line panel also
included the leukaemia cell lines, K562 and HL60. Interestingly, the bands
corresponding to eEFlA2 on the Western blots are of slightly different sizes in the
different cell lines. The eEFlA2 band in PEOl4, PEOl6 and HeLa cell protein
extracts are slightly larger than the bands in the rest of the cell lines. This size
difference suggests eEFl A2 may be post translationally modified in these cell lines.
Additionally, the size of eEFl A2 in wild type mouse muscle is larger than that seen
in any of the cell lines suggesting some difference between the human and mouse
protein. This again could be due to post translational modifications in the mouse
protein that are not present in the human protein.
It is becoming apparent that most cell lines express eEFlA2, regardless of their
tissue of origin. A panel of cell lines were examined for eEFlA2 expression by
Western blot and the results are shown in figure 4.3 and table 4.1. Of the ten
different cell lines examined only one, HepG2, was negative for eEFlA2 expression.
This is a cell line derived from a human hepatocellular carcinoma and it is known
that normal liver is negative for eEFlA2 expression.
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Figure 4.1 Expression of eEFlA2 at the RNA level in ovarian cancer cell lines.
Quantitative real-time RT-PCR analysis reveals that the expression of eEFlA2 at the
RNA level in ovarian cancer cell lines is similar to expression at the protein level.
PEOl and PE04 are negative for eEFlA2 at the RNA and protein level. K562 and
HL60 are leukaemia cell lines.
eEFlA2 52kDa
GAPDH 36kDa
Figure 4.2 Western blot analysis of the expression of eEFlA2 in ovarian cancer
cell lines.
HeLa cell and mouse muscle protein extracts are known to express eEFlA2 and act
as positive antibody controls and lymphoblastoid is a negative control. PEOl4, 16
and HeLa cells show slightly higher bands for eEFlA2 suggesting that protein may
be post-translationally modified in these cell lines.



















































Figure 4.3 eEFlA2 expression in a panel of cell lines derived from a variety of
tissues and cancers.
eEFlA2 is commonly expressed in cell lines. The only cell line identified as
negative for eEFlA2 expression in this panel was HepG2.
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Table 4.1 Expression ofeEFlA2 in a variety ofcell lines
Cell line Tumour/Tissue type eEFlA2 expression
HeLa Cervical carcinoma Yes
HepG2 Hepatocellular carcinoma No
MCF-7 Breast carcinoma Yes
MDA MB 231 Breast carcinoma Yes
PC12 Phaeochromocytoma (rat) Yes
HCT116 Colon cancer Yes
SHSY5Y Neuroblastoma Yes
4.2.2 eEF1 A2 expression in normal ovary and primary ovarian cancers
Expression of eEFl A2 at the RNA level has previously been examined in an ovarian
surface epithelial cell line (Anand et al., 2002) and reported to be negative. In order
to test this at the protein level, immunohistochemistry was performed on sections of
normal whole ovary with intact ovarian surface epithelium. The results are shown in
figure 4.4. eEFlA2 does in fact seem to be expressed at the protein level in the
ovarian surface epithelium, contradicting the previous report. Additionally, eEFlA2
is also expressed in lutenized stromal cells in the normal ovary. These cells are
found scattered at the edge of the degenerating corpus luteum and are
endocrinologically active, secreting androgenic steroids. The novel expression
pattern of eEFl A2 in the ovary is interesting and may shed new light on the role the
protein is playing in normal cell and organ function.
The expression of eEFl A2 was then examined in a commercial tissue array
containing cores from ovarian cancers by immunohistochemistry. Representative
images of the cancer cores can be seen in figure 4.5. The sections were analysed by
a pathologist and histoscored for expression of eEFlA2. The histoscores for each
cancer type were then grouped into negative (0% at 0 intensity), weak (histoscore 1-
100), moderate (histoscore 101-200) and strong (201-300) and the results are
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N2
Figure 4.4 eEFlA2 expression in normal ovary
N1 shows expression of eEFlA2 in lutenised stromal cells at the edge of a
degenerating corpus luteum. N2 shows the expression of eEFlA2 in the ovarian
surface epithelium (OSE).
Figure 4.5 eEFlA2 expression in ovarian cancer (page 124)
HOV304 is a formalin fixed section from ovarian tumour number FIOV304, which is
a clear cell ovarian cancer and was positive at the RNA and protein level for eEFlA2
expression. T1-T3 are clear cell carcinomas from the commercial tissue array. All
the clear cell carcinomas show high eEFlA2 levels in the epithelium and are
negative for eEFlA2 in the stroma. T4 is an example of a weak eEFlA2-expressing
papillary serous cystadenocarcinoma, T5 is a weak expressing endometrioid
carcinoma, and T6 is a weakly expressing mucinous cystadenocarcinoma. This
clearly illustrates the much stronger eEFlA2 expression level in clear cell
carcinomas compared to the other histological subtypes. CI is the secondary only
control of the tumour T3. Nl, N2 and T1-T3 are at x40 magnification. T4-T6 and
CI are at x20 magnification.
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represented in table 4.2. A limited amount of information was available with this
commercial array: the age of the patient and histological subtype. It appears that
there is an association between high expression of eEFl A2 and histological subtype
in these cancers.






Clear cell 5 1 1 1 2
Serous 15 3 12 0 0
Endometrioid 5 3 2 0 0
Mucinous 2 0 1 1 0
It is apparent from these results that clear cell carcinomas express eEFlA2 more
strongly in comparison to serous, endometrioid and mucinous ovarian cancers; in
total 15% of the ovarian cancers represented on this tissue array express eEFlA2 at a
moderate to high level but 60% of the clear cell carcinomas express eEFlA2 at a
moderate to strong level.
4.2.3 Analysis of eEF1A2 expression at the RNA and protein levels in a
panel of ovarian cancers
In order to investigate the expression of eEFl A2 at both the RNA and protein level
in ovarian cancers, we obtained a panel of human ovarian cancers (coded HOV) for
which RNA, protein and tumour sections were available from most tumours. These
ovarian cancer samples represent the common histological subtypes of ovarian
cancers. The number of available samples in each histological subtype are listed
table 4.3.
Table 4.3 Clinical data available with the in-house TMA
Cancer Total RNA Protein IHC
histotype
Clear cell 7 4 5 2
Serous 27 18 26 14
Endometrioid 13 12 11 8
Mucinous 6 2 2 4
Total 53 36 44 28
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Using real-time RT-PCR analysis the levels of eEFlA2 were assessed in 36 ovarian
cancers and the results shown in figure 4.6a, as well as in figure 4.6b that illustrates
the low level eEFlA2-expressing tumours more clearly. The majority of the cancer
samples showed very low levels of eEFlA2 expression, however, 3 out of the 4 clear
cell cancers analysed (75%) had detectable expression of eEFlA2; only 4 of the 18
serous cancers analysed (22%), 5 of the 12 endometrioid cancers (42%) and neither
of the mucinous cancers showed expression at the RNA level.
To confirm this result at the protein level, protein samples from many of the
corresponding cancers were analysed for eEFlA2 expression by Western blot. The
results are shown in figure 4.7. In some cancers, such as HOV77, eEFlA2 was
expressed at the RNA but not the protein level when assessed by Western blot
suggesting some post-transcriptional mechanism is controlling the expression in
these tumours or that a decrease in stability of the RNA or protein results in a lack of
detectable protein on the Western blot. Alternatively, Western blot analysis could be
too insensitive to detect eEFl A2 expression in these tumours. Four of the five clear
cell carcinomas analysed expressed eEFlA2, as well as one serous and two
endometrioid tumours. In total 16% of the tumours analysed using Western blot
expressed eEFlA2. The results of expression analysis of eEFl A2 at the RNA and
proteins levels, as well as the commercial TMA, are shown in table 4.4.



















Clear cell 4 75 5 80 5 40
Serous 18 22 23 4 14 0
Endometrioid 12 42 11 18 9 0
Mucinous 2 0 5 0 2 0
Total 36 44 30
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It is clear from the table above that eEFl A2 appears to be most highly expressed at
the RNA and protein level in clear cell carcinomas. Overall, 33% of the ovarian
cancers expressed eEFlA2 at the RNA level and 15% expressed the translation
factor at the protein level. Twenty eight of the above tumours had been sectioned
and these were also available for eEFlA2 expression analysis by
immunohistochemistry. This data is presented in table 4.5.
Table 4,5 Expression ofeEFlA2 in HOV tumour samplesfor which both Western











8 Serous Negative Negative 1
9 Endometrioid Negative Strong 1
14 Endometrioid Positive Negative 2
76 Serous Negative Weak 2
88 Endometrioid Negative Negative 2
180 Serous Negative Weak 1
270 Serous Negative Negative 1
278 Serous Negative Negative -
285 Serous Negative Negative -
295 Mucinous Negative Negative Negative
296 Endometrioid Negative Moderate 2
300 Endometrioid Negative Weak 1
303 Serous Positive Strong -
304 Clear cell Positive Strong 3
308 Endometrioid Negative Negative Negative
311 Serous Negative Negative -
380 Clear cell Positive Negative -
386 Serous Negative Moderate 2
397 Serous Negative Weak -
432 Unknown Negative Negative -
449 Mucinous Faint positive Negative -
491 Endometrioid Negative Negative -
496 Serous Negative Negative 1
512 Mucinous Negative Moderate 2
518 Mucinous Negative Weak -
524 Serous Negative Strong 3
538 Serous Negative Negative 1
545 Serous Negative Strong 1
560 Endometrioid Negative Negative 1
TOTAL 29
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The IHC analysis revealed that many of the cancers that were positive at the RNA
level using quantitative RT-PCR but not at the protein level by Western blot, were in
fact positive by immunohistochemistry, as shown in table 4.5. RNA levels were
classified as negative (no transcript), 1 (<1 standardised amount of eEFlA2
message), 2 (between 1 and 2) ard 3 (>2). Tumours HOV9, 296, 386, 389, 397, 512,
518, 524, 545 were positive at the RNA level and by IHC but not on Western blot
analysis. Tumours HOV386 and HOV524 express moderate to high levels of
eEFlA2 at the RNA level and therefore the negative result by Western blot was
perhaps not expected but the positive IHC result suggests that Western blot analysis
was not sensitive enough to detect the protein expression in these cancers. An
example of the IHC staining of these tumour sections can be found in figure 4.5
(HOV 304). The IHC staining does appear to correlate better with the RNA
expression seen in the HOV panel suggesting that it is a more sensitive and effective
technique than Western blotting for analysing protein expression in tumours. In total
5 (18%) tumours showed weak eEFlA2 expression, 3 (11%) showed moderate
eEFlA2 expression, and 5 (18%) showed strong eEFlA2 expression. Therefore, in
total 29% of the HOV ovarian tumours expressed moderate to high levels of eEFlA2
at the protein level when assessed by IHC, 33% express eEFlA2 at the RNA and
15% express eEFlA2 when assessed by Western blot. In addition, 15% of cancers
analysed on the commercial TMA expressed eEFlA2 at a moderate to high level.
4.2.4 There is a significant association between high eEF1A2 expression
and the clear cell carcinoma histological type of ovarian cancer
There was no apparent association between the grade, stage of the ovarian cancers
and eEFl A2 expression, however there did appear to be expression of eEFlA2 in the
majority of the clear cell carcinomas investigated. In order to test whether the
apparent association between eEFl A2 expression and clear cell carcinomas was
statistically significant, a Fisher's exact test was used to test the results from
immunohistochemical and Western blot analysis. For the immunohistochemical
results a 2x2 contingency table was constructed with clear cell carcinomas and other
histological types of ovarian cancer against [weak to negative] expression, and
[moderate to strong] expression of eEFlA2; this gave a significant association
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between moderate and strong expression of eEFlA2 and CCC, p=0.03, see 2x2
contingency table below.
Weak and Negative Moderate and strong
Clear cell carcinomas 2 3
Other histological subtypes 21 1
Western blot data was divided into clear cell carcinomas and other cancer
histological types versus positive and negative for eEFlA2 expression; this also gave
a highly significant association between eEFl A2 expression and CCCs, p=0.0012,
the 2x2 contingency table is shown below.
Positive Negative
Clear cell carcinomas 1 4
Other histological subtypes 36 3
4.2.5 Further immunohistochemical analysis of an ovarian cancer tissue array
with a high clear cell carcinoma representation
The lack of clinical data available with the commercial ovarian cancer array meant
its usefulness in assessing clinical associations with eEFlA2 expression were
limited. We therefore obtained a tissue micro array from Alistair Williams,
Edinburgh New Royal Infirmary. This in-house array contains cores from 171
different ovarian cancers, 30 ofwhich are clear cell carcinomas, allowing me to
confirm or otherwise the association seen in the limited number of samples from the
previous analyses.
Four different slides of the TMA (AGOV1-4), i.e. 4 cores from each tumour and one
on each slide, were stained with the rabbit anti-eEFlA2 antibody 1A2-3 using the
Envision immunohistochemistry protocol. Positive and negative human control
tissues were also subjected to the immunohistochemical protocol to confirm antibody
specificity and a secondary only control was included.
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Representative microscope images of the cores can be found in figure 4.8. The slides
were then scored using the histoscore method detailed previously on each slide and
an average histoscore for each cancer, from the scores for all four cores, was
calculated. The TMA AGOV4 was also examined by the pathologist Alistair
Williams and histoscored using an automated method for quantification ofDAB
staining (method not detailed). The average histoscores obtained by automated
analysis are shown in brackets in table 4.6.
Table 4.6 Average histoscores ofeEFlA2 expression by histological subtype on a









Clear cell 45% (0.07%) 87.6(14.5)
Endometrioid 13.3% (0%) 66.2 (5.7)
Serous 40% (0.06%) 73.15 (2.3)
Mucinous 19% (0%) 48.7 (8.2)
Mixed 50% (0%) 103.7 (9.3)
Mixed including clear cell 43% (0.1%) 81 (27)
MMVT 17% (0%) 46.5 (11.5)
The above representation of average histoscores calculated by eye, suggests that
although eEFlA2 is more highly expressed on average in clear cell ovarian cancers
than in the other main subtypes (apart from mixed for which there are very few
tumours), eEFl A2 expression is not present in substantially more CCCs compared to
the serous or endometrioid tumours. The histoscores on AGOV4 only, by automated
analysis (data in brackets), are all very low but are higher in the clear cell and mixed
+ clear cell histological types of ovarian cancer.
Chapter 4 eEFlA2 is highly expressed in clear cell ovarian carcinomas 133
'
Kf-" 1 ' f Wi
T111
1 ■m*% t - . IHm■HHHi
Tl
; J't








V- ' V *
. *'• ■ v:":
• m - ■ . <
, 9 * -i# * . '• • ' ' '"•<? - ■ ,
T6 SO
Figure 4.8 Immunohistochemical eEFlA2 staining of epithelial ovarian cancer
cores on an in-house tissue micro array.
(Tl) A clear cell carcinoma with the highest histoscore for eEFlA2 expression. (T2)
clear cell carcinoma Tl at a lower magnification. (T2 and T3) Clear cell carcinomas
staining weakly for eEFlA2. (T4) mucinous carcinoma (T5) serous carcinoma (T6)
endometrioid carcinoma all showing weak expression of eEFlA2. (SO) Secondary
antibody only control on Tl. All images are at x40 magnification apart from Tl
(right) and SO, which are at x20 magnification.
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When the histoscores are subdivided into negative, weak, moderate, and strong for
eEFlA2, see table 4.7, clear cell carcinomas are the only histological type that
express eEFl A2 strongly. The numbers in each category from automated scoring of
AGOV4 are shown in black and manual scoring results are shown in red.
Table 4.7 The degree ofeEFlA2 expression in ovarian histological subtypes.








Clear cell 30 30 18 4 10 13 1 10 1 3
Serous 50 52 34 3 16 34 3 15 0 0
Endometrioid 29 28 23 3 6 20 0 3 0 0
Mucinous 9 21 6 1 3 16 0 4 0 0
Mixed 10 10 7 0 3 5 0 5 0 0
Mixed + clear
cell
11 13 5 0 5 8 0 5 1 0
MMVT 5 5 2 1 5 3 0 1 0 0
The manual histoscoring technique appears to elevate the scores of the cores into
weak and moderate, from the negative classification they were assigned in the
automated scoring method. If indeed the automated histoscores are more accurate
and thus only 5% of the ovarian cancers express eEFl A2 at a moderate to high level,
this is substantially lower than the 15% exhibiting this expression level in the
commercial tissue array. In addition only 2 out of the 30 (6%) clear cell carcinoma
cores on the in-house TMA showed positive staining for eEFlA2 as opposed to 40%
of clear cell tumour cores on the commercial TMA expressing eEFl A2 strongly.
This additional evidence does appear to suggest that eEFlA2 is not preferentially
expressed in clear cell carcinomas.
In conclusion, an association between eEFl A2 expression and ovarian clear cell
carcinomas was found in the analysis of a panel of 57 ovarian cancers by quantitative
real-time PCR and Western blot analysis as well as by immunohistochemistry on a
commercial tissue array. However, although the highest eEFl A2-expressing ovarian
tumours on the large in-house TMA were clear cell carcinomas, the association was
no longer apparent.
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4.6 Discussion
My observation of eEFlA2 expression in the normal ovarian surface epithelium is
contrary to a previous report that the OSE is negative for eEFlA2 (Anand et ah,
2002). Anand et al. used a normal ovarian epithelial cell line called NOV-61,
derived from OSE, to investigate the expression of eEFlA2 at the RNA level by
Northern blotting. My immunohistochemical analysis was carried out on whole
ovary including intact OSE and therefore is perhaps more representative of the actual
expression in the human OSE. Transformation and culturing cells can cause
alteration in gene expression and I have shown that the majority of cell lines
analysed express eEFlA2, regardless of their tissue of origin. In addition, I observed
expression of eEFlA2 in 10 of 12 ovarian cancer cell lines; this is higher than the
percentage ofpositive primary ovarian tumours suggesting transformation induces
eEFl A2 expression. In a microarray analysis of genes differentially expressed in
cultured normal ovarian surface epithelial cells (HOSE) and epithelial cells from
epithelial ovarian cancers (CSOC), eEFl A2 was shown to be expressed 7.3-fold
higher in HOSE than CSOC cells (Matei et al., 2002). The expression of eEFl A2 I
observed in the OSE was not higher than the expression at the protein level in the
epithelial ovarian cancers I analysed - particularly the clear cell histological subtype
- but the higher expression in HOSE observed by Matei et al. may be due to the
culturing of the epithelial cells. In conclusion there is evidence to suggest that
eEFlA2 is expressed in normal OSE and it is not clear why Anand et al. did not find
the normal OSE cell line NOV-61 to be positive for eEFlA2, despite the fact that it
was derived from a cell type we have shown to be positive for eEFlA2 and the high
frequency of eEFlA2 expression in cultured cells.
The origin of epithelial ovarian cancers is a topic of great debate. One theory is that
the majority of epithelial ovarian cancers arise from the ovarian surface epithelium
due to incessant ovulation (Fathalla, 1971) or from OSE inclusion cysts in the
ovarian stroma (Radisavljevic, 1977). However, a proportion of mucinous tumours
are thought to have a germ cell origin and a large percentage of clear cell carcinomas
and endometrioid cancers are hypothesised to form from the precursor lesion of
endometriosis (Feeley and Wells, 2001). Therefore the OSE may only be a totally
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appropriate normal tissue of origin control for serous adenocarcinomas and not other
histological types of ovarian cancer. The fact that normal OSE expresses eEFlA2
and two-thirds of ovarian cancers do not suggests that this is not the tissue of origin
ofmany of these cancers or that eEFl A2 expression is down-regulated during
malignant progression of the majority of ovarian cancers.
Not only did the majority of ovarian cancer cell lines appear to express eEFlA2 but
PE014 and PE016 appeared to express a slightly larger protein than the other cell
lines. One possible explanation for this size difference is that PE014 and 16 express
a post translationally modified form of eEFlA2. For example there are two
predicted phosphorylation sites in eEFlA2 that are highly conserved between mouse,
chicken and xenopus and are not present in eEFl A1 (Newbery et ah, in preparation)
and these sites are shown in figure 4.9 (the sequences were aligned using Clustal W
(Thompson et ah, 1994)). It is possible that eEFlA2 is phosphorylated in the PE014
and 16 cell lines and this could potentially alter the function of the protein. Anand et
al. used Northern blot analysis to detect expression of eEFl A2 in a panel of ovarian
cancer cell lines and found only four of the ten cell lines were positive for the
translation factor (Anand et al., 2002). Interestingly they showed OVCAR4 to be
negative for eEFl A2 whereas my Western blot analysis suggests this cell line does in
fact express eEFlA2. The difference between my results and those of Anand et al.
may be due to the higher sensitivity of real-time RT-PCR and Western blots over
Northern blot analysis or differences between sublines of the cell line. Joseph et al.
examined the expression of 36 translation factors in a variety of cancer cell lines and
found that eEFl A2 showed the most significant level of overexpression and was
present in 9 of the 10 cell lines analysed (Joseph et al., 2004). This is consistent with
the levels of eEFlA2 expression I observed in the cell lines.
eEFlA2 expression was detected in 33% of ovarian cancers at the RNA level and
15% at the protein level by Western blot and 28% by IHC in the HOV panel of
tumours, suggesting that Western blotting is not detecting eEFlA2 present in some
tumours.
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Figure 4.9 Clustal W alignment of eEFlA protein sequences from Human,
Mouse, Chicken and Xenopus
The top three sequences are xenopus, mouse and human eEFlA2. The bottom three
sequences are human, mouse and chicken eEFlAl. There are very few amino acid
differences in eEFlA between species or between the two variants, eEFlA2 and
eEFl Al. The predicted phosphorylation sites present in eEFl A2 but not eEFlAl are
shown surrounded by a black box. These regions are highly conserved between
species. A star (*) indicates amino acid identity, two dots indicate a conservative
amino acid difference, and one dot a semi-conservative substitution.
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For instance tumours HOV386 and 524 were positive for eEFlA2 using quantitative
real-time RT-PCR and IHC but not using Western blot. In total, of thel4 tumours
that were positive at the RNA level but negative for protein expression using
Western blot, 9 were positive for eEFl A2 when investigated using IHC. This
suggests that IHC on tumour sections and not Western blotting should be used to
investigate protein expression and that eEFlA2 is expressed only at the RNA level
and not at the protein level in only 5 of the tumours that were investigated by IHC.
Additionally, approximately the same proportion of the HOV tumours express
eEFlA2 at the RNA level (33%) and at the protein level (29%) when assessed by
IHC suggesting that IHC gives a more accurate picture of eEFl A2 expression.
A significant association between eEFlA2 expression and clear cell ovarian
carcinomas (CCC) was observed when detecting eEFlA2 using Western blots
(p=0.0012) and immunohistochemistry on the commercial TMA (p=0.03). Clear cell
carcinomas only constitute approximately 10% of all ovarian cancers but eEFlA2 is
expressed in approximately one-third of ovarian cancers, making the observation of
an association with CCC surprising. Although the HOV panel contains mostly
serous carcinomas, which is representative of the proportion of ovarian cancers that
arise in humans, it contains more than 10% clear cell carcinomas (10 of 53, 19%)
potentially explaining the identification of the association in the HOV panel analysis.
CCC is a very distinct subtype of epithelial ovarian carcinoma, often described as
having a poor prognosis due to its resistance to platinum-based chemotherapy (Goff
et ah, 1996). The identification of genes differentially expressed in CCC could be
important in determining the genetic cause of the poor prognosis of this subtype
compared to others. As mentioned previously, eEFlA2 has been identified by
microarray analysis to be more highly expressed in CCC compared to other
histological subtypes of epithelial ovarian cancer (Schwartz et ah, 2002). Although
my initial analysis confirmed this observation a caveat to my analysis was that it was
carried out on a small number of clear cell carcinomas (n=10). The small number of
clear cell carcinomas in the ovarian cancer panel and TMA reflects the fact that CCC
is rare, accounting for only 10% of all cases of epithelial ovarian carcinoma. The
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lack ofCCCs in the analysis was overcome by the inclusion of a larger tissue array
containing cores from 30 different clear cell carcinomas. In this analysis 45% of the
CCCs expressed eEFlA2 at a moderate to strong level when histoscored by eye.
This is not substantially different from the proportion of serous (40%) or mixed
(50%) ovarian cancers that express eEFl A2 at this level and consequently the
significant association between CCC and moderate to strong expression of eEFlA2
has not been replicated in this larger TMA. Nevertheless, 4 of the 5 high eEFlA2-
expressing tumours were CCCs suggesting that eEFlA2 is more highly expressed in
this histological subtype. In summary, the analysis of a larger number of clear cell
carcinomas suggests that eEFlA2 would not in fact be a good biomarker for CCC, as
it had first appeared.
The histoscoring of tissue microarray AGOV4 by Alistair Williams using an
automated method for quantification ofDAB staining did not show good
concordance with the average histoscores ofmultiple cores or the AGOV4 scores
obtained by eye. In fact, the majority of the histoscores of eEFl A2 levels generated
by automated analysis were negative or low. Only one clear cell tumour and one
tumour ofmixed histology including clear cell was histoscored as high (201-300) for
eEFl A2. Although the detailed protocol for the automated technique is unpublished
the analysis involves the subtraction of background staining observed on the
secondary-only control from the histoscore for each individual core. The intensity of
staining and the volume of tumour exhibiting that staining are measured and the
volume adjusted score is produced, in much the same way as is done by eye. The
subtraction of background staining was not carried out in the manual histoscoring
and may account for some of the differences in histoscores using the different
methods. Additionally, the automated technique may not be as sensitive to subtle
levels of staining. On the other hand the automated method may give a more
accurate picture of the actual level ofDAB staining on the tumour cores. Taking the
automated histoscores as correct, the percentage of cores that stained moderate to
strong for eEFlA2 was 5%, as opposed to 15% in the commercial array. Given that
the 15% is more consistent with the results from my RNA (33%) and protein (16%)
analysis and with the proportion of eEFl A2-expressing ovarian tumours identified
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by Anand et al. (Anand et al., 2002) this suggests that the results from the
commercial TMA may be more accurate. The in-house TMA was stained using the
Envision secondary antibody staining method and this method when used on a breast
cancer TMA also resulted in a lower number of eEFlA2-positive tumours compared
to the earlier IHC protocol, suggesting that there may be a technical problem with the
in-house TMA. It is also possible that a difference in the way the in-house TMA was
produced resulted in fewer eEFlA2-positive tumours, such as tissue fixation or
storage.
The observation that p53 is rarely mutated in CCC (Okuda et al., 2003) is
particularly interesting considering that eEFlA2 expression in breast carcinomas
appeared to associate weakly with tumours that did not show mutations in p53.
Therefore wild-type p53 may be important to eEFlA2 expression in these breast
cancers and clear cell carcinomas. Equally interesting is the profile of abnormalities
in DNA sequence copy number in clear cell adenocarcinomas. Increases in copy
number that have been identified in more than 20% ofCCCs include an increase in
copy number of 20ql3-qter, the chromosomal location ofEEF1A2. This
amplification of20ql3-qter correlated with increases in 17q25-qter and together the
presence of these two amplicons correlated with recurrent disease and non-surviving
patients. Amplifications were also observed at various loci on chromosome 8q that
occurred more frequently in disease-free, surviving patients. This suggests there are
2 subtypes ofCCC, one being associated with increases in 8q and the other with
increases in 17q25-qter and 20ql3-qter, the latter being poorer prognosis (Suehiro et
al., 2000). Therefore, in the CCCs that eEFlA2 isn't expressed there may be a
prevalence of 8q amplification and vice versa. Additionally, eEFlA2 may be one of
the genes in the 20ql3-qter amplicon that is contributing to the more aggressive
nature of this subtype of CCC. However, the recent identification of an association
between increased 20 year survival and eEFlA2 expression in breast cancers
suggests this may not be the case (Kulkarni et al., 2006).
The chemoresistant nature ofCCCs distinguishes them from other histological types
(Sugiyama et al., 2000). As eEFl A2 may be highly expressed in some CCCs
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compared to the other histological types it could be involved in this distinct
phenotype. Indeed, glutathione peroxidase 3 is involved in the oxidative stress
response and is highly expressed in CCCs and it has been suggested that this
contributes to the chemoresistance exhibited by CCCs (Hough et ah, 2001), possibly
by decreasing the high levels of the free radicals induced by chemotherapy that
would otherwise lead to irreversible cell damage and eradication of the tumour by
overloading the antioxidant system (Kong and Lillehei, 1998).
On the other hand, oxidative stress has been proposed to decrease the efficacy of
chemotherapy. Platinum coordination complexes, the chemotherapeutic drug to
which CCCs are commonly resistant, induce high levels of oxidative stress.
Oxidative stress during chemotherapy induces lipid peroxidation generating
electrophilic aldehydes leading to a decrease in the efficacy of chemotherapy by
reducing the rate of cellular proliferation and inhibiting apoptosis. Oxidative stress
induces apoptosis by causing DNA damage, but in excessive oxidative stress (as
occurs in Platinum-based chemotherapy) caspase activity is inhibited by the binding
of electrophilic aldehydes to the active site (Conklin, 2004). eEFlA2 overexpression
is thought to be protective against apoptosis induced by hydrogen peroxide (H2O2) (a
mediator of oxidative stress) (Chen et al., 2000) and even more so in combination
with peroxiredoxin-1; this anti-apoptotic effect is thought to be mediated by an
increase in the abundance of the pro-survival factor Akt (Chang and Wang, 2006).
Therefore eEFlA2 expression in clear cell carcinomas could possibly contribute to
chemoresistance by contributing to the inhibition apoptosis in high oxidative stress.
In conclusion, eEFl A2 is expressed in up to one-third of epithelial ovarian
carcinomas and this expression is particularly high in clear cell carcinomas compared
to other histological subtypes, however the apparent association of moderate to high
eEFl A2 expression and clear cell carcinomas was not reproduced with a larger
TMA.
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Chapter 5: The mechanism of overexpression of eEF1A2 in
ovarian cancer
5.1 Introduction
Amplifications at 20q13 in ovarian cancer
Regions of 20q are frequently observed to be amplified in ovarian cancer. It is likely
that genes in regions of recurrent imbalance in cancer are important in the
pathogenesis of that disease. Many studies have found that it is a region in 20ql3.2
that is frequently amplified in ovarian cancer (Tanner et al., 2000), (Diebold et ah,
2000); this region does not include EEF1A2 which is located at 20ql3.3. On the
other hand other studies have suggested that amplification in ovarian cancer may also
involve 20ql3.3, and that 20ql3.2 and 20ql3.3 may in fact be separate amplicons.
CGH in 25 malignant ovarian tumours showed that 20ql3.2-qter was a frequently
observed chromosomal amplification, particularly in advanced stage and high grade
tumours and may be associated with disease progression (Sonoda et ah, 1997). A
study of a small number of clear cell ovarian adenocarcinomas suggested that they
can be divided into two subtypes based on recurrent copy number changes; those that
show an amplification of 8q and those that harbour amplifications in both 17q25-qter
and 20ql3-qter. Amplifications at 20ql3-ter in these clear cell adenocarcinomas
tended to occur more frequently in later stage cancers (stage II-IV) and were
significantly higher in high-grade malignant tumours. Importantly they also
identified that 20ql3-qter amplifications were significantly more frequent in
recurrent disease/non-surviving patients (Suehiro et ah, 2000). Watanabe et al. also
identified 20ql2-13 to be frequently amplified in ovarian cancer cell lines (Watanabe
et ah, 2001). The frequent amplification of20ql3-qter in ovarian cancer suggests
that this region contains oncogene(s) and EEF1A2 is a potential candidate; this was
recently confirmed by Anand et al. who determined that EEF1A2 is amplified in
25% of ovarian cancers, overexpressed in one-third of ovarian cancers, and capable
of transforming NIH 3T3 cells as well as driving tumour formation in mouse
xenografts (Anand et ah, 2002).
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DNA methylation and cancer
Methylation is a heritable epigenetic modification ofDNA that acts to regulate the
expression of genes. DNA methylation involves the addition of a methyl group to
the 5th carbon position on the ring of cytosine within CpG dinucleotides via
methyltransferase enzymes (Doerfler, 1983),(Riggs and Jones, 1983). Vertebrate
DNA is generally depleted of the dinucleotide CpG, however some genes contain
CpG islands, which are regions that show a high frequency ofGC compared to the
bulk genome. These CpG islands are associated with the 5'ends of housekeeping
genes and approximately half of tissue-specific genes. Tissue-specific genes also
contain CpG islands at their 3' ends and some genes can contain CpG islands at both
the 5' and 3' ends (Gardiner-Garden and Frommer, 1987). CpG islands nearly
always encompass gene promoters and exons and the CpGs within islands are
generally unmethylated while whose outside islands are generally methylated
(Costello and Plass, 2001). EEF1A2 is a tissue-specific gene and contains putative 5'
and 3' CpG islands. It has been shown that in many tissue-specific genes there is no
methylation in the normal tissues in which they are expressed. In normal cells
methylation is important for the transcriptional repression of imprinted genes
(Brannan and Bartolomei, 1999) and X-chromosome inactivation (Migeon, 1994). It
has also been shown to be important in the maintenance of chromosomal integrity in
gene deficient regions such as pericentromeric heterochromatin and as a defence
against mobile genetic elements (Bestor, 1998). For a comprehensive review of
DNA methylation patterns see (Bird, 2002).
In cancer, methylation has been widely shown to be abnormal. Tumours in general
show a specific alteration in methylation pattern: global DNA demethylation
concomitant with local hypermethylation at the 5' regulatory regions of certain
genes; the level and frequency of hypomethylation has been shown to increase with
tumour progression. This pattern of aberrant methylation has been observed in pre-
malignant cells suggesting it is not simply a consequence of the malignant state. It is
not known whether genome hypomethylation and localised hypermethylation are
mechanistically linked. Hypermethylation can inactivate gene transcription in cancer
either by biallelic methylation or methylation accompanied by mutation. Examples
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of aberrant hypermethylation leading to gene silencing have been identified in genes
involved in many of the processes ofmalignant progression. These include
Retinoblastoma (RB), E-cadherin (CDH1) and the oestrogen receptor 1 (ESR1), see
review by (Costello and Plass, 2001).
Global hypomethylation has been suggested to contribute to malignancy by
transcriptional activation of oncogenes, activation of latent retrotransposons and
chromosomal instability. Hypomethylation and activation ofproto-oncogenes is less
well studied than hypermethylation in tumour suppressor genes. C-myc, Ha-Ras and
ERB-A1 have been shown to harbour demethylation at individual CpGs but there is
no evidence that this leads to activation of the gene (Kisseljova and Kisseljov, 2005).
However, tissue-specific genes with regulatory regions that are methylated in normal
tissues have been shown to be demethylated and expressed in tumours. An example
of this is the proto-oncogene HOX11, which is a transcription factor that is only
expressed during embryogenesis. In T-cell acute lymphoblastic leukaemia HOX11 is
expressed and its promoter is unmethylated but in normal T cells the promoter is
methylated (Watt et al., 2000). A further example is the tissue-specific gene
Synuclein y, usually expressed in peripheral nervous system, Synuclein y is highly
expressed and the CpG island in exon 1 hypomethylated in breast and ovarian cancer
cell lines and primary breast cancers but hypermethylated and not expressed in
normal breast cell lines or normal mammary tissue and ovarian surface epithelium
(OSE) (Gupta et ah, 2003). This could potentially be the case in EEF1A2; the CpG
island in exon 1 of the gene may be methylated in normal OSE and hypomethylated
in ovarian cancer. Hypomethylation is also thought to lead to the expression of
cancer-testis antigens called MAGE, GAGE and LAGE, and genes involved in
invasion and metastasis, such as uPA, in certain cancers (Kisseljova and Kisseljov,
2005).
The mechanism of overexpression of eEF1A2 in ovarian cancer
EEF1A2 was identified as a potential oncogene in ovarian cancer by Anand et al.
They observed, using FISH, that an increase in EEF1A2 copy number was present in
14 of the 53 (25%) of the primary ovarian cancers. Of the primary tumours
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expressing eEFl A2 (3 of 11 tumours analysed), one did not show amplification in
the gene suggesting another mechanism could be responsible for inappropriate
expression of the protein (Anand et al., 2002). The small number ofprimary ovarian
cancers analysed for eEFlA2 expression and mechanism of overexpression, makes it
difficult to conclude whether or not gene amplification is the main mechanism by
which eEFlA2 overexpression is mediated. I therefore, having completed
expression analysis of eEFl A2 in a panel of ovarian cancers, sought to establish the
possible mechanism(s) mediating the overexpression of the gene. As described
above, overexpression of eEFlA2 is likely to involve DNA amplification but gene
mutation and methylation may also play a role.
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5.2 Results
5.2.1 A quantitative real-time PCR method for determining the copy
number of EEF1A2 in ovarian cancer
In addition to RNA and protein from the ovarian cancer panel (HOV) there was also
DNA available. Using a real-time PCR assay I determined the copy number of
EEF1A2 in the panel of ovarian tumours for which I have previously determined the
expression status of eEFlA2. Analysis of copy number at a particular locus is
routinely determined using techniques such as FISH or CGH. However, I only had
DNA (and not cell lines) from these ovarian tumours in limited amounts available to
me and therefore had to use a PCR technique. With larger quantities ofDNA
available to me I could have also used Southern blotting to assess the copy number of
EEF1A2.
I began by designing primers in the intron ofEEF1A2 to utilise in the quantification
of the copy number of the EEF1A2 locus. The intronic sequences in EEF1A2 and
EEFlA1 are, unlike the coding sequence, highly diverged and therefore using
primers annealing to this sequence avoids primer cross hybridisation with EEFlA1 or
with any of the EEF1A1 pseudogenes. For normalisation of total DNA amount in the
reaction I used 3 different pairs ofmicrosatellite primers. This technique, although
not commonly used for copy number determination, has been used by Ginzinger et al
(Ginzinger et al., 2000). Ginzinger et al. used PCR analysis of copy number at
microsatellite loci to determine relative DNA sequence copy number. They used this
technique to determine the copy number ofZNF217 in ovarian cancers and to
replicate a study that found an association between an increase in copy number and
decreased survival. Microsatellite markers are useful as reference genes because the
primers and PCR reaction conditions are well characterised, and they are distributed
throughout the genome. I used three pairs of the microsatellite primers used by
Ginzinger et al. in their human reference pool 2; these amplify regions of the genome
thought to be stable in ovarian cancers (Ginzinger et al., 2000). These were D2S385,
which amplifies a region of chromosome 2q31, D5S643 that amplifies a region in
5q32 and D1 IS 1315 that amplifies a region of 1 lpl5. Three reference microsatellite
markers were used because cancers are genomically unstable and therefore if one of
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the three pairs of primers gave a dramatically different amount of product from the
others this one could be excluded from the analysis.
In order to assess the validity of the technique the copy number ofEEF1A2 was
determined in 5 different DNA samples from human blood obtained from the
National Blood Transfusion service. These are expected to have a normal
chromosomal content and therefore be diploid for EEF1A2. The average copy
number of EEF1A2 in these samples was 2.4. In order to further validate this
technique gDNA from blood was spiked with 1000 copies of a human EEF1A2 Pi-
derived artificial chromosome (PAC) and analysed for EEF1A2 copy number in
triplicate. The EEF1A2 copy number is then normalised to the reference locus copy
number and the EEF1A2 copy number in the spiked DNA is standardised to the copy
number is the unspiked control DNA. The copy number of the spiked DNA was
approximately 1160 (SD+/- 457) times that of the unspiked DNA, see figure 5.1.
The standard deviation is large (40% of the mean) suggesting that there was large
variation between the replicates and that the measurement is not as accurate as it
could be. Perhaps a more effective validation of the method would have been to
construct a standard curve of known copy numbers ofEEF1A2 from a human PAC
or BAC containing the EEF1A2 genomic sequence.
I then determined the EEF1A2 copy number by the above method in ovarian cancers
that express eEFlA2 at the RNA and/or protein level, as well as 8 ovarian cancers
that do not express eEFl A2 see figure 5.2. The EEF1A2 copy number was
normalised to the copy number of 3 control microsatellite loci thought to be stable in
ovarian cancer. EEF1A2 was amplified at a significant level (more than 2 SDs from
normal DNA) in 12 of the 15 (80%) ovarian cancers expressing eEFlA2 at the RNA
or protein level. In cancers HOV183, 481 and 179 EEF1A2 copy number was less
than two standard deviations from the copy number in normal blood DNA and
therefore there is no evidence of amplification. In those cancers not expressing
eEFl A2, all eight had EEF1A2 copy numbers significantly exceeding that found in
normal diploid blood DNA.
















Figure 5.1 Real-time PCR analysis of EEF1A2 copy number in gDNA and
gDNA spiked with an E777/12-con ta in ing PAC.
EEF1A2 copy number was normalised to the copy number of 3 reference
microsatellites. The normalised level of EEF1A2 is 1160 times higher in PAC
spiked gDNA than in gDNA alone. This confirms the PCR technique for analysis of
EEF1A2 copy number is effective.
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Figure 5.2 EEF1A2 copy number in ovarian cancers
The mean normalised EEF1A2 copy number in normal gDNA (black), ovarian
cancers expressing eEFlA2 at the RNA and/or protein level (red) and ovarian
cancers that do not express eEFl A2 (blue). Error bars show 2 SDs of the mean.
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The copy number ofEEF1A2 ranged from low, 3-5, to medium 6-12; none of the
cancers showed high copy numbers at this locus. Unexpectedly, the range of copy
numbers appears to be very similar between the expressing and non-expressing
cancers. In fact it was a non-expressing tumour, HOV170, which showed the
greatest EEFJA2 copy number. The similar pattern of copy number changes
between non-expressing and expressing tumours suggests that gene amplification is
not the only mechanism mediating the overexpression of eEFlA2 and may even be
irrelevant for overexpression.
The level ofEEF1A2 amplification does not appear to be associated with histological
subtype, FIGO stage or grade of the ovarian cancers or with recurrent non/surviving
patients, see table 5.1.
Table 5.1 The levels ofEEFlA2 amplification and tumour histological subtype,
















3.7 183 Y Serous 3 2 Y
3.8 481 Y Endometrioid 3A 3 N
4.2 179 Y Endometrioid 4 3 Y
4.4 76 N Serous 3 3 Y
4.4 470 N Serous 3C 3 N
4.8 380 Y Clear cell 1A 2 N
5.1 8 N Serous 3C 3 Y
5.4 5 Y Endometrioid 1C 3 N
5.6 104 Y Clear cell lc Y
5.9 303 Y Serous 3C 3 N
6.17 388 N Serous 4 3 Y
6.5 308 Y Endometrioid 2C 3 N
6.7 77 N Clear cell 3B 3 Y
7.3 304 Y Clear cell 2C N
7.5 12 Y Clear cell 1C 2 N
7.9 188 Y Serous 4 3 Y
8.1 14 Y Endometrioid 3 3 Y
8.3 417 N Endometrioid 3C 3 N
8.5 88 Y Endometrioid 1C 2 Y
9.5 21 N Serous 3 3 Y
10 524 Y Serous 3C 3 Y
10.4 496 N Serous 1C 3 N
12 170 N Serous 3 3 Y
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A comparison of the EEF1A2 copy number against the expression of eEFlA2 at the
RNA level also suggests that there is no correlation between level of amplification
and expression, see figure 5.3. For some of the tumours only protein and not RNA
was available for expression analysis and therefore these tumours are not represented
in this figure.
The real-time PCR technique used for this analysis suggests that 80% of the ovarian
cancers analysed have an amplification ofEEF1A2. Anand et al. found using FISH
that amplification of 20ql3.3 was only present in 25% of ovarian cancers and many
other studies suggest that amplification at different regions on chromosome 20ql2-
13 occur in approximately 50% of ovarian cancers (Sonoda et al., 1997; Tanner et
al., 2000). However, Diebold et al. have identified a amplification at 20ql3.2 in
70% of dissociated nuclei from invasive ovarian carcinoma mainly of the serous type
(Diebold et al., 2000). Nevertheless, the majority of studies have shown 20q
amplification to be found at a frequency of approximately 50% in ovarian cancers
suggesting that either the PCR technique does not give an accurate picture of the
EEF1A2 copy number or that this gene is independently amplified to a higher extent
than the surrounding region on chromosome 20.
5.2.2 The increase in EEF1A2 copy number is not due to chromosome 20
polyploidy
The real-time PCR technique used to determine the copy number ofEEF1A2 does
not allow the differentiation between a gene or chromosomal region amplification
and a whole chromosome 20 number aberration. In order to determine whether any
increase in copy number is due to polyploidy of chromosome 20 a real-time PCR
technique was again used. Primers that amplify microsatellite loci on the p arm of
chromosome 20, D20S804 and D20S819, were used to determine the amount of 20p
present in the cancers and then compared to the copy number ofEEF1A2 determined
previously. D20S804 is located at 20pll.23 and D20S819 is located at 20pl2.3;
these primers amplify regions separated by 10Mb of sequence.
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Figure 5.3 eEFlA2 expression at the RNA level in ovarian cancers with
increasing copy number.
It is apparent that an increase in EEF1A2 copy number (left to right) does not result
in an increase in the RNA expression level of eEFlA2.
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A slightly different real-time PCR amplification and analysis method was used to
assess the copy number at the 20p loci from that used to quantify the EEF1A2 copy
number. For normalisation ofDNA amount only the microsatellite primer D2S385
was used. The region of chromosome 2pl3 that these primers amplify did not show
copy number alterations compared to the other reference microsatellite primers in
previous analysis and therefore can be used in isolation for normalisation of these
same DNA samples in this instance. The PCR efficiency of D20S804 and D20S819
was determined following the previous method. D20S804 was then subsequently
chosen for the initial analysis of copy number of 20p.
A standard curve method was used in this analysis and involves the inclusion of a
standard curve for each primer pair on every PCR plate. This method can be applied
to this experiment because only 2 products are being amplified whereas 4 where
being amplified in the EEF1A2 copy number analysis. The standard quantity mean
for each DNA sample was calculated relative to the standard curves. A ratio of the
standard quantity mean ofD20S819 and D2S385 was then taken. In the majority of
the ovarian cancers this ratio was approximately 1, as expected if there are diploid
copies at both loci, see figure 5.4. However, ovarian cancers HOV303, 104, 417,
496 and 76 appeared to show losses at 20pl2 and HOV 14 appeared to have a gain in
this region. I therefore repeated quantitative real-time analysis on these DNA
samples using the D20S819 primers. Tumours HOV303 and 104 still showed a loss
of 1 copy at this region, suggesting a 20p deletion or a whole chromosome deletion
in these cancers. If there is a whole chromosome deletion present in these tumours
then the EEF1A2 locus amplification would be double that quoted in the results.
HOV417, 496 and 76 showed diploid copy numbers at the 20pl 1 locus suggesting
that these tumours contain a haploid deletion at a region in 20pl2 but not a whole
arm or chromosome aberration. Tumour 14 also showed amplification at 20pl 1 as
well as 20pl2, suggesting a chromosome 20 duplication or a large amplicon of 10Mb
may be present in this tumour. Interestingly, the marker at 20pl 1 appears to be
tetraploid while the marker at 20pl2 appears to be hexaploid. This suggests that
perhaps there are two separate amplicons within 20p 11-12 or that there is whole
chromosome number aberration together with localised amplification in one or both
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Figure 5.4 Chromosome 20 ploidy analysis using 20p microsatellite primers.
20p copy number in normal genomic blood DNA for both 20p loci, D20S804 and
D20S819, is diploid (ratio of 20p locus to reference locus D2S385 — 1). Most
ovarian cancers (numbered along the x axis) were also diploid at 20pll or 20pl2,
however tumours HOV303 and 104 appear haploid at 20pl2-13 and HOV14 shows
an amplification at 20pl 1-12. Loss in region 20pl2 only, is seen in tumours 417, 76
and 496. In green is the normalised amount of D20S819 and in red D20S804.
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of the regions. Overall, the analysis of copy number at 20p using this method
suggests that all of the cancers, apart from HOV14, 303 and 104, are diploid for
chromosome 20. Therefore the increase copy numbers at the EEF1A2 locus must be
due to regional amplification in the majority of the tumours. The size and boundaries
of the amplified region of20ql3 could be determined by this method if pairs of
primers amplifying multiple regions along chromosome 20 were used. Due to time
constraints and quantity ofDNA limitations I did not carry this out.
5.2.3 Sequencing of EEF1A2 for the identification of activating mutations
Activating mutations in genes can alter the function of the protein if located in the
coding region of the gene or alter splice sites potentially altering splicing in the
transcript. In order to determine whether any of the low EEF1A2 gene copy number
ovarian cancers (3-5 copies) that overexpress eEFl A2 have alterations in the gene I
sequenced the 8 exons.
Primers were designed to amplify each of the 8 exons ofEEF1A2 by PCR (Newbery
PhD thesis, 2002). These primers required different PCR conditions outlined in the
methods. Primers designed by myself and those designed by Helen Newbery are
indicated in the methods. The amplified PCR fragment of each exon was then
sequenced either using the PCR primers or internal sequencing primers, again either
designed by myself or Helen Newbery.
Cancers HOV183, 481, 179, 380, 5 and 104 were sequenced (gene copy numbers 3-
5) and the sequence compared to the Ensembl published sequence of genomic
EEF1A2 chromosome:NCbi36:20:6i5892i0:61601549: - l. To align the sequences I
used EMBL-EBI EMBOSS pairwise alignment algorithm. A published common
single nucleotide polymorphism (SNP) was identified in exon 3 in cancer 183 base
3780: C/T; however no sequence alterations were identified in the coding exons (2-8)
of any of the low EEF1A2 copy number cancers. All the tumours analysed also
contained 2 SNPs in exon 8 at bases 11547: G/C and 11491: T/C.
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The only sequence alteration I identified was the following in exon 1 of cancer 183:
g. 637G>A substitution, see figure 5.5. This sequence alteration was present in both
the forward and reverse sequence and is not listed as a common polymorphism in
this gene. Exon 1 is a non coding exon in the 5'UTR ofEEF1A2 and therefore the
sequence alteration will have no effect on the amino acid sequence of the protein. I
subsequently aligned the 5'UTR regions ofMus musculus, Rattus norvegicus and
Homo sapien EEF1A2 sequences using EMBL-EBI ClustalW program (Thompson et
al., 1994) and this is shown in figure 5.6. It is apparent that the region of the 5'UTR
containing the sequence variation in tumour HOV183 is not well conserved between
the three species, in fact in rat the nucleotide at this position is an A, suggesting it is
not a functionally important region.
5.2.4 Methylation analysis of the EEF1A2 5' CpG island by bisulphite
sequencing
The above analysis ofEEF1A2 copy number and exon sequence suggests that
eEFl A2 overexpression in these ovarian cancers is not fully explained by gene
amplification or mutation. Another possible mechanism by which eEFlA2 may be
overexpressed is by changes in methylation in the CpG island in the promoter region
of the gene. I used the EMBL-EBI EMBOSS CpGPlot/CpGReport/Isochore (Rice et
al., 2000) program for analysis of the genomic sequence ofEEF1A2 (AF163763)
(Bischoff et al., 2000). This program analyses the genomic sequence and identifies
regions of high CpG dinucleotides relative to the bulk genome, called CpG islands.
The program parameters were set to an observed/expected ratio of 0.6, a GC content
over > 50% and the length of sequence to >200bp. This algorithm then predicted 4
CpG islands in EEF1A2, see figure 5.7. The first is found at the 5' end of the gene,
spanning across the first exon (nucleotides 1702-2434) and is 733bp in length. The
more 3' CpG islands are found in exon 4 (nucleotides 6064-5405) and exon 6 (9334-
9537). Importantly, the CpG rich-regions in exon 4 and 6 are considered too small to
be CpG islands by current accepted criteria. Finally there is a large CpG island at the
very 3' end of the gene (nucleotides 11334-12053) around exon 8. Importantly, this
3' CpG island may be the promoter CpG island of the neighbouring gene KCNQ2.
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Help
ibl Sequence Name: 183_1F1 Run ended: May 16, 2006
120 130 140 ISO 160 170
AC C5 TCAATAQ 5 T55ACCCCC TCCCAGAGATAAAACCGCCGGCGCCGGCGCCGCCAGTC
abl Sequence Name 183_1R3 Run aided: May 16, 2006
320 330 340 350 360 37
HGCGCCGGCGGTTTTATNTCTGGGAGGGGGTCCACCTA.TTGACGGTGGCGGCGC
Figure 5.5 Tumour 183 contains a sequence variation in exon 1 ofEEF1A2
The sequence traces for forward and reverse sequencing products of exon 1 analysis
in tumour HOV183. The arrows denote sequence variation g. 637G>A substitution.
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ENSMUSTO 0 000055990 CATCCCATCTGCCAGCCGCTCGGCGCCCGCCTCCCCCCTCCGGTACCGCATTGCCGTACT
ENSRNOT00000016947 CACCCCATCTGCCAGCCTCCCGGCGCCCGCCTCCCCCCTCCGGTACCGCATTGCCGTACT
ENSTOO000217182
ENSMUSTO 0 000055990 GCAGGGGCGCAGTGCATTGCGCCGGCACCGTCAATAGGTGGACCCCCTCCTGGAGAGATA
ENSRNOTO 0 000016947 GCAGGGGCGCAGTGCATTGCGCCGGCACCGTCAATAGGTGGACCCCCTCCTAGAGAGATA
ENSTOO000217182 ACTGCGCCGCCACCGTCAATAGGTGGACCCCCTCCCGGAG- -ATA
* ******* ************************* * * * * * *
ENSMUSTO 0 000055990 AAACCGCCGGCGCCGGCGCCACCAGTCCTTCTGACTGAGTCCTCGGCTCTGGAGTTCCTG
ENSRNOTO 0 000016947 AAACCGCCGGCGCCAGCGCCACCAGTCCCTCTGACTGAGACCTCGGCTCTGGAGTTCCTG
ENSTOO000217182 AAACCGCCGGCGCCGGCGCCGCCAGTCCCTCTGGCTGAGACCTCGGCTCCGGAATCACTG
************** ***** ******* * * * * ***** ********* *** * * * *
ENSMUST00 000055 990 CCCAGCATATACCCTCAACCCCAAACCAGAGCCCCCACAGT GCCAGCCCCTCCCTCA
ENSRNOTO 0000016947 CCCAGCAAATACCCTCAACCCAGAGCCAGAGCCCCCACAGT GCCAGCCCGTCCCTCA
ENST00000217182 C AGCCCCCCTCGCCCTGAGCCAGAGCACCCCGGGTCCCGCCAGCCCCTCACACT








Figure 5.6 EEF1A2 sequence alignment from Mus musculus, Rattus norvegicus
and Homo sapiens, the nucleotide showing sequence variation in HOVI83 is not
highly conserved.
The top sequence is from Mus musculus, the middle sequence is from Rattus
norvegicus and the bottom sequence from Homo sapiens. The nucleotides
highlighted in red correspond to the nucleotide showing alteration in HOY 183.
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Figure 5.7 Putative CpG islands in EEF1A2 predicted using EMBL-EBI
EMBOSS CpGPlot/CpGReport/Isochore.
EEF1A2 is predicted to contain 4 CpG islands. The 5' CpG island is upstream of the
start codon and spans exon 1. The second and third are found within exons 4 and 6
of the gene but are too small to be classified as CpG island by accepted criteria. The
final 3' CpG island covers exon 8 but may be a CpG island of the neighbouring gene
KCNQ2.
Chapter 5 The mechanism of overexpression of eEFl A2 in ovarian cancer 160
The CpG island most likely to be effective in gene expression regulation is the 5'
island spanning exon 1 in the promoter region of the gene. Jan Bergmann, an
undergraduate student in our lab, set up a bisulphite sequencing method for analysis
of the methylation status at this CpG island in EEF1A2 (see Chapter 2: Materials and
Methods) and I subsequently used this protocol for analysis of the methylation status
of this predicted island in DNA from ovarian tissues.
I began by selecting two eEFlA2-expressing ovarian cancers, HOVs 179 and 104,
two cancers that do not express eEFlA2 HOV470 and 308, and two normal whole
ovary DNA samples HOV548 and 440. I then treated the DNA with bisulphite in
order to convert all unmethylated cytosine nucleotides to uracil. I subsequently used
PCR to amplify a 548bp region of the 5' EEF1A2 CpG island from each of the
converted DNA samples. The primers used for this PCR (designed by Jan
Bergmann) amplify the EEF1A2 sequence from 1547bp to 2095bp. This 548bp
region includes approximately 50% of the CpG island - 68 CpG dinucleotides.
Subsequently, I used TA cloning and sequencing to analyse the methylation at the
CpG dinucleotides in this region ofEEF1A2.
The results of the bisulphite sequencing were then analysed using the BiQ analyzer
program (Bock et ah, 2005). This program aligns the sequence ofmultiple clones
with the genomic sequence of interest. It then checks the sequence for converted
cytosines and sequencing errors and advises that any sequence with less than 90%
converted cytosines and 80% sequence similarity should be excluded from analysis
to ensure sequencing errors and incomplete bisulphite conversion do not influence
the methylation analysis. Finally the program produces plots of the methylation
status at each CpG dinucleotide in the sequence. The results of this analysis can be
found in figure 5.8.
The DNA clones from the two ovarian cancers expressing eEFl A2, HOV179 and
104 contained methylated CpGs before the start of the CpG island but then showed
no methylation in the CpG island itself. The non-eEFlA2 expressing ovarian
tumours showed very little methylation in the CpG dinucleotides before the island or
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Figure 5.8 Methylation analysis of the EEF1A2 5'CpG island by bisulphite
sequencing
Above shows lollipop diagrams produced by BiQ Analyzer. Open circles denote
unmethylated CpG dinucleotides, while closed circles denote methylated CpG
dinucleotides. (a) Tumours 179 and 104 do express eEFlA2 and show some
methylation in CpG dinucleotides proceeding the island but no methylation within
the CpG island, (b) Tumours 308 and 470 do not express eEFlA2 and there are very
few methylated CpGs either within the island or proceeding it. (c) DNA from 2
different normal whole ovaries. There is little methylation present at any CpG
dinucleotides within the sequence.
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in the island itself, however each clone did have at least one methylated CpG in the
CpG island. DNA extracted from normal whole ovary contained no methylated
CpGs apart from one clone that had 2 methylated CpGs in the CpG island and one 5'
to this region.
Overall, this preliminary analysis on a small number ofDNA samples suggests that
methylation is highly unlikely to be involved in the regulation of eEFlA2 expression,
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5.5 Discussion
Due to the fact that only a small amount ofDNA and no cell lines were available
from the ovarian cancers for which I did expression analysis it was not possible to
use CGH or Southern blot to identify amplifications in EEF1A2. An alternative
technique that can be used to measure copy number is FISH on tumour tissue. This
could have been carried out on the ovarian TMAs and HOV tumour sections
however the number ofTMAs were limited and a suitable number were not available
for optimisation of the protocol. I therefore used a real-time PCR technique adapted
from Ginzinger et al. (Ginzinger et al., 2000) as DNA from the HOV panel was in
plentiful supply. I have shown that this alternative technique allows determination of
DNA copy number in tumours, as well as the distinction between chromosome 20
polyploidy and regional amplification. The degree of amplification ofEEF1A2 at
20ql3.3 did not appear to correlate with the histological subtype, stage or grade of
the tumour or with disease recurrence. This is at odds with previous studies that
suggest that 20ql3 amplification correlates with late stage, high grade ovarian
cancers (Sonoda et ah, 1997),(Suehiro et ah, 2000).
The majority of the ovarian cancers (80%) that I analysed also appeared to show
amplification in EEF1A2. However, Anand et al. only identified EEF1A2
amplification in 25% of the ovarian cancers analysed (Anand et al., 2002). This may
reflect the differences in the techniques used to determine the copy number of
EEF1A2. Anand et al. used FISH whereas I used quantitative real-time PCR. The
main caveat to the use of quantitative PCR is that the technique can introduce
variation into the results. PCR variation between gene specific primers and reference
gene primers can cause discrepancies in normalisation. This is somewhat controlled
for by measuring the PCR efficiency of each primer set and this was done in
triplicate. It may also be that real-time PCR is a more sensitive technique than FISH
for identifying copy number changes and this has lead to the elevation of the
percentage of ovarian cancers showing amplification ofEEF1A2. The fact that this
technique showed amplification at 20p in only one tumour also suggests that the
technique is valid and that the apparent amplification in EEF1A2 is real. Importantly
EEF1A2 appears to be amplified in 80% of ovarian cancers, a frequency far higher
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than that suggested by previous studies (Anand et ah, 2002), suggesting than
although the technique is technically valid, in practice it may not be suitable for
measuring gene copy number in cancers. Further validation of the technique is
necessary in order to determine if the technique is valid. For instance the use of a
cell line in which the EEF1A2 copy number has been determined by FISH and the
real-time PCR technique could be used to determine if the correct copy number is
being measured using the PCR technique.
20pl 1-12 loss was identified in three of the ovarian cancers and loss of 20pl 1 was
present in an additional three of the cancers. Furthermore, tumour HOV14 appeared
to show amplification at 20p. Copy number changes at 20p are not a frequent
observation in epithelial ovarian cancers however LOH at 20p in serous
adenocarcinomas (Okada et al., 2002) and 20p amplification, has been observed in
ovarian cancer (Sonoda et al., 1997). Genes immediately surrounding the
microsatellite marker at 20pl2 include PLCB1, PLCB4 and PAK5. Phospholipase C
Beta 1 and 4 (.PLCB1/4) encode different isoforms of a protein that catalyzes the
formation of inositol 1,4,5-triphosphate and diacylglycerol from phosphatidylinositol
4,5-biphosphate, these being involved in Akt activation (Osaki et al., 2004). PLCB1
has been identified in the nucleus and nuclear phosphoinositides are thought to be
potentially involved in maintaining chromatin in a transcriptionally active
conformation. In addition, a decrease in the level of nuclear PLCB1 has been
associated with the development of acute myeloid leukaemia (Martelli et al., 2005).
p21-activated kinase 5 (PAK5), located at 20pl2, encodes a serine/threonine protein
kinase known to be an effector of Racl/Cdc42 GTPases. Racl and Cdc42 play a role
in cytoskeletal regulation and cell motility, and therefore PAK5 is not a potential
tumour suppressor gene but rather a candidate oncogene (Jaffer et al., 2002). A
candidate tumour suppressor gene at 20pl2.3 is proliferating cell nuclear antigen
(PCNA). PCNA has been shown to perform a role in eukaryotic DNA replication,
where it acts as a sliding clamp for replicative DNA polymerases. Subsequently,
PCNA has been identified as playing a role in multiple cellular functions including
DNA repair, translesion DNA synthesis, chromatin remodelling and regulation of the
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cell cycle (Maga and Htibscher, 2003). The role of PCNA in DNA repair suggests
that PCNA is a candidate tumour suppressor gene on chromosome 20p.
A somewhat unexpected observation was that the pattern ofEEF1A2 copy number
appears to be the same in both non-eEFlA2 and eEFl A2 expressing tumours. This
suggests that copy number alterations are not the only mechanism causing EEF1A2
expression and that EEF1A2 amplification does not necessarily lead to increased
transcription levels. Additionally, higher EEF1A2 copy number cancers do not
express eEFl A2 at higher RNA levels. The DNA and RNA were, however,
extracted from whole ovarian tumour samples and not from microdissected cancer
epithelial cells to exclude stromal contamination. This therefore means that the RNA
expression levels I obtained may not be an accurate representation of the expression
level of eEFlA2 in the malignant cells. Nevertheless, all of the above suggest that
gene amplification is not a significant player in determining whether eEFlA2
expression occurs and at what level this expression occurs at in these ovarian
cancers. The lack of any apparent relationship between EEF1A2 copy number and
eEFl A2 expression levels could also be due to the fact that the PCR technique may
not be giving an accurate copy number measurement.
In order to identify whether mutation in EEF1A2 may have lead to overexpression of
the gene I sequenced all 8 exons of the gene in the low copy number tumours. Only
low copy number tumours were sequenced because if only one copy of the gene in a
high copy number contained the mutation, the signal from the mutant would be
swamped by the other copies of the gene thus making the sequencing difficult to
interpret. None of the tumours showed sequence variation in the coding exons or in
the non-coding region of exon 8. Tumour FIOV183 contained a G>A transversion in
exon 1, a non-coding exon that is covered by the 5' CpG island. Interestingly, this
tumour showed no amplification in EEF1A2 and indeed had the lowest EEF1A2
copy number. It is not clear what significance, if any, this sequence variation has in
the expression of eEFlA2. The 5' and 3' UTRs ofmRNAs are thought to be
important in the post-transcriptional regulation of gene expression. This can include
the modulation of translational efficiency, mRNA stability and subcellular
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localisation (Mignone et al., 2002). Tumour HOV183 expresses eEFlA2 at the RNA
but not the protein level therefore this mutation may be important in post-
transcriptional regulation. Nonetheless, the lack of protein expression means this
mutation is not important in cancer. Additionally, the lack of species conservation of
the sequence surrounding this sequence variation observed in tumour HOV183, also
suggests the region may not be an important regulatory region.
The limited analysis ofmethylation status of the EEF1A2 5' CpG island in ovarian
cancers that express and do not express eEFlA2 as well as DNA extracted from
normal whole ovary, suggests that methylation is not important in the regulation of
transcription from this gene; nevertheless the three groups of samples did show
subtle differences in methylation. The eEFlA2 expressing cancers, HOV179 and
104, exhibited methylation of CpG dinucleotides upstream of the CpG island but no
methylation within the island. This is opposite to the typical situation observed in
cancer where there is genome wide hypomethylation concomitant with CpG island
hypermethylation, but is typical of the situation observed in normal tissues. The non-
expressing tumours, on the other hand, showed little methylation in CpG
dinucleotides proceeding the CpG island or in the island itself. One of the clones
from normal ovary DNA sample HOV548 exhibited methylation at 3 CpG
dinucleotides within the CpG island whereas the other clones from both sample
HOV548 and 440 contained few if any methylated CpGs. This suggests that the
more highly methylated clone DNA may have originated from a specific cell type in
the ovary. Overall, the 5' CpG island ofEEFJA2 does not appear to be methylated
in normal ovary, or ovarian cancers expressing and not expressing eEFlA2.
The choice of normal ovary control is a highly debated issue within ovarian cancer
research. It is thought that epithelial ovarian cancers arise from the ovarian surface
epithelium: a single cell epithelial layer surrounding the ovary (Auersperg et al.,
1997). This single cell layer is often destroyed during surgery due to its delicate
nature. When the OSE is preserved it is cultured in order to increase the number of
cells and therefore the amount ofDNA, RNA and protein that can be obtained and
this is often used as the normal ovary control in experiments. However, it is possible
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that transformation and culturing of the OSE can alter methylation patterns, as is
known for other cell types in culture, and therefore is perhaps not a good control for
methylation analysis in normal ovary. I used normal whole ovary as a control, and as
detailed in chapter 4, eEFl A2 is expressed in lutenised stromal cells as well as the
OSE but not in the stroma. The majority of the ovary is composed of stroma and
therefore the DNA from whole ovary will mainly have originated from fibroblasts.
Hence it is difficult to identify a suitable control for this analysis. However, there is
no discernable difference in methylation between eEFl A2 expressing and non-
expressing tumours, which acts as an additional control.
The results from analysis ofEEF1A2 copy number, mutation and methylation status
analysis suggest that none of these mechanisms are highly significant in mediating
the overexpression of eEFl A2; therefore another mechanism could be involved. For
example the activation of transcription ofEEF1A2 by a transcription factor
aberrantly expressed in cancer could induce eEFlA2 overexpression in some
cancers. Alternatively, the predominant mechanism of eEFlA2 overexpression
could be gene amplification but this could be being obscured by the PCR technique
used in this analysis. Further validation of the real-time PCR technique used to
measure EEF1A2 copy number would be required to determine whether this is the
case.
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Chapter 6: The role of eEF1 A2 in oncogenesis
6.1 Introduction
The non-canonical functions of eEF1A1 and eEF1A2
The eukaryotic elongation factors 1A1 and 1A2 have both been shown to be involved
in the elongation step ofprotein synthesis where they bind and transport aminoacyl-
tRNA to the A-site of the ribosome in a GTP dependent manner. In addition to its
role in translation elongation, eEFl A1 is thought to perform many other so called
non-canonical functions including cytoskeletal binding and remodelling
(Dharmawardhane et ah, 1991), the susceptibility of rodent fibroblasts to
transformation (Tatsuka et al., 1992), and oxidative stress (Chen et ah, 2000).
eEFlAl and eEFlA2 are 98% similar and 92% identical at the amino acid level
(Lund et ah, 1996) and therefore it would be reasonable to assume that the two
proteins have similar functions. However, there is evidence that eEFlAl and
eEFl A2 perform different non-canonical functions as there are clear differences in
their properties. For example eEFl A1 has been demonstrated to be pro-apoptotic
and eEFl A2 anti-apoptotic in serum deprived myotubes in culture (Ruest et ah,
2002). Additionally, eEFl A2 but not eEFlAl has been shown to interact with
perioxiredoxin-1 (Prdxl) in mouse brain (Chang and Wang, 2006). Finally, EEF1A2
has been identified as a putative oncogene (Anand et ah, 2002) whereas EEFlAl has
not, suggesting that eEFl A2 performs different roles to eEFl Al and that when
eEFl A2 is inappropriately expressed this can result in oncogenesis. The fact that
both variants of eEFl A are highly evolutionarily conserved and the occurrence of
developmental switching from eEFl Al to eEFlA2 in brain, heart and skeletal
muscle in mice (Khalyfa et ah, 2001) also suggests that eEFlAl and eEFlA2
perform distinct functions.
Elongation factor 1A and the cytoskeleton
There is a large amount of evidence to suggest that eEFl A interacts with, and can
alter the structure of, the cytoskeleton. A protein of approximately 50kDa
(provisionally named ABP-50) was identified as having actin bundling activity and
was isolated from the amoebae ofDictyostelium discoideum (Demma et ah, 1990).
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This ABP-50 protein was later identified as elongation factor 1A (Yang et al., 1990).
Dharmawardhane et al. found that in resting Dictyostelium discoideum eEFl A
showed a diffuse localisation within the cytosol but upon stimulation of the cells with
cAMP eEFl A translocated to filopodia. In resting cells only 10% of eEFlA was
shown to be associated with the cytoskeleton. eEFlA also interacts with G-actin or
non-filamentous actin and this interaction is inhibited by GTP but not GDP.
However the bundling of F-actin was unaffected by guanine nucleotides
(Dharmawardhane et al., 1991). eEFlA was also shown to co-localise with poly(A)
mRNA at actin filament intersections in human fibroblasts (Bassell et al., 1994). The
interaction of eEFlA with F-actin was shown to be pH dependent, unlike the
interaction of the elongation factor with aatRNA, and the binding of F-actin and
aatRNA was suggested to be mutually exclusive (Liu et al., 1996). Edmonds et al.
also observed that the eEFlA-induced bundling of F-actin was dependent on pH
(Edmonds et al., 1995). Owen et al. observed that eEFlA from Dictyostelium
discoideum cross linked actin with a unique bonding rule that meant actin filaments
were rotated at 90° to one another leading to the exclusion of other actin bundling
proteins (Owen et al., 1992). Liu et al. showed that eEFlA localised with /3 actin
mRNA and F-actin in the protrusions of chicken embryo fibroblasts and that the C-
terminal domain was responsible for binding. This implicated eEFlA in (3 actin
mRNA localisation (Liu et al., 2002). When overexpressed in Saccharomyces
cerevisiae, eEFlA causes reduced budding and altered actin distribution and cellular
morphology (Munshi et al., 2001).
eEFl A has also been shown to bind, bundle and stabilise microtubules in plants
(Moore and Cyr, 2000) and to associate with the mitotic apparatus of Sea urchin eggs
(Ohta et al., 1990). Kuriyama et al. also observed an association between eEFlA,
the centrosome and mitotic apparatus in dividing sea urchin eggs (Kuriyama et al.,
1990). Moore et al. also showed that eEFlA from Daucus Carota can modulate the
dynamic behaviour ofmicrotubules in a calcium/calmodulin dependent manner
(Moore et al., 1998). Direct binding of eEFl A from carrot cells with microtubules
has been observed (Durso and Cyr, 1994) and severing ofmicrotubules by eEFl A
has been reported (Shiina et al., 1994). Overexpression of eEFl A in fission yeast
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resulted in the cells showing elliptic, curved or branched type abnormal morphology
and growth defects at high temperatures and this was suggested to be due to eEFlA's
ability to alter the actin and tubulin cytoskeleton in yeast (Suda et ah, 1999).
The interaction of eEFl A with the cytoskeleton has been suggested to facilitate the
spatial and temporal regulation of protein synthesis (Edmonds, 1993). It has been
shown that channelling of aatRNA from aatRNA synthetase to eEFlA and then to
the ribosome without diffusion in the cytosol occurs during protein synthesis
(Negrutskii and Deutscher, 1991). The ability of eEFlA to alter cytoskeletal
organisation could directly alter the efficiency of translation because most mRNA is
anchored on actin or tubulin filaments (Condeelis, 1995). Additionally, the
interaction of eEFlA with the cytoskeleton may be unrelated to its role in translation
and could allow regulation of the cytoskeletal structure in, for instance, response to
extracellular stimuli.
The role of eEF1 A in heat shock and cancer
Heat shock proteins (HSPs) are encoded by distinct gene families and named
according to their relative molecular mass (Mr), for instance Hsp27, Hsp60 and Hsp
70. The expression ofHSPs is mediated by the binding of activated HSF1 (a
transcription factor) to specific DNA sequences in their promoter regions. The
primary function ofHSPs is to bind to unfolded proteins that accumulate in response
to cellular stress, such as excessive temperature, and prevent catastrophic protein
aggregation and subsequently refold the proteins with the aid of chaperonins. In
addition HSPs also inhibit programmed cell death in order to allow time for repair of
the proteome (Calderwood et al., 2006). HSPs are expressed in a wide range of
cancers and their expression is associated with poor prognosis and resistance to
therapy (Ciocca and Calderwood, 2005). This overexpression is mediated by loss of
p53 function and by the expression of oncogenes such as ERBB2 and c-Myc.
Overexpression ofHsp90 leads to self sufficiency for growth signals in cancer cells
by maintaining signalling proteins in an active conformation. Hsp90 also stabilises
mutant proteins that arise during oncogenesis such as v-Src, Bcr-Abl and p53.
Hsp70 and Hsp27 are involved in the inhibition of programmed cell death. Hsp90 is
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essential for telomerase stability and has therefore been implicated in the inhibition
of replicative senescence. Hsp70 and Hsp90 stabilise the primary sensor of hypoxia
HIFlo, leading to the transcription of factors involved in the proliferation and
motility of vascular endothelial cells including vascular endothelial growth factor
and nitric oxide synthetase. Finally, tumours overexpressing HSF1 and HSPs show
an increased tendency to invade and metastasise by unknown mechanisms, see
review by (Calderwood et al., 2006).
HSF1 activation involves trimerisation and acquisition of specific DNA-binding
activity. It was widely believed that HSF1 activation occurred as a result of the
removal of inhibition imposed by chaperones including Hsp90. However, the fast
kinetics ofHSF1 activation (Jolly et al., 1999) suggested that this diffusion
controlled mechanism was probably not responsible for HSF1 activation (Shamovsky
et al., 2006). A recent paper by Shamovsky et al. suggests that eEFl A may be
essential for HSF1 activation. They identified eEFlA as bound to immobilised-
HSF1 after incubation with lysate from heat-shocked BHK-21 or HeLa cells. They
also identified a 600 nucleotide non-coding RNA called heat shock RNA-1 (HSR1)
as being required for HSF1 activation. The authors suggest that eEFl A can
accumulate in cells following heat shock due to translational shut down and
cytoskeletal collapse enabling it to partake in HSF1 activation (Shamovsky et al.,
2006). Importantly, the methods used in this analysis did not distinguish between
eEFlAl and eEFlA2, or only investigated HSF1 activation with purified eEFlAl,
and therefore we do not know if eEFl A2 is also involved in HSF1 activation.
Diagram 6.1 depicts the model proposed by Shamovsky et al. for HSF1 activation
involving eEFlA and HSR1.
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Diagram 6.1 Activation ofHSF1 by eEFIA and HSR1 following heat shock,
taken from (Shamovsky et al., 2006).
Interestingly, motor neurons have been shown to have an insufficient stress response.
Two percent of patients with amyotrophic lateral sclerosis (ALS), characterised by a
loss ofmotor neurons in the brain and spinal cord, have autosomal dominant
mutations in Cu/Zn-superoxide dismutase (SOD-1) that is thought to result in
structural changes in the protein leading to aggregation (Durham et al., 1997; Rosen
et al., 1993). Expression ofmutant SOD-1 in motor neurons in culture results in
aggregation of the protein and cell death, but the same effect was not seen in
nonvunerable cells such as hippocampal neurons expressing mutant SOD-1 (Durham
et al., 1997). This suggests that motor neurons are deficient in their heat-shock
protein mediated response to mutant SOD-1, resulting in ALS. Batulan et al. showed
that after heat shock at 42°C for 1 hour, non-neuronal cells in culture expressed
Hsp70 but motor neurons in culture did not. Other conditions of heat shock were
also tested and the authors concluded that motor neurons did not show activation of a
stress response following heat shock. This observation of failure ofmotor neurons to
express Hsp70 was repeated in the motor neurons ofmutant SOD-1 transgenic mice
and ALS patients. They found that the inability to mount a heat shock response
occurred at the level of HSF1 activation (Batulan et al., 2003). Motor neurons do not
express eEFlAl in their cytoplasm (some eEFlAl expression can be seen in the
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nucleus) but do express eEFlA2 cytoplasmically (Newbery et al., in preparation).
Therefore, if it is eEFlAl and not eEFlA2 that is involved in HSF1 activation this
may explain why motor neurons are defective in the heat-shock response and
consequently implicate eEFlAl and eEFl A2 in the disease characteristics ofALS in
which motor neurons are preferentially vulnerable to disease.
In order to investigate the functions of eEFlA2, how these could differ from
eEFlAl, and their potential importance to the role of eEFlA2 in oncogenesis, I used
immunofluorescence in cancer cells to investigate the subcellular localisation of
eEFlA2 and eEFlAl; any potential difference in localisation could suggest that the
isoforms are performing different roles. I also used RNA interference of eEFlA2 in
cancer cells to investigate any phenotypic change that could result from eEFlA2
ablation. Finally, I used RNA interference to knockdown eEFlAl or eEFlA2 in
HeLa cells and then subjected the cells to heat shock in order to try to determine if
eEFl A2 is also involved in the heat shock response and whether there is
compensation by one protein in the absence of another.
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6.2 Results
6.2.1 The subcellular localisation of eEF1A in cell lines
Investigation of the subcellular localisation of eEFlAl and eEFlA2 in cancer cells
may give a clue to any differences in function between the proteins and the role that
eEFlA2 is potentially playing in oncogenesis. I therefore set about to examine the
subcellular localisation of eEFlA2 in the breast cancer cell line MCF-7. This cell
line expresses both eEFlA1 and eEFlA2 at high levels, as is common in transformed
cell lines.
The first approach used was to attempt to identify the subcellular localisation of
endogenous eEFlAl and eEFlA2 using the isoform-specific antibodies by
immunofluorescence (IF). These antibodies were tested for specificity using HeLa
and MCF-7 cells, expressing both eEFlA variants, and NIH 3T3 (mouse) and
lymphoblastoid cells that only express eEFl A2. A cell line that only expresses
eEFlA2 and not eEFlA1 was not available for use as a negative control for eEFl A1
expression and to our knowledge does not exist. A variety of fixation methods were
used including ice-cold methanol, 2-4% paraformaldehyde as well as
methanol:acetone and all the available antibodies to eEFlA2 (1A2-1, 2 and 3) and
eEFlAl (1A1-1 and 1A1-3) were tested at various concentrations and incubation
times, this is represented in table 6.1. All three antibodies to eEFlA2 and both
antibodies to eEFl A1 gave a similar staining pattern in the different cell types. This
was a faint, diffuse, often granular staining in the cytoplasm of the cells, particularly
in the perinuclear region. However, the same faint staining pattern was observed in
secondary antibody-only controls. As well as this staining of the eEFlA2 negative
mouse fibroblast cell line NIH 3T3 and human lymphoblastoid cell line with the
eEFl A2 antibodies showed a similar result to that seen in HeLa and MCF-7 cell lines
that are positive for eEFlA2. I therefore concluded that the isoform-specific
antibodies, although very effective in Western blotting and immunohistochemistry,
are unsuitable for use in immunocytochemistry. The reason for the antibody not
working in immunocytochemistry is likely to be the difference in antigen retrieval
techniques used for the different applications. Western blotting involves denaturing
the protein with detergent and heating, and immunohistochemistry involves heating
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Table 6.1 Method variations attemptedfor immunofluorescent staining of











10 minutes room temperature
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Primary antibody incubation times
30 mins room temperature
1 hour room temperature
2 hours room temperature
4°C overnight
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Donkey anti-sheep Alexa 594
Goat anti-rabbit Alexa 488






30 mins room temperature
1 hour room temperature
2 hours room temperature
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in antigen retrieval solutions. On the other hand the antigen retrieval in
immunocytochemistrymay not be stringent enough to expose the antigen to the
antibody. Alternative methods for analysis of eEFlA2 subcellular expression
include cell fractionation and Western blotting or in situ hybridisation to visualise the
subcellular localisation of the eEFlA2 transcript. In order to visualise the subcellular
localisation of the eEFl A2 protein I went about obtaining tagged eEFlA2 constructs
so that these could be used to determine the subcellular localisation of the protein
using antibodies to the tags; in this instance I decided to use V5 and Green
Fluorescent Protein (GFP) tags. V5-tagged eEFlA2 was purchased from Invitrogen,
this is the full length eEFlA2 cDNA cloned into the pcDNA3.1/GS vector, resulting
in the expression of full length eEFlA2 expressed under a CMV promoter and
tagged at the C-terminus with the V5 peptide and six polyhistidines. I sequenced the
eEFlA2 insert to confirm that the sequence was correct. To determine whether
eEFl A2 is expressed from the construct, I transfected PEOl cells (eEFlA2 negative)
with pcDNA3.1/GS-eEFlA2 and used extracted protein from these cells in a
Western blot: probing with an anti-V5 antibody and 1A2-1 antibody. Protein lysate
from pcDNA3.1/GS-eEFl A2-transfected cells showed a band of approximately
52kDa in size when probed with the anti-eEFlA2 antibody or anti-V5 antibody that
was not present in untransfected, mock or empty vector controls, see figure 6.1.
Unexpectedly, a band slightly smaller than 52kDa was present in the Western blot
probed with the anti-eEFlA2 antibody in protein lysate from PEOl cells mock
transfected, DNA-only controls (DNA added into cells with no transfection) and
cells transfected with V5-tagged eEFlA2 or GFP-eEFlA2 but not in untransfected
cells. This suggests that a slightly smaller eEFl A2 protein is induced by cellular
stress due to transfection or that a low level of eEFl A2 is expressed in PEOl cells.
The later would mean that in cells transfected with V5-tagged eEFlA2 the higher
band represents the V5 tagged protein and the lower band the native protein. The V5
tag consists of 14 amino acids and is approximately 5kDa in size. The size
difference between the two bands could be determined using a higher resolution
molecular weight marker and running the protein on a higher percentage acrylamide
gel. Alternatively the smaller bands may be present due to non-specific binding of
the antibody to eEFl A1.
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I then went on to clone the full length eEFlA2 and eEFlAl cDNA sequences into
the vector pcDNA-DEST53, a Gateway destination vector from Invitrogen, resulting
in the expression of an N-terminal Green Fluorescent Protein (GFP) tagged protein in
mammalian cells. The Gateway method offers advantages over traditional cloning
methods as restriction enzymes are not used. The cDNA is first cloned into an entry
vector using the site specific recombination properties ofbacteriophage lambda and
can be then shuttled between different destination vectors easily to make expression
clones. Again, the constructs were sequenced to confirm that there were no sequence
alterations in the inserted eEFl A2 and eEFl A1 and Western blotting of protein
lysates from transfected PEOl cells gave a band at approximately 80KDa (GFP is
apx 30kDa in size) when probed with the 1A2-1 or 1A1-1 antibodies, see figure 6.1
The V5 and GFP-tagged eEFlA2 expressing constructs were then transiently
transfected into MCF-7 cells and PEOl cells and immunofluorescence used to
determine the subcellular localisation of the protein: examples of staining can be
seen in figure 6.2, no images from PEOl cells are included due to poor quality.
eEFlA2 tagged with V5 or GFP exhibits a diffuse cytoplasmic localisation with a
concentration of expression around the nucleus; this expression pattern fits with its
role in translation, which takes place in ribosomes at the endoplasmic reticulum
(which has a perinuclear localisation) and in the cytoplasm of the cell. The
localisation of eEFl A2 tagged with either V5 or GFP appeared to be similar and no
eEFlA2 was located in the nucleus of the MCF-7 cells. Cells transfected with empty
pcDNA3.1/GS vector and stained for V5 using the anti-V5 antibody did not show
any staining and the secondary only control was also negative.
I then went on to investigate the possibility of co-localisation of eEFlA2 with the
cytoskeleton. eEFlA has been shown to associate with the actin cytoskeleton in
yeast where it can bind actin filaments (Dharmawardhane et al., 1991; Yang et al.,
1990) and can cross-link actin causing the formation of large gel-like structures of
actin bundles (Edmonds et al., 1995). In addition eEFlA associates with
microtubules in higher plant cells (Durso and Cyr, 1994) and sea urchin embryos
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Figure 6.1 Western blot analysis of PEOl cells transfected with tagged eEFlA2
and eEFlAl constructs.
(a) Western blot of PEOl cell lysates from untransfected (U); DNA only controls
(C2a) pcDNA3.1/GS, (C2b) pcDNA-DEST53, (C2c) pcDNA3.1/GS-eEFlA2 and
(C2d) pcDNA3.1-DEST53-eEF 1A2; (V5-1A2) pcDNA3.1/GS-eEFlA2 transfected
cells 24 and 48 hours post-transfection; (CI) mock transfection 24 and 48 hours post-
transfection; (GFP-1A2) pcDNA-DEST53-eEFlA2 transfected cells 24 and 48 hours
post transfection; (M) MCF-7 positive antibody control; (P) PEOl negative antibody
control. GAPDH was used as a loading control. In pcDNA3.1/GS-eEFlA2 a large
band corresponding to eEFlA2 is present. A band of approximately 80kDa is
present in PEOl cells transfected with pcDNA3.1-DEST53-eEFlA2. (b) Western
blot of protein lysate from PEOl cells transfected with pcDNA3.1/GS (V5e) and
pcDNA3.1/GS-eEFlA2 (V5-la2) 24 and 48 hours post transfection probed with an
anti-V5 antibody. One band at approximately 50kDa is visible in pcDNA3.1/GS-
eEFlA2 transfected cells only, (c) Western blot of protein lysate from PEOl cells
transfected with pcDNADEST53-eEFlA1 (GFPe) and pcDNA-DEST53-eEF1A2
(GFP-lal) and probed with the anti-eEFlAl antibody. A band of approximately
80kDa is only present in cells transfected with GFP-tagged eEFlAl. PEOl cell
lysate (PEOl) is a positive antibody control and wild type mouse muscle (muscle) a
negative antibody control.
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Figure 6.2 Subcellular localisation of eEFlA2 in MCF-7 cells.
(a) MCF-7 cells transfected with V5 tagged eEFlA2 and stained by
immunofluorescence with an anti-V5 antibody, (b) MCF-7 cells transfected with
GFP-eEFlA2. eEFlA2 tagged with V5 and GFP shows a diffuse cytoplasmic
localisation with a concentration of staining around the nucleus, (c) pcDNA3.1/GS
empty vector transfected cells stained with the anti-V5 antibody show no staining
and (d) secondary Alexa Fluor 594 goat anti-mouse IgG only was also negative.
Nuclei are counterstained in DAPI. Images (a), (b) and (c) are at x40
magnification, image (d) is at xlO magnification.
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(Hamill et al., 1994) and has been found to possess microtubule-severing activity in
Xenopus and fibroblasts (Shiina et al., 1994). It is not known whether both eEFl Al
and eEFl A2 or only eEFlAl is capable of cytoskeletal binding and remodelling and
the localisation of eEFl A2 in relation to the cytoskeleton has not been investigated in
human cancer cells. Tubulin was visualised using an anti-a-tubulin antibody, F-actin
using fluorescently conjugated Phalloidin and eEFl A2 simultaneously visualised in
transfected MCF-7 cells using an anti-V5 antibody and the GFP-eEFl A2 expressing
construct. Representative images can be found in figures 6.3. V5-eEFl A2 and GFP-
eEFl A2 showed some co-localisation with tubulin, particularly in the perinuclear
region of the cells. eEFl A2 overexpressing MCF-7 cells also appeared to show no
differences in tubulin morphology when expressing eEFl A2 compared to those
transfected with empty vector controls (see figure 6.5) suggesting that under these
conditions of forced overexpression, eEFlA2 is not causing cytoskeletal
remodelling.
An interesting observation was that V5-tagged eEFlA2 appeared to localise strongly
to cellular protrusions in some transfected MCF-7 cells, see figure 6.4. V5-tagged
eEFlA2 was found highly concentrated in focal areas at the edges of the cells and
these protrusions may be involved in adhesion or motility. This localisation was not
as clearly seen in cells transfected with GFP-tagged eEFl A2, however this may be
because GFP is a large tag and could disrupt correct subcellular localisation of
eEFlA2 when conjugated to it. Alternatively, the localisation of eEFlA2 at the cell
periphery in foci may be an artefact of V5-tagging and overexpressing the protein.
Nevertheless, F-actin showed strong co-localisation with V5-eEFlA2 in these
cellular protrusions and this can be seen in figure 6.4. eEFlA2 therefore also
showed partial co-localisation with actin in MCF-7 cells. These F-actin containing
protrusions were also identified in cells transfected with empty vector controls and
therefore did not seem to be induced by eEFlA2 overexpression in transfected MCF-
7 cells. Again the F-actin structure within the cells overexpressing eEFlA2 did not
appear to be different from that observed in cells transfected with empty vector, see
figure 6.5. The localisation of eEFl A2 in cellular protrusions suggests that eEFl A2
may be involved in cell adhesion or motility, this having obvious implications for the
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Figure 6.3 Tubulin and eEFlA2 subcellular localisation in MCF-7 cells
(a+b) GFP-eEFlA2 (green) and tubulin (red) show partial co-localisation around the
nucleus (yellow), (c+d) V5-eEFlA2 (red) and tubulin (green) show a similar pattern
of localisation as GFP-eEFlA2 in MCF-7 cells, (e+f) Interestingly, some cells
showed a concentration of V5-tagged eEFlA2 in distinct foci at the edges of the cell
(indicated by arrows). DAPI staining of the nucleus is shown in blue, (a-d) are xlOO
magnification, (e) and (f) x40 magnification.
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Figure 6.4 eEFlA2 and actin subcellular localisation in MCF-7 cells
(a + b) GFP-eEFlA2 (green) and phalloidin staining of F-actin (red), (c + d) V5-
eEFlA2 (green) and Alexa Fluor 594 phalloidin staining of F-actin (red) in MCF-7
cells. Cellular protrusions containing high concentrations of F-actin can be seen at
the edges of the cells and some co-localisation between eEFlA2 and F-actin can be
observed. Images are at xlOO magnification, (e) Secondary antibody Alexa Fluor
594 donkey anti-sheep IgG and Alexa 488 donkey anti-mouse IgG only (f) Alexa
Fluor 594 goat anti-mouse IgG only (g) Alexa Fuor 594 donkey anti-sheep IgG only,
xlO magnification











Figure 6.5 Cytoskeletal staining of MCF-7 cells transfected with empty vectors
pcDNA3.1/GS and pcDNA-DEST53.
(a) MCF-7 cells transfected with pcDNA3.1/GS and stained with an antibody against
tubulin and (b) Alexa Flour 594 phalloidin, x40 magnification (c) MCF-7 cells
transfected with pcDNA-DEST53 and stained with an antibody against tubulin and
(d) Alexa Fluor 594 phalloidin against F-actin. xlOO magnification. The cytoskeletal
structure in MCF-7 cells transfected with empty vectors is similar to that seen in
MCF-7 cells overexpressing eEFlA2 suggesting that high levels of eEFlA2
expression (as I have observed in some breast tumours) may not alter cytoskeletal
structure.
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function of eEFl A2 as an oncogene. Alternatively this localisation may allow spatial
localisation of protein synthesis. Further work would be required to properly identify
the protrusions and characterise the effect of eEFlA2 overexpression on motility and
adhesion in various cancer cells. eEFl A1 subcellular localisation was investigated in
the ovarian cancer cell line PEOl. The localisation was also visualised in MCF-7
cells however I was unable to obtain satisfactory images at the time of these
experiments. GFP-tagged eEFlA1 was transiently transfected into PEOl cells and
viewed under a fluorescent microscope, see figure 6.6. eEFlAl showed a diffuse
cytoplasmic expression pattern similar to the subcellular localisation observed for
eEFlA2. No eEFl A1 appeared to localise in the nucleus. Similarly partial co-
localisation with the F-actin and tubulin cytoskeleton was observed and although
there appeared to be some co-localisation of eEFl A1 with F-actin in cellular
protrusions these levels were not as high as observed for eEFlA2. Partial co-
localisation with tubulin and F-actin was observed in the perinuclear region of the
cell, as seen with eEFlA2. Again the tubulin and F-actin structure within eEFlAl
overexpressing PEOl cells did not appear to differ from cells expressing only
endogenous eEFlAl.
6.2.2 RNA interference of eEF1 A2 expression in cancer cell lines: the
trials and tribulations
RNA interference (RNAi) can be a powerful tool for ablation of expression of
proteins and subsequent determination of the role of a protein within cells both in
vitro and in vivo. During RNAi double stranded RNA (dsRNA) is processed into
short interfering (si)RNAs of approximately 20 base pairs in length containing 2
nucleotide 3' overhangs by the dsRNA endonuclease DICER. This siRNA then
enters the RNA-induced silencing complex (RISC) that mediates the degradation of
complementary mRNA transcripts and this step involves Argonaute proteins among
others, see review (Filipowicz, 2005).
The identification ofEEF1A2 as a potential oncogene has lead me to attempt to
investigate the function of eEFl A2 in cancer cells. Using RNA interference to ablate
eEFlA2 expression in cancer cell lines, and subsequent analysis of any resulting
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Figure 6.6 GFP-eEFlAl,F-actin and tubulin localisation in PEOl cells.
(a-c) PEOl cells transfected with GFP-eEFlAl (green) and stained with Alexa Fluor
594 phalloidin to F-actin (red) and plated on glass coverslips. Many F-actin rich
cellular projections can be seen in these cells. Partial co-localisation between
eEFlAl and F-actin can be seen both in the perinuclear region of the cell and in the
cellular protrusions, (d) GFP-eEFlAl (green) and anti-tubulin (red) in PEOl cells.
Some co-localisation can be observed in the perinuclear region of the cells. xlOO
magnification.
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phenotype, should provide an insight into its function. As all cell lines I have tested
that express eEFlA2 also express high levels of eEFlAl, knocking down eEFlA2 in
these cells should not significantly reduce the global level of translation.
Additionally, it is initiation and not elongation that is thought to be the rate limiting
step of translation and eEFlA is in vast excess over other components of the
translational machinery. Therefore we propose that knocking down eEFlA2 should
not have an effect on the rate of translation. A table summarising the techniques and
protocols I used for RNA interference can be found at the end of this chapter in table
6.4.
6.2.2.1 siRNA oligos for ablation of eEF1 A2 expression in HeLa and
MCF-7 cells
My initial approach to RNA interference (RNAi) of eEFlA2 expression was to use a
pool of four siRNAs targeted to the eEFlA2 transcript, produced by Dharmacon, and
transiently transfect them in HeLa cells. HeLa cells are derived from a cervical
epithelial cancer, are easy to transfect and express both eEFlAl and eEFlA2 at high
levels. They are therefore suitable for this application. Preliminary analysis using
these pooled oligos and oligofectamine as a transfection reagent suggested that the
technique worked well. eEFlA2 levels, as determined by Western blot, were more
than 70% lower in eEFl A2-targeted siRNA transfected cells at 24 and 48 hours post-
transfection compared to untransfected and mock transfected cells, see figure 6.7.
By 72 hours post-transfection the levels of eEFlA2 were returning to normal.
Western blot analysis confirmed that the oligos did not knockdown eEFlA1 and
were therefore specific to eEFlA2. I observed a decrease in cell number in eEFlA2
siRNA transfected cells compared to controls including cells transfected with non-
targeting siRNA. Non-targeting siRNA was also obtained from Dharmacon and is a
siRNA with no known sequence homology to human transcripts that acts as a control
for off target effects of siRNA administration. As well as HeLa cells this technique
was also applied to MCF-7 cells. MCF-7 is a human breast adenocarcinoma cell line
and is therefore potentially a more relevant cell line for the investigation of the role
of eEFlA2 in cancer as eEFl A2 is expressed in up to one third of breast cancers.
Investigation of eEFl A2 function in ovarian carcinoma cell lines would also be




Mock untrans eEFlA2 Mock untrans EEF1A2 Mock untrans eEFlA2
24 hours 48 hours 72 hours
Figure 6.7 eEFlA2 knock down in HeLa cells using pooled siRNAs targeted to
eEFlA2
Mock transfected (mock), untransfected (untrans) and cells transfected with siRNAs
against eEFlA2 (eEFlA2) were pelleted at 24, 48 and 72 hours post-transfection and
the protein analysed by Western blot. By 24 hours post-transfection eEFlA2 levels
are negligible in cells treated with eEFlA2 siRNA. eEFlAl levels are not knocked
down showing that the siRNAs are specific to eEFlA2. By 72 hours the level of
eEF!A2 is beginning to return to normal.
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relevant. Quantification of cell number in subsequent experiments suggested that
ablation of eEFlA2 expression in MCF-7 cells resulted in a decreased cell number,
see figure 6.8. This suggested that a non-canonical function(s) performed by
eEFl A2 may be essential to HeFa and MCF-7 cells in culture, on the assumption that
global translation levels are not altered due to the presence of eEFlAl. It could be
that MCF-7 expressing decreased amounts of eEFlA2 exhibit a decrease in the rate
of proliferation compared to those expressing unaltered levels of eEFlA2 or that they
are undergoing apoptosis. It is important to note that the cell count in cells
transfected with non-targeting siRNA was variable and on occasion also lower than
mock and untransfected cells suggesting that there is toxicity associated with the
presence of siRNA in the cell.
Many attempts to replicate eEFlA2 knockdown using pooled siRNA gave very
variable results. The ablation level of eEFlA2 expression was not consistently at or
above 70% and was often low to zero. Optimisation to increase knockdown of
eEFlA2 by alteration of oligo:oligofectamine ratio to 1:3, 1:6 and 1:9, as well as cell
plating density from 3x 104 to 3.5x104 and 4xl04 per well of a 24 well plate worked
to a degree but was also inconsistent.
6.2.2.2 A decrease of eEF1A2 expression in MCF-7 cells does not alter
the rate of proliferation of the cells
eEFlAl has been found to associate with the mitotic apparatus of Sea Urchin eggs
and injection ofmAb to eEFlAl blocks the formation of the mitotic spindle
(Toriyama et ah, 1988) (Ohta et ah, 1990); providing evidence that eEFlAl may
have an important role in mitosis. If eEFlA2 has a role in mitosis in mammalian
cells this could be important to its function as an oncogene. In rapidly proliferating
cells there is also evidence of an upregulation of eEFlA mRNA levels, for instance
in cells in culture (Sanders et ah, 1992), embryos (Krieg et ah, 1989) and in highly
proliferating human cancers (Grant et ah, 1992). The reason for this is unknown and
somewhat puzzling as eEFl A is already found in vast molar excess of the other
components of the translational apparatus in normally proliferating cells. However,
evidence of overexpression of eEFl A in rapidly proliferating cells does suggest it
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Figure 6.8 Partial eEFlA2 knockdown in MCF-7 cells using eEFlA2 siRNA,
and cell counts showing a decrease in cell number in eEFlA2 knockdown cells.
(a) Untransfected (untrans), mock transfected (mock), non-targeting oligo (neg), and
eEFlA2 targeted siRNA (EEF1A2) treated cells were pelleted at 24 hours and 48
hours post transfection. Western blot analysis shows partial knock down of eEFl A2
at 24 and 48 hours, (b) Cell counts suggest that there is a decrease in cell number in
MCF-7s treated with eEFlA2 siRNA compared to controls.
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has a role in cell growth and proliferation. Additionally, eEFlA2 overexpression in
NIH 3T3 cells decreases their doubling time suggesting that eEFl A2 expression may
have a role in cell cycle regulation (Anand et ah, 2002). To investigate whether
eEFlA2 ablation by RNAi in cancer cells in culture leads to a concomitant decrease
in proliferation I conducted RNAi of eEFl A2 in MCF-7 cells and measured their rate
ofproliferation using a BrdU (5-bromo-2'-deoxyuridine) assay. 5-bromo-2'-
deoxyuridine is a thymidine analogue that, when added to the medium of cells in
culture, is incorporated into the replicating DNA of cells in S phase. Using a FITC
conjugated antibody against BrdU, cells that have incorporated the thymidine
analogue into their DNA can be identified by immunofluorescence as having green
nuclei. MCF-7 cells were first transfected with eEFlA2 pooled targeted oligos as
well as the non-targeted oligo in duplicate and these cells were split between a well
and glass coverslips. Controls included untransfected and mock transfected cells.
Western blotting ofprotein lysates from these cells taken at 24, 30 and 48 hours after
transfection showed that eEFl A2 levels were lower in cells transfected with
EEFl A2-targeted siRNAs compared to controls. In particular at 48 hours post
transfection the level of eEFl A2 in eEFlA2-siRNA treated cells was approximately
80% lower than that in controls, see figure 6.9. BrdU staining was carried out on
coverslips at 24, 30 and 48 hours post transfection and nuclei were counter stained in
DAPI, representative images can be seen in figure 6.10. The number of BrdU
positive nuclei (green) and BrdU negative (DAPI positive) nuclei were counted and
the results are shown in table 6.2 and figure 6.9. Two counts were performed on
each duplicate of each treatment at each time point.
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Figure 6.9 Western blot showing eEFlA2 levels in MCF-7 cells treated with
pooled siRNA targeting eEFlA2 and the percentage of BrdU positive cells
following RNAi treatment.
Western blot showing eEFlA2 protein levels in untransfected (U), mock transfected
(M), non-targeting siRNA (N) treated and siRNA to eEFlA2 (1A2) treated MCF-7
cells in duplicate at 24, 30 and 48 hours post-transfection. (a) eEFlA2 levels are
knocked down, particularly at 48 hours post transfection. (b) GAPDH has been used
as a loading control. HeLa cell lysate (h) acts as a positive eEFlA2 antibody control
and lymphoblastoid cells (lb) as a negative control. In boxes are duplicate protein
lysates from cells transfected with siRNA targeted to eEFl A2. (c) The percentage of
cells in S-phase as determined by BrdU analysis of MCF-7 cells following siRNA
treatment and controls. The percentage of BrdU positive cells is not different in cells
in which eEFlA2 has been knocked down compared to MCF-7 cells treated with
non-targeting oligos.
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Untransfected 24 hours
Non-targeted 24 hours
eEF!A2 siRNA 24 hours
Figure 6.10 BrdU assay on MCF-7 cells treated with
siRNA against eEFlA2 and controls.
Left: x 40 magnification image of BrdU stained nuclei
(green) and DAPI stained nuclei (blue)
Below: x 20 magnification representative images of
BrdU stained cells in untransfected, mock transfected,
non-targeting siRNA treated and eEFl A2 siRNA treated
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24 hours 640 108.75 51.25 32.3
Untransfected 30 hours 615 98 55.75 36.9
48 hours 636 99 60 37.7
24 hours 614 98 55.5 36.1
Mock 30 hours 557 91.5 47.75 34.0
48 hours 959 151 88.75 37.2
Non-targeting
oligo
24 hours 638 116.5 43 27.5
30 hours 811 130.5 72.25 35.5
48 hours 715 136.5 42.25 22.7
EEF1A2
targeting oligo
24 hours 471 80.75 37 31.3
30 hours 676 100.5 68.5 40.5
48 hours 623 115.25 40.5 26.4
Untransfected and mock transfected MCF-7 cells at 24, 30 and 48 hours after
treatment had between 30-40% of cells in S phase or proliferating. MCF-7 cells
transfected with non-targeting and eEFl A2-targeted siRNAs showed a similar
pattern of proliferation to one another. At 24 and 48 hours approximately 20-30% of
the cell population was in S phase and at 30 hrs post transfection 35-40% of the cells
were proliferating. These results suggest that transfection of siRNA in MCF-7 cells
may decrease their rate ofproliferation. There appeared to be no significant
difference in the number ofproliferating cells in those treated with non-targeted
siRNA or siRNA targeting eEFl A2 suggesting that eEFlA2 knockdown (that was
particularly high at 48 hours post transfection) does not alter the percentage of cells
that enter S phase of the cell cycle. The fact that eEFlA2 expression ablation is not
complete might also lead to a lack of phenotypic change in these cells. There was no
significant difference in the percentage of cells in S phase when subjected to the
different RNA interference treatments (p=0.25, One-way repeated measures
ANOVA).
An alternative more rapid method that could be used to assay cell growth or
proliferation is an MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay. This is a colorimetric assay in which yellow MTT is reduced to
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purple formazan in the mitochrondria of living cells and the absorbance is measured
at 500-600nm by a spectrophotometer.
The reasons for the variability in knockdown of eEFl A2 using siRNAs might be due
to the RNA oligos degrading when in storage or during use. Advice from the
manufacturer suggested that some pooled oligos can form a complex when frozen
leading to destruction of the RNA. Due to the technique being unreliable I decided
to use short hairpin RNAs targeted to the EEFl A2 transcript to ablate eEFlA2
expression instead.
6.2.2.3 Short hairpin (sh)RNAs induce an interferon response in MCF-7s
I designed three different shRNAs targeted to different regions of the eEFlA2
transcript that show low similarity to eEFlA1 in order to ensure specificity. T1B1
was designed to a region of exon 3, T2B2 to a region of exon 5, and T3B3 to a region
of exon 6. I also designed a non-targeting oligo (NEGT1B1) that, by Blast searching
of human nucleotide database in NCBI, I determined to have no significant
homology to any human transcripts. These constructs were cloned into the
Invitrogen BLOCK-iT U6 RNAi Entry Vector that allows the expression of shRNA
in mammalian cells under the control of the human U6 promoter and subsequently
sequence verified the clones. Transient transfection of the shRNA constructs into
MCF-7 cells using oligofectamine as a transfection reagent resulted in high levels of
cell death in both cells transfected with eEFl A2-targeted and non-targeting shRNAs.
Despite their toxicity, constructs T1B1 and T3B3 appeared to be the most effective at
ablating eEFl A2 expression as determined by Western blot, see figure 6.11.
Stripping and reprobing the western blot with an antibody against eEFl A1 showed
that the shRNAs are specific to eEFlA2.
In order to determine whether the toxicity was due to bacterial contaminants in the
DNA plasmid maxipreps I produced new maxipreps using endotoxin-free protocol,
however this did not decrease the toxicity of the shRNA vectors. dsRNA of less than
30 nucleotides in length is thought to be too short to trigger an interferon response in
mammalian cells (Elbashir et al., 2001). However it has been observed that some








Figure 6.11 RNAi of eEFlA2 using three different shRNA constructs targeted to
eEFlA2.
RNAi in MCF-7 cells using shRNA constructs. Protein lysates from untransfected
(U) MCF-7 cells, and MCF-7 cells treated with the three eEFlA2 shRNAs T1B1,
T2B2 and T3B3 were analysed for eEFlA2 and eEFlAl expression by Western
blotting. At 48 hours post transfection shRNAs T1B1 and T3B3 are effective at
ablating eEFlA2 expression. T2B2 does not appear to be functional. T1B1 and
T3B3 are specific to eEFl A2, shown by the fact that eEFlAl levels are not altered in
cells treated with these constructs. GAPDH has been used as a loading control.
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shRNA vectors are capable of triggering the expression of interferons in mammalian
cells. Bridge et al. observed that transfection of human lung fibroblasts with
shRNAs cloned into lentiviral vectors as well as pSUPER-based plasmid vectors
resulted in the induction ofmany interferon target genes including
2'5'oligoadenylate synthetase (OAS1), a classic interferon target gene. Importantly,
Bridge et al. did not see an induction of the interferon response in these cells when
transfected with chemically synthesised siRNA duplexes corresponding to the
shRNAs (Bridge et al., 2003). I set about determining whether the shRNA vectors
used in my system were inducing an interferon response in the MCF-7 cells. Firstly,
I transfected the cells with 0.1, 0.2, 0.4 and 0.8/xgs of eEFl A2-targeted (T1B1) and
non-targeting (NEGT1B1) shRNA plasmids and subsequently pelleted the cells for
RNA extraction at 24, 48 and 72 hours following transfection. I also quantified the
toxicity using a trypan blue dye exclusion assay, results ofwhich can be seen in
figure 6.12. Transfection of small amounts of T1B1 and NEGT1B1 plasmids (0.1/xg
and 0.2 /xg) did appear to reduce the toxicity compared to 0.6 /xg and 0.8 /xg of the
plasmids. To determine whether the interferon response has been induced in these
cells I conducted quantitative RT-PCR to analyse the levels of OAS1 in cells
transfected with T1B1 and JLTB at 24 and 48 hours post-transfection and compared
these to levels in untransfected and mock transfected cells. It can be clearly seen in
figure 6.12 that by 48 hours post-transfection shRNA plasmids have induced a large
up-regulation in the levels of OAS1 (up to 800 times higher than the level in
untransfected MCF-7 cells), particularly at higher plasmid concentrations. The
eEFl A2 targeted shRNA T1B1 appears to induce higher upregulation of OAS1
compared to the non-targeted shRNA.
In order to attempt to overcome the induction of the interferon response I also used
the interferon response-defective cell line HCT 116 (Stojdl et al., 2000). This should
have overcome the toxicity of the shRNA as the cells are unable to mount an
effective interferon response. Unfortunately eEFlA2 was not knocked down in these
cells and I turned to a new technique that could potentially not only overcome the
interferon response but that would also allow me to use a more relevant cell line.





CD CD CD CD
T— CM CM CO
O O O O O o O
CD CD CD CD
0 (D < 0 < 0














CD CD CD CD
3
T— T— csj CM CO
O o o O O o O
CD CD CD CD
















U 24 M 24 1A201 1A20.2 1A20.8 NEG01 NEG 0.2 NEG O 4 NEG 0.8 U 48 M 48 1A20.1 1 2 0.2 1 k2 .4 1A2 0 8 NEG O 1 NEO 0 2 NEG O 4 NEG 0.8
48
Figure 6.12 Cell viability and expression of OAS1 in cells transfected with
shRNA vectors T1B1 and NEGT1B1 using Oligofectamine.
(a) A trypan blue dye exclusion assay was used to assess cell viability in
untransfected, mock transfected and 0.1-0.8/xg of shRNA plasmid transfected MCF-
7 cells, 24, 48 and 72 hours post transfection. Toxicity is particularly apparent in
cells transfected with OAfig and 0.8/tg of plasmid. (b) Quantitative RT-PCR analysis
of the levels of 0AS1 normalised to GAPDH and standardised to the levels in
untransfected cells 24 hours post-plating shows that OAS1 is upregulated in cells
transfected with shRNA constructs, particularly by 48 hours post-transfection.
0AS1 levels appear highest in cells transfected with the eEFlA2 targeting shRNA
construct T1B1.
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6.2.2.4 Transfection of shRNAs using a Nucleofector does not induce
an interferon response in MCF-7 cells
Nucleofection is an alternative transfection technique that combines electroporation
using the Nucleofector with a transfection solution (Amaxa Biosystems). The
electroporation settings and transfection solution that give optimal transfection are
specific to the cell line and this technique results in the plasmid being delivered
directly to the nucleus with high efficiency (up to 80-90% transfection). It is known
that long dsRNA within the cytoplasm ofmammalian cells trigger the interferon
response thereby using the nucleofector system, which targets the plasmid directly to
the nucleus, may circumvent the response.
Transfecting the BLOCK-iT RNAi entry vector shRNA clones T1B1 and T3B3, as
well as an additional eEFlA2-targeting shRNA JLTB taken from (Kulkarni et al.,
2006) by nucleofection into MCF-7 cells resulted in high transfection efficiencies (as
measured using a Green Fluorescent Protein vector control) and in many cases a
substantial knockdown of eEFlA2 levels, see Figure 6.13. Importantly, there was
no evidence of substantial toxicity in cells transfected with any of the shRNA
constructs (above which you would expect to see due to nucleofection), suggesting
that nucleofection does indeed avoid the triggering of the interferon response.
However this technique, as with the pooled siRNA oligos, gave inconsistent results
in the degree of eEFlA2 ablation obtained between assays and did not work at all on
occasion despite the high transfection efficiencies obtained using nucleofection. This
inconsistency meant assaying a phenotype in eEFlA2-knockdown cells was difficult.
6.2.2.5 Partial eEF1A2 ablation in MCF-7 cells does not alter their cell
cycle distribution or increase the number of cells in apoptosis
To investigate whether eEFlA2 ablation by RNAi in cancer cells in culture leads to a
concomitant change in cell cycle distribution and apoptosis I first conducted RNAi in
MCF-7 cells using constructs T1B1 and JLTB which both target eEFl A2, as well as
the non-targeting shRNA construct NEGT1B1, in duplicate. Additional controls
included untransfected and mock transfected MCF-7 cells. MCF-7s were transfected
using a nucleofector and plated in 6-well plates; analysis of transfection levels of a
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Figure 6.13 Western blots showing knockdown of eEFlA2 in MCF-7 cells
using shRNAs T1B1, T3B3 and JLTB transfected by nucleofection.
Top: Knockdown of eEFlA2 is substantial in MCF-7 cells transfected with shRNAs
T1B1, T3B3 and co-transfected with both constructs at 15 and 46 hours post
transfection. CI is a control in which cells are mock transfected and C2 is a control
in which cells are not transfected but incubated with DNA.
Bottom: Western blot showing eEFlA2 levels in MCF-7 cells transfected with
T1B1, T3B3 and JLTB at 20 hours and 42 hours post transfection. Knockdown of
eEFlA2 appears partially successful at 42 hours post transfection. N denotes
protein lysate from cells transfected with the non-targeting shRNA NEGT1B1. C2A-
D are DNA only controls where A is T1B1, B is T3B3, C is JLTB and D is
NEGT1B1.
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GFP control plasmid by Fluorescent Activated Cell Sorting (FACS) suggested the
transfection efficiency was at 80%. Analysis of eEFl A2 protein levels by Western
blot showed that eEFlA2 knockdown had occurred in cells transfected with T1B1
and JLTB, figure 6.14. There was an obvious difference in the level of knockdown
between duplicates highlighting the inconsistency of the shRNA technique. It
appears that at the most, eEFl A2 is at 40-50% of the level in controls in eEFlA2
shRNA transfected cells.
In order to analyse the cell cycle distribution of these cells and to look for any
indication of apoptosis I used propidium idodide staining of the cellular DNA and
FACS analysis. Propidium iodide intercalates in the major groove ofDNA
producing a highly fluorescent adduct. Analysis by FACS allows the distinction of
cells in cell cycle stages G2/M, S, G1 as well as those in apoptosis, by their DNA
content. Cells in G1 have a uniform diploid DNA content and therefore appear as a
sharp peak of fluorescence at the lower end of the DNA content scale. Cells in G2/M
have twice the normal cell content (4n) and the mean DNA content of this peak is
approximately twice that of the G1 peak. Cells in S phase have a range ofDNA
contents from just above that in G1 to just below that in G2/M and therefore appear
as a broader population on the FACS histogram. Cells in the sub G1 population
(DNA content less than diploid) have fragmented DNA and therefore represent the
apoptotic or necrotic fraction of the cell population. FACS generated histograms
showing the DNA content in the experimental cell populations can be seen in figure
6.15. FACS analysis of the cell cycle distribution was more accurately quantified
using Multicycle AV, an advanced cell cycle analysis software program from
Phoenix Flow Systems. The percentage of cells in Gl, S and G2/M as well as
apoptosis/necrosis is represented in table 6.3.
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Figure 6.14 eEFlA2 protein levels in MCF-7 cells treated with shRNA
constructs targeted to eEFlA2.
MCF-7 cells were mock transfected (M) and transfected with shRNA constructs
against eEFlA2 (T1B1 and JETB) and non-targeting shRNA (NON) by
nucleofection and protein samples collected at 48 hours post transfection. eEFlA2
levels have been partially ablated. Protein loading is even as shown by GAPDH
quantification. MCF-7 (M) is a positive antibody control and lymphoblastoid (FB) is
a negative control.
T
M T1B1 JFTB NON M FB
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Figure 6.15 Analysis of the cell cycle distribution and apoptosis in MCF-7 cells
treated with eEFlA2 targeted shRNA, using propidium iodide staining.
Histograms produced by FACS analysis of cells stained with propidium iodide are
shown on the left hand side of each figure. Fraction E are apoptotic/necrotic cells,
fraction B are cells in Gl, C denotes cells in S phase and D are cells in G2/M.
Results from accurate quantification of cell cycle distribution using advanced
analysis software are shown on the right hand side of each figure. (A) untransfected
MCF-7 cells, (B) Mock transfected, (C) T1B1 eEFlA2 shRNA transfected cells
duplicate a and (D) duplicate b, (E) JLTB eEFlA2 shRNA transfected cells
duplicate a and (F) duplicate b, (G) non-targeting shRNA transfected cells duplicate
a and (H) duplicate b.
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Table 6.3 Cell cycle distribution ofRNAi treatedMCF-7 cells, (a) and (b) refer to



















0% 58.6 30.7 6.0 4.69
Mock
transfected
0% 55.2 15.4 6.3 23.0
T1B1 a
30% 47.3 15.0 4.8 32.8
T1B1 b
50% 40.3 17.0 3.8 38.4
JLTB a
0% 51.9 15.5 5.5 27.0
JLTB b
60% 51.6 20.3 5..7 22.4
NEGT1B1 a
0% 43.1 13.3 5.4 38.1
NEGT1B1 b
0% 45.1 16.6 4.5 33.7
There does not appear to be a significant difference in cell cycle distribution between
cells in which eEFlA2 has been knocked down by more than 50% (TlBlb, JLTBb)
compared to those in which transfection of eEFlA2-targeting shRNAs has been
unsuccessful in knocking down the protein (TlBla and JLTBb). This suggests that
either a decrease in eEFl A2 levels in MCF-7 cells has no effect on their cell cycle
distribution or that the level of eEFl A2 knockdown is not high enough to produce a
phenotype. Also, it appears that transient transfection ofMCF-7 cells using the
nucleofector has an effect on cell cycle distribution in MCF-7 cells; decreasing the
percentage of cells in S phase and increasing the number of apoptotic cells compared
to untransfected MCF-7s. The level of apoptosis in cells transfected with shRNA is
approximately 10% higher than that in the mock transfected cell population
suggesting that there is some toxicity associated with shRNA expression or the DNA
plasmid preparations. Importantly, the JLTB construct appeared less toxic than
T1B1 or NEGT1B1 and the reason for this is unknown but could be due to there
being less bacterial contamination in the JLTB plasmid preparation compared to the
others. In conclusion this analysis is of limited value as transient transfection
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appears to have a greater effect on cycle distribution and cell death than partial
knockdown of eEFl A2. This may also be the case in some assays of other
phenotypes suggesting that transient transfection of shRNAs is not a powerful tool
for discerning the non-canonical functions of eEFlA2. Perhaps more useful would
be a stable cell line in which shRNA against eEFl A2 is constitutively expressed.
Both viral and non-viral vectors are available for this application, however due to
time constraints I was unable to utilise this technique.
6.2.3 The role of eEF1A1 and eEF1A2 in heat shock
It was suggested by Shamovsky et al. that eEFl A was necessary for HSF1 activation
and hence the heat shock response in HeLa cells (Shamovsky et al., 2006).
However, the techniques used meant that it was not apparent if eEFlA2 is also
involved in HSF1 activation. In order to investigate the potential role of eEFlAl and
eEFlA2 in heat shock I used RNA interference in HeLa cells to ablate the expression
of eEFlAl and eEFlA2 and subsequently heat shocked the cells and assayed for the
stress-induced Hsp70 (Hsp72) expression by Western blot. Heat shock protein 70
(Hsp70) family members include: Hsc70 or Hsp73, a constitutively expressed
chaperone protein; Hsp70 or Hsp72, a stress-induced protein; BiP or Grp78, that is
localised to the endoplasmic reticulum where it is involved in protein folding and can
be upregulated in response to stress; and mtHsp70 or Grp75, a mitochondrial Hsp70
(Mayer and Bukau, 2005). In order to assay for the induction of the heat shock
response I used an antibody against the stress-induced heat shock protein Hsp70 or
Hsp72 (Stressgen).
To ablate the expression of eEFlAl or eEFlA2 I used pre-designed siRNAs
(Ambion). Three siRNAs targeted to eEFlAl and three siRNAs targeted to eEFl A2
were available and tested in HeLa cells for efficacy. Two of the three sets of siRNAs
were very effective at knocking down eEFlAl and the same was found with the
siRNAs against eEFlA2. This is shown in figure 6.16. eEFlAl has been knocked
down to approximately 10% of the level seen in untransfected cells. eEFlA2 knock
down by two of the oligos has resulted in almost complete ablation of eEFl A2
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expression in the HeLa cells. Therefore these oligos are very effective at knocking
downeEFlAl and eEFlA2.
I then went on to repeat this experiment but to look at the expression ofHsp70 in
heat-shocked HeLa cells in which eEFlAl or eEFlA2 expression had been ablated.
Hsp70 expression should be upregulated following heat shock, as described by
(Shamovsky et al., 2006). I first tested HeLa cells for the upregulation ofHsp70 by
heat shocking them for 1 hour at 40°C or 42°C in a waterbath and allowing 2, 7 or 24
hours post-heat shock for protein production. Control cells were treated in the same
manner but kept at 37°C. Protein analysis by Western blot showed up regulation of
Hsp70 in heat-shocked HeLa cells compared to controls, see figure 6.16. There was
however some expression of Hsp70 in HeLa cells incubated at 37°C.
I then went on to conduct RNAi against eEFl Al or eEFl A2 in HeLa cells and heat
shocked the cells for one hour at 42°C and allowed two hours for protein synthesis
before pelleting the cells. The protein lysate from these cells was then run on a
Western blot and analysed for the expression of eEFlAl or eEFl A2, Hsp70 and
GAPDH (loading control). The results of this analysis can be seen in figure 6.17. It
appears that in HeLa cells with approximately 80% knockdown of eEFl Al
expression and no alteration in eEFl A2 (Western blot not shown), an increase in
Hsp70 is still produced following heat shock suggesting that HSF1 activation is still
able to proceed. Similarly, in HeLa cells in which the expression of eEFl A2 has
been completely ablated but eEFlAl levels remain unaltered, Hsp70 expression still
appears to be upregulated in response to heat-shock however this upregulation is less
apparent and was therefore quantified using image analysis software, see figure 6.18.
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Figure 6.16 Western blot analysis of eEFlAl and eEFlA2 knockdown using the
Ambion pre-designed siRNAs and Hsp70 (72) levels in heat shocked HeLa cells
compared to non-heat shocked.
(a) Left: levels of eEFlAl expression in cells treated with siRNAs 1 Al-1 and
1A1-2, but not 1A1-3, is approximately 10% of that in untreated cells. Wild-type
mouse muscle (muscle) is a negative eEFlAl control. Right: eEFlA2 expression
levels have been almost completely ablated in HeLa cells treated with siRNAs 1A2-1
and 1A2-2 but not 1A2-3. MCF-7 is a positive eEFlA2 control and PEOl is a
negative eEFlA2 antibody control, (b) HeLa cells were plated in small flasks and
the flasks incubated at either 37°C, 40°C or 42°C for one hour. The cells were then
allowed to recover for 2 hours, 7 hours or 24 hours, after which time the cells were
pelleted for Western blot analysis. Each treatment was carried out in duplicate.
Levels of inducible Hsp70 (Hsp72) were analysed using a Hsp70 specific antibody.
GAPDH was used as a loading control. It is apparent that levels of Hsp72 increase
upon heat shock, the highest increase is seen when the cells are incubated at 42°C.
Boxes are shown around duplicates of heat shocked cell lysates.
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Figure 6.17 Western blot analysis of Hsp70(72) expression levels following RNA
interference of eEFlA1 or eEFlA2 and heat shock.
(a) HeLa cells were either untransfected (unt), or transfected with siRNA 1A2-1 or
1A2-2, a negative control siRNA (Neg) and either heat shocked at 42°C (H) or
incubated at 37°C (N). Cells in which eEFlAl has been knocked down (1A1-1 and
1A1-2) are included to show that the 1A1-1 and 1A1-2 siRNAs are specific to
eEFlAl. MCF-7 (M) and PEOl (P) are positive and negative eEFlA2 antibody
controls respectively. The increase in Hsp70 expression is still apparent in heat
shocked HeLa cells despite the complete absence of eEFlA2 expression, suggesting
eEFlA2 is not necessary for HSF1 activation, (b) HeLa cells were untransfected
(unt), mock transfected (mock), transfected with two siRNAs targeting eEFlAl
(1A1-1 and 1A1-2) or treated with a non-targeting siRNA (Neg). PEOl (P) and
mouse muscle (mus) are positive and negative eEFlAl antibody controls. It is
apparent that in cells in which eEFlA1 levels have been substantially reduced Hsp70
upregulation in response to hest shock is still occurring. The presence of Hsp70 in
HeLa cells incubated at 37°C suggests that the anti-Hsp70 antibody is non-specific or
that treatment with siRNA elicits the stress response in these cells, albeit at a lower
level.
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Figure 6.18 Expression levels ofHsp70 normalised to GAPDH.
Levels of Hsp70 protein present in the Western blot shown in figure 6.17a were
quantified and normalised to the loading control GAPDH using image analysis
software. It is apparent that in HeLa cells in which eEFlA2 expression has been
completely ablated (1A2-1 and 1A2-2) there is still an increase in Hsp70 levels in
response to heat shock (H) compared to non-heat shocked cells (N).
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Immunofluorescent analysis of eEFlA2 and eEFlA1 subcellular localisation in
MCF-7 and PEOl cells using tagged eEFlA2/eEFlAl constructs suggests that both
isoforms have a diffuse cytoplasmic localisation with a concentration in the
perinuclear region of the cell and, in some cases, localisation to F-actin rich cellular
protrusions. The localisation of eEFlA in the cytoplasm and perinuclear region fits
with its role in translation, where eEFlA may be interacting with ribosomes located
on the endoplasmic reticulum or cytoskeletal bound polysomes. In addition to this
perinuclear localisation being involved in its role in translation, elongation factor 1A
has been implicated in mRNA localisation. Elongation factor 1A was identified as
the major component of a complex bound to the 3'UTR ofMetallothionein-1 (MT-
1), a region that has been identified as important to the perinuclear localisation of the
mRNA. Mickleburgh et al. hypothesised that eEFlA tethered MT-1 mRNA to the
perinuclear cytoskeleton, this being important for subsequent nuclear import ofMT-1
protein where it performs roles in Gl/S transition and DNA damage (Mickleburgh et
al., 2006). Whether this role is performed by eEFlAl and eEFlA2 or just eEFl Al is
not clear but I have demonstrated that both eEFlA2 and eEFlAl co-localise with
tubulin in the perinuclear region ofMCF-7 cells.
Elongation factors 1A2 and 1 Al also show partial co-localisation with F-actin at
cellular protrusions in some cells. These cellular protrusions are F-actin rich and
have the appearance of fillopodia. Lamellipodia, filopodia and membrane ruffles are
involved in cell motility, organisation ofmembrane domains, phagocytosis and
substrate adhesion. Filopodia are composed of actin bundles that extend beyond the
edge of the broader flatter lamellipodium and these appear to be present in some of
the MCF-7 and PEOl cells observed. Many proteins have been shown to be
important in actin bundling in filopodia including fascin and fimbrin, for a review of
lamellipodia see (Small et al., 2002). In cell migration the initial step involves the
protrusion of the cell membrane driven by localised actin polymerisation. This can
be in response to chemotactic stimuli, such as epidermal growth factor (EGF).
Carcinoma cells are thought to move along the extracellular matrix (ECM) by
extending pseudopods at the leading edge. These pseudopods are functionally
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equivalent to lamellipodia that are observed in cells migrating in 2 dimensional
culture experiments. These pseudopods attach to collagen containing fibres through
adhesion structures called focal complexes. When migrating through dense
extracellular matrix invasive cancer cells extend protrusions with the ability to
degrade and remodel the ECM. These actin rich protrusions capable ofprotein
degradative activity have been termed invadopodia and are particularly important in
the invasion of cancer cells into blood vessels, for review see (Yamaguchi et al.,
2005). Therefore these actin-rich cellular protrusions are pivotal to the invasion and
metastasis of carcinomas.
eEFlA has been demonstrated to bind and bundle actin in yeast and, by
immunofluorescence, to be found in filopodia and other cortical regions containing
actin bundles (Yang et al., 1990). eEFl A2 may also bind and bundle actin in
mammalian cells as suggested by its co-localisation with F-actin in what appear to be
filopodia. Further experimental analysis would be required to determine whether
these actin-rich cellular protrusions are in fact filopodia. For instance as well as F-
actin other markers to filopodia include Fascin and VASP, and co-staining of
eEFlA2 with these additional markers, could confirm or otherwise the identity of the
protrusions. Interestingly in a yeast-two hybrid screen of a mouse brain cDNA
library using a GAL4-eEFlA2 fusion bait, eEFl A2 was shown to interact with
Fascin (Chang and Wang, 2006) suggesting that eEFlA2 could co-localise with this
marker in the filopodia in mammalian cells. Lamellipodia and filopodia are
important to cell motility. The potential localisation of eEFlA2 to filopodia in MCF-
7 cells suggests that it could be important in motility and hence this could have an
implication in the invasion and metastasis of eEFlA2-expressing cancer cells.
eEFlA2 was also shown to by yeast two-hybrid analysis to interact with other
cytoskeletal proteins including ABP280, Keapl, mRif and RanBPM (Chang and
Wang, 2006).
GFP-eEFlAl also appears to localise to the cellular protrusions in PEOl cells but to
a lesser extent than eEFlA2. This may be due to the N-terminal fusion ofGFP to
eEFlAl, as eEFl A2 did not show as strong localisation to cellular protrusions when
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tagged with GFP but did when tagged with V5. If indeed eEFl A2 and not eEFlA1
is found in fdopodia this would clearly suggest that the isoforms perform different
roles within cell motility. The observation of eEFlA (eEFlA1 or eEFl A2 not
distinguished) at the invading edge of breast tumours does also suggest that eEFlAl
or eEFl A2 or both isoforms may have a role in invasion or motility in cancer cells
(Zhu et al., 2003). eEFl A has also been identified to be more highly expressed in rat
metastatic breast tumours compared to non-metastatic tumours, suggesting a role in
metastasis (Edmonds et al., 1996).
Analysis of the subcellular localisation of eEFl A1 in rat mammary adenocarcinoma
cell lines and human fibroblasts has been carried out. In the metastatic rat mammary
adenocarcinoma cell line MTLn3, Edmonds et al. found eEFlA to have a diffuse
cytoplasmic localisation with increased levels in surface projections containing F-
actin. They also observed a perinuclear distribution that they attributed to
association with ribosomes on the endoplasmic reticulum. Upon stimulation of the
cells with epidermal growth factor (EGF), eEFlA was shown to be associated with
the F-actin rich zone at the edge of the de novo lamellipods (Edmonds et al., 1996).
This is similar to the localisation ofV5-eEFlA2 that I observed in MCF-7 cells and
to the localisation ofGFP-eEFlAl in some PEOl cells. This suggests that eEFlAl
has a similar localisation to eEFlA2 and that the presence of the GFP fusion on
eEFlAl is obscuring this localisation so it is only seen in a few cells. In an
immunofluorescent study of the localisation of eEFl A in human primary fibroblasts,
eEFl A was found to show a diffuse cytoplasmic distribution and unexpectedly a
strong nuclear localisation. Interestingly, they did not find any co-localisation of
eEFlA with the actin cytoskeleton (Sanders et al., 1996). I also observed a diffuse
cytoplasmic localisation of eEFlAl but I did not observe GFP-eEFlAl in the
nucleus.
EGF stimulation of cells in culture and observation of eEFlAl and eEFl A2
localisation could also be useful in further investigating the putative localisation of
the isoforms in cellular protrusions as it has been demonstrated that in resting
Dictyostelium discoideum cells eEFlA is associated with G-actin but upon
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chemoattractant administration eEFlA binds F-actin (Dharmawardhane et al., 1991).
Therefore the amount of eEFlA2 and eEFlAl that translocates to F-actin upon EGF
administration could be compared. Also plating of cells on fibronectin coated
coverslips rather than glass coverslips is a more effective substrate for migration of
cells and visualising lammelipodia. It is also important to note that the localisation
of eEFlA2 (and potentially eEFlAl) at F-actin rich cellular protrusions could be due
to the localised synthesis ofproteins required for cell motility, adhesion etc... and
not due to a potential non-canonical function in F-actin bundling.
In order to further look into the role of eEFl A2 in cancer cells I used RNA
interference to attempt to knockdown eEFl A2 expression in HeLa and MCF-7 cells
and then look at any resultant phenotype. The initial use ofpooled siRNAs targeted
to eEFlA2 did result in knockdown of eEFlA2 levels in HeLa and MCF-7 cells,
however the technique was problematic. siRNAs appeared effective initially but
were ineffective upon subsequent use. This inconsistency suggests that the pooled
siRNAs are degrading. Reasons for this may be that the four siRNAs form a
complex when frozen that results in degradation. I chose to use shRNA constructs as
these are DNA oligos cloned into a vector and therefore not as susceptible to
degradation.
This alternative approach to RNAi of using shRNA vectors also uncovered an
unexpected problem with the technique, the triggering of the interferon response.
Interferons (IFNs) are cytokines that function in host defence against viruses.
Double stranded RNA is a replicative intermediate of some viruses and triggers an
innate immune response. This leads to the secretion of IFNa and IFN/3 that binds to
the interferon receptor on the cell surface resulting in activation of a signalling
cascade involving Janus tyrosine kinases and resultant phosphorylation of signal-
transducing activators of transcription known as STATs and expression of interferon
stimulated genes. These IFN stimulated genes include the gene encoding the enzyme
2',5'oligoadenylate synthetase. 2',5'oligoadenylate synthetase polymerizes ATP
into a series of2'-5 linked oligomers and this activates endoribonucleic degradation
of viral RNA. IFNa and IFN/3 also activate the protein kinase PKR that
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phosphorylates the eukaryotic protein synthesis initiation factor eIF-2, inhibiting
translation and thus perturbing viral replication. These responses to dsRNA are not
sequence-specific and can ultimately result in cell growth inhibition and apoptosis
(Janeway, 2001).
It has previously been reported that dsRNA of less than 30 nucleotides did not trigger
the interferon response and effectively lead to ablation of target gene expression
(Elbashir et al., 2001). However, Bridge et al. observed triggering of the interferon
response in human lung fibroblasts by 21 nucleotide shRNAs in plasmid-based
expression vectors as well as lentiviral vectors. They found that increasing vector
dose increased the level of interferon response suggesting that the accumulation of
unprocessed or aberrantly processed Pol III transcripts may be triggering the IFN
response (Bridge et ah, 2003). Accumulation of unprocessed dsRNA might be the
cause of the induction of the IFN response in my system and decreasing the dose of
eEFl A2 and non-targeting shRNA vectors did appear to decrease the level of OAS1
expression. In addition to IFN induction by shRNA vectors Sledz et al. have
observed that a variety of siRNAs of 21 nucleotides in length can also trigger an IFN
response in human cell lines (Sledz et ah, 2003). This suggests that the IFN response
can be triggered by siRNAs as well as longer unprocessed or aberrantly processed
Pol III transcripts produced from shRNA vectors. Targeting of the shRNA vector
directly into the nucleus using nucleofection overcame the induction of the IFN
response and may be a useful tool in decreasing this off target effect that can be
induced in RNA interference.
On an occasion of successful eEFlA2 knockdown using pooled eEFlA2 siRNAs a
BrdU assay suggested that 90% ablation of eEFlA2 in MCF-7 cells has no effect on
the rate ofproliferation of these cells in culture. The evidence behind this
investigation was that forced expression of eEFlA2 in NIH 3T3 cells has been
shown to decrease their doubling time and when expressed in ES-2 cells and
xenografted into nude mice it accelerated growth (Anand et ah, 2002). I therefore
hypothesised that eEFl A2 ablation in cancer cells in culture might result in a
decrease in proliferation and therefore a decrease in BrdU positive cells compared to
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those expressing eEFlA2. Transfection ofMCF-7 cells with siRNA, including non-
targeting oligo, appears to result in a decrease in the number of cells in S phase by 48
hours post transfection. This suggests that there is some toxicity associated with
siRNA and that this may be an off target effect of siRNA treatment. The number of
cells in which eEFlA2 expression has been ablated in S phase is not significantly
lower than that seen in cells treated with non-targeting oligo suggesting eEFlA2
does not perform a role in the proliferation rate ofMCF-7 cells. Alternatively
eEFl A2 may perform a role in proliferation but because eEFlA2 knockdown,
although substantial, is not complete the residual eEFlA2 may be sufficient for there
to be no phenotypic change in these cells. Complete knockdown of eEFlA2, as may
be achieved using cell lines stably expressing a shRNA construct targeted to
eEFlA2, could be used to determine whether complete absence of the elongation
factor effects proliferation.
Upon partial knockdown of eEFl A2 in MCF-7 cells using shRNA vectors JLTB and
T1B1 the cell cycle distribution and percentage of cells in apoptosis were measured
by propidium iodide staining and FACS analysis. Both mock transfection and
transfection of targeted and non-targeted shRNA constructs resulted in a decrease of
cells in Gl, S and G2/M and an increase in the number of apoptotic cells. This
increase in apoptosis is to be expected as the nucleofection is known to result in
some cell death. This cell death was higher in those cell populations nucleofected
with shRNA vectors suggesting their expression harbours some additional toxicity.
This toxic effect was less prominent in cells transfected with the JFTB construct
perhaps suggesting that this plasmid preparation was cleaner or that the shRNA
sequence induced less toxicity. Again there appears to be no difference between in
cell cycle distribution in cell populations in which eEFlA2 expression has been
partially ablated. Ruest et al. observed that in mouse C2C12 and rat L6A Myoblast
cell lines, when eEFl A2 expression levels were high and cells were then serum
deprived more cells remained viable. However, when eEFl Al expression was high
in these cells more apoptosis was observed. This function of eEFlA2 and eEFlAl
was shown to exert its effect through caspase-3 (Ruest et al., 2002). Therefore, in
this system eEFlA2 is anti-apoptotic and eEFlAl is pro-apoptotic. This suggested
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that eEFl A2 may be protective against apoptosis induced by serum starvation.
Additionally, eEFlA2 has been shown to be protective against oxidative stress
(H2O2) induced apoptosis in NIH 3T3 cells (Chang and Wang, 2006). However,
knockdown of eEFlA2 does not result in a greater amount of apoptosis in MCF-7s
compared to cells expressing high levels of the factor. It may be that this anti-
apoptotic role would only be exposed by induction of apoptosis in the MCF-7 cells
with H2O2 or serum starvation and that eEFlA2 is not required for cell survival in the
absence of these stresses. Initial RNAi of eEFlA2 using siRNAs did suggest that
knockdown of the protein resulted in a decrease in cell number compared to controls,
and it was not clear whether this phenotype was due to a decrease in proliferation or
an increase in apoptosis. However, subsequent experiments suggest that eEFlA2
ablation does not result in a decrease in cell number. It may also be that initial RNAi
experiments sufficiently knocked down eEFl A2 to levels that produced a phenotype
and that subsequent experiments have not been as successful. Again complete
ablation of eEFl A2 by stable expression of eEFlA2 shRNA may answer this
question but if cell viability is compromised by loss of the factor the use of inducible
shRNA constructs may be necessary.
The final siRNAs used in RNA interference of eEFlA1 or eEFlA2 in HeLa cells
were effective. These siRNAs were pre-designed by Ambion and consisted of three
individual siRNAs targeted to each of eEFlAl and eEFl A2. Of these three siRNAs,
two effectively resulted in the knockdown of eEFl A1 or eEFlA2 when transfected
into HeLa cells. These siRNAs are single siRNAs rather then the pooled siRNAs
and therefore may be more effective because a complex between different siRNAs
cannot form and hence the single siRNAs are not degrading during freezing.
Additionally, the individual siRNAs may be more effectively designed than the
pooled oligos and this may also make them more effective. There did not appear to
be any toxicity associated with transfection of the Ambion siRNAs into HeLa cells
suggesting they also do not trigger an interferon response.
HeLa cells in which eEFlA1 or eEFlA2 expression had been ablated appeared to
still be capable of HSF1 activation and subsequent Hsp70 upregulation in response to
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heat shock. This suggests that one of two things (or indeed both hypotheses) may be
true: firstly, that both eEFl A1 and eEFl A2 are capable ofparticipating in HSF1
activation and hence in cells in which one of the variants has been knocked down the
other variant is able to compensate. Secondly, it may be the case that eEFl A1 and
eEFlA2 are not essential for FISF1 activation, contrary to the suggestion by
Shamovsky et al. that it is; however this was not conclusively shown (Shamovsky et
al., 2006). Also, eEFlAl knockdown using siRNA only resulted in an approximate
50% reduction in the level of eEFlAl compared to untreated cells and this remaining
eEFl A1 may be sufficient for HSF1 activation to proceed.
The specificity of the FIsp70 antibody is, however, somewhat questionable. In HeLa
cells that have not been exposed to cellular stress such as heat shock it would be
expected that the stress-induced Hsp70 should not be present but it can be seen from
the Western blot that there is Hsp70 present in these cells. Additionally, the eEFlAl
and eEFl A2 antibody controls, protein lysate from MCF-7 and PEOl, but not wild-
type mouse muscle, also have high levels ofHsp70 expression. This could be due to
the anti-Hsp70 antibody cross reacting with the constitutive Hsc70. Alternatively,
the sealing of the plates when incubated at 37°C may induce a stress response in the
cells and hence Hsp70 activation. This seems less likely as the antibody detected
large amounts of Hsp70 in the control protein lysates, MCF-7 and PEOl, and these
cells were not treated in any way that should induce a stress response before protein
extraction.
The effectiveness of the Ambion pre-designed siRNAs in inducing eEFlAl and
eEFl A2 knockdown means that this tool could be used for many assays of gene
function in different cell lines and should provide valuable information regarding
function of these two proteins.
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Chapter 7 Discussion
7.1 Evidence for a role of eEF1A2 in breast and ovarian cancers prior to
the PhD
Prior to the start of this project a limited amount of research regarding the role of
eEFl A2 in cancer had been carried out. Chromosomal arm 20q and the region
20ql3 was known to be frequently amplified in breast and ovarian cancers, among
other cancers (Courjal et al., 1996). Anand et al. identified overexpression of
eEFlA2 in approximately one-third of ovarian cancers and found that forced
expression of eEFlA2 in NIH 3T3 cells resulted in a transformed phenotype and
tumour formation when xenografted into nude mice, suggesting that EEF1A2 is an
oncogene (Anand et ah, 2002).
7.2 Summary of results
In breast cancers I observed moderate to high expression of eEFlA2 at the RNA and
protein level in up to two-thirds ofbreast cancers analysed. This moderate to high
eEFlA2 expression level appeared to associate with oestrogen receptor (ER) positive
cancers (p=0.016) however further investigation suggested that EEF1A2 is not an
oestrogen responsive gene. The Letrozole and ERaRNAi in MCF-7 cells did not
confirm or otherwise if eEFlA2 is oestrogen responsive and therefore additional
more effective experiments would be needed to determine how eEFlA2 expression
relates to the oestrogen receptor. In epithelial ovarian cancer eEFlA2 was expressed
in 15-30% of tumours analysed and high levels of expression of eEFlA2 were
observed in clear cell carcinomas. eEFlA2 overexpression in ovarian cancer does
not appear to be mediated by mutation or methylation and is not consistently
associated with gene amplification. Another method of evaluation ofEEF1A2 copy
number such as FISH would be required to confirm or otherwise the frequency of
EEF1A2 amplification and hence determine the predominant mechanism of
overexpression. Partial knock down of eEFlA2 expression in HeLa and MCF-7 cells
does not result in a decrease in the percentage ofproliferating cells or an alteration in
the cell cycle distribution and apoptosis in these cells. Recent evidence suggested
that eEFl A was required for HSF1 activation and the expression of heat shock
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proteins in response to cellular stress (Shamovsky et al., 2006). The knock down of
either eEFlAl or eEFlA2 in heat shocked EleLa cells using RNA interference does
not appear to impede the expression ofHsp70, suggesting that the heat shock
response does not depend on either eEFlAl or eEFlA2 exclusively.
7.3 The role of eEF1A2 in tumourigenesis: evidence from functional
studies
RNA interference has not shed much light on the role of eEFlA2 in cancer cells in
culture. RNA interference did suggest that eEFlA2 is not involved in the control of
proliferation in cancer cells in culture. This is supported by the finding ofKulkurni
et al. showing eEFlA2 expression correlated negatively with Ki67 in breast cancer,
suggesting that eEFlA2 is not associated with mitotic index and hence not involved
in proliferation (Kulkarni et al., 2006). The cells in culture in which eEFlA2 had
been knocked down (HeLa and MCF-7) were viable and this suggests that eEFlA2 is
not required for cell viability and that the levels of eEFlAl present are sufficient to
fulfil the need for protein elongation in the cells. Equally, HeLa cells in which
eEFlAl but not eEFlA2 had been knocked down also appeared viable under the
microscope suggesting that the two proteins can perform comparably in protein
synthesis however a more detailed assay for cell viability would be required to
properly confirm this.
The literature does provide some clues to the role that eEFlA2 could be performing
in cancer. For instance as mentioned previously eEFlA2 could be involved in
protection of cells from apoptosis induced by oxidative stress (Chang and Wang,
2006). Alternatively it could be that eEFlA2 has a role in actin remodelling and this
may be particularly important in cancer cell invasion and metastasis. My observation
of eEFlA2 co-localisation with actin at what appear to be filopodia in MCF-7 cells
suggests that the elongation factor could be involved in cell migration. The
identification of an interaction between eEFlA2 and fascin (an actin bundling protein
found in filopodia) in a yeast two-hybrid screen by Chang et al. (Chang and Wang,
2006) is consistent with the observation that eEFlA2 is localised to these cellular
protrusions. Overexpression of tagged eEFlAl and eEFlA2 in MCF-7 and PEOl
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cells did not seem to result in any alteration in the cytoskeleton of these cells - as has
been observed in Saccharomyces cerevisiae (Munshi et al., 2001) - perhaps
suggesting the actin remodelling properties of eEFlA in yeast are different from
mammalian eEFlA. Additionally, overexpression of eEFlAl or eEFlA2 did not
seem to increase the number of cellular protrusions formed compared to cells
expressing empty vector. The fact that eEFl A2 expression has been correlated with
an increased 20 year survival in breast cancer, suggests that eEFlA2 expression is
not associated with aggressive, invasive, metastatic breast cancers (Kulkarni et al.,
2006). eEFl Al has been shown to activate phoshotidylinositol-4-kinase (Yang et
al., 1993) and eEFlA2 overexpression has been demonstrated to increase the levels
ofAkt (Chang and Wang, 2006) and therefore eEFl A2 may regulate tumourigenesis
through these pathways. More in vitro and in vivo assays would be required to
determine the role that eEFlA2 could be playing in cancer. It is still not known
whether it is the function of eEFl A2 in translation or a potential non-canonical
function that is mediating its role in cancer.
7.4 The potential of eEF1 A2 as a biomarker or therapeutic target
My expression studies in breast and ovarian cancer suggest that eEFl A2 could be a
useful biomarker or therapeutic target in these cancers. More work looking at
associations between eEFlA2 expression and clinical features, such as response to
chemotherapy or survival time, would better define how eEFl A2 could be a useful
marker in breast and ovarian cancer. eEFl A2 could be a possible therapeutic target
as eEFl A2 appears to only be exclusively expressed in terminally differentiated cell
types that perhaps do not have a high need of protein synthesis compared to tumour
cells. However, the phenotype ofwasted mice suggests that decreasing levels of
eEFl A2 could result in a motor neuron disease-like phenotype.
7.5 Chromosome 20q13 amplification and EEF1A2
It is possible that the expression of eEFlA2 I have observed in breast and ovarian
cancer is simply a consequence of the gene's location within the 20q amplicon and
that other genes at this locus are the important proto-oncogenes. Multiple regions
along the q arm of chromosome 20 are amplified, as well as the entire q arm, and
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often this amplification is at 20ql3.2, which is proximal to the EEF1A2 locus.
Candidate oncogenes in the 20ql3 amplicon(s) include ZNF217, AurA, and PTK6
and AIB1. ZNF217 is a putative transcription factor that has been shown to cause
immortalization of human mammary epithelial cells and to increase telomerase
activity and stabilise telomere length (Nonet et ah, 2001). Aurora kinases belong to a
family ofmitotic protein kinases involved in the regulation of centrosomal and
mitotic activity. Aurora A kinase overexpression in NIH 3T3 cells results in
transformation and amplification of the AurA gene and overexpression of the protein
has been observed in cancer (Ferrari, 2006). 20ql3 amplification has been shown to
associate with high grade breast tumours showing aneuploidy (Tanner et al., 1995),
and overexpression of aurora A kinase has been shown to cause centrosome
amplification, chromosomal instability and aneuploidy (Zhou et ah, 1998). PTK6
encodes a non-receptor tyrosine kinase (Brk) and is located close to EEF1A2 at
20ql3.3. It is thought that epidermal growth factor (EGF) stimulates the
phosphorylation ofpaxcillin by Brk leading to activation ofRacl resulting in the
promotion of cell motility and invasion (Chen et ah, 2004). This is interesting as
20ql3 amplification has been shown to be associated with aggressive breast tumours
with lymph node involvement (Courjal et al., 1996), and Brk expression may be
involved in conferring this property in 20ql3 amplified tumours. Interestingly, Brk
has been shown to be expressed in approximately two-thirds of breast tumours
(Barker et al., 1997) (similar to my results for eEFlA2) and its expression in mouse
fibroblasts and mammary epithelial cells potentates their anchorage independent
growth and, in the latter cell type, their response to epidermal growth factor
(Kamalati et al., 1996). Amplified in breast cancer 1 (AIB1) is located at 20ql2. It
is a member of the pl60/steroid receptor coactivators family and has been shown to
interact with the estrogen receptor and enhance ER-dependent gene expression
(Anzick et al., 1997). 20q gain is common in ER positive breast cancers (Cingoz et
al., 2003) and AIB1 may be involved in enhancing signalling from the receptor in
these breast cancers. In addition, AIB1 amplification has been identified in 25% of
sporadic ovarian tumours and may activate oestrogen-dependent growth-promoting
pathways in ovarian epithelial cells (Tanner et al., 2000). The expression ofmultiple
genes within the 20ql3 amplicon(s) and along the entire 20q arm may act
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synergistically, through interplay between oncogenic pathways, to enhance or drive
tumourigenesis and EEF1A2 could be an important player. My finding that eEFlA2
expression levels do not appear to correlate with copy number suggests that eEFlA2
overexpression is not only due to gene amplification.
7.6 Future work
7.6.1 The expression of eEF1 A2 in breast cancer
The expression of eEFlA2 in different sets ofbreast cancers appeared to be different.
For instance in the cores of tumours on the commercial tissue array eEFl A2
expression appeared to be moderate to high in more than 60% of the breast cancers.
Equally the expression of eEFl A2 was also moderate to high in a large percentage of
the oestrogen receptor positive cancers at the RNA level. However, the percentage
of tumours on the in-house array that expressed eEFlA2 was substantially lower than
that observed in the other breast tumour sets analysed. Unfortunately this
discrepancy meant that analysis for clinical correlations was not possible and
therefore I was not able to utilise this TMA, for which there is significant clinical
data available, to determine whether eEFlA2 expression associated with clinical
features. Future work would include further analysis of eEFlA2 expression in more
breast tumours and hopefully the identification of clinical associations. One of the
most interesting observations of eEFl A2 expression in breast cancers was that
eEFlA2 appeared to be expressed in many precursor breast lesions and therefore an
array containing examples of hyperplastic lesions and DCIS would be a useful tool
for investigating the possibility that eEFl A2 overexpression is an early event in the
molecular pathway of breast cancer progression.
7.6.2 The expression of eEF1A2 in ovarian cancer
A similar problem with discrepancies between eEFlA2 expression levels in different
panels of ovarian cancer samples also meant that identification of clinical
associations was not possible. Initial analysis of eEFlA2 expression in epithelial
ovarian tumours on a commercial tissue array and a panel of ovarian cancers for
which RNA, DNA and protein was available showed an association between
eEFlA2 expression and clear cell carcinomas (CCC). However this association was
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apparent but not statistically significant in a study of a larger in-house tissue array for
which clinical information was available. Therefore future work would include the
analysis of further clear cell carcinomas to confirm or otherwise this association and
to optimise eEFlA2 staining by immunohistochemistry. The expression of eEFlA2
in clear cell carcinomas could contribute to the distinct clinical features of this
subtype. Particularly interesting is the resistance of clear cell carcinomas to
platinum-based chemotherapy. It would be interesting to study the specific role of
eEFlA2 in clear cell carcinomas and platinum-based chemotherapy resistance,
perhaps using an in vitro model. Clear cell carcinomas cells in culture, such as
HAC-2 or SMOV-2 cells, could be used in an RNA interference assay in which
eEFlA2 expression is knocked down and the resistance to therapy investigated.
Cells could be treated with various concentrations of cisplatin (CDDP) and
sensitivity determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay in cells expressing and not expressing eEFlA2. This protocol
has been used by Itamochi et al. to investigate the mechanism ofCisplatin resistance
in clear cell carcinoma of the ovary (Itamochi et al., 2002). In addition previous in
vitro studies have demonstrated that CCC cells in culture exhibit resistance to CDDP
as well as doxorubicin, cyclophosphamide, and etoposide (Gorai et al., 1995).
7.6.2 The mechanism of eEF1A2 overexpression
The mechanism of overexpression of eEFlA2 in ovarian cancers remains a mystery.
It is not clear whether gene amplification plays a role in eEFlA2 expression and
further analysis ofEEF1A2 copy number using another technique such as FISH is
required to determine this. Mutation and methylation do not appear to mediate
eEFlA2 overexpression in the ovarian cancers analysed. Inappropriate expression of
a trans-acting factor, such as a neuronal specific transcription factor, could play a
role in eEFl A2 overexpression and this would be an interesting avenue of
investigation. This question could be addressed using a microarray to look for
expression of transcription factors in cancers that express eEFl A2. My analyses
were carried out on a small number of ovarian cancers and therefore extending the
analysis to include more ovarian cancers, particularly for mutation analysis, could
perhaps be useful. It would also be interesting to look at the mechanism of eEFlA2
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overexpression in other cancers such as breast cancer. It is very possible that the
mechanism of overexpression is different in different cancers and even between
different subtypes, be they histological or clinical, within cancer of a specific organ.
In a chemical screen for methylation-silenced genes in a gastric cancer cell line
Yamashita et al. identified that eEFlA2 expression was upregulated by greater than
16-fold following 5-aza-dC treatment of the cell line, using an oligonucleotide array.
The methylation of the 5' CpG island ofEEF1A2 was examined in other gastric
cancer cell lines and primary tumours by methylation-specific PCR and shown to be
methylated in 3/6 cell lines but only 1/10 primary gastric cancers (Yamashita et al.,
2006). This work suggests that in some tissues and cancers the methylation status of
the 5'CpG island ofEEF1A2 could be involved in regulating eEFlA2 expression. In
extension to analysis of the methylation status of the 5'CpG island ofEEF1A2 in
cancers, investigation in normal human and mouse tissues that express and do not
express eEFlA2 would be informative.
7.6.3 The expression and role of eEF1 A2 in other cancers
As well as ovarian and breast cancers there is also evidence to suggest that eEFlA2
is involved in other human cancers. For instance it would be interesting to
investigate the role of eEFl A2 in lung cancers, particularly because eEFlA
expression has been shown to correlate with short overall survival time (Li et al.,
2006) and it is not known if it is eEFlAl or eEFl A2 that shows this association due
to the use of a non-specific antibody in immunohistochemical analysis. Comparative
genomic hybridisation assays have meant that the identification of single copy gains
at 20q or high level amplifications have been identified in many different cancers
including bladder cancer (Hurst et al., 2004), pancreatic cancer (Kitoh et al., 2005),
oesophageal squamous cell carcinoma (Fujita et al., 2003), and colon cancer
(Douglas et al., 2004), to name but a few. Investigating the expression and potential
role of eEFlA2 in these cancers could determine ifEEF1A2 is an important
oncogene in many different cancers
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7.6.4 The role of eEF1 A2 in oncogenesis
Further analysis of eEFlA2 function using in vitro and in vivo models is required to
elucidate the mechanism by which eEFlA2 could be oncogenic. Stable cell lines
expressing eEFl A1 or eEFlA2 targeted shRNAs would perhaps be an effective in
vitro model for analysing the differences in function between the two eEFlA
proteins. Using constructs with different targeting efficiencies could also prove
useful for the analysis of phenotypic change upon subtle changes in eEFlA levels.
In order to answer the question ofwhether eEFlA1 and eEFlA2 are involved in the
translation of different mRNAs (I believe this to be unlikely) and if this is
contributing to oncogenesis, proteome analysis of cells in which eEFl A1 or eEFlA2
are exclusively expressed could be carried out. Two-dimensional acrylamide gel
electrophoresis and mass spectrometry could be utilised to identify those proteins
that are potentially differentially expressed. The global level of translation can be
measured in cancer cells upon eEFlA1 or eEFlA2 ablation by measuring the rate of
poly(U)-directed [3H]polyphenylalanine synthesis. Conversely, the effect of
overexpression of either of the eEFlA proteins on the global rate of translation could
also be determined. RNA interference could also be used to investigate the potential
role of eEFl A in the PI3-K/Akt oncogenic pathway by looking at the levels of
activated Akt (using specific antibodies to the phosphorylated protein) in cells
expressing and not expressing the eEFlA variants.
The potential role of eEFlA2 in invasion and metastasis could also be investigated
using RNA interference in an invasive cell line such as MDA-MB231. The effect of
eEFl A2 ablation on the invasive potential of the cell line could be investigated using
a matrigel invasion assay. Conversely overexpression of eEFlA2 in a non-invasive
cell line such as PEOl, that does not express endogenous eEFl A2, could be used in a
matrigel assay to look for increased invasiveness. Additionally, further investigation
into the potential localisation of eEFl A1 and eEFlA2 at cellular protrusions would
be interesting. A scratch wound assay could be used to look at filopodia formation in
cells expressing the GFP tagged eEFl A1 and eEFlA2 and plated on fibronectin.
There is also increasing evidence that eEFl A2 is anti-apoptotic and this could be
investigated using the eEFlA2 knockdown or overexpressing cell lines to evaluate if
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alterations in eEFlA2 levels have an effect on hydrogen peroxide induced apoptosis
for instance. The same assays can be applied to cells lines in which eEFl A1 has
been knocked down or overexpressed (although we are yet to identify a cell line that
does not express endogenous eEFlAl at high levels) to determine if eEFl A1 and
eEFlA2 have different roles in apoptosis.
Further overexpression studies to perhaps determine whether eEFlA1 and eEFlA2
have opposing non-canonical functions in cell lines could be done by creating
chimeric eEFlA1/eEFlA2 constructs. For instance the GTP-binding domains are
located at the N-terminus of the eEFl A proteins, and this region shows few
differences between eEFl A1 and eEFlA2, but the regions thought to be important
for cytoskeletal interaction are located at the C-terminus where more differences
between the two proteins are located. Therefore engineering eEFlA1 clones with the
C-terminus replaced by the C-terminus of eEFlA2, and vice versa, could be
informative. For instance the anti-apoptotic function of eEFl A2 could be altered or
ablated in the eEFlA2/eEFlA1 chimeric protein. Also using cloning to produce
eEFlAl and eEFlA2 proteins with mutated GTP-binding domains and analysing the
ability of these proteins to transform NIH 3T3 cells could potentially be used to
identify whether it is the function of eEFlA2 in translation or in other cellular
processes that enables it to transform rodent fibroblasts. Importantly, the ability or
otherwise of eEFl A1 to transform rodent fibroblasts and to result in tumour
formation when xenografted into nude mice has not been investigated and would be
important in determining if both eEFl A variants are oncoproteins.
In vivo models of eEFlA2 and its role in cancer could include the overexpression of
the translation factor in, for instance, mammary epithelium of the mouse and
observation for tumour formation. This could be achieved by the production of a
transgenic mouse expressing eEFl A2 under the control of a whey acidic protein
promoter (WAP) or mouse mammary tumor virus long terminal repeat (MMTV)
promoter to produce a mammary tumour model of eEFl A2 expression (Hutchinson
and Muller, 2000). Transgenic mouse models of ovarian cancers have also recently
been produced. Connolly et al. successfully modelled ovarian cancer in mice by
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expressing the potent transforming gene SV40 TAg under the control of the MISIIR
promoter. Expression of the MISIIR-TAg transgene lead to the formation of poorly
differentiated carcinomas of the ovary in female mice and these tumours showed
characteristics of the human disease such as intraperitoneal dissemination (Connolly
et ah, 2003). Flesken-Nikitin et al. used Cre-/oxP-mediated gene inactivation by the
intrabursal administration of AdCMVCre to model the role of TP53 and Rbl in
epitheilial ovarian carcinogenesis (Flesken-Nikitin et al., 2003). Another technique
utilised to generate mouse models of ovarian cancer is to produce genetic alterations
in mouse or human ovarian surface epithelial cells either in a cell line and then to
inoculate the cells into immunocompromised mice subcutaneously, or
intraperitoneally (Cheng et al., 2005; Fiu et al., 2004; Orsulic et al., 2002).
Alternatively, Orsulic et al. isolated and cultured mixed ovarian cells from p53
deficient transgenic mice expressing the avian retrovirus receptor TVA and infected
them with multiple vectors carrying sequences encoding the oncogenes c-myc, k-ras
and Akt. They found that any two of these oncogenes were capable of inducing
tumour formation when infected cells were injected into various sites in the animal
(Orsulic et al., 2002). Therefore using techniques similar to those described above
transgenic mouse models of eEFlA2 in ovarian and breast cancer could be produced.
7.6.5 The role of eEF1 A1 and eEF1A2 in heat shock
In HeFa cells in which eEFl A2 expression had been completely ablated using RNA
interference it appeared that Hsp70 was still induced following heat shock treatment
at 42°C for 1 hour. Likewise, eEFlAl was knocked down to approximately 20% of
the level in untreated HeLa cells and the level of induction of the stress-activated
Hsp70 following heat shock appeared equal to that observed in cells expressing
eEFlAl at normal levels. This suggests that either both eEFlAl and eEFlA2 are
capable of HSF1 activation or that the involvement of eEFIA is not essential for
HSF1 activation. Alternatively, Hsp70 expression could be induced independently
ofHSF1, however Shamovsky et al. suggest that this is not the case (Shamovsky et
al., 2006). The mechanism ofHSF1 activation was previously thought to occur
spontaneously by the relief of inactivation by bound HSPs. However, the fast HSF1
activation kinetics (Jolly et al., 1999) suggested that this diffusion controlled
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mechanism was probably not responsible for HSF1 activation (Shamovsky et al.,
2006). Indeed, Shamovsky et al. recently showed that HSF1 was activated and that
elongation factor 1A and a non-coding RNA, HRS1, were required for this
activation. eEFlA purified from rat liver (this is therefore eEFlAl because liver
does not express eEFlA2) together with HSR1, was shown to activate HSF1
indicating that eEFlAl does perform this function (Shamovsky et al., 2006). My
RNA interference has not conclusively shown whether eEFlA2 also is involved in
HSF1 activation. In cells in which eEFlAl expression has been knocked down to
approximately 20% of the level seen in untreated cells Hsp70 upregulation appears to
occur. This suggests that either eEFlA2 is also capable of performing in the
activation ofHSF1 or that the residual eEFlAl in the RNAi-treated cells is sufficient
to perform in this process. To rectify this remaining question RNA interference in
which stable expression of an effective shRNA targeted to eEFlAl has resulted in
complete ablation of eEFlAl expression in cell lines also expressing eEFlA2, could
be used to test for HSF1 activation in the absence of eEFlAl. Additionally, the use
of eEFl A2 purified from mouse skeletal muscle together with HSR1 could be used
in an assay ofHSF1 activation. More direct assays ofHSF1 activation include an
electromobility shift assay (EMSA), to determine ifHSF1 is bound to DNA. Also
the use of a reporter plasmid such as the one used by Shamovsky et al., which
consisted of a luciferase reporter fused to an inducible human HSP70 promoter,
could be used to monitor HSF1 activation in cells in which RNA interference has
been used to knockdown the expression ofeEFlAl.
7.6.6 Elongation factor 1A2 and its interaction with TCTP and Prdxl
The recent interesting observation of an interaction between eEFlA (not clear if
eEFlAl or eEFlA2) and translationally controlled tumour protein (TCTP) has given
some clue as to a potential mechanism of eEFlA's role in cancer (Cans et al., 2003).
TCTP was shown to be significantly down-regulated during tumour reversion in cell
lines selected with Paravirus or stably transfected with SLAH-1, both ofwhich result
in the selection of reverted tumour cells. Additionally, down regulation of TCTP
using anti-sense cDNA in the human leukaemia cell line U937 resulted in apoptosis
(Tuynder et al., 2002). eEFIA and eEFlB/3 were also identified in the yeast-two
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hybrid hunt as a TCTP interactor and TCTP was shown to impair GTP/GDP
exchange on eEFIA by stabilising the GDP bound form and antagonising eEFlB/3-
mediated exchange (Cans et ah, 2003). The first investigation to carry out would be
to determine whether it is eEFlAl, eEFlA2 or both that interact with TCTP. This
could be done by co-immunoprecipitation experiments in cell lines expressing all
three of the proteins using the eEFl Al and eEFlA2 specific antibodies and an
antibody raised to TCTP. Expression analysis of eEFlA2 and TCTP could also be
carried out by immunohistochemistry to determine if the two proteins are co-
expressed in cancers. Expression of TCTP would have to be analysed at the RNA
and proteins levels as its expression is post-translationally regulated. Subsequent in
vitro analysis using RNA interference could be used to analyse the role of eEFl A2 or
eEFl A1 and TCTP proteins in cancer cell lines. This is currently under investigation
in the Abbott group by Helen Newbery. Equally, perioxiredoxin-1 (Prdxl) has been
identified as an eEFl A2 interactor in a yeast two-hybrid screen (Chang and Wang,
2006) and similar assays could be used to investigate whether these two proteins are
co-expressed in cancers and to investigate their potential anti-apoptotic function in
cancer cell lines. This yeast two-hybrid screen identified many potential eEFlA2-
interactors and investigating these would also be informative (Chang and Wang,
2006).
In conclusion much work still remains to answer the fundamental questions
surrounding the potential role of eEFl A2 in cancer. It is important to determine
whether both EEF1A2 and EEF1A1 are oncogenes or if only EEF1A2 is an
oncogene. Secondly, the mechanism by which eEFlA2 is overexpressed still
remains elusive and requires further study. Thirdly, it will be very interesting to
determine if it is through its role in translation that eEFl A2 is oncogenic or
alternatively if the oncogenesis is mediated by a specific non-canonical function of
eEFlA2 that is not performed by eEFl Al.
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Abstract
Background: The tissue-specific translation elongation factor eEFIA2 was recently shown to be
a potential oncogene that is overexpressed in ovarian cancer. Although there is no direct evidence
for an involvement of eEF IA2 in breast cancer, the genomic region to which EEFIA2 maps, 20q 13,
is frequently amplified in breast tumours. We therefore sought to establish whether eEFIA2
expression might be upregulated in breast cancer.
Methods: eEFIA2 is highly similar (98%) to the near-ubiquitously expressed eEFIAI (formerly
known as EFI-a) making analysis with commercial antibodies difficult. We have developed specific
anti-eEFIA2 antibodies and used them in immunohistochemical analyses of tumour samples. We
report the novel finding that although eEF IA2 is barely detectable in normal breast it is moderately
to strongly expressed in two-thirds of breast tumours. This overexpression is strongly associated
with estrogen receptor positivity.
Conclusion: eEFIA2 should be considered as a putative oncogene in breast cancer that may be a
useful diagnostic marker and therapeutic target for a high proportion of breast tumours. The
oncogenicity of eEFIA2 may be related to its role in protein synthesis or to its potential non-
canonical functions in cytoskeletal remodelling or apoptosis.
Background
Breast cancer is the most common cancer in females
worldwide; there are an estimated 1 million new cases per
year [1], The identification of changes in gene expression
in breast tumours relative to normal surrounding tissue is
clearly of great importance in terms of prognostic indica¬
tors and therapeutic targets.
The translation elongation factor eEFlA2 was first identi¬
fied as a tissue-specific variant of eEFIAI (formerly
known as EF-la) in the early 1990s [2,3]. The two forms
of eEFIA are encoded by separate loci, but the resulting
proteins are 92% identical and 98% similar. Whereas
eEFIAI is widely expressed, eEFlA2 is normally expressed
only in neurons and muscle [3-5]. The first specific
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evidence implicating eEFlA2 in tumourigenesis came in
2002 when Anand et al [6] showed that eEFlA2 was
expressed in 30% of ovarian tumours, but not in normal
ovary. The genomic region towhich eEFlA2 maps, 20ql3,
had been known for many years to be amplified in a high
proportion ofovarian and breast tumours [7]; [8], but the
EEF1A2 gene maps closer to the telomere than the region
previously implicated. Anand et al showed that 14/53
tumours had amplifications of the region surrounding
EEF1A2 [6], In the same paper, forced expression of
eEFlA2 in cells was demonstrated to confer tumourigenic
properties on NIFI3T3 cells, and to give rise to tumours in
xenografted nude mice. Although 20ql3 amplification is
commonly observed in breast cancer, there has as yet been
no evidence for overexpression of eEFlA2 in breast
tumours. However, eEFlAl, the widely-expressed iso-
form, was recently shown to be upregulated in the infil¬
trating edge of invasive breast tumours compared with the
tumour core by microarray analysis of laser microdis-
sected material, confirmed by immunohistochemistry [9].
In this analysis the antibody used was one that detects
both eEFlAl and eEFlA2 with equal intensity, so it is con¬
ceivable that eEFlA2 contributes to this pattern of
expression.
We have generated antibodies (Newbery et al, in prepara¬
tion) that allow us to distinguish between the highly
related isoforms eEFlAl (which is expressed in normal
breast) and eEFlA2 (which is thought to be expressed
only in muscle and neurons). Using these isoform-specific
antibodies, we show that eEFlA2 expression is barely
detectable in normal human breast tissue, but that the
gene is moderately to strongly expressed in 63 % of breast
tumours examined. Furthermore, there is a strong correla¬
tion between eEFlA2 overexpression and estrogen recep¬
tor (ER) positivity.
Methods
Quantitative Real-time Reverse Transcription-PCR (RT-
PCR)
Breast cancer samples were obtained in the Edinburgh
Breast Unit (Western General Hospital, Edinburgh) with
patients' informed consent and ethical committee
approval. Biopsies were snap frozen and stored in liquid
nitrogen until RNA extraction. Before RNA extraction the
frozen tissue was defrosted and stabilized in RNA-later-
ICE reagent (Ambion). Total RNAwas extracted with RNe-
asy-mini columns (Qiagen).
Amount and purity ofRNA were evaluated by spectropho¬
tometry. RNA integrity was confirmed by agarose gel elec¬
trophoresis. Total RNA was isolated from tumour and
normal tissue using Qiagen RNeasy kits (Qiagen). RNA
was treated with DNase using DNAfree kit (Ambion,
Cambridgeshire) and 1 pg was used for RT-PCR using Ret-
roscript kit (Ambion, Cambridgeshire, UK). TaqMan
Assay-on-Demand gene expression pre-designed primer
and probe sets from Applied Biosystems, Cheshire, UK
were used for EEF1A2 (Assay # Hs 00157325 ml) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
control; Hs 99999905 ml). In a 10 pi reaction volume per
well of a 394-well plate, 0.5 pi of primers, 5 pi ofTaqMan
PCR Master Mix, no AmpErase UNG 10x, and 4.5 pi of
diluted cDNA were added (Applied Biosystems, Cheshire,
UK). Real-time RT-PCR and the quantification of RT-PCR
products were performed and the products analyzed using
an ABI Prism 7900HT Sequence Detection System, and
the appropriate software (SDS3.1) according to the man¬
ufacturer's instructions (Applied Biosystems, Cheshire,
UK).
Western blots
Protein lysates from cell lines were prepared using previ¬
ously published protocols [10]. Western blot analyses
were carried out using standard protocols. The blots were
incubated with primary anti-eEFlA2 rabbit antibody and
primary anti-eEFlAl sheep antibody diluted 1:200 in
blocking solution, as well as primary anti-glyceraldehyde-
3-phosphate dehydrogenase polyclonal mouse antibody
(Chemicon International, Hampshire, UK) diluted
1:10000. Blots were then incubated in the appropriate
horse radish peroxidase conjugated secondary antibody
(Dako Cytomation, Cambridgeshire, UK) at 1:500. Detec¬
tion was performed using enhanced chemiluminescence
detection kit (Amersham Biosciences, Buckinghamshire,
UK).
Immunohistochemistry
Specimens of normal and cancerous tumours were
obtained with informed consent and local ethical com¬
mittee approval from patients undergoing surgical treat¬
ment at the Royal Infirmary of Edinburgh and Western
General Hospital, Edinburgh. A breast tumour histoarray
(CB2) produced by SuperBioChips (AMS Biotechnology,
Oxfordshire, UK) was also used. Formalin fixed, paraffin
embedded sections of human normal tissue and tumour
tissue were deparaffinized with xylene, rehydrated, treated
with picric acid and microwaved in citric acid pH6. Slides
were blocked in a 1:5 dilution of sheep serum for 30 min¬
utes at room temperature. Primary anti-eEFlA2 rabbit
antibodies were used at a concentration of 1:10 diluted in
PBS, for 40 minutes at room temperature and secondary
goat anti-rabbit IgG biotin conjugated antibody (Dako
Cytomation, Cambridgeshire, UK) was used at 1:200 at
room temperature for 30 minutes. Slides were incubated
with StreptABC complex/HRP (Dako Cytomation, Cam¬
bridgeshire, UK) at room temperature for 30 minutes and
in diaminobenzidene (Sigma Fast DAB, Sigma, Dorset,
UK) for 2 minutes at room temperature. Finally slides
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were counterstained in haematoxylin, dehydrated and
mounted in pertex.
Immunohistological scoring methods
The breast tumour sections and normal breast sections
(CB2, SuperBioChips, AMS Biotechnology, Oxfordshire,
UK) were scored as weak, moderate and strong staining
for eEFlA2. Weak staining was considered as background
since this level of staining is seen in normal tissue. Stro¬
mal tissue was negative in all cases. Blind scoring was car¬
ried out by two independent researchers. Two slides were
analysed, representing different levels within tumours,
and each of these was stained with a different antibody to
eEFlA2. Almost perfect correlation was seen between the
two slides.
Statistical methods
Fisher's exact test was used to test for associations between
negative and weak eEFlA2 expressing tumours or moder¬
ately and strongly overexpressing tumours with ER posi-
tivity. For breast tumour Quantitative Real-time RT-PCR
data, a two-sample t-test allowing for difference in vari¬
ance between the two samples was used to test the differ¬
ence between the mean standardised quantity of RNA for
the ER-positive and ER-negative groups. P values thatwere
less than or equal to 0.05 were considered significant.
Results
Expression analysis in breast tumours
Since 20ql3.3 amplification is commonly seen in breast
tumours as well as ovarian tumours, and because analysis
of the SAGE database at NCBI indicated that eEFlA2 was
more highly represented in breast tumours than in nor¬
mal breast tissue (unpublished observations) we decided
to examine eEFlA2 expression in breast tumours at both
the RNA and protein level. Initially, we usedWestern blot¬
ting with an anti-eEFlA2 antibody to examine expression
in a number of commonly-used cell lines. The anti-
eEFlA2 antibody was raised against a peptide that differs
significantly between eEFlAl and eEFlA2 (Newbery et al,
in preparation); specificity was confirmed by lack ofsignal
from tissues taken from wasted mice which have a null
mutation of eEFlA2 [5]. The majority of transformed cell
lines showed high levels of expression of eEFlA2 (Figure
1); in addition, it has previously been shown that NIH3T3
cells do not express eEFlA2 except when they become
confluent [2,6]. We therefore chose not to place any
emphasis on the analysis of breast cancer cell lines as
opposed to primary tumour samples since eEFlA2 expres¬
sion seems to be a common property of transformed cells,
rather than being specific for a tumour type. Instead, we
carried out real-time quantitative RT-PCR ofRNA samples
from breast tumours. The results obtained are shown in
Figure 2A. It can be seen that whereas extremely low levels
of expression are detected in RNA samples from normal
breast and from a benign breast tumour, most malignant
tumour samples showed moderate to high (up to 30-fold
higher than normal breast) expression levels. On average,
the estrogen receptor (ER)-negative tumours showed only
1.2 times higher expression than the normal sample
whereas ER-positive tumours had 8.4 times higher expres¬
sion (Figure 2B). The difference in eEFlA2 expression lev¬
els between the estrogen receptor negative tumours and
estrogen receptor positive tumours is 7.2 units (P =
0.0087, t-test, 95% confidence interval 2.0 to 12.4 units).
No protein extracts were available from these tumours for
Western blot analysis so we then examined expression of
eEFlA2 by immunohistochemistry on a commercial tis¬
sue array of normal and tumour breast samples using the
anti-peptide antibodies described above. The array con¬
tained sections from 46 cases of cancer and 7 normal
breasts; the results obtained are shown in Figure 3. None
of the normal breast sections showed any more than faint
staining. No stromal staining was observed and tumour
staining within a sample was near-uniform. Of the
tumour samples, 5 showed strong expression of eEFlA2
(11%) and 22 showed moderate expression (48%). The
remainder appeared to have no more staining than nor¬
mal breast. None of the three lobular carcinomas on the
slide showed any eEFlA2 overexpression. There was no
significant correlation between eEFlA2 expression level
and tumour grade or lymph node positivity (data not
shown). The tumours had all been previously assessed for
p53 status; there appeared to be an association between
overexpression of eEFlA2 and wild-type p53, but this was
not statistically significant. The tendency to association
may be a reflection of the significant association between
ER positivity and p53 negativity (p = 0.012) in these
tumour samples. Only four out of the 22 ER-negative
tumours showed staining beyond background levels and
none had strong staining. We found a significant associa¬
tion between eEFlA2 overexpression (scored as moder¬
ate/strong) and ER positivity (P = 0.016, Fisher's exact
test). We then went on to examine 16 tissue sections from
ER positive breast tumours obtained from patients at the
Western General Hospital. Of these, 13 showed moderate
or strong staining with the anti-eEFlA2 antibody. Overall
then, 40 out of 63 breast tumours (63%) examined by
immunohistochemistry showed significant overexpres¬
sion of eEFlA2.
Discussion
We have shown that the putative oncogene eEFlA2 is
upregulated in a high proportion of breast tumours. This
upregulation is considerably more significant in ER-posi¬
tive tumours. There is little or no detectable expression of
eEFlA2 in normal breast tissue. It is not yet known
whether this overexpression results from amplification of
the EEF1A2 gene in all cases; in the study of ovarian
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Western blot analysis using an anti-eEFIA2 antibody on a range of cell lines. The loading control is GAPDH.
tumours by Anand et al [6] at least one tumour showed
overexpression in the absence of gene amplification, sug¬
gesting that there are other mechanisms bywhich the gene
can be upregulated. There is a strong association between
ER-positivity and eEFlA2 overexpression which is worthy
of further study.
There also appears to be a weak correlation between the
absence of p53 mutations and eEFlA2 overexpression. It
is possible that eEFlA2 is not upregulated in tumours
with p53 mutations because wild-type p53 is required for
expression of eEFlA2 in certain cell types; it has been
shown that p53 can upregulate expression ofeEFlAl [11],
and the p53 binding sites identified in the gene encoding
eEFlAl are shared with that encoding eEFlA2 (unpub¬
lished observations). On the other hand it is conceivable
that upregulation of eEFlA2 expression rather than p53
mutation is an alternative route for tumours to evade
apoptosis in certain cancers.
The basis for the oncogenicity of eEFlA2 is still unclear.
We, like Anand et al, have shown that the levels ofeEFlAl
in tumours which over-express eEFlA2 are unchanged
(data not shown), suggesting that these tumours might
have a greater capacity for protein synthesis. However, it
has been known for many years that eEFIA is in excess
over the other components of the translation elongation
apparatus [12], so eEFIA is unlikely to be rate-limiting in
protein synthesis. eEFlAl has been shown to determine
the susceptibility of a number of independent cell lines to
chemical- and UV-induced transformation [13] and has
been identified as an actin binding protein in rat breast
tumour cells, where it was found to be more highly
expressed in metastatic than non-metastatic cells [14], It is
not yet clear whether these properties are shared with
eEFlA2, but the availability of specific antibodies that dis¬
tinguish between the two isoforms should allow us to
shed light on this. One hypothesis is that the non-canon¬
ical ("moonlighting") properties of eEFlAl [15] and
eEFlA2 differ so that, for example, the way eEFlA2 inter¬
acts with the cytoskeleton might differ from that of
eEFlAl and affect the properties of cells which are
expressing high levels of both isoforms. It has been
shown, for example, that forced overexpression of eEFIA
affects the cytoskeleton in both S. pombe and S. cerevisiae
[16,17], Alternatively, it has been shown that eEFlAl and
eEFlA2 differ in terms of their response to apoptotic
agents [18]; the finding that eEFlA2 is anti-apoptotic, at
least in certain conditions, has obvious implications for
the possible role of eEFlA2 in tumourigenesis. The obser¬
vation that eEFlA2 expression is seen in the majority of
cell lines, regardless of the tissue of origin, suggests that
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(A) Real-time RT-PCR analysis of RNA from breast tumours. Each block on the x axis represents a different tumour. The
amount of eEFIA2 message is shown normalised to GAPDH and expressed relative to the level of expression in the normal
breast RNA samples (=l). ER-negative tumours are shown in white, ER-positive tumours are shown in black. The difference in
mean expression between ER-positive and ER-negative samples is 7.2 units (p = 0.0087), 95% Confidence Interval 2.0 to 12.4
units. (B) Average standardised RNA levels in ER-negative and ER-positive breast tumours. This difference is significant (P =
0.0087, t-test).
eEFlA2 expression may be triggered by the general proc¬
ess of transformation. This idea is strengthened by the fact
that most of the few cell lines which do not express
eEFlA2 tend to be untransformed, such as NIH3T3 cells
(Figure 1).
The presence of increased levels of eEFlA2 in breast
tumours may provide a useful new diagnostic marker.
Further, eEFlA2 may prove to be a feasible target for ther¬
apeutic intervention. It has already been shown that
growth-factor mediated eEFlAl expression can be
blocked with anti-EGF antibodies [19]; it would be of
interest to examine the response ofeEFlA2 to similar anti¬
bodies. Investigations into non-canonical functions of
eEFIA molecules may shed new light on mechanisms of
oncogenicity.
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Immunohistochemistry of eEF IA2 in the breast. The panel labelled N shows the antibody staining weakly in a normal breast
section. Panels TI to T5 show breast tumours staining strongly with the anti-eEF IA2 antibody. Magnification * 10.
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Expression of eEFIA2 is associated with clear cell histology in
ovarian carcinomas: overexpression of the gene is not dependent
on modifications at the EEFIA2 locus
VAL Tomlinson1, HJ Newbery1, JH Bergmann1, J Boyd1, D Scott2, NR Wray1, GC Sellar2, H Gabra2'4,
A Graham3, ARW Williams3 and CM Abbott1'*
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The tissue-specific translation elongation factor eEFIA2 is a potential oncogene that is overexpressed in human ovarian cancer.
eEFIA2 is highly similar (98%) to the near-ubiquitously expressed eEFIAI (formerly known as EFI-a) making analysis with
commercial antibodies difficult. We wanted to establish the expression pattern of eEFIA2 in ovarian cancer of defined histological
subtypes at both the RNA and protein level, and to establish the mechanism for the overexpression of eEFI A2 in tumours.We show
that while overexpression of eEFI A2 is seen at both the RNA and protein level in up to 75% of clear cell carcinomas, it occurs at a
lower frequency in other histological subtypes. The copy number at the EEFIA2 locus does not correlate with expression level of
the gene, no functional mutations were found, and the gene is unmethylated in both normal and tumour DNA, showing that
overexpression is not dependent on genetic or epigenetic modifications at the EEFIA2 locus. We suggest that the cause of
overexpression of eEFI A2 may be the inappropriate expression of a trans-acting factor. The oncogenicity of eEFI A2 may be related
either to its role in protein synthesis or to potential non-canonical functions,
British Journal of Cancer advance online publication, 17 April 2007; doi: 10.1038/sj.bjc,6603748 www.bjcancer.com
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Ovarian cancer accounts for 4% of cases of female cancers; it has
the highest fatality-to-case ratio of all gynaecological cancers,
largely because the vast majority of cases are late-stage at
presentation. Tumours arising from the surface epithelium
represent the most common form of ovarian cancer. Although a
number of molecular mechanisms underlying ovarian tumour-
igenesis have been identified, a single model of progression has not
been described, possibly because of the heterogeneous nature
of ovarian carcinoma (Shih Ie and Kurman, 2004). Primary ovarian
adenocarcinomas are divided into four common distinct morpho¬
logical subtypes: serous, mucinous, endometrioid, and clear cell.
Although clear-cell tumours are frequently confined to the ovaries
at presentation, they are associated with a poor prognosis and are
thus treated as high-grade neoplasms (Schwartz et al, 2002). The
incidence of clear-cell tumours among epithelial ovarian cancers is
around 10%. Clear-cell tumours tend to be resistant to platinum-
based chemotherapy, giving rise to a poor prognosis (Itamochi
et al, 2002).
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Translation factor eEFlA2 is a tissue-specific variant of eEFIAI
(previously called EF-lot). While eEFIAI is almost ubiquitously
expressed, expression of eEFlA2 is normally confined to muscles
and neurons (Lee et al, 1992; Knudsen et al, 1993). The gene
encoding eEFIAI is on 6ql3 and eEFlA2 on 20ql3.3 (Lund et al,
1996). The encoded proteins are 92% identical and 98% similar.
Whereas lack of eEFlA2 gives rise to the wasted mouse phenotype
(Chambers et al, 1998), which involves motor neuron degeneration
(Newbery et al, 2005), inappropriate overexpression has now been
linked to cancer. Anand et al (2002) showed that eEFlA2, while
not normally expressed in ovary, is expressed in 30% of ovarian
tumours . The mechanism for the overexpression appeared to be
gene amplification in most, but not all, cases. Anand et al (2002)
were also able to demonstrate that ectopic expression of eEFlA2
in NIH3T3 cells gives rise to colony formation in soft agar and
increases growth rate. Furthermore, overexpression in rat fibro¬
blasts enhances focus formation, and eEFlA2-expressing ES-2
ovarian cells and NIH3T3 cells injected into nude mice give rise to
tumour formation. There was however no information on which
types of ovarian tumours show overexpression of eEFlA2 and
expression was assessed at the RNA level only. eEFlA2 has been
identified in an expression microarray study as one of a number
of genes that are highly expressed (ca. fourfold) in clear cell
ovarian tumours than other histological subtypes of ovarian cancer
(Schwartz et al, 2002). We recently showed that EEF1A2 is also a
potential oncogene in breast tumours (Tomlinson et al, 2005).
eEFIA2 in clear cell ovarian tumours
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We have now set out to examine eEFlA2 expression in a panel
of ovarian tumours of defined histological subtypes. We have
generated and used a panel of antibodies that allow us to
distinguish between the highly related variants eEFlAl (which is
expressed in normal breast and ovary) and eEFlA2 (which is
thought only to be expressed only in muscle and neurons under
normal circumstances) (Newbery et al, in preparation). We show
in a panel of ovarian tumours that while a high proportion of clear
cell carcinomas overexpress eEFlA2, a far smaller proportion
of serous, endometrioid and mucinous tumours have high levels of
eEFlA2 expression. Furthermore, we show that (1) DNA copy
number at the EEF1A2 locus is unrelated to expression level, (2)
there are no activating mutations in the eEFlA2 coding sequence
in tumours where there is overexpression in the absence of gene
amplification and (3) the methylation status of the EEF1A2 gene is
unrelated to expression level.
MATERIALS AND METHODS
Patient samples: ovarian tumours
Primary ovarian (HOV) tumour material and non-malignant
tissues were obtained from patients having undergone gynaecolo¬
gical surgery in the Lothian University Hospitals NHS Trust.
Institutional ethical approval was granted for this work by the
Lothian University NHS Trust Medicine/Clinical Oncology Re¬
search Ethics Subcommittee. Tissue samples were excised and
stored in liquid nitrogen. Non-malignant tissue samples were
derived from patients who underwent bilateral oophorectomies for
suspected malignancy, but were found to have benign histologies;
samples were collected from apparently normal contralateral
ovaries. Tumours were reviewed by subspecialist gynaecological
pathologists, and categorised according to stage and histological
type and grade.
Quantitative real-time reverse transcription-PCR
(RT-PCR)
RNA was prepared from ovarian samples and cell lines as
described previously (Sellar et al, 2003). Total RNA was isolated
from tumour and normal tissue using Qiagen RNeasy kits (Qiagen,
Crawley, UK). RNA was treated with DNase using DNAfree kit
(Ambion, Cambridgeshire, UK) and 1/(g was used for RT-PCR
using Retroscript kit (Ambion). TaqMan Assay-on-Demand from
Applied Biosystems, Cheshire, UK was used for EEF1A2 (Assay;
Hs 00157325ml) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH-, control; Hs 99999905ml). In a 10 jd reaction volume per
well of a 394-well plate, 0.5 //I of primers, 5 /A of TaqMan PCR
Master Mix, no AmpErase UNG 10 x , and 4.5 /d of diluted cDNA
were added (Applied Biosystems). Real-time RT-PCR and the
quantification of RT - PCR products were performed and the
products analysed using an ABI Prism 7900HT Sequence Detection
System, and the appropriate software (SDS3.1) according to the
manufacturer's instructions (Applied Biosystems).
Western blots
Protein lysates from cell lines were prepared using previously
published protocols (Gilmour et al, 2002); the same method was
used for primary tumour samples, but in these cases tissue was
initially homogenised in extraction buffer before determination of
protein content. Western blot analyses using 10 fig protein were
carried out using standard protocols. The blots were incubated
with primary anti-eEFlA2 rabbit antibody diluted 1:200 in
blocking solution, as well as primary anti-GAPDH polyclonal
mouse antibody (Chemicon International, Hampshire, UK) diluted
1:10000. Blots were then incubated in the appropriate HRP
conjugated secondary antibody (Dako Cytomation, Cambridge¬
shire, UK) at 1:500. Detection was performed using enhanced
chemiluminescence detection kit (Amersham Biosciences, Buck¬
inghamshire, UK).
Immunohistochemistry
A computerised search of the archives of the Department of
Pathology was used to identify 168 cases of ovarian carcinoma of
the common epithelial types. Slides were retrieved and the
histological classification reviewed by a gynaecological pathologist.
Four representative areas of viable tumour tissue were identified
and marked on the slides, and the corresponding areas in the
paraffin blocks used as the source of tissue for the tissue
microarray (TMA). Tissue cores (0.6 mm diameter) were sampled
from each of the four areas, and mounted into separate recipient
paraffin blocks by the use of a custom-made instrument (Beecher
Instruments, Silver Springs, MD, USA). In the ensuing paraffin
array blocks, the tissue cylinders were aligned and marked for
identification according to a chart. The recipient TMA blocks
were baked at 56°C for 10min before sectioning, and 3 /<m paraffin
sections were cut by standard microtomy. A histoarray (CJ1)
produced by SuperBioChips (AMS Biotechnology, Oxfordshire,
UK) was also used. Formalin fixed, paraffin embedded, sections of
human normal tissue, tumour tissue and TMAs were deparaffi-
nised with xylene, rehydrated, treated with picric acid, and
microwaved in citric acid at pH 6. Slides were blocked in a 1:5
dilution of sheep serum for 30 min at room temperature. Primary
anti-eEFlA2 rabbit antibody was used at a concentration of 1:10
diluted in phosphate-buffered saline (PBS), for 40 min at room
temperature and secondary goat anti-rabbit IgG biotin conjugated
antibody (Dako Cytomation, Cambridgeshire, UK) was used at
1:200 at room temperature for 30min. Slides were incubated with
StreptABC complex/HRP (Dako Cytomation) at room temperature
for 30 min and in diaminobenzidene (Sigma Fast DAB, Sigma,
Dorset, UK) for 2min at room temperature. Alternatively, after the
primary antibody step slides were washed in PBS and three drops
of ChemMate DAKO EnVision/HRP Rabbit/Mouse secondary
antibody (DAKO Cytomation) added to each slide. Slides were
incubated for 30 min at room temperature and then washed in PBS.
The DAB-containing substrate working solution was prepared by
mixing 50 parts ChemMate Substrate Buffer withl part ChemMate
DAB + Chromogen (DAKO Cytomation). One millilitre of this
solution was added to each slide and incubated for 5 min. Finally,
slides were counterstained in haematoxylin, dehydrated and
mounted in pertex.
Immunohistological scoring methods
The ovarian tumour histoarray (CJ1 SuperBioChips AMS Biotech¬
nology, Oxfordshire, UK) and normal ovarian sections were given
a histoscore. For each score, the percentages of the tumour tissue
(excluding stroma) which stain strongly (3), moderately (2) and
faintly (1) were assessed. The Histoscore was calculated by
multiplying the percentage of tumour tissue staining by the score
in each category, and adding these values to give a maximum of
300. Expression in the TMAs was assessed using a modification of
the method of Tolivia et al (2006).
Statistical methods
Fisher's exact test was used to test for associations between
positive protein expression and tumour subtypes of clear cell
carcinomas vs all other tumour types combined.
Mutation analysis
For mutation analysis of the EEF1A2 gene, primer pairs were
designed for each exon (see supplementary data). PCR was carried
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out using Taq polymerase from Invitrogen (Paisley, UK), except in
the cases of exons 1 and 8, that required the use ofDyNAzyme EXT
DNA polymerase (Finnzymes, NEB, Hitchin, UK) with cycling
conditions consisting of an initial denaturation step at 94°C for
5min followed by 32 cycles of 30 s at 94°C, 30 s at the annealing
temperature and 30s at 72°C (60s when using DyNAzyme). PCR
products were then sequenced using BigDye v3.1 (Applied
Biosystems) according to the manufacturer's conditions.
Methylation analysis
Methylation analysis was carried out using bisulphite sequencing
of a 548 bp region of the EEF1A2 CpG island. The EZ DNA
Methylation Kit (Zymo Research) was used to convert 1 /ig ofDNA
from ovarian tumours HOV 104, 179, 548, and 557 and from
normal whole ovary samples 440 and 470 according to the
manufacturer's protocol. The resulting DNA was amplified using
the following primers: 5'-AGGGATTGGAAATTAGTAGATTT and
5'- AAAAAAAATCCACCTATTAA and Roche Fast Start Taq DNA
polymerase. Cycling conditions were a 5min initial denaturation
step at 95°C followed by 44 cycles of 95°C for 30 s, 52°C for 30 s,
and 72°C for 90 s. The converted PCR products were cloned into
the pCR2.1 vector using the TA Cloning Kit (Invitrogen) following
the manufacturer's protocol. Clones (2-5 for each original DNA
sample) were sequenced as before and the results analysed using
BiQ Analyser software (http://biq-analyser.bioinf.mpi-inf.mpg.de/)
(Bock et al, 2005).
Quantitative real-time PCR analysis of copy number
For EEF1A2 DNA copy number analysis two sets of intronic
primers were designed (see supplementary data online). Primers
designed to amplify microsatellite loci in regions of chromosomes,
which are normally stable in ovarian cancers were used for
normalisation of total DNA amount. This was based on the method
of DNA copy number analysis used by Ginzinger et al (2000). For
determination of copy number at 20p primers from microsatellite
loci on 20p were used and normalised relative to D5S643.
Quantitative real-time PCR analysis was carried out using a MyiQ
Single Color Real-Time PCR machine (BioRad, Hemel Hempstead,
UK) and iQ SYBR Green Supermix (2 x ) (BioRad). Standard
curves were conducted on lOOng DNA extracted from normal
blood that was serially diluted five times from 1:10 to 1:100000.
200 ng of DNA from each tumour was used in a 25 /A reaction.
Cycling conditions were an initial 8.5 min denaturing step at
95°C followed by 40 cycles of 95°C for 30 s, and 72°C for 30 s.
Fluorescent signal collection was carried out at elongation (72°C).
A melt curve was included to confirm primer specificity and minus
DNA controls were included to confirm that there was no
contamination. Standard curves were used to determine the PCR
efficiency for each primer set. Primers were used at 200 nM giving a
PCR efficiency of between 90 and 110%. EEF1A2 copy number was
then calculated using the (Pfaffl (2001) method of analysis. The
copy number of EEF1A2 in normal blood DNA was determined
using an average value from analysis of five different blood DNA
samples. The use of three microsatellite loci for normalisation
allowed for the exclusion of outlying values. Copy number at the
chromosome 20p microsatellites D20S804 and D20S819 was
calculated using the standard curve method of analysis (Applied
Biosystems User bulletin #3).
RESULTS
Expression analysis of ovarian tumours
We assessed RNA and protein samples taken from the same group
of ovarian tumours, all of which had been assessed for histological
subtype. Initially, we carried out real-time RT-PCR to assess the
level of expression of eEFlA2 mRNA in the tumour panel. The
results are shown in Figures 1A and B and Table 1; whereas three
out of the four clear cell tumours analysed (75%) had detectable
overexpression of eEFlA2, only four of the 18 serous tumours
(22%), five of the 12 endometrioid tumours (42%) and neither of
the mucinous tumours were overexpressing. Similar RT - PCR
analysis of a panel of ovarian cancer cell lines shows most cell lines
to overexpress eEFlA2 compared with a human leukaemic cell line
(HL60), with levels as high as 70-fold higher in the most extreme
instance (OVCAR5). The results are shown in Figure 1C.
We went on to use anti-peptide antibodies (Newbery et al, in
preparation) against eEFlA2. The antibodies were raised against
synthetic peptides, which were designed to maximise the
differences between eEFlAl and eEFlA2. Western blots are shown
in Figure 2A. eEFlA2 protein is expressed at detectable levels in
most clear cell tumours (four out of five tumours analysed; 80%),
but only one out of 23 serous papillary tumours and two out of 11
endometrioid tumours. None of the five tumours with a mucinous
component had detectable eEFlA2 expression. Six of the seven
clear cell tumours analysed in total were overexpressing at either
the RNA or protein level or both. Unfortunately, only a few
tumours had both RNA and protein extracts available; of these,
only one (14) was positive at both RNA and protein levels; s 308,
80, 21, and 300 were negative at both RNA and protein level and s
9, 76, 88, 386, 77, and 5 had detectable expression at the RNA level
but not at the protein level. In this set of tumours, the expression
of eEFlA2 is highly significantly associated with the clear cell
carcinoma subtype when compared with all other tumour sub¬
types combined (P<0.0012, Fisher's exact test). The eEFlA2-
positive tumours represent less than 16% of our total tumour
panel, in contrast to the 26% figure obtained by Anand et al (2002).
This may simply represent the different frequency of clear cell
neoplasms in the two sets of samples, or reflect the higher numbers
of tumours that are positive at the RNA level, but which do not
express the protein. This may suggest that the mechanism of
overexpression of eEFlA2 in the tumours does not necessarily lead
to the production of a stable protein.
When we examined expression of eEFlA2 by Western blotting
in ovarian cancer cell lines we again found most cell lines to show
high levels of expression. The results are shown in Figure 2B. This
is in contrast with the results of Anand et al (2002), who found
overexpression in 4 out of 13 cell lines, but is in agreement with
previous results in our lab where we found most transformed cell
lines to express eEFlA2 (Tomlinson et al, 2005) and the study by
Joseph et al (2004) showing eEFlA2 expression in nine out of 10
cancer cell lines examined. The size of the eEFlA2 band appears to
shift slightly from one sample to the next suggesting the possibility
of post-translational modifications that vary between samples.
We then carried out immunohistochemistry. We wanted to
extend the Western blot analysis, but also to establish whether
there is any detectable expression in any cell type in the normal
ovary. Figure 3 shows the results obtained with normal tissue. The
only cells that were expressing eEFlA2 were luteinised stromal
cells, and the ovarian surface epithelium (OSE); there was no
staining in the secondary only control. We then analysed a
commercial TMA with 57 analysable tissue cores, and a TMA
constructed from local cases of ovarian carcinoma as described
above, containing a further 91 analysable cores of a single (i.e. not
mixed) histological subtype, 148 in total. It can be seen from
Figure 3 and Table 2 that the results are largely consistent with
those obtained by Western blotting. For the commercial array,
although one serous tumour and one mucinous tumour stained
moderately, the only epithelial ovarian tumours to display strong
staining with the anti-eEFlA2 antibody are clear cell carcinomas.
Moderate or strong expression was seen in 60% of clear cell
carcinomas by immunohistochemistry on this array. The associa¬
tion between clear cell carcinomas and moderate or strong
expression of eEFlA2, in comparison to the other tumour types,
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Figure I (A) Real-time RT-PCR analysis of RNA from ovarian tumours. The amount of eEFIA2 message is shown normalised to GAPDH. Arrows
indicate clear cell carcinomas. Samples showing lower levels of expression are shown separately to display small amounts of expression at higher resolution.
(B) As in (A), but showing the lower part of the scale. (C) Real-time RT-PCR analysis of RNA from ovarian cancer cell lines. The amount of eEFIA2
message is shown normalised to GAPDH. The negative control is HL60, a leukaemia cell line.







Clear cell 4 75 5 60
Serous 18 22 23 4
Endometrioid 12 42 11 18
Mucinous 2 0 5 0
GAPDH = glyceraldehydes-3-phosphate dehydrogenase. Samples are scored as
positive at the RNA level if they have a score greater than 0.5 when normalised
to GAPDH (see Figure I A).
was significant (P= 0.03, Fisher's exact test). For the in-house
array a less strong correlation with histological subtype was seen.
Only one tumour fell into the 'strong' category, with a histoscore of
229, and this was a clear cell tumour, but there were far more
negatively and weakly staining tumours overall; the total
percentage of tumours with moderate or strong histoscores was
5% for this TMA in contrast to the 19% for the commercial TMA.
Nevertheless, when the scores were combined, all three of the
tumours with a histoscore of > 200 were clear cell carcinomas.
DNA analysis of the EEF1A2 locus in ovarian tumours
Anand et al (2002) have previously shown that the EEF1A2 locus
is amplified in two out of three tumours they found to be
overexpressing eEFlA2, suggesting that amplification of the gene
may not be the only mechanism mediating overexpression. We did
not have access to cell lines from the tumours we had studied at
the RNA and Western level, but did have DNA, so we used a real-time
PCR method to estimate the copy number of the EEF1A2 locus.
This was based on the method of Ginzinger et al (2000), but
control primers were selected from regions that are normally
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Figure 2 (A) Western blot analysis of protein extracts from ovarian
tumours. Sample numbers are the same as those shown in Figure I A. The
same blot is shown having been exposed sequentially to eEFIA2 and
GAPDH antibodies with a stripping step in between each antibody. The
controls are HeLa, which expresses both eEFIAI and eEFIA2,
lymphoblastoid cells (LB) which express only eEFIAI, and adult mouse
muscle, which expresses only eEFIA2. Clear-cell tumours are indicated by
bold underlined type. (B) Western blot analysis of protein extracts from
ovarian cancer cell lines. The negative control is a lymphoblastoid cell line
and the positive controls are HeLa, which we have previously found to
express eEFIA2 at high levels, and mouse muscle.
genomically stable in ovarian cancer; three sets were used in case
of between-tumour variation. The copy number of EEF1A2 was
estimated using primers within an intron to avoid amplification
of EEFIAI. We also estimated copy number at two loci on 20p,
to distinguish between amplification of 20q and polyploidy.
The results are shown in Figure 4; EEF1A2 was amplified at a
significant level (more than 2s.d. from normal DNA) in 12 of the 15
(80%) ovarian cancers expressing eEFlA2 at the RNA or protein
level. Only one of these, tumour HOV 12, also had an increase in
copy number at 20p. However, all eight of those cancers not
expressing eEFlA2 also had copy numbers significantly exceeding
that found in normal diploid blood DNA. It is clear that there is no
obvious correlation between copy number and gene expression;
indeed, a non-expressing tumour, number HOV170, shows the
greatest EEF1A2 copy number. The similar pattern of copy number
changes between non-expressing and expressing tumours suggests
that gene amplification is not the primary mechanism underlying
the overexpression of eEFlA2.
We therefore, went on to establish whether the methylation
status of the EEF1A2 gene differs between ovarian tumours and
normal ovarian tissue. We used bisulphite sequencing to compare
the methylation profile of 548 bp of the CpG island at the 5' end
of the EEF1A2 gene in DNA samples from normal ovary, from
tumours that do not express eEFlA2 and from overexpressing
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Figure 3 Immunohistochemistry of normal ovary (A, B) and ovarian cancer (C-F) sections. Staining in the normal ovary can be seen to be confined to
luteinised stromal cells (NI) and low level expression in the ovarian surface epithelium (N2). HOV304 corresponds to one of the clear-cell tumors that was
also analysed by RT-PCR and Tl and T2 are clear-cell tumours from the histoarray. T3 is a negative staining tumour. Magnification x 10.
© 2007 Cancer Research UK British Journal of Cancer (2007), I - 8
eEFI A2 in clear cell ovarian tumours
VAL Tomlinson et a\
Table 2 Immunohistochemistry for eEFIA2 in different ovarian tumour types using a commercial TMA and an inhouse TMA
Tumor type Number analysed Negative % Weak % Moderate % Strong %
Clear cell 35 19 54 10 29 3 9 3 9
Serous 64 35 54 26 40 3 5 0 0
Endometrioid 38 29 76 9 24 0 0 0 0
Mucinous 11 6 54 4 36 1 10 0 0
Total 148 89 60 49 33 7 5 3 2
TMA= tissue microarray. A histoscore of 0 is recorded as negative, between I and 100 as weak, between 101 and 200 as moderate and over 201 as strong.
5^^ ^ -\A off" && ^ ^
DNA analysed
Tumours expressing eEF1A2 Tumours not expressing eEF1A2
Figure 4 Mean normalised EEFIA2 copy number in normal gDNA (horizontal stripes), ovarian cancers expressing eEFI A2 at the RNA and/or protein
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Figure 5 'Lollipop' diagrams produced by BiQ Analyser. Open circles denote unmethylated CpG dinucleotides, while closed circles denote methylated
CpG dinucleotides. (A) Tumours 179 and 104, which do express eEFIA2 and show some methylation in CpG dinucleotides preceding the island, but no
methylation within the CpG island. (B) Tumours 308 and 470 which do not express eEF IA2. There are very few methylated CpGs either within the island
or preceding it. (C) DNA from two different normal whole ovaries. There is little methylation present at any CpG dinucleotide within the sequence.
tumours. It can be seen in Figure 5 that although the CpG
dinucleotides immediately 5' to the CpG island were methylated,
the CpG island itself was unmethylated in all cases, suggesting
that hypomethylation of the EEF1A2 gene in tumours is not a
mechanism for overexpression.
Finally, we sequenced the coding and untranslated regions of
the EEF1A2 gene in those tumours, which were overexpressing
eEFlA2, but which had low copy number (and were thus amenable
to analysis by sequencing without the potential complication of
sequence differences between gene copies). This group comprised
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six tumours in total. All eight exons (including non-coding exon 1
and the 3'UTR in exon 8) were sequenced together with flanking
intronic regions spanning splice sites. Apart from two established
single nucleotide polymorphisms (SNPs), the only sequence
alteration identified was a G to A substitution in exon 1 of tumour
183. This sequence alteration was present on both strands and is
not a known SNP; unfortunately DNA from normal tissue from the
same individual was not available, so it is not possible to establish
whether this is a tumour-specific change. However, given both that
exon 1 is noncoding, and that this tumour shows expression of
eEFlA2 at the RNA but not the protein level, the mutation is
unlikely to be of functional significance in terms of cancer. The
mechanism by which eEFlA2 is overexpressed in these tumours
thus remains elusive, but it is clearly of interest that over-
expression is able to occur in the absence of mutation or
demethylation, and that there is no correlation between over-
expression and amplification.
DISCUSSION
We have shown that, depending on the detection method used, up
to 75% of ovarian clear cell carcinomas show overexpression of
eEFlA2 at the protein level. At the RNA level, we find that 33% of
ovarian tumours in total overexpress eEFlA2, which is consistent
with the 30% figure reported by Anand et al (2002). In contrast to
the results of Anand et al (2002), we found some expression of
eEFlA2 in normal ovary, both in the OSE (from which tumours are
thought to arise), and in small nests of luteinised stromal cells. We
can not detect eEFlA2 expression in the vast majority of ovarian
tumours examined, however, which argues against the idea that
tumour overexpression is simply a feature of the cells from which
the tumours have arisen. Rather, it seems likely that inappropriate
expression of eEFlA2 contributes to tumorigenicity, as shown by
Anand et al (2002).
The finding that eEFlA2 overexpression at the protein level is
often associated with clear cell carcinomas is intriguing. Our
results are consistent with, and extend, those obtained from
microarray analysis by Schwartz et al (2002), who identified
eEFlA2 as one of a group of genes that are highly expressed in
clear cell carcinomas than other ovarian tumours. It is unclear why
eEFlA2 overexpression would be found particularly in clear cell
tumours. One possibility is that there is a link with p53; we found a
weak but not statistically significant association between eEFlA2
expression and p53 wild-type status in breast tumours (Tomlinson
et al, 2005), and clear cell carcinomas of the ovary normally
express p53. Alternatively, Schwartz et al (2002) showed a
tendency to upregulate stress response genes in ovarian clear-cell
tumours, which may be relevant given that eEFlA2 is a known
binding partner of peroxiredoxin Prdxl (Chang and Wang, 2006).
The availability of a specific antibody that recognises eEFlA2,
but not eEFIA1, may be of use in a clinical setting once further
clinical correlations have been performed.
We have carried out a number of analyses of ovarian tumour
DNA to establish the mechanistic basis of the overexpression of
eEFlA2. Although amplification of the gene is seen in many
tumours there is no correlation between locus amplification and
gene expression, suggesting that this cannot be the sole underlying
mechanism of overexpression. Amplification was seen just as
frequently in tumours that do not express eEFlA2; it would be of
interest to examine the expression levels of other genes within this
amplicon. We sequenced the EEF1A2 gene from a number of
tumours with low copy number, but failed to find any mutations
that could be activating or otherwise lead to overexpression
(although it remains a possibility that there are mutations in
regulatory regions of the gene in some tumours); similarly, there
was no correlation between methylation status and expression. It is
clear therefore that overexpression does not depend on genetic or
epigenetic changes at the EEF1A2 locus; we suggest that the
overexpression may be mediated by the inappropriate expression
of a trans-acting factor in certain tumours. Microarray assays
could be informative in this regard.
It is still unknown why eEFlA2 should have oncogenic
properties in tissues in which the closely related eEFlAl is already
expressed at high levels. It has been suggested that a straightfor¬
ward increase in protein synthesis capacity could be responsible
(Thornton et al, 2003). It is also possible, however, that the two
eEFIA isoforms have subtly (or even substantially) different non-
canonical roles. Certainly, it has been demonstrated in myoblasts
that while eEFlAl is pro-apoptotic (Ruest et al, 2002), eEFlA2 is
anti-apoptotic. Moreover, it has recently been shown that
co-expression of eEFlA2 and peroxiredoxin, Prdxl, renders
NIH3T3 cells dramatically resistant to apoptotic death induced
by exposure to oxidative stress (Chang and Wang, 2006). There are
numerous reports of the cytoskeletal modifying properties of
eEFlAl (Condeelis, 1995; Edmonds et al, 1996); again, these might
differ from eEFI A1 to eEFlA2 and possibly relate to tumour
invasion and propensity to metastasize. Further in vitro and
clinical correlation studies should shed light on this. In the
meantime, eEF!A2 could provide a useful new diagnostic marker
for a sub-set of ovarian tumours, and ultimately a possible target
for therapy.
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